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Genomes are constantly challenged by agents that promote DNA damage, with interstrand 
crosslinks (ICLs) representing a particularly dangerous lesion. Ongoing work in the Wilkinson 
laboratory aimed at identifying novel agents that target Trypanosoma brucei, the causative 
agent of African trypanosomiasis, identified several prodrugs that once activated form ICLs in 
this protozoan parasite. To understand the complexity of ICL repair systems that T. brucei 
employs to resolve such damage, a variety of null mutant lines were generated that lack 
activities postulated to fix such lesions. Phenotypic screens using various DNA damaging 
agents revealed that TbMRE11, TbEXO1, TbCSB, TbCHL1, TbFAN1, TbBRCA2 and 
TbRAD51 all help to resolve ICLs, implicating components of the homologous recombination, 
nucleotide excision repair and mismatch repair pathways in resolving this form of damage: 
This approach demonstrated that components of the translesion synthesis pathway (TbREV2 
and TbREV3) do not play a significant role in ICL repair. In many organisms, nucleases 
belonging to the SNM1/PSO2 family play a key and specific role in the repair of ICLs with 
this property extending to the T. brucei homologue, TbSNM1. To assess whether there is a 
functional linkage between the DNA repair factors noted above and TbSNM1, a series of 
double null mutants were constructed and the susceptibility of these lines to ICL inducing 
agents determined. Identification of their epistatic/non-epistatic interactions revealed that T. 
brucei expresses at least two ICL repair systems with one pathway involving the concerted 
activities of TbSNM1/TbCSB/TbEXO1, that we postulate functions to repair ICLs encountered 
by the transcriptional machinery, while the other is centred upon TbMRE11/TbFAN1/TbEXO1 
that may help resolve lesions which cause stalling of DNA replication forks. By unravelling 
how T. brucei repairs ICLs, specific inhibitors against key components of these pathways could 
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Trypanosomatida represents an order of protozoan parasites belonging to the class 
Kinetoplastida. Most are monoxenous, primarily affecting insects, although several have 
evolved strategies to infect secondary hosts that as a grouping can effect a range of organisms 
including plants, invertebrates or vertebrates (Stevens et al., 2001).  Characteristically, 
trypanosomatid cells in at least one of their life cycle stages have a long slender morphology 
and possess a single flagellum. Together, these combine to give these parasites a distinctive 
corkscrew-like motility resulting in the order name: “trypó” and “soma” are Greek for “drill” 
and “body”, respectively. Being eukaryotes, Trypanosomatida contain a number of ‘classical’ 
membrane-bound organelles such as the nucleus, mitochondria, endoplasmic reticulum but 
interestingly also harbour several ‘unusual’ structures including glycosomes, which represent 
modified peroxisomes that play a key role in glycolysis, a kinetoplast that contains the 
mitochondrion genome, and a small invagination of the plasma membrane called the flagellar 
pocket where the flagellum exits the cytoplasm (Figure 1.1) (Stevens et al., 2001; Barrett et 
al., 2003; Lopes et al., 2010). 
 
 
Figure 1.1: Typical structure of 
trypanosomatid cell.  
The image shown is of the trypomastigote 
form of Trypanosoma cruzi and illustrates 
the organelles found in this parasites life 
cycle stage (Teixeira et al., 2012).  
 
Trypanosomatids are responsible for a number of insect transmitted diseases that are of 
medical and veterinary importance. The pathogens Trypanosoma cruzi, Trypanosoma brucei 
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and Leishmania are of particular note as they cause Chagas disease (also known as American 
trypanosomiasis), human African trypanosomiasis (HAT; also known as African sleeping 
sickness) and Leishmaniasis, respectively. Together, over 7 million people are infected by one 
of these agents resulting in around 55,000 deaths per year (‘WHO | World Health 
Organization’, 2018). In addition to their direct effect on human health, these infections have 
had a major impact on the economic development of poor, rural populations in Latin America, 
sub-Saharan Africa and south-east Asia. With a series of other viral, bacterial and parasitic 
diseases, trypanosomatid infections are recognised by the World Health Organisation (WHO) 
as 'neglected tropical diseases' (NTDs) that often trap individuals and their families in a cycle 
of poverty and disease (CDC - Global Health - Neglected Tropical Diseases, 2018). Breaking 
this sequence is a major aim of many non-government organizations (NGOs) such as the Drugs 
of Neglected Diseases initiative, Médecins Sans Frontières and Pan American Health 
Organization with such agencies playing key roles in the development and implementation of 
new preventative strategies, novel diagnostic procedures and treatment schedules to combat 
such deliberating conditions. In relation to human infectious trypanosomatids, these 
approaches have seen a dramatic fall in HAT and Chagas disease (Simarro et al., 2011). Buoyed 
by the success of such strategies, Dr Jean Jannin, Coordinator of the Innovative and Intensified 
Disease Management unit of the WHO Department for Control of Neglected Tropical Diseases, 
commented that the target is to eliminate HAT as a public-health problem by 2020 by bringing 
down the incidence of the disease to less than 1 case per 10 000 of the population in at least 
90% of the areas where cases exist (‘WHO | Trypanosomiasis, human African (sleeping 
sickness)’, 2017).  
 
1.2 Human African trypanosomiasis  
The first accounts of HAT are closely linked with the 18th Century slave trade with ship 
doctors and naval surgeons noting several symptoms associated with the captured people. The 
first accurate report of the neurological conditions of the disease were identified in 1734 by 
John Aktins with other characteristic signs such as localised lymphadenopathies subsequently 
described by  the English physician Thomas Winterbottom (Steverding, 2008). It is now 
recognised that HAT is a problem across the whole of sub-Saharan Africa where two 
discernible forms of the disease are prevalent with each disorder caused by a different T. brucei 
sub-species. In modern times there have been three major HAT epidemics with the first of these 
lasting approximately one decade (1896-1906), primarily affecting Uganda, Kenya and the 
Congo Basin resulting in the death of an estimated 800,000 people (Steverding, 2008). This 
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resulted in a drive to find a cure for this devastating disease and lead to the development of the 
organo-arsenical compound tryparsamide and Bayer 205, now known as suramin. During the 
1920’s through to the late 1940’s the second HAT outbreak occurred at a number of sites across 
sub-Saharan Africa with the above treatments being used to treat infected individuals. This 
promoted the then colonial powers to implement active measures based on mobile disease 
surveillance teams to identify and treat infected people, the application of vector/host reservoir 
control strategies aimed at targeting disease spread and continue the development of new 
therapies with the latter resulting in discovery of pentamidine and melarsoprol. The most recent 
epidemic occurred during the last three decades of the 20th Century (1970’s to the late 1990’s) 
with highest prevalence in Angola, the Democratic Republic of the Congo, South Sudan and 
Uganda. The reasons for this outbreak are numerous but are primarily associated with political 
instability. As such, NGO-mediated intervention and treatment strategies could not be 
implemented with the estimated number of new cases and deaths hitting a peak in the mid-
1990’s with an estimated 450,000 new HAT cases and predicted 66,000 deaths in one year 
alone (Figure 1.2) (Ruiz-Postigo et al., 2012). As political tensions eased, the situation 
regarding HAT has drastically improved with only 2,804 cases reported in 2015 (Figure 1.2), 
a figure which grossly underestimates the true extent of the problem, estimated at 20,000 cases 
(‘WHO | Trypanosomiasis, human African (sleeping sickness)’, 2017). One major reason for 
this success has been the employment of the nifurtimox eflornithine combination therapy 
(NECT), the first co-administered treatment to target this infection. With sustained preventative 
and therapeutic strategies, the goal for the eradication of HAT as a medical problem from all 
of its endemic sites by 2030 has been envisaged by the WHO Department of Control of 
Neglected Tropical Diseases in Geneva (Qian and Zhou, 2016).  
 
1.2.1 Distribution of disease 
The distribution of HAT in sub-Saharan Africa is solely determined by the geographical 
range of its insect vector, the tsetse fly. Approximately 30 different Glossina species and sub-
species found in riverine, savannah or forest habitats have been recorded to transmit the 
causative agent through the arthropods haematophagic behaviour. In contrast to some other 
insect transmitted parasitic diseases (e.g. malaria and leishmaniasis), both male and female 
tsetse flies are able to spread HAT via a salivarian route. One area of the insect’s life cycle that 
is amenable to vector control concerns their reproductive strategy. Unlike many other insects, 
female tsetse flies are viviparous, investing their energy into giving birth to one fully formed 
larvae at a time. This aspect of the arthropods life cycle allows vector control teams a window 
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of opportunity to target the fly, thus preventing disease transmission. Other routes for spread 
of HAT, such as sexual and congenital transmission, modern medical practices (e.g. blood 
transfusions) and lab-based injuries, have been reported for this condition but these are 
uncommon (Franco, 2014).  
 
 
Figure 1.2: Estimated number of human African trypanosomiasis cases. 
Total number of estimated new cases of human African trypanosomiasis based on WHO data 
from 1990–2016 (‘WHO | Trypanosomiasis, human African (sleeping sickness)’, 2017).  
 
1.3  Causative agent 
In relation to location, transmission, epidemiology and disease staging, HAT can be split 
into two distinct variants, both caused by different sub-species of T. brucei. In West and Central 
Africa, T. brucei gambiense is responsible for a chronic infection termed West African 
trypanosomiasis (WAT) which accounts for 98% of all recorded HAT cases. The parasite is 
predominantly transmitted anthropomorphically by riverine and forest dwelling tsetse flies 
with this disease form being commonly associated with rain forest, river or lake habitats (Table 
1.1). Within a human host, T.b. gambiense parasitaemia is generally low with many individuals 
being asymptomatic and therefore acting as a reservoir for the disease. In eastern and southern 
regions of Africa the so-called East African trypanosomiasis (EAT) prevails. Caused by T. 
brucei rhodesiense, the acute form of the disease is associated with dry bush and woodland, 
and transmitted by savannah dwelling tsetse flies (Table 1.1). Commonly found in animal 
reservoirs, particularly ungulates, EAT is a zoonosis with high parasitaemia commonly noted 
in an infected individual. As a result, this form of HAT can kill a patient within a month of 
being infected (Brun et al., 2010).  
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Table 1.1: Comparisons between different forms of human African trypanosomiasis 
Table adapted from (Stevens et al., 2001). 
 
1.3.1 Parasite life cycle  
The two sub-species of T. brucei show similar life cycle strategies in their insect and human 
hosts (Figure 1.3). Transfer of the parasite-infected insect saliva occurs when the tsetse fly 
takes a blood meal from a mammalian host. Trypanosomes in the metacyclic trypomastigote 
(MT) form are injected into the victim’s blood and/or lymphatic systems where they transform, 
possibly in response to a temperature shift, into long slender bloodstream form trypomastigotes 
(LS-BSF). Here, the parasite multiplies by binary fission to colonise the above circulatory 
systems with fluctuating parasitaemia, and if left untreated, can eventually cross the blood brain 
barrier to infect the cerebrospinal fluid. The oscillation of T. brucei numbers in the bloodstream 
and lymphatic system occurs in response to antibody-mediated immune insults with this 
pathogen able to alter its surface coat and hence antigenic profile presented to the host. This 
process, known as antigenic variation, involves the periodic changing of their variant surface 
glycoprotein (VSG), which acts as an antigen, with the vast majority of cells in a given wave 
of parasitaemia expressing the same form of the surface protein. The chronic nature of a HAT 
infection can be maintained as the parasite is able to call upon more than 1000 encoding genes 
and pseudogenes (Horn and McCulloch, 2010). At the peak of parasitaemia in a given wave, 
LS-BSF can express a stumpy induction factor which triggers differentiation of some of these 
trypanosomes into short stumpy bloodstream form trypomastigotes (SS-BSF) (Seed and 
Wenck, 2003). This new form of the parasite is pre-adapted for transmission into the insect 







Causative agent T.b rhodesiense T.b gambiense 
Tsetse fly location Savannah Riverine 
Ecology Dry bush and woodland Rain forest, rivers, or lakes 
Geographical location East/Southern Africa West/Central Africa 
Transmission  Zoonotic  Anthropomorphic  
Non-human hosts Wild & domestic animals Rare 
Epidemiology Sporadic Endemic with cases of 
epidemics 
Prognosis  Rapid progression to death 
(weeks to months) 
Slow progression (~1 year) 
leading to death 
Parasitaemia High Low 
Asymptomatic carriers Rare Common 
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When a tsetse fly takes a bloodmeal, both LS-BSF and SS-BSF are taken up into the insect’s 
midgut where the former trypanosome form dies. In response to a drop-in temperature and 
metabolites (e.g. citrate/cis-aconitate) present in the flies’ digestive tract, the latter 
trypomastigote then undergoes another round of differentiation leading to procyclic form 
trypomastigotes (PCF) (Czichos, Nonnengaesser and Overath, 1986). This parasite stage 
divides by binary fission and colonises this region of the arthropod. The parasite makes its way 
to the tsetse fly salivary gland, possibly via a mechanism involving conversion of the PCF to 
an epimastigote form (EP). Here, the EP attaches to epithelial cell lining of this insect organ 
via its flagellum, divides by binary fission and potentially undergoes genetic exchange (the 
latter step is not an obligatory part of the T. brucei life cycle). When the EP density increases 
to high levels, the cells transform into MT parasites, detaching from the epithelial lining of the 
salivary gland and entering its lumen ready for transmission into the next mammalian host 
(Stevens et al., 2001; Matthews, Ellis and Paterou, 2004). 
 
Figure 1.3: T. brucei life cycle.  
Image sourced from (Center for disease control (CDC) 2015). Available from: 
http://www.cdc.gov/parasites/sleepingsickness/biology.html.  
1.3.2 Staging and pathologies 
The interaction of bloodstream form trypomastigotes with the human host causes defined 
pathological outcomes that can be divided into two distinct stages (Figure 1.4). The early or 
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haemolymphatic stage of HAT occurs while the parasite is found systemically within the 
bloodstream and lymphatic system. Towards the peak of parasitaemia, trypanosomes are 
recognised by host immune mechanisms which stimulates the production of pyrogenic 
cytokines such as tumour necrosis factor, interleukin-1, interleukin IL-6 and interferons. This 
results in a characteristic fever which declines following parasite clearance. The process is then 
repeated with each subsequent wave of parasites such that the patient presents with a so-called 
relapsing fever with a periodicity of 5 to 7 days. Other signs of HAT can be manifested at this 
point such as localised lymphadenopathies with 50% of patients infected with T. b. rhodesiense 
also displaying a chancre at the site of the tsetse fly bite. If left untreated, the parasite can 
penetrate the blood brain barrier resulting in a series of neurological conditions that represent 
the late or meningoencephalitic stage of HAT. Here, the patient can exhibit anorexia, apathy 
and lassitude, have severe sleep disturbance patterns (hence the alternative name for HAT, 
African sleeping sickness) and undergo personality changes. Towards the end of this phase of 




Figure 1.4: Progression of HAT in a human host.  
T. brucei rhodesiense and T. brucei gambiense progression in a human host. Image adapted 
from Wiser (2011) ©2010 from Protozoa and Human Disease by Wiser.  
 
1.3.3 Diagnosis 
Currently, diagnosis of HAT is based on a combination of direct microscopic screening 
techniques for the presence of the parasite in blood, lymph and cerebral spinal fluids and/or 
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indirect serology (Kennedy, 2013). WHO guidelines are only available for WAT which can be 
applied to patients displaying the aforementioned disease signs and/or populations living in an 
endemic site. In both cases, undiluted blood samples are collected and analysed using the 
serology-based Card Agglutination Test for Trypanosomiasis (CATT). If positive, the above 
analysis is then repeated on a diluted blood sample. If the CATT is negative for either of the 
above, no further action is required. However, if the individual is positive after screening the 
diluted sample, the blood is microscopically analysed for the presence of the parasite: For T.b. 
gambiense a parasite enrichment process is often required due to the low parasitaemia 
associated with such infections. If this proves negative, an additional sample is taken a few 
days later to account for possible fluctuations in the individual. If either sample is parasite 
positive, the cerebral spinal fluid of that individual is then checked to determine disease 
staging. Based on these outcomes, appropriate chemotherapies can then be administered 
(‘WHO | Trypanosomiasis, human African (sleeping sickness)’, 2017). 
 
As CATT is specific for T.b. gambiense, this element of the diagnostic procedure cannot be 
applied to EAT. Given the low incidence rate of EAT, it is not financially favourable to develop 
a diagnostic test for this form of the condition. Here, direct observation of the parasite in bodily 
fluids is assessed without the need for any form of enrichment step.  
 
1.4 Anti-trypanosomal therapy 
Treatment of HAT is comprised of three monotherapies, pentamidine, suramin and 
melarsoprol, and the combinational therapy NECT. These drugs are used differently according 
to 1. the disease stage an individual presents with, and 2. the parasite sub-species an individual 
is infected with. 
 
Pentamidine, an aromatic diamidine (Figure 1.5), administered as daily intramuscular 
injections over the course of 7-10 days, is the preferred treatment for early stage infections of 
T. brucei gambiense. This drug has restricted usage as its positive charge at physiological pH 
means it is unable to cross the blood brain barrier to target late stages of HAT. A series of 
trypanosomal transporters (P2 - purine transporter; AQP - aquaglyceroporin 2; LAPT - low 
affinity pentamidine transporter) help concentrate the drug in the trypanosomal cell to 
millimolar concentrations which leads to its cytotoxic effects in the parasite (Bernhard et al., 
2007; ORTIZ et al., 2009; Baker et al., 2012; Graf et al., 2013). It is postulated that this drug 
undergoes a multifactorial attack on the trypanosomes mitochondria by preventing 
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mitochondrial DNA synthesis and promoting the collapse of the mitochondria membrane 
potential (Wilkinson and Kelly, 2009; Alsford et al., 2012).  
 
 
Figure 1.5: Structures of different clinically relevant trypanocidal agents.  
Image obtained from (D’Silva, 2007).  
  
Early stage EAT can be treated with the polysulphonated naphthylamine (Figure 1.5) drug 
suramin that is administrated by weekly intravenous injections over the course of 5-6 weeks. 
Again, due to charge, this drug does not readily cross the blood brain barrier thus restricting its 
use. Uptake of suramin occurs through receptor-mediated endocytosis within the flagellar 
pocket. This process is triggered by binding of the drug to parasite surface proteins such as 
ISG75 and VSG isoforms with ligand/receptor complexes then transferred through the 
endocytic pathway to the lysosome (Leung et al., 2011). Through the action of peptidases and 
proteases, suramin is released and transferred from the vesicular lumen by a major facilitator 
superfamily transporter. The precise mechanism of suramin is unclear but by virtue of its 
negative charge, in vitro biochemical studies have shown it could block endocytic and 
glycolytic activities with cell-based phenotypic assays, indicating it may interfere with 
polyamine synthesis and N-acetylglucosoamine synthesis (Wilkinson and Kelly, 2009; Alsford 
et al., 2012).   
 
The only drug able to target the late stage of both HAT forms is melarsoprol. This compound 
is a trivalent, melaminophenyl arsenical prodrug (Figure 1.5) that is administered as a very 
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painful intravenous injection:  the adjuvant used to suspend melarsoprol is polyethylene glycol 
which causes the collapse of blood vessel epithelial layers that manifests as a burning sensation 
in the patient. Additionally, this therapy is highly toxic causing death in about 5% of the 
individuals it is administered too. By uncharacterised mechanisms that may result from host 
activities, melarsoprol is converted to its druggable form melarsen oxide. This (and 
melarsoprol) can be internalised by the P2 and AQP transporters where it can readily form 
complexes with thiol-containing molecules (Bernhard et al., 2007; Baker et al., 2012). The 
main free thiol in trypanosomes is trypanothione and it has been shown that this can readily 
conjugate with melarsen oxide, with the resultant complexes inhibiting trypanothione-
dependent enzymes (Alsford et al., 2012). Resistance to melarsoprol can be readily achieved 
in the laboratory through mutation of the P2 transporter and loss or reduction of AQP activity 
with such lines also displaying cross resistance to pentamidine (Mäser et al., 1999; Graf et al., 
2013). Worryingly, these phenotypes have been observed in the field with treatment failures 
associated with these aforementioned genetic alterations (Bernhard et al., 2007). 
 
Therapeutic switching of both nifurtimox, originally used as an antichagasic treatment, and 
eflornithine, initially developed as an anticancer agent, has resulted in NECT, the only 
combinational therapy available against HAT. Previous work revealed that eflornithine was a 
highly effective anti-HAT agent, earning it the name of the resuscitation or miracle drug. 
However, it was also extremely expensive, thereby limiting its usage. The use of NECT has 
drastically reduced the cost of treatment such that it now represents WHOs recommended 
therapy against late stage WAT. Following intravenous infusion, eflornithine, a variant of 
ornithine, is taken up by parasite via a specific amino acid transporter, AAT6, and then goes 
on to act as an irreversible inhibitor of ornithine decarboxylase, a key enzyme in polyamine 
and trypanothione synthesis (Baker, Alsford and Horn, 2011; Schumann Burkard, Jutzi and 
Roditi, 2011). The orally administered and hydrophobic 5-nitrofuran nifurtimox can readily 
pass through cell membranes. In the trypanosome, this prodrug enters the parasites single 
mitochondrion where it undergoes type I nitroreductase (NTR) mediated activation, an enzyme 
absent from human cells. This reaction goes on to generate a series of nitroso, hydroxylamine 
and open chain nitrile metabolites with the latter displaying high cytotoxicity. To date, there 
have been no NECT treatment failures although laboratory-based studies have shown that 
reduction of AAT6 or NTR activities can result in eflornithine or nifurtimox resistance, 




1.5 DNA damage and repair 
DNA is a biological structure that is highly prone to different types of damage. If left 
unchecked, these can cause alterations to the encoding nucleotide sequence and/or promote 
chromosome instability. These insults arise from various endogenous sources such as errors in 
DNA processing and reaction of DNA with metabolic products, or as result of exogenous 
influences including exposure to chemicals or radiation. As a consequence, cells have evolved 
a series of distinct and complementary DNA repair pathways that function to fix the variety of 
lesions that may arise (Sancar et al., 2004; Boiteux and Jinks-Robertson, 2013; Kreuzer, 2013). 
A healthy cell requires a balance between DNA damage and repair mechanisms with disease 
or cell death occurring when appropriate DNA repair does not occur (Friedberg, 1995).   
 
1.5.1 General overview 
DNA damage can be broadly separated into 1. single base changes, 2. large structural 
distortions and 3. breakage events, with each type of damage requiring a series of specific 
repair mechanisms (Figure 1.6).  
 
Single base changes can include nucleotide alkylation, hydrolysis, oxidation, depurination, 
depyrimidination and deamination events as well as tautomeric shifts which have mutagenic 
effects on the cellular genome (Waters et al., 2009). These toxic lesions can be neutralized by 
the direct reversal repair (DRR), base excision repair (BER) or nucleotide excision repair 
(NER) pathways with the invoked repair mechanism determined by the exact alteration event 
that has taken place. DNA alkylation events can be readily reversed by the DRR pathway with 
O6-alkylguanine DNA alkyltransferase (MGMT) playing a critical role in the transfer of the 
mutagenic alkyl-group onto its own protein backbone. For other single base changes, the NER 
and BER operate with the latter pathway playing the major role. BER can be divided into short-
patch BER that functions to repair only the affected nucleotide or long-patch BER where a 
wider region surrounding the damage is fixed. These pathways rely upon the unaltered 




Figure 1.6: DNA damage and repair pathways.  
Different types of damage to DNA (both endogenous and exogenous) and the respective 
cellular repair mechanisms. Image taken from (Genois et al., 2014). 
 
Structural DNA distortions, in particular adduct formation, photodimerism and DNA 
intercalation events, require more complex repair mechanisms due to the torsional stress 
created on the nucleic acid backbone (Waters et al., 2009). Photodimerism, most commonly 
cyclobutane pyrimidine dimers (CPD), is the UV-mediated bonding between up to 4 parallel 
or neighbouring nucleotides resulting in major helix distortion. DNA intercalation events 
usually involve the insertion of chemical moieties (e.g. ethidium bromide) between nucleotides 
causing a stretching of the DNA helix. These events are predominantly detected and repaired 
via the NER pathway with additional assistance from the mismatch repair (MMR) pathway. 
The NER pathway can be divided into transcription-coupled NER (TC-NER) and global-
genome NER (GG-NER), with different pathways exploited at different points in the cell cycle.  
 
The most lethal type of DNA damage are breakage events that result in the impediment of 
both transcription and replication. Exposure to ionizing radiation or cytotoxic agents can result 
in double strand breaks (DSBs) with potential loss of whole sections of genomic material 
dependent on 1. the extent of material lost during the damage, 2. the length of the overhanging 
strand after the breakage event and 3. introduction of errors in the overhanging strands 
(Jackson, 2002). Due to the lethality of this type of damage, three pathways play a role in 
repairing such lesions. Substantial damage to both strands of DNA can be repaired by the non-
homologous end joining (NHEJ) or homologous recombination (HR) pathways. NHEJ 
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involves the direct assembly of the 5’ and 3’ termini of the DNA double helix with the possible 
loss of 5’ and 3’ sequences and introduction of base errors. The HR pathway is employed for 
error-free DSB repair with sequences upstream from the damage used as templates for sister 
chromatid searches. The translesion synthesis (TLS) pathway can be employed to bypass 
lesions when repair is unfavourable e.g. during transcription/replication.  
 
Single strand breaks are repaired by the single strand annealing (SSA) pathway which 
involves a simple ligation of the overhanging strand back to the DNA backbone. 
 
In certain situations, DNA crosslinks can form involving reaction of the nucleic acid 
structure with another, usually nucleophilic chemical entity that contains at least two reactive 
centres. This can result in 1. intrastrand crosslinks, where the mutagen covalently bonds to 
bases within the same DNA strand, 2. interstrand crosslinks, where the mutagen covalently 
bonds to bases within complementary DNA strands or 3. formation of DNA-protein complexes. 
Any combination of the above ‘classical’ DNA repair pathways can be invoked as crosslinking 
can cause single base changes, large structural distortions and/or breakage events (Peter J 
McHugh, Spanswick and Hartley, 2001). 
 
A comprehensive list of the components of each DNA repair pathway can be found at the 
Trypanosomatid DNA repair resource; https://sites.google.com/site/trypdnarepair/home.  
 
1.5.2 Trypanosomal DNA repair pathways 
Comparative studies relating to how T. brucei repairs DNA damage have been performed 
with many of components of the HR, MMR, BER, TLS, NER and MMEJ pathways identified. 
A comprehensive list of the components of each DNA repair pathway found at the 
Trypanosomatid DNA repair resource (reviewed in (Passos-Silva et al., 2010; Genois et al., 
2014)). A key finding from such metadata analyses corroborated by experimental observations 
is that trypanosomes lack a functional NHEJ pathway despite expressing several components 
of this system (e.g. Ku70, Ku80 and ARTEMIS) (Glover, McCulloch and Horn, 2008; Genois 
et al., 2014).  
 
Functional analysis of the trypanosomal NER pathway indicates that the transcription 
coupled pathway preferentially operates relative to the global-genome mechanism (Machado 
et al., 2014). This may reflect that trypanosomatid gene expression is polycistronic with 
27 
 
transcription of the vast majority of genes effectively being ‘on’ all the while with regulation 
of each cistron occurring post-transcriptionally. As such there is an absolute requirement in 
these parasites to have their TC-NER mechanism constantly functioning as a sentinel to 
identify and repair lesions encountered during transcription. In other organisms, stalled RNA 
polymerase acts to target CSA and CSB to the site of DNA damage. These enzymes displace 
the polymerase from the DNA and recruit TFIIH NER factors to promote DNA helix 
unwinding (e.g. XPB, XPD, etc) to create an open bubble structure that is maintained in this 
state by a preincision complex (e.g. RPA, XPA) prior to a dual incision event mediated by the 
ERCC1-XPF complex and XPG (Lagerwerf et al., 2011; Genois et al., 2014; Iyama et al., 
2015). This results in single stranded DNA that is filled in by DNA polymerases using the 
undamaged, complementary strand as template followed by ligation of the sugar-phosphate 
backbone. The GG-NER system differs slightly from the TC-NER counterpart primarily in 
how the damage is detected which involves the damage recognition activities of DDB1/DDB2 
or XPC/Rad23b complexes. These then recruit TFIIH NER factors and promote repair as 
described for TC-NER.  
  
Several components of TC-NER (e.g. TbCSB, TbXPB, TbXPBz and TbXPG) and GG-NER 
(TbXPC) have been identified and characterised in T. brucei with their role in the 
corresponding pathway confirmed. Intriguingly, a number of elements such as CSA, XPA, 
DDB2 and components of the TFIIH complex are apparently missing (Machado et al., 2014). 
Based on such differences it is implicit that this parasites TC- and GG-NER pathways are 
distinct from model eukaryotic organisms, a feature that may be exploitable in terms of 
chemotherapeutic development. 
 
Cells are able to bypass certain DNA lesions using the TLS pathway with different systems 
predominating at various points within the cell cycle. During the S-phase, the so-called 
polymerase switching model operates. Here, stalling of DNA replication complex at a site of 
DNA damage causes posttranslational modification of proliferating cell nuclear antigen 
(PCNA) that leads to replacement of the incumbent DNA polymerase within the replication 
complex with a TLS specific DNA polymerase (Waters et al., 2009). At other times within the 
cell cycle, the TLS pathway operates through the so-called gap-filling model (Shen et al., 2006; 
Waters et al., 2009). In this situation, detection of a stalled transcription complex by NER 
factors can result in recruitment of the TLS specific DNA polymerases (Enoiu, Jiricny and 
Schärer, 2012). Using ssDNA present in a transcription bubble as template, these protein 
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complexes guide the addition of nucleotides at the lesion site to generate a dsDNA molecule 
with DNA ligases then operating to maintain the integrity of the sugar-phosphate backbone. 
Several TLS specific DNA polymerases can operate in these two models with these differing 
in their fidelity: TLS DNA polymerases are said to be error-free (high fidelity) or error-prone 
(low fidelity). In the latter case, the polymerase activity can lead to ‘secondary’ base mismatch 
mutations that require downstream repair (e.g. by the MMR pathway). To date, little is known 
about the trypanosomal TLS pathways although these systems are known to operate with at 
least five TLS polymerases (polymerase nu (PolN), polymerase zeta (PolZ), polymerase theta 
(PolQ), polymerase eta (PolH) and polymerase kappa (PolK)) implicated in these activities 
(Machado et al., 2014; Zurita-Leal, 2016). Two trypanosomal TLS polymerases, PPL1 and 
PPL2, have been implicated with trypanosomal TLS activity (Rudd et al., 2013).  
 
Many trypanosomal components of both HR pathways, single strand annealing and 
synthesis-dependent strand annealing pathway, have been functionally characterised and linked 
to one way these parasites undergo antigenic variation (Horn, 2014; Morrison, McCulloch and 
Hall, 2015). In other organisms, the synthesis-dependent HR pathway relies on detection of a 
break by the MRE11-RAD50-NBS1 (MRN) complex with DNA resection processing single 
stranded DNA (ssDNA). This DNA acts as the guide for the strand exchange reaction, carried 
out by RAD51 and maintained by the activities of BRCA2, PALB2, RAD52 and RAD51 
paralogs. This complex carries out the homology search for an intact sister chromatid sequence 
with RAD51 and RAD54 mediating the cross-over. With strand synthesis complete, the 
invading strand dissociates from the complex and anneals to the complementary sequence with 
gaps filled and nicks ligated to complete repair. The single strand annealing pathway operates 
in a RAD51-independent complex with substantial cleavage of 5’ and 3’ termini at a DSB 
followed by single strand annealing and ligation. Several components of the single strand 
annealing and synthesis-dependent strand annealing pathway have been identified and 
characterised in T. brucei including the initial detection and resection activities of TbMRE11 
and TbRAD50, recombinase activity of TbRAD51 and ancillary activities of TbBRCA2 and 
TbRAD51 paralogues (TbRAD51-1 to TbRAD51-4) (McCulloch and Barry, 1999; Robinson, 
McCulloch, Conway, Browitt and Barry, 2002; Hartley and McCulloch, 2008; Dobson et al., 
2011). This work has shown that not all components of the HR pathway present in this parasite 
with absence of RAD52 and PALB2 noted in various in silico analyses of the T. brucei genome 




Mismatch repair, often referred to as the postreplicative repair pathway, is employed at 
mismatched base errors with damage recognition carried out by the MutS (MSH2, MSH6 and 
MSH3) heterodimer and lesions cleaved by the endonuclease activity of MutL (MLH1, MLH3 
and PMS1) homodimers. This complex recruits EXO1, a 5’-3’ exonuclease, which carries out 
exonucleolytic degradation of the nucleotide. DNA synthesis is carried out by a DNA 
polymerase with nicks in both strands sealed by DNA ligases. Almost all components of the 
MMR machinery are conserved in trypanosomatids: MutS-like genes in the parasite (e.g. 
TbMSH2, TbMSH8 and TbMSH3) have been identified and characterised to play a role in both 
nuclear and mitochondrial DNA repair (Barnes and McCulloch, 2007), MutL-like genes, 
primarily PMS1 and MLH1, have also been functionally characterised however no 
characterisation of an EXO1 homologue has been studied (Szankasi and Smith, 1992; Bell et 
al., 2004).  
 
1.6 Interstrand crosslinks and their repair 
The covalent bonding of two complementary strands of DNA leads to formation of an 
interstrand crosslink (ICL). This form of DNA damage is highly detrimental to a cell as it can 
block any process that requires DNA strand separation and can result in stalling of the 
transcription and/or replication machinery, mismatch errors and loss of genomic material. As 
few as one ICL in a bacterial cell or 20 in a mammalian cell can result in the death of that cell 
(Dronkert and Kanaar, 2001). To survive such insults, a series of activities have been co-opted 
to generate multiple, complementary and overlapping repair systems. These function at 
different points in the cell cycle with the nature of the mechanisms varying between groups of 
organisms (P J McHugh, Spanswick and Hartley, 2001; Clauson, Schärer and Niedernhofer, 
2013). As such, comparative studies involving humans don’t necessarily inform what the 
situation is in yeast, which in turn do not reflect mechanisms employed by trypanosomes. 
Therefore, each organism’s ICL REPAIRtoire is distinct. 
 
1.6.1 ICLs: definition, formation and significance  
ICLs are predominantly but not exclusively formed by exogenous chemicals with many 
anticancer agents exploiting their detrimental effects. In rare cases, ICLs can be formed 
endogenously by ionizing radiation, oxidative stress and simple unsaturated aldehydes that are 
generated during lipid peroxidation and prostaglandin synthesis promoting such lesions (Noll, 
Mason and Miller, 2006; Clauson, Schärer and Niedernhofer, 2013). These ICL inducing 
agents have two reactive centres with one of these commonly becoming activated and reacting 
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with a guanine residue on one DNA strand (Noll, Mason and Miller, 2006). This interaction 
then promotes activation of the second reactive centre, facilitating binding to a nearby guanine. 
Many ICL forming chemicals favour interacting with this particular base due to the large 
electrostatic potential that occurs between two guanine residues resulting in preference of 
alkylation events at guanine-rich regions of DNA (Noll, Mason and Miller, 2006). The 
sequences targeted by different ICL promoting compounds vary e.g. nitrogen mustards 
preferentially reacting at 5′-GNC-3′ sites, mitomycin C favouring 5′-CG-3′ sequences, and 
platinum-based compounds promoting the binding at 5′-GC-3′. An exception to this pattern are 
the psoralen-based compounds as they show a marginal preference for 5′-TA-3′ and 5′-AT-3′ 
sequences (Figure 1.7).  
 
 
Figure 1.7: Structures of different types of ICL inducing agents.  
Structures redrawn on ChemDoodle.  
 
Nitrogen mustards are chemical structures that contain a chloroethylamine grouping in their 
backbone and function by promoting alkylation events primarily affecting nucleic acid targets. 
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For those that induce ICLs, e.g. mechlorethamine and cyclophosphamide (Figure 1.7), at least 
two such groupings are present on the structures’ backbone, both of which can form highly 
reactive and nucleophilic centres. In the presence of DNA, particularly where 5′-GNC-3′ 
sequences are found, the terminal chloride found on one arm of the alkyl reactive centre is 
displaced to form an aziridinium ion that attacks the N7 position of a guanine resulting in the 
alkylation of that base. In 1 to 2% of cases the terminal chloride found on the second reactive 
centre undergoes a similar event leading to ICL formation (Dronkert and Kanaar, 2001). This 
damage results in structural distortion of the double helix (Rajski and Williams, 1998).  
 
A number of ICL forming compounds contain at least one aziridinyl grouping in their 
structure with these being embedded within (‘trapped’) or as a side chain (‘free’) on the 
chemicals backbone. In all situations, an activation event is required to promote formation of 
a reactive centre. For compounds such as CB1954 and RH1 (Figure 1.7) that contain two or 
more ‘free’ aziridinyl moieties, the above leads to formation of an aziridinium ion that then 
promotes ICL formation analogous to that noted for the nitrogen mustards. In chemicals such 
as the mitomycins, where the azirinidyl is ‘trapped’, activation causes a redistribution of 
electrons through the indolequinone ring structure that promotes DNA binding to sites 
neighbouring the aziridinyl. Initially, a methoxy grouping adjacent to the aziridinyl is 
eliminated from the chemical backbone leading to formation of a quinone methide. In the 
presence of DNA, particular where 5′-CG-3′ sequences are found, the methide then functions 
as a nucleophile to promote formation of firstly a monoadduct at the N2 position of a guanine 
base on strand of DNA then a bisadduct by reaction with the N2 position of a guanine base on 
the complementary strand (Meredith et al., 2017). 
 
Other ICL inducing agents of note include the platinum-based and furocoumarin-containing 
compounds (Figure 1.7). In the case of the former, as represented by cisplatin and carboplatin, 
moieties in the structure (e.g. the chloride ions in cisplatin) are slowly displaced by water to 
create aquo complex intermediates with the water subsequently supplanted by a purine 
nucleotide, particularly guanine, at the N7 position. Most damage via platinum-based 
compounds occurs within the same DNA strand (intrastrand crosslink) with a minor component 
(~10%) being interstrand in nature (Peter J McHugh, Spanswick and Hartley, 2001). In the 




Furocoumarin-containing compounds such as psoralen and angelicin promote ICLs by a 
mechanism distinct from that described above. Analogous to UV-induced pyrimidine dimer 
formation, these are photoactivated such that their furan and pyrone rings form cyclobutane 
structures with thymidine residues found on opposite DNA strands leading to the crosslink 
formation and intercalation at 5’-TA-3′ and 5′-AT-3′ sequences (Friedberg, 1995).  As with the 
platinum-based agents, ICL formation constitutes a minor component of any resultant DNA 
lesion.  
  
To conserve genome integrity, all cells exploit various combinations of enzymes from the 
“classical” DNA repair pathways to resolve ICL damage. The precise makeup of these systems 
is unclear as different mechanisms predominate at different stages in the cell cycle while 
evolutionary diverse organisms employ distinct mechanisms to accomplish this task 
(Lehoczký, McHugh and Chovanec, 2007; McVey, 2010; Hashimoto, Anai and Hanada, 2016). 
Broadly, in a mechanism initiated by stalling of a DNA replication complex, the damaged DNA 
is processed through “unhooking” of the ICL from the nucleic acid backbone with the 
concomitant formation of a DSB (Hashimoto, Anai and Hanada, 2016). Using complementary 
DNA sequences (e.g. from a sister chromatid), enzymes from the HR pathway function to fix 
this break and, in conjunction with components from the TLS pathway, completely remove the 
“unhooked” ICL from the DNA backbone. In a DNA replication independent mechanism, 
components of the NER pathway recognise, cleave and “unhook” the ICL from one strand of 
the DNA backbone (Hashimoto, Anai and Hanada, 2016). This generates a single stranded gap 
within the nucleic acid molecule with the dsDNA structure restored through TLS activity. 
Another round of NER and TLS then completely removes the “unhooked” ICL from the DNA. 
As the above mechanisms involve TLS, which can be error prone, the MMR pathway operates 
as a sentinel to fix any damage that may arise. Due to the complexity of ICL repair, the focus 
of this literature review will exclusively centre on the ICL repair systems found in Escherichia 
coli, Saccharomyces cerevisiae and mammalian cells.  
 
1.6.2 ICL repair in E. coli 
Over the last 40 years, a picture of the E. coli ICL repair system, often referred to as the 
Cole Model of ICL repair (Cole, 1971) (Figure 1.8), has been elucidated and shown to involve 
the coordinated activity of components of the NER and HR pathways. Here, the UvrABC 
constituents of the bacterial NER pathway function in the 1. DNA damage recognition (UvrA 
and UvrB), 2. unwinding the DNA strand surrounding the lesion (UvrB), and 3. cleaving the 
33 
 
DNA backbone either side of the ICL (UvrC) (Houten et al., 1986). In certain cases where the 
torsion strain caused by the crosslinking event creates structural distortions to the DNA double 
helix, additional helicase activities (e.g. UvrD) can be employed to aid the unwinding process 
(Noll, Mason and Miller, 2006). The above generates an ‘unhooked crosslink’ with the ICL 
remaining covalently attached to one strand of the DNA backbone. Sequences immediately 
upstream of the initial incision are processed by the exonuclease activity of DNA Polymerase 
I (Pol I) which in turn recruits RecA from the HR pathway. By virtue of its recombinase 
activity, RecA then promotes strand invasion from a related DNA sequence, a process aided 
by the activities of RecB, RecC, and RecD (these act in strand recognition, binding of terminal 
ends and processing of breaks). The above results in a Holliday junction that can be resolved 
using the RuvABC complex (Houten et al., 1986). Following recombination, a second round 
of UvrABC-mediated incision is performed on the other strand, releasing the ‘unhooked 
crosslink’ from the DNA backbone to create a gap that is filled by Pol I and DNA ligase 
activities.  
Figure 1.8: ICL repair systems in E. coli.  
E. coli expresses two distinct ICL repair systems one being HR-dependent and the other being 
a TLS-dependent mechanism. Crosslinked DNA (DNA and crosslink shown in black and red, 
respectively) is unhooked from the double helix by the activity of NER factors (purple arrows) 
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(part 1). The unhooked ICL remains attached to one of the DNA strands while a small formed 
in the other. This gap can then filled by a HR-mediated strand invasion process (part 2) or a 
TLS-dependent mechanism (part 3): The homologous template used in the former is shown in 
brown while the newly synthesised DNA noted in the latter is in blue. The ICL is then 
completely removed from the DNA structure by a second round of NER (part 4) followed by 
DNA polymerase and DNA ligase activities (part 5). Parts 1, 2, 4 and 5 constituent the so-
called Cole Model for ICL repair. Imaged adapted from (Huang and Li, 2013).  
  
In addition to the above Cole Model, an alternative recombination-independent ICL repair 
system has been also proposed. In this case, following the initial UvrABC incision, DNA Pol 
IV catalyses TLS activity past the still attached ‘unhooked crosslink’ with the integrity of the 
sugar-phosphate backbone maintained by downstream DNA ligase activity. As above, a second 
round of UvrABC incision completely removes the crosslink from the genome with Pol I and 
DNA ligase activities filling in the resultant gaps (Kumari et al., 2008) 
 
1.6.3 S. cerevisiae ICL repair systems 
Many of the features displayed in the E. coli ICL repair system are mirrored in simple 
eukaryote organisms such as budding yeast, S. cerevisiae, although the complexity and 
overlapping nature of these systems alters throughout the cell cycle (Figure 1.9). Throughout 
most of this cycle (G0-, G1-, early S- and G2-phase), a NER and TLS pathway similar to the 
bacterial mechanism predominates, which additionally incorporates novel ICL repair specific 
activities displayed by the nuclease PSO2 (also known as SNM1) (Part A of Figure 1.9). In this 
system, stalling of the transcriptional machinery at an ICL promotes ubiquitination of PCNA 
that then functions to recruit components, including nucleases, of the NER pathway. These 
proceed to mediate the unhooking of the ICL from one strand of the double helix (Waters et 
al., 2009). RAD1 (with RAD10) and RAD2 possess endonuclease activities that cleave 
sequences  5’ and 3’ around the damaged DNA, respectively, with RAD4/RAD14 postulated 
to aid in recognition of the adduct and the RAD3/RAD25 helicases acting to unwind the DNA 
helix (Sarkar et al., 2006). The PSO2 nuclease then processes the ’unhooked crosslink’ to 
remove all the bases up to and across the linkage present within this sequence (Bonatto et al., 
2005). The resultant gap is then filled by damage-tolerant TLS polymerases (e.g. REV1 
and REV3) with the sugar-phosphate backbone reformed by DNA ligases (Ho et al., 2011). As 
with the E. coli systems, a second round of NER coupled with DNA polymerase/ligase 




Cells that encounter ICLs while in the late S-phase utilize a series of factors from the NER, 
MMR and HR pathways that act in concert help resolve the lesion (Part C of Figure 1.9). In 
this system, the NER pathway is believed to carry out the initial incision events either side of 
the ICL. If not repaired by the PSO2-dependent pathway, an approaching replication fork can 
stall in the immediate vicinity of the lesion resulting in recruitment of MPH1, MUTSα and 
MGM101. MPH1 causes the replication fork to reverse and allows loading of EXO1 onto the 
‘unhooked crosslink’ (Ward et al., 2012). This nuclease then removes the bases from this 
sequence up to but not beyond the ICL, with any resulting gap on the other strand filled by 
damage-tolerant TLS polymerases and DNA ligases. A second round of NER activity begins 
processing the DNA strand containing the ‘unhooked crosslink’ with the lesion being 
completely uncoupled from this backbone with any gap filled via DNA polymerase/ligase 
activities. Before DNA replication can recommence, the nascent leading or lagging (one not  
 
 
Figure 1.9:  ICL repair systems in yeast.  
Yeast express at least three distinct ICL repair mechanisms whose activities appear to be cell 
cycle dependent. Initial incision of the damaged DNA is common to these systems and employs 
NER factors. For cells in the G0-, G1-, early S- or G2 phase, a PSO2/TLS-dependent 
mechanism functions (A) while cells in the S-phase employ HR-based activities (B). An 
alternative G2-phase system that functions independently of PSO2 and involves EXO1 in 
conjunction with TLS activities has also been reported (C). The final steps of mechanisms A, 
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B and C is common with the ICL completely removed from the DNA structure by a second 
round of NER followed by DNA polymerase and DNA ligase activities. Starting DNA and 
crosslink are shown in back and red, respectively while the purple arrows correspond to the 
incisions made by NER factors. Newly synthesised DNA as a result of DNA repair is shown 
in blue, the homologous DNA template used in the HR mechanism is shown in brown while 
newly synthesised leading and lagging DNA strands associated with replication forks is in 
green. Image adapted from (Barber et al., 2005).  
 
both) DNA strand undergoes a DSB that is repaired by components of the single strand 
annealing HR pathway: RAD52 is recruited to the site of DNA damage through interaction 
with MGM101 with ancillary factors such as CHL1 and SLX4 aiding this event (Kenneth F. 
Grossmann et al., 2001; Ward et al., 2012; Munari et al., 2013).  
 
In addition to the PSO2-dependent G2-phase ICL repair system, an alternative mechanism 
may also operate (Part B of Figure 1.9). Incision and processing events possibly involving NER 
components leads to unhooking of the ICL with sister chromatids then providing a template for 
MRE11- and RAD51-dependent HR (Kenneth F. Grossmann et al., 2001). It is hypothesised 
that a second round of NER coupled with DNA polymerase/DNA ligase activities completely 
removes the ICL from the genome. 
 
1.6.4 Mammalian ICL repair 
Two cell-cycle dependent ICL repair systems have been identified in mammalian cells. A 
transcription-coupled ICL repair system utilises components of the NER and TLS pathways as 
well as the ICL-specific activity of SNM1 (homolog of PSO2) for removal of crosslinks (Figure 
1.10). The second and dominant ICL repair system termed the Fanconi Anaemia (FA) pathway 
is a replication-coupled mechanism (Sancar et al., 2004). This system is favoured due to a 
readily available sister chromatid sequence which enables error-free repair (mammalian cells 
are diploid organisms) (Hashimoto, Anai and Hanada, 2016) (Figure 1.11). This system was 
initially discovered through genetic profiling of patients with Fanconi Anaemia, a genetic 
condition associated with bone marrow failure, of which over 20 linkage groups and hence 
defective genes (termed FA factors) have been described (Moldovan and D’Andrea, 2009; 
Krishnan, Tay and Ito, 2015).  
 
1.6.4.1 ICL repair in transcriptionally active cells 
In transcriptionally active cells, an ICL can block progression of the transcription machinery 
leading to stalling of the RNA polymerase complex. This results in recruitment of factors such 
as CSB and UHRF1 (a RING finger protein) to the lesion site with these interacting directly or 
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through a partner(s) with other DNA repair enzymes such as SNM1, XPG and XPF-ERCC1 
(Iyama et al., 2015; Hashimoto, Anai and Hanada, 2016). The XPF-ERCC1 and XPG 
endonucleases make the initial 5’ and 3’ incisions around the ICL with nucleolytic degradation 
of the resultant unhooked sequence occurring through SNM1 (PSO2 in yeast) processing (Al-
Minawi et al., 2009; Wood, 2011; Zhang and Walter, 2014; Abdullah et al., 2017). The 
resultant gap on the strand not containing the unhooked ICL is then filled using damage tolerant 
TLS polymerases such as Pol ζ, Pol η, Pol ι, Pol Θ or Pol κ in conjunction with DNA ligase 
(Sarkar et al., 2006; Ho et al., 2011; Sharma and Canman, 2012). Once this strand has been 
repaired the ICL is completely removed by a second round of NER incision, DNA polymerase 
and DNA ligase activities. 
 
Figure 1.10: ICL repair system in transcriptionally active mammalian cells.  
The mechanism outlined here is analogous to that of the Cole Model (see Figure 1.8). Image 
adapted from (Huang and Li, 2013).  
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1.6.4.2 ICL repair in dividing cells 
ICL-induced collapse of replication forks are recognised and repaired in a mechanism that 
involves: 1. recognition of the damaged DNA and assembly of eight proteins that form the so-
called FA core complex, 2. activation of the FANCD2/FANCI heterodimer that functions as a 
recruitment complex and 3. association of effector factors that operate to resolve the ICL. The 
activities of all these proteins constitute the FA pathway (Figure 1.11) with the components 
involved listed in Table 1.2: Note, the factors listed in this table are those that have been directly 
associated with FA but it is clear that other components are implicated in this repair system but 
loss of these activities do not result in the genetic condition (or have not yet been identified). 
 
Factor Function/DNA 
FA core complex  
FANCA Creation of FA core complex in nucleus 
FANCB FA core complex structure dimerization.  
FANCC Adaptor for substrates in FA core complex 
FANCE Adaptor for substrates in FA core complex 
FANCF Anchor FANCM to FA core complex  
FANCG (XRCC9) Creation of FA core complex in nucleus 
FANCL Part of the FA core complex as a E3 ligase to alter ubiquitinated 
proteins 
FANCM (MPH1) Helicase activity to detect damage and upregulate 




FANCD2 Ubiquitinated when DNA damage sensed by FA core complex 
FANCI Ubiquitinated when DNA damage sensed by FA core complex 
FA effector proteins   
FANCD1 (BRCA2) Homologous recombination  
FANCJ (CHL1) Helicase downstream of FANCD2/FANCI ubiquitination  
FANCN (PALB2) Regulates and interacts with FANCD1 after ubiquitination of 
FANCD2 
FANCO (RAD51C) Homologous recombination  
FANCP (SLX4) Endonuclease to cleave ICL 
FANCQ (XPF) Exonuclease to cleave ICL 
FANCR (RAD51) Homologous recombination 
FANCS (BRCA1) Unloading of replication machinery at stalled replication fork 
FANCT (UBE2T) E2 enzyme for ubiquitin transfer to substrates  
FANCU (XRCC2) Homologous recombination  
FANCV (MAD2) Cell cycle checkpoint protein 
Table 1.2: FA Repair factors:  
The above table depicts the key proteins involved in the Fanconi Anaemic Repair Pathway 
including their aliases (in parenthesis) where available (Moldovan and D’Andrea, 2009; Genois 





ICL damage can lead to stalling of a replication fork(s) and alteration of the chromatin 
structure. Together, this alteration in the DNA configuration is recognised by the FANCM 
helicase that goes on to recruit other components of the FA core complex (FANCA, -B, -C, -
E, -F, -G and -L) to the lesion site, a process aided by various ancillary factors such as FAAP24, 
MHF1 and MHF2 (Moldovan and D’Andrea, 2009; Tan and Deans, 2017). Within this 
complex, FANCF acting as a scaffold protein, FANCA and FANCG function to guide the 
complex to nucleus and to site of DNA damage within the genome while FANCC and FANCE 
act as adapters for various substrates required for downstream activities: Note that the 
displacement of the replication fork does not occur during the assembly of the FA core complex 
but is reversed back along the newly synthesised DNA strands under the guidance of FANCM. 
The key role of the FA complex is to act as a ubiquitin ligase, an activity mediated by FANCL 
and FANCT, resulting in the monoubiquitination and activation of lysine residues present on 
FANCD2 and FANCI (Moldovan and D’Andrea, 2009; Ward et al., 2012). 
 
Activation of the FANCD2/FANCI heterodimeric results in recruitment of FAN1 and 
FANCP (SLX4) to the site of DNA damage which together with FANCQ (XPF)-ERCC1 and 
MUS81-EME1 cleaves the DNA backbone at sequences 5’ and 3’ to the DNA lesion 
((Moldovan and D’Andrea, 2009; Siddiqui et al., 2017). This results in the unhooking of the 
ICL from one of the DNA strands creating a gap within the other strand adjacent to where the 
newly synthesised DNA strands associated with replication forks is found (Part A of Figure 
1.11). TLS polymerases along with DNA ligase fill in the gap and links the parental ICL-
containing DNA molecule to one of the newly synthesised DNA strands. The ICL is then 
completely removed by a second round of NER/DNA polymerase and DNA ligase activity. 
During the above gap filling, the other newly synthesised DNA strand forms a DSB that is 
presumably recognised by the MRN complex. This guides components of the HR pathway (e.g. 
FANCD1, FANCR, FANCO, FANCU) to mediate recombination between the broken dsDNA 
molecule with the newly repaired DNA structure generated from the second round of 
NER/DNA polymerase and DNA ligase activities. This results in reformation of the Y-sharked 
forked structure that can serve as a template for recommencement of DNA replication (Wang, 





Figure 1.11: ICL repair in dividing mammalian cells.  
FA factors (dark blue) recognise crosslinked DNA (red and black) through stalling of a single 
replication fork (A) or convergence of two replication forks (B) resulting in the recruitment of 
FA effector proteins. These proteins unhook and process the DNA surrounding the ICL to 
create a double strand break which is repaired by the HR pathway (blue). Given this pathway 
is activated by stalling of the replication fork, leading and lagging strands are shown in green. 
The activity of TLS polymerases fill any remaining gaps in the DNA strand (blue). The ICL is 
completely removed from DNA by a second round of incision by NER factors. Image adapted 
from (Huang and Li, 2013; Krishnan, Tay and Ito, 2015).  
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Due to the bidirectional nature of DNA replication, ICLs can actually cause the stalling of 
two converging DNA replication forks (I. Chaudhury, Stroik and Sobeck, 2014; Zhang and 
Walter, 2014). Such X-shaped structures (Part B of Figure 1.11) can be resolved using the 
mechanism outlined above although in this case two of the other newly synthesised DNA 
strands both form DSBs. In this situation, the above HR mediated repair systems are activated 
with the newly repaired DNA strand serving as template. The outcome of this event is 
formation of two dsDNA molecules and the disassociation of the replication machinery. 
 
1.7 ICL repair in T. brucei 
To date reports relating to how trypanosomes resolve ICLs are limited although some 
components of the NER pathways (e.g. TbXPC, TbCSB, TbXPG and TbXPBz) may 
potentially be involved in this process (Machado et al., 2014). Recent work has established that 
T. brucei expresses TbSNM1, a member of the SNM1/PSO2 family of nucleases (Sullivan et 
al., 2015). This group of enzymes are characterised by the presence of metallo-β-lactamase 
(MβL; pfam12706) and β-CASP (named after its representative members CPSF, Artemis, 
SNM1 and PSO2; pfam10996) domains that together function to bind zinc atom(s) that is 
central to their catalytic activity (Allerston et al., 2015) (Figure 1.12). Most eukaryotic 
organisms express one SNM1/PSO2 homologue with these playing a key and specific role in 
ICL repair (Li and Moses, 2003): They do not participate in the resolution of any other form 
of DNA damage. Mammals are unusual in that they possess three distinct orthologs belonging 
to this family of nucleases with SNM1A (or DRLCE1A) functioning in solely ICL repair, 
SNM1B (or Apollo) playing additional roles in the processing DNA hairpin structures and 
telomeric maintenance, while SNM1C (or Artemis) is involved in generate antibody diversity 
through VDJ recombination (Dominski, 2007; Hazrati et al., 2008).  
 
 
Figure 1.12: Comparison of domain structure in SNM1/PSO2 nucleases.  
Schematic diagrams showing the domain alignment of the yeast (ScPSO2), human 
(HsSNM1A, HsSNM1B and HsSNM1C) and trypanosomal (TbSNM1) SNM1/SPO2 
homologues (Sengerová et al., 2012). 
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For those members of the SNM1/PSO2 family that have been characterised, a 5′-3′ 
exonuclease and flap endonuclease catalytic activity have been reported dependent upon the 
substrate present which play a key role in the processing of unhooked ICLs (Li, Hejna and 
Moses, 2005; Hazrati et al., 2008). Unusually, these enzymes mediate the nucleolytic 
degradation of such unhooked regions up to and beyond the crosslink with this resulting in 
them playing a key role in the resolution of such damage. The structure of human SNM1A and 
B has recently been solved and shown to contain an MβL fold consisting of 11 β-sheets with 
the β-CASP domain inserted between strands 10 and 11 (Figure 1.13) (Allerston et al., 2015). 
Several charged residues have been implicated in zinc co-factor coordination although the 
number of metals ions appears to vary between the two mammalian isoforms; SMM1A binds 
one zinc ion, facilitated by residues H732, H734, D736, H737, H793, D815, D838, E993, and 
H994 while SNM1B interacts with two metal ions using these same conserved residues Binding 
of the nuclease to the template is via a wide DNA binding groove located between the two 
domains with the size of this region governing the ability of the enzyme to read through a 
crosslink.   
 
Figure 1.13: Overall structure of SNM1A.  
SNM1A, PDB 4B87, is shown as a cartoon representation with α-helices shown in purple and 
β-sheets in yellow. The zinc ion is centrally depicted as a grey sphere. The β-CASP domain 
(bottom) is an insert between MBL (top) strands 10 and 11.  
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1.8 Research Aims 
The goal of this project centres upon deciphering the repair systems used by T. brucei to 
resolve ICLs. By analysing these mechanisms, we aim to unravel their importance to the 
pathogen with the future intention of exploiting these systems in drug development. The 
specific aims are to: 
 
1. Identify which T. brucei DNA repair proteins are involved in resolving ICLs within the 
parasite. 
2. Evaluate for any epistatic or non-epistatic interaction between components of the 
trypanosomal ICL repair system(s) 
3. Assess the relationship between TbSNM1 structure & function by analysing the relative 
importance of key amino acids postulated to be involved in catalytic activity, nucleic 
acid substrate specificity and localisation. 




2. Material and Methods 
2.1 Cell culturing and storage 
2.1.1 Maintenance of bacterial strains 
The E. coli strain XL1-Blue (recA1, endA1, gyrA96, thi-1, hsdR17(rK-, mK+), supE44, 
relA1, lac, [ F', proAB, lacIqZΔM15::Tn10(tetr)]) was grown in NZCYM (10 g l-1 enzymatic 
casein digest, 1 g l-1 Casamino acids, 5 g l-1 yeast extract, 5 g l-1 NaCl, 0.98 g l-1 MgSO4; 
Melford Laboratories Ltd) broth or on plates (NZCYM broth supplemented with 15g l-1 
bacteriological agar no. 1; Oxoid) at 37°C. Recombinant E. coli were cultivated in or on this 
medium supplemented with 100 µg ml-1 ampicillin (Sigma-Aldrich). 
 
For long-term storage, bacterial strains were deposited at -80°C in 1 ml aliquots of growth 
medium containing sterile 20% (w/v) glycerol (Sigma-Aldrich) in 1.2 ml cyrogenic vials 
(Nunc). To revive such reserves, a small scrapping (~10-50 µl) of the frozen bacterial line was 
transferred into NZCYM broth (5 ml) and cultured at 37°C. 
 
2.1.2 Maintenance of Trypanosoma brucei brucei 
The Trypanosoma brucei brucei (referred to here as Trypanosoma brucei/T. brucei) 
bloodstream form (BSF) trypomastigotes stocks used in this project are listed in Table 2.1.  
 
Organism  Source 
T. brucei Lister 427, antigenic type MITat 1.2, clone 221a (Doyle JJ, Hirumi H, Hirumi 
K, Lupton EN, 1980) 
T. brucei 221 Tbsnm1Δ  (Sullivan et al., 2015) 
T. brucei 2TAG1 (Alsford et al., 2005) 
T. brucei 2TAG1 Tbsnm1Δ gfp-Tbsnm1 (Sullivan et al., 2015) 
T. brucei 2TAG1 gfp-Tbsnm1 (Sullivan et al., 2015) 
T. brucei 2T1 pBSF-TbNTR-9e10  (Wilkinson et al., 2008) 
T. brucei 2T1 RNAi-TbTAO Prof J. Kelly, LSHTM 
T. brucei SMB (Wirtz et al., 1999) 
T. brucei SMB RNAi-TbSODB (Wilkinson et al., 2006) 
T. brucei 221 RH1R (Meredith et al., 2017) 
Table 2.1: Trypanosoma brucei strains used in this project.  
 
T. brucei BSF trypomastigotes were cultured at 37°C under a 5% (v/v) CO2 atmosphere in 
HMI-9 (Hirumi H, 1989) (Invitrogen) media supplemented with 3g l-1 sodium bicarbonate 
(Sigma-Aldrich), 0.014% (w/v) β-mercaptoethanol (Sigma-Aldrich) and 10% (w/v) heat-
inactivated Foetal Bovine Serum (Pan Biotech) (Hirumi H, 1989). Genetically modified 
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parasite lines were maintained in this medium containing 2.5 μg ml−1 hygromycin, 10 μg ml−1 
blasticidin, 2 μg ml−1 puromycin, 2 μg ml−1 G418 or 2 μg ml−1 phleomycin. In certain 
experiments where activation of an inducible promoter was required, 1 μg ml−1 tetracycline 
(Sigma-Aldrich) was added to the growth medium. 
 
For long-term storage, trypanosomal cultures were frozen slowly (2-3 days) to -80°C as a 1 
ml aliquot (growth medium containing 20% (w/v) glycerol (Sigma-Aldrich)) in 1.2 ml 
cyrogenic vials (Nunc) using a Cryo 1°C Mr. Frosty™ Freezing Container (Nalgene) 
containing isopropanol. Samples were then transferred into liquid N2. To revive parasite stocks, 
the entire 1 ml stabilate was quickly thawed, transferred to fresh parasite growth medium (10 
ml) and cultured as described above. 
  
2.2 Trypanocidal compounds and DNA damaging agents 
 A range of anti-parasitic agents and treatments, many of which promote DNA damage, 
were used in this project. These were purchased from Sigma-Aldrich (methyl methanesulfonate 
(MMS), hydroxyurea (HU), phleomycin, CB1954), Melford Laboratories Ltd (blasticidin, 
puromycin, G418, hygromycin) or Cambridge Biosciences (mechlorethamine). Other 
chemicals were supplied free of charge by Prof. Mike Barrett (University of Glasgow; 
difluoromethylornithine (DFMO), megazol), Prof. Simon Croft (London School of Hygiene 
and Tropical Medicine; benznidazole, nifurtimox), Prof. Longqin Hu (Rutgers, The State 
University of New Jersey, New Jersey, USA; LH34), and Prof. Chris Scofield & Prof. Peter 
McHugh (University of Oxford; ML302-HCl, ML302-F Na, Si4-33, LBE314, Ceftriaxone). 
UV irradiation was performed with a Stratalinker UV crosslinker (Stratagene). 
 
2.2.1 Plasmids 
The precursor plasmids used in this study to construct the trypanosomal gene 
deletion/disruption/expression vectors reported here are pKO-TcFHM-HYG, pKO-TcFHM –
NEO, pKO-TcFHM –BLA, pKO-TcFHM–PAC (all de Padua et al., 2017), pKO-TbSNM1-




2.3 Nucleic Acid Extractions  
Plasmid DNA was extracted from E. coli using the GeneJet™ Plasmid Miniprep kit 
(ThermoFischer Scientific) according to the manufacturer’s on-line protocol 
(https://tools.thermofisher.com/content/sfs/manuals/MAN0013117_GeneJET_Plasmid_Minip
rep_UG.pdf: last accessed 26/12/2017). Purified plasmid DNA was stored at -20°C. 
 
T. brucei genomic DNA (gDNA) was extracted from Phosphate Buffer Saline (PBS: Sigma 
Aldrich) washed parasites (approximately 5×107) using the GeneJet™ Genomic DNA 
purification kit (ThermoFischer Scientific) according to the manufacturer’s on-line ‘Cultured 
Mammalian Cells Genomic DNA Purification Protocol’ 
(https://tools.thermofisher.com/content/sfs/manuals/MAN0012656_Genomic_DNA_Purificat
ion_UG.pdf: last accessed 26/12/2017). Purified gDNA was stored at 4°C. 
 
T. brucei total RNA was extracted from PBS washed parasites (approximately 5×107) using 
the RNeasy® Mini kit with the QIAshredder homogenizer and the RNase-free DNase hit add-
ons (all Qiagen) according to the manufacturer’s ‘Purification of Total RNA from Animal Cells 
using Spin Technology’ on-line (http://www.bea.ki.se/documents/EN-
RNeasy%20handbook.pdf: last accessed 26/12/2017). All RNA samples were stored at -20°C.   
 
2.4 Nucleic acid manipulation  
2.4.1 cDNA synthesis 
Complementary DNA (cDNA) was synthesized from purified T. brucei total RNA using the 
qScript™ cDNA Synthesis Kit (Quantabio). Briefly, in a 0.2 ml thin walled micro-centrifuge 
tube, parasite RNA (10 μl), nuclease-free H2O (5 μl), 5X qScript Reaction Mix (containing an 
optimized buffer, magnesium, oligo(dT) and random primers, and dNTPs) (4 μl) and qScript 
reverse transcriptase (1 μl) were combined to give a 20 μl total volume. The reaction was then 
placed in a TC-412 thermal cycler (Techne) and subjected to once cycle at 5 minutes at 22°C, 
60 minutes at 42°C, 5 minutes at 85°C and then held at 4°C. 
 
2.4.2 DNA amplification 
A variety of DNA fragments were amplified from different DNA templates (parasite 
genomic DNA, parasite cDNA, plasmid DNA etc) using oligonucleotide primers synthesised 
by Sigma Aldrich (see Appendix 1b for primer information) and dNTP stocks purchased from 
ThermoFisher Scientific. Dependent upon the downstream usage of the DNA fragment, some 
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reactions were performed using the high-fidelity Vent® DNA polymerase (New England 
Biolabs) while others were conducted with a low fidelity Taq DNA Polymerase (New England 
Biolabs) and their respective x10 buffers. 
 
A typical DNA amplification reaction with a final volume of 50 μl was set up and contained 
1 x Taq Buffer with KCl-Mg2+ free (20 mM Tris HCl, 10 mM (NH4)2SO4, 10 mM KCl), 200 
μM dNTPs, 1.5 to 5 mM Mg2+, 2.5 % (v/v) DMSO (Sigma Aldrich), ~0.1 ng μl-1 template 
DNA, 50 pmol of each forward/reverse primer and 1 U Vent® or Taq DNA polymerase. Using 
a peqSTAR thermal cycler (PEQLab Biotechnologie GmbH) or TC-412 thermal cycler 
(Techne), a standard PCR programme was performed. This consisted of an initial denaturation 
step at 96 °C for 2 minutes, followed by 30 cycles of 96 °C for 30 seconds (denaturation), 55 
°C for 30 seconds (annealing) and 72 °C for 30 seconds (extension). At the end of the 30th 
cycle, a further extension step of 10 minutes at 72°C was added and the samples were then 
incubated at 4°C. Dependent upon the template and primer combination used, the 
denaturation/annealing/extension conditions (temperature and time) were adjusted to optimise 
each amplification. 
 
In some cases, and using MyTaq™ Red Mix (Bioline), a multiplex PCR method was used 
to generate several amplicons in a single reaction. A typical DNA amplification with a final 
volume of 25 μl contained 1x MyTaq™ Red Mix (MgCl2, dNTPs, MyTaq DNA Polymerase 
and enhancers concentrations optimized by manufacturer), T. brucei gDNA (~20 ng) and 
forward/reverse primers (usually 1 pmol µl-1; see Appendix 1b). Using a peqSTAR thermal 
cycler (PEQLab Biotechnologie GmbH) or TC-412 thermal cycler (Techne), a standard PCR 
programme was performed (see above). 
 
2.4.3 Reverse transcription quantitative PCR  
Reverse transcription quantitative PCR (RT-qPCR) was performed on T. brucei cDNA 
using PerfeCTa® SYBR® Green FastMix® kit (Quantabio). A typical reaction contained 1x 
PerfeCTa SYBR Green FastMix (MgCl2, dNTPs, AccuFast Tag DNA polymerase, SYBR 
Green I dye and stabilizers concentrations optimized by manufacturer), cDNA (100 to 1000 
ng) and a pre-optimised concentration of forward/reverse primer (usually 1 pmol µl-1). In some 
cases, additional MgCl2 was added to the above mix to optimise the reaction. Samples were 
loaded into the wells of a clear 96 well plate and an adhesive cover (Bio-Rad) used to seal the 
plate. Using a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad), an amplification 
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programme was performed. This consisted of a single initial denaturation step at 95 °C for 2 
minutes, followed by 30 cycles of 95 °C for 30 seconds (denaturation), 55 °C for 30 seconds 
(annealing) and 68 °C for 30 seconds (extension). At completion of the amplification, a melt 
curve analysis was carried out to ensure target specificity. Fluorescence data collected during 
the amplification was analysed using CFX96 Touch Software (Bio-Rad). From the resultant 
sigmoidal curves, cycle threshold (CT) values were obtained and exported into Excel 2007 
(Microsoft). Data was analysed by the comparative CT method (Schmittgen TD, 2008) by 
normalizing the sequence of interest against a standardized control (Tbtert) that was examined 
in parallel (Brenndörfer and Boshart, 2010).  
 
2.4.4 Site directed mutagenesis  
The Single Primer Reactions In Parallel-Site Directed Mutagenesis (SPRINP-SDM)  
approach (Edelheit, Hanukoglu and Hanukoglu, 2009), as outlined in Figure 2.1, was used to 
introduce specific mutations into Tbsnm1 using the template plasmid pRPa-GFP-Tbsnm1 
(Sullivan et al., 2015). A total of fourteen mutations were attempted in order to alter the amino 
acid of interest to alanine (primers used are shown in Table 2.2). Four of the residues evaluated 
were hypothesised to play a role in protein localisation (R428, R429, R430 & H431), one in 
mediating nucleic acid specificity (V518) and nine in catalytic activity/zinc co-factor binding 
(D40, H78, H80, D82, H83, H159, H178, D221 & H496). These were selected based on the 
sequence alignment shown in (Sullivan et al., 2015). 
 
A typical 25 µl SPRINP-SDM reaction was set up by combining 1× Q5 reaction buffer 
containing 2 mM MgSO4 (New England Biolabs), 200 μM dNTPs (New England Biolabs), 5 
% (v/v) DMSO (New England Biolabs), 500 ng pRPa-GFP-TbSNM1 template DNA, 10 pmol 
µl-1 primer (either the forward or reverse; Table 2.2) and 0.5 U Q5 high fidelity polymerase 
(New England Biolabs) in a thin-walled 0.5 ml microcentrifuge tube. The tube contents were 
consolidated by centrifugation and the sample subject to DNA amplification using a TC-412 
thermal cycler (Techne). A standard DNA amplification programme consisted of a single initial 
denaturation cycle (98 C for 30 seconds), followed by 30 cycles of 96 C for 10 seconds 
(denaturing stage), 50 C for 30 seconds (annealing stage), 72 C for 600 seconds (extension 
stage) before a single, final extension cycle (72 C for 120 seconds). Samples were then 





Figure 2.1: Single Primer Reactions In Parallel Site Directed Mutagenesis (SPRINP-
SDM).  
A forward and reverse reaction, each containing a primer modified with the desire mutation, 
was carried out separately. Both forward and reverse reactions were combined for annealing. 
There were three possible combination during annealing: 1. forward parental strand with 
reverse parental strand, 2. forward PCR product strand annealing to reverse PCR product 
strand, 3. parental strand with PCR product strand with the second option as the desired 





Residue role /primer 
name 
Primer sequence (5’3’) Resultant 
plasmid 
Localisation   
  Tbsnm1-R428A-F GGCAGACCAGTGAGAGCAAGGCATGGAGAAGGC pRPa-GFP-
Tbsnm1-R428A   Tbsnm1-R428A-R 
 
GCCTTCTCCATGCCTTGCTCTCACTGGTCTGCC 
  Tbsnm1-R429A-F GGCAGACCAGTGAGAGCAAGGCATGGAGAAGGC pRPa-GFP-
Tbsnm1- R429A   Tbsnm1-R429A-R 
 
GCCTTCTCCATGCCTTGCTCTCACTGGTCTGCC 
  Tbsnm1-R430A-F AGACCAGTGAGAAGAGCACATGGAGAAGGCACC pRPa-GFP-
Tbsnm1- R430A   Tbsnm1-R430A-R 
 
GGTGCCTTCTCCATGTGCTCTTCTCACTGGTCT 
  Tbsnm1-H431A-F CCAGTGAGAAGAAGGGCAGGAGAAGGCACCGCA pRPa-GFP-
Tbsnm1- R431A   Tbsnm1-H431A-R TGCGGTGCCTTCTCCTGCCCTTCTTCTCACTGG 
   
Substrate specificity  
  Tbsnm1-V518A-F CTCGTGGTGCCAACGGCATCAAAAGAAGCGTTC pRPa-GFP-
Tbsnm1-V518A   Tbsnm1-V518A-R GAACGCTTCTTTTGATGCCGTTGGCACCACGAG 
   
Enzyme activity/co-factor binding  
  Tbsnm1-D40A-F GTTGCTATCCTTGTTGCAGCGTTTGTTCACACA pRPa-GFP- 
Tbsnm1-D40A   Tbsnm1-D40A-R 
 
TGTGTGAACAAACGCTGCAACAAGGATAGCAAC 
  Tbsnm1-H78A-F TTGTTTTTTCTCTCGGCATTCCATTCGGATCAT pRPa-GFP- 
Tbsnm1-H78A   Tbsnm1-H78A-R 
 
ATGATCCGAATGGAATGCCGAGAGAAAAAACAA 
  Tbsnm1-H80A-F TTTCTCTCGCACTTCGCATCGGATCATTACAGCGG pRPa-GFP- 




  Tbsnm1-D82A-F TCGCACTTCCATTCGGCACATTACAGCGGTATT pRPa-GFP- 
Tbsnm1-D82A   Tbsnm1-D82A-R 
 
AATACCGCTGTAATGTGCCGAATGGAAGTGCGA 
  Tbsnm1-H83A-F CACTTCCATTCGGATGCATACAGCGGTATTACT pRPa-GFP- 
Tbsnm1-H83A   Tbsnm1-H83A-R 
 
AGTAATACCGCTGTATGCATCCGAATGGAAGTG 
  Tbsnm1-H159A-F TTGATACCCGCTAATGCATGTCCTGGTGCAGTT pRPa-GFP- 
Tbsnm1-H159A   Tbsnm1-H159A-R 
 
AACTGCACCAGGACATGCATTAGCGGGTATCAA 
  Tbsnm1-H178A-F TTCGGCACGATTCTCGCAACGGGTGATTTTCGC pRPa-GFP- 
Tbsnm1-H178A   Tbsnm1-H178A-R 
 
GCGAAAATCACCCGTTGCGAGAATCGTGCCGAA 
  Tbsnm1-D221A-F GATGTGCTCTTCCTTGCAAATACATACTGCCAA pRPa-GFP- 
Tbsnm1-D221A   Tbsnm1-D221A-R 
 
TTGGCAGTATGTATTTGCAAGGAAGAGCACATC 
  Tbsnm1-H496A-F ATTCCCTACAGTGAGGCATGTTGCTTTTCCGAA pRPa-GFP- 
Tbsnm1-H496A   Tbsnm1-H496A-R TTCGGAAAAGCAACATGCCTCACTGTAGGGAAT 
Table 2.2: Primers used to create single point mutations in pRPA-GFP-TbSNM1 plasmid.  
Primers to mutate D40, H78, H80, D82, H83, H159, H178, D221, H496, R428, R429, R430, 
H431 & V518 residues into alanines in the pRPa-GFP-Tbsnm1 plasmid with resultant plasmids 
are shown. Highlighted sequences correspond to the mutated residues to alanine residues. 
 
The two DNA amplification reactions (forward and reverse) associated with each mutation 
were combined and subject to an annealing temperature gradient. Here, the samples were 
incubated at 95 C for 300 seconds, before sequentially transferring to 90 C for 60 seconds, 
80 C for 60 seconds, 70 C for 30 seconds, 60 C for 30 seconds, 50 C for 30 seconds and 
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40 C for 30 seconds. The DNA were then digested at overnight 37 ºC with DpnI (New England 
Biolabs). 
 
2.4.5 Fractionation of DNA by conventional agarose gel electrophoresis 
Conventional agarose gel electrophoresis was used to separate DNA molecules between 100 
bp to 10 kbp. Dependent on the fragment sizes, the gels used varied in regard to their size and 
agarose concentrations while the voltage and run times were altered to achieve the desired 
fractionation result. A standard 0.8-1.2% (w/v) agarose gel was made by dissolving (0.8 to 1.2 
g) agarose powder (Bioline) in (100 ml) 1X TAE (40 mM Tris base (Sigma-Aldrich), 40 mM 
acetic acid (VWR), 1 mM EDTA (Sigma-Aldrich)) containing ethidium bromide (0.1 mg l-1: 
Sigma-Aldrich) by boiling using a microwave. The molten agarose was allowed to cool to 
around 60°C, dispensed into a sealed gel tray containing a comb and the agarose allowed to 
solidify. Once cast, the gel was placed into a gel electrophoresis tank containing 1X TAE 
supplemented with 0.1 mg l-1 ethidium bromide. DNA samples (containing DNA loading dye) 
and a 1 kb GeneRuler™ (Thermo Fischer Scientific) were loaded onto the gel and the samples 
fractionated through the gel by applying a constant voltage (70-100 V) across the gel for 40 
minutes to 2 hours: in some cases overnight electrophoresis (18 hours) using a 15 V constant 
voltage were performed. Migration of the samples through the agarose matrix was followed by 
monitoring the bromophenol blue and xylene cyanol dye fronts present in the samples loading 
buffer. When the DNA had migrated the desired distance, the agarose gel was visualized on a 
UV transluminator and documented (Syngene). 
 
2.4.6 Restriction digestion 
The restriction enzymes (and the associated 10x restriction buffers) used in this project are 
listed in Table 2.3 and were sourced from New England Biolabs and/or ThermoFisher 
Scientific. A typical 20 μl restriction digestion was set up by combining the DNA sample (4 
μl) sample, 10x restriction buffer (2 μl), sterile distilled water (13 μl) and restriction enzyme 
(1 μl: ~10 units) in a 1.5 ml microcentrifuge tube. The tube contents were consolidated by 
centrifugation and incubated at an appropriate incubation temperature, typically 37 C, for 1 to 
3 hours. The reaction was halted by addition of a 1/10th volume (2 μl) of loading dye (10 mM 
Tris-HCl pH 7.6, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM 




Enzyme Restriction site NEB 
Buffer 
 Enzyme Restriction site NEB 
Buffer 
Asc1 GG^CGCGCC 4  HindIII A^AGCTT 2 
ApaI GGGCC^C 4  Kpn1 GGTAC^C 1 
BamHI G^GATCC 3  Not1 GC^GGCCGC 3 
BglI GCCNNNN^NGGC 3  SacI GAGCT^C 1 
Cla1 AT^CGAT 4  SacII CCGC^GG 4 
EcoRI G^AATTC EcoRI  XbaI T^CTAGA 4 
EcoRV GAT^ATC 3     
Table 2.3: Restriction enzymes, their restriction sites and corresponding buffer used in 
this study.  
The above table details restriction enzymes, the corresponding restriction site and resultant 
buffer used in the cloning steps of this project. The “^” symbol denotes the DNA cleavage site 
on the single strand shown. 
 
2.4.7 DNA purification 
DNA fragments (~200 bp to 10 kb) were purified in solution or from an agarose gel slice 
using the GeneJet™ Gel Extraction kit (ThermoFischer Scientific) according to the 
manufacturer’s on-line protocol (https://tools.thermofisher.com/content/sfs/manuals/ 
MAN0012661_ GeneJET_ Gel_Extraction_UG.pdf: last accessed 26/12/2017). Purified DNA 
was stored at -20°C. 
 
2.4.8 DNA Ligation 
A typical ligation reaction (final volume of 30 µl) was set up by combining purified, digested 
vector (5 µl) and insert (21 µl) DNAs, 10x ligation buffer (50 mM Tris-HCl, 10 mM MgCl2, 
10 mM dithiothreitol, 1 mM ATP, pH 7.5) (3 μl) (New England Biolabs) and T4 DNA ligase 
(1 μl; 400 units) (New England Biolabs) in a 1.5 ml microcentrifuge tube. The tube contents 
were consolidated by centrifugation and incubated at room temperature for a minimum of 2 
hrs. In parallel, a control ligation was performed where the insert DNA had been replaced with 
sterile distilled H2O. 
 
2.4.9 Construction of gene deletion/disruption vectors 
A flow diagram illustrating the cloning steps used to generate the gene deletion/disruption 
vectors used in this project is shown in Figure 2.2. In this process, DNA fragments containing 
the 5’ or 3’ untranslated region (UTR)/coding sequence of the gene of interest (Tbcsb, 
Tbmre11, Tbexo1, Tbrev2, Tbrev3, Tbfan1, Tbchl1, Tbhel1) were amplified from T. brucei 
gDNA and digested with SacI (or SacII where appropriate)/XbaI or ApaI/KpnI, respectively. 
These fragments were gel purified and sequentially cloned either side of a drug resistance 
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cassette containing genes that encode for hygromycin B phosphotransferase (hyg), neomycin 
phosphotransferase (neo), blasticidin-S deaminase (bla) or puromycin N-acetyltransferase 
(pac), plus ancillary sequences needed for the correct processing of the transcript. These above 
enzymes confer resistance to the selective agents hygromycin B, G418, blasticidin and 
puromycin, respectively. The primer combinations, band sizes and the resultant gene 
deletion/interruption vectors are listed in Table 2.4.  
2.4.10 DNA Sequencing 
The concentration of the template DNA was determined using a NanoDrop™ UV 
Spectrophotometer (ThermoFisher Scientific). An aliquot of this sample (~1 µg) along with an 
appropriate primer (20-30 pM) was then commercially sequenced by Eurofins Genomics. The 
resultant outputs were analysed on Chromas (http://technelysium.com.au/wp/chromas/) and 
BLAST (https://blast.ncbi. nlm.nih.gov/Blast.cgi). 
 
2.5 Bioinformatics 
DNA sequences encoding for or having potential to encode for TbCSB (Tb927.7.4080), 
TbMRE11 (Tb927.2.4390), TbEXO1 (Tb927.8.3220), TbREV2 (Tb927.7.1090), TbREV3 
(Tb927.8.3290), TbCHL1 (Tb927.10.3550), TbHEL1 (Tb927.7.2970) and TbFAN1 
(Tb927.10.7540) along with their flanking regions were identified from the TriTryp database 
(http://tritrypdb.org/tritrypdb/) with homologues identified using a reciprocal best Blast hit 
analysis. The deduced protein sequences were aligned to the counterparts expressed by other 
organisms using CLUSTALΩ (http://www.ebi.ac.uk/Tools/msa/clustalo/) and domain 
structures evaluated using HMMR (http://www.ebi.ac.uk/Tools/hmmer/). To determine 
potential cellular localisation and possible amino acid targeting motifs, a variety of on-line 
tools were used including TrypTag (Dean, Sunter and Wheeler, 2017), PSORT II 
(https://psort.hgc.jp/),   NucPred  (http://www.sbc.su.se/~maccallr/nucpred/), Nuc-PLoc 
(http://www.csbio.sjtu.edu.cn/bioinf/) Nuc-PLoc/) and cNLS Mapper 
(http://nlsmapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi). Phylogenetic relationships 
of DNA sequences were evaluated using the Phylogeny.fr “One Click” mode tool 
(http://www.phylogeny.fr/index.cgi) (Dereeper et al., 2008): sequence alignments were 
performed using MUSCLE (Edgar, 2004), curation using GBLOCKS (Castresana, 2000), 
phylogeny using PhyML 3.0 (Guindon et al., 2010) and tree rendering using TreeDyn 




 Figure 2.2: Cloning schematic to create disruption vectors.  
A. Illustration depicting insertion of a PCR-amplified 5’ untranslated region (UTR)/coding sequence of the gene of interest (GOI) into a vector 
containing a drug resistance cassette (DRC) to facilitate disruption of genes (see Appendix 1a). Both DNA pieces were digested with SacI/XbaI 
and ligated together. B. Insertion of the 3’ GOI/UTR into the previously generated vector. These DNA fragments were digested with ApaI/KpnI, 
purified and ligated together to create the final disruption/deletion vector.   
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using Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index) (Kelley et al., 
2015) with data analysed (and in silico mutagenesis) carried out on PyMOL 
(https://pymol.org/2/).  
2.6 Bacterial Transformation 
Competent E. coli were generated using a CaCl2-based technique (M. Mandel, 1970). Briefly, 
a bacterial stock culture was diluted 1:10 into fresh NZCYM medium (generally 1 ml stock in 
10 ml fresh medium) and the new culture grown with aeration at 37°C for two hours: at this 
point the optical density at 600 nm of the culture was between 0.6-1.0. The cells were harvested 
by centrifugation (3,555 g for 5 minutes), suspended in an equal volume (generally 10 ml) ice 
cold 0.1 M CaCl2 and incubated on ice for 10 minutes. The cells were re-harvested by 
centrifugation (3,555 g for 5 minutes) and the pellet suspended in a 1/10th volume (generally 1 
ml) of ice cold 0.1 M CaCl2. The DNA to be transformed (generally 30 µl of a ligation reaction 
or 1 µl purified plasmid DNA) was added to an aliquot (100 µl) of the CaCl2 suspended 
competent cells, the mixture held on ice for 10-30 minutes, heat shocked at 42 °C for 2 minutes 
then immediately returned to ice for a further 2 minutes. The transformed bacteria were plated 
onto NZCYM agar plates containing an appropriate antibiotic for plasmid selection and left to 
incubate overnight at 37 °C to allow growth of colonies. 
2.7 T. brucei nucleofection 
T. brucei was transformed using the Amaxa® nucleofection system (Lonza) (Burkard, 
Fragoso and Roditi, 2007). Parasites (5 to 7 x107 per transfection) in the exponential phase of 
growth were harvested by centrifugation (1,600 g for 10 minutes at room temperature), residual 
growth medium removed and the pellet resuspended in 100 l Human T-cell Nucleofector® 
solution (Lonza): this solution was made no more than 5 minutes before use by combining 82 
l of reagent A with 18 l reagent B in the Human T-cell Nucleofector® kit. The cell suspension 
was immediately transferred to a nucleofection cuvette containing ~10 g DNA (in 10 l) to 
be transformed and parasite electroporation performed using the Amaxa Nucleofector® device 
set to programme X-001. The cells were transferred into pre-warmed HMI-11 (generally 48 
ml) medium and left at 37 °C. After at least 6 hours, selective antibiotics were added to the 
transformed culture, aliquots (generally 2 ml) transferred into the wells of a 24 well plate and 
the parasites incubated at 37 °C under a 5 % (v/v) CO2 atmosphere. In some cases, a 1:10 
dilution of the transformed culture were set up prior to addition of the selective antibiotics. 
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Gene Nature of integration 5’ fragment region 3’ fragment region Vectors generated 
Tbmre11 gene disruption (34%) 670 bp - 5’ region of Tbmre11 
(Tbmre11-KO1/ Tbmre11-KO2) 






Tbexo1 gene disruption (50%) 600 bp - 5’ region of Tbexo1 
(Tbexo1-KO1/ Tbexo1-KO2) 






Tbcsb  gene deletion (100%) 425 bp - 5’ UTR of Tbcsb 
(Tbcsb-KO1/ Tbcsb-KO2) 




Tbrev2 gene disruption (67%) 806 bp - 5’ region of Tbrev2 
(TbREV2-KO1/ TbREV2-KO2) 




Tbrev3 gene disruption (80%) 344 bp - 5’ region of Tbrev3 
(Tbrev3-KO1/ Tbrev3-KO2) 




Tbhel1 gene disruption (60%) 495 bp - 5’ UTR of Tbhel1 
(Tbhel1-KO1/ Tbhel1-KO2) 






Tbchl1 gene disruption (65%) 557 bp - 5’ region of Tbchl1 
(Tbchl1-KO1/ Tbchl1-KO2) 




Tbfan1 gene disruption (72%) 415 bp - 5’ region of Tbfan1 
(Tbfan1-KO1/ Tbfan1-KO2) 




Table 2.4: Schematic for interruption/deletion of all genes analysed in this study.  
The above table lays out percentage disruption/deletion of every gene studied in this report, with percentage deletion/disruption of said gene 
calculated according to percentage of gene removed using this technique. Also shown are the primers (sequences can be found in Appendix 1b) 
used to amplify 5’ and 3’ UTRs/GOIs with resulting band sizes for each amplification reaction. This enabled the creation of a ll vectors listed in 
the last column.  
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Drug-resistant T. brucei were apparent 5-7 days post-transfection. 
 
Using the above approach, a series of genetically engineered T. brucei lines were generated.  
The lines created were divided into those that were: 
1. null for a single DNA repair enzyme (Table 2.5) 
2. null for two DNA repair enzymes (Table 2.6) 
3. expressing mutated version of Tbsnm1 in a Tbsnm1-deficient background (Table 2.7) 
4. expressing Tbntr in a Tbmre11- or Tbexo1-deficient background (Table 2.8) 
 
T. brucei line Selectable markers 
221 Tbmre11Δ Hygromycin, G418 
221 TbcsbΔ Hygromycin, G418 
221 Tbexo1Δ Hygromycin, G418 
221 Tbrev2Δ Hygromycin, G418 
221 Tbrev3Δ Hygromycin, G418 
221 Tbhel1Δ Hygromycin, G418 
221 Tbchl1Δ Hygromycin, puromycin 
221 Tbfan1Δ Hygromycin, G418 
Table 2.5:  Parasite lines lacking one DNA repair enzyme.  
Each single null parasite line generated in this study with corresponding selectable markers 
used to maintain the engineered line.    
 
 
T. brucei line Selectable markers 
221 Tbsnm1Δ Tbmre11Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ TbcsbΔ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbexo1Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbrev2Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbrev3Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbhel1Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbchl1Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbsnm1Δ Tbfan1Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbmre11Δ TbcsbΔ Blasticidin, puromycin, hygromycin, G418 
221 Tbmre11Δ Tbfan1Δ Blasticidin, puromycin, hygromycin, G418 
221 Tbmre11Δ Tbexo1Δ Blasticidin, puromycin, hygromycin, G418 
221 TbcsbΔ Tbexo1Δ Blasticidin, puromycin, hygromycin, G418 
Table 2.6:  Parasites lacking two DNA repair enzymes.  
Shown in this table are all double null lines generated for this report, including each selectable 







T. brucei line Selectable markers 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-D40A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H78A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H80A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-D82A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H83A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H159A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H178A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-D221A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-R428A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-R429A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-R430A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-R431A Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-V518A  Blasticidin, puromycin, hygromycin 
2TAG1 Tbsnm1Δ gfp-Tbsnm1-H496A  Blasticidin, puromycin, hygromycin 
Table 2.7:  Parasite lines expressing mutated version of Tbsnm1 in a Tbsnm1-deficient 
background.  
Conditional cell lines generated for TbSNM1 structure and function assays in this study with 
lines null for Tbsnm1 and expressing a mutated GFP-tagged TbSNM1. Also shown are the 
selectable markers used to maintain all cell lines detailed. The parental 2TAG1 (2T1) is 
phleomycin resistant. 
 
T. brucei line Selectable markers 
2TAG1 Tbmre11Δ Tbntr++ Blasticidin, puromycin, hygromycin 
2TAG1 Tbexo1Δ Tbntr++ Blasticidin, puromycin, hygromycin 
Table 2.8: Tbntr expressing lines generated in this study.  
Tbexo1 and Tbmre11 were both deleted in a background overexpressing TbNTR with all 
selectable markers used to maintain said lines shown above. The parental 2TAG1 (2T1) is 
phleomycin resistant. 
 
2.8 Analysis of recombinant parasites 
2.8.1 Cumulative growth assays 
T. brucei BSF parasites in the logarithmic phase of growth were seeded at 1 × 104 parasites 
ml-1 in 5 ml HMI-11 medium in a well of a 6-well plate and then incubated at 37 oC in a 5 % 
(v/v) CO2 atmosphere. Each day, the cell density of each culture was measured using a 
Neubauer haemocytometer. When the number of parasites reached ~1 to x 106 ml-1, a new 
culture seeded at 1 × 104 parasites ml-1 was set up.  This analysis was carried out over a 8 to 14 
day period. Growth curves were generated using GraphPad Prism (GraphPad Software Inc.). 
All growth assays were performed in triplicate and each count at each time point expressed as 





2.8.2 Anti-proliferation assays 
All growth inhibition assays were carried out in 96-well plates. T. brucei BSF parasites in 
the logarithmic phase of growth were seeded at 1 x 104 cells ml-1 in 200 µl HMI-11 medium 
containing various concentrations of the compound under study. Control assays performed in 
parallel included culturing cells grown in the absence of drug (100 % growth) and a medium 
background control. After incubation at 37 °C for 3 days, resazurin (Sigma Aldrich) was added 
to each well at a final concentration of 12.5 mg l-1 (or 2.5 g resazurin per well). The plates 
were further incubated for 6-8 hours at 37 °C before measuring the fluorescence of each culture 
using a Gemini Fluorescent Plate reader (Molecular Devices) at λEX =530 nM and λEM =585 
nM with a filter cut off at 550 nM. The colour change (and subsequent fluorescence) of 
resazurin (blue) to resorufin (reddish pink) stems from the reduction of the input dye by viable 
cells with the change in fluorescence being proportional to the amount of cells present. 
Therefore, the highest fluorescence values were observed in untreated cultures, whereas the 
lowest was observed in the absence of cells (e.g. background control).  
 
To calculate the fluorescence value at each compound concentration (flv), the following 
calculation was used: 
    flv = flraw - flbackground                                  equation 1 
 
where flraw  is the raw fluorescence value at a given compound concentration and flbackground is 
the average background fluorescence value of the medium control. 
The fluorescence value at a given compound concentration (flv) was then expressed as a % 
growth relative to the average fluorescence value for untreated cultures (fldrug=0): 
  % growth at given [compound] = flv/fldrug=0 x 100                  equation 2 
 
Data expressed as % growth was used to construct dose response curves from which the 
compound concentration that inhibits cell growth by 50 % (EC50) was extrapolated using the 
non-linear regression tool on GraphPad Prism (GraphPad Software Inc.). The statistical 
significance of any differences in parasite susceptibilities was assessed using the Student's t 
test calculator (GraphPad Software Inc.). 
 
2.8.3 Cell imaging  
T. brucei BSF parasites in the logarithmic phase of growth and cultured with (or without) 1 μg 
ml-1 tetracycline for 36 hours were pelleted (800 g for 10 minutes), washed twice in PBS before 
being suspended in 2% (w/v) paraformaldehyde in PBS at a density of ~1 x 107 cells ml-1. 
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Following incubation at room temperature for 20 minutes, an aliquot (20 μl) of the parasite 
suspension (~1 x 105 cells) was air dried onto a single well of a 10-well printed microscope 
slide (Hendley-Essex). The slides were then incubated in 100 % (v/v) methanol at -20 °C for 
30 minutes, washed once in PBS before being allowed to dry. Vectashield Mounting Medium 
containing 4′,6-diamidino-2-phenylindole (DAPI) (Vectorshield Laboratories) was dispensed 
across the surface of the slide, a cover slip placed over the wells of that slide and a seal (clear 
nail varnish) applied around the edge of the coverslip. The seal was allowed to harden overnight 
at room temperature in the dark and the slides stored at 4 °C until use. Florescence, DAPI and 
phase images were captured using a Leica DMRA2 upright epi-fluorescent microscope fitted 
with a digital camera (Hamamatsu Photonics). 
 
For cell cycle arrest assays, T. brucei were treated as described above except that the parasites 
were incubated for varying time periods in different concentrations of mechlorethamine prior 
to fixation, their immobilization onto a slide and the DAPI/phase images captured. The DAPI 
and phase images were then merged using ImageJ. To determine whether mechlorethamine 
treatment affected the trypanosome, parasites at various stages in cell cycle were identified in 
asynchronous cultures by staining their nuclear (N) and mitochondrial (known as the 
kinetoplast (K)) genomes with DAPI. The ratio of these two DNA-containing structures within 
a single cell represents an excellent marker for the trypanosomal cell cycle, with T. brucei in 
the G1/S phase having a 1N1K arrangement, those in G2/M phase possessing a 1N2K ratio 
while cells displaying a 2N2K profile are in the post-M stage (Woodward and Gull, 1990; T.N. 
Siegel, D.R. Hekstra, 2008; Glover and Horn, 2012). For each cell line at each 
mechlorethamine treatment, the DNA staining pattern observed for a minimum of 600 cells 
was analysed and the number of cells at each cell cycle stage expressed as a % relative to the 
total parasite count.  
 
2.8.4 Immuno-fluorescence assay 
T. brucei BSF parasites in the logarithmic phase of growth and cultured in the presence of 
30µm mechlorethamine for varying time periods, were pelleted (800 g for 10 minutes), washed 
twice in PBS before being suspended in 2% (w/v) paraformaldehyde in PBS at a density of ~1 
x 107 cells ml-1. Following incubation at room temperature for 20 minutes, an aliquot (20 μl) 
of the parasite suspension (~1 x 105 cells) was air dried onto a single well of a 10-well printed 
microscope slide (Hendley-Essex). The slides were then washed in PBS for 5 minutes, treated 
with 0.5 % Triton-X (Sigma) in PBS for 15 minutes followed by an additional wash of the slide 
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in PBS (5 minutes). Slides were then incubated in blocking solution (50 % [v/v] Fetal Bovine 
Serum (FBS) in PBS) for 45 minutes followed by incubation in blocking solution (3 % (v/v) 
FBS in PBS) containing primary antibody (rabbit anti-γH2AX (supplied by Dr R. McCulloch, 
University of Glasgow (Glover and Horn, 2012) at a 1:250 dilution) for 45 minutes. Slides 
were then washed twice in PBS for 5 minutes with subsequent incubation of slides in blocking 
solution (3 % (v/v) FBS in PBS) containing secondary antibody (Goat anti-Mouse IgG (H+L) 
Alexa Fluor 488 at a dilution of 1:1000) for 45 minutes. Slides were finally washed three times 
in PBS, 5 minutes per wash. Vectashield Mounting Medium containing 4 ′,6-diamidino-2-
phenylindole (DAPI) (Vectorshield Laboratories) was dispensed across the surface of the slide, 
a cover slip placed over the wells of that slide and a seal (clear nail varnish) applied around the 
edge of the coverslip. The seal was allowed to harden overnight at room temperature in the 
dark and the slides stored at 4 °C until use. Florescence, DAPI and phase images were captured 
using a Leica SP5 confocal microscope (Leica Microsystems (UK) Ltd. Images were 
subsequently measured for intensity levels using Fiji (https://fiji.sc/) with additional collation 
of images on Microsoft Powerpoint.  
 
2.8.5 Parasite extracts 
Parasites (5 to 8 x 107) in the logarithmic phase of growth were pelleted by centrifugation 
(1,640 g for 10 minutes), suspended in sterile PBS (1 ml) and transferred to a 1.5 ml 
microcentrifuge tube. The cells were harvested (16,000 g for 1 minute), the supernatant 
removed and the parasites lysed in Laemmli buffer (10 % (v/v) glycerol, 2.3 % (w/v) SDS, 5 
% (v/v) β-mercaptoethanol, 62 mM Tris.Cl pH 6.8, 0.002 % (w/v) bromophenol blue) at a 
density of 1 x 106 cells μl-1. Aliquots were denatured (96ºC for 5 minutes) prior to separation 
alongside a PageRuler prestained Protein Ladder (ThermoFischer Scientific) on a 12 % SDS-
PAGE in a  1x SDS-PAGE running buffer (25 mM Tris-HCl, 200 mM glycine, 0.1% (w/v) 
SDS) using a Mini-PROTEAN® II cell system (Bio-Rad) set at a constant voltage 120 V for 
90-120 minutes at 4 °C. Gels were either stained for 1 hour in Coomassie Blue solution (0.05 
% (w/v) Coomassie brilliant blue, 10 % (v/v) acetic acid, 50 % (v/v) methanol) followed by 
destaining in boiling distilled water (gels scanned using a Xerox Flatbed Scanner), or 




2.8.6 Protein blotting and immunodetection 
Protein blotting was carried out using a Trans-Blot Semi-Dry Transfer Cell (Bio-Rad), in 
accordance with the manufacturer’s instructions. A piece of 0.45 µm Protan nitrocellulose 
membrane (GE Healthcare) and 8 pieces of standard thickness blotting paper (Whatman), all 
cut to the size of the SDS-PAGE gel, and the SDS-PAGE gel itself were soaked in transfer 
buffer (25 mM Tris, 192 mM glycine, 0.5 % (w/v) SDS, 20 % (v/v) methanol) for 15 minutes. 
Four piece of wetted blotting paper were laid on the anode of the transfer cell on to which was 
placed the nitrocellulose membrane. The SDS-PAGE gel was then sandwiched between the 
membrane and four additional pieces of wetted filter paper, with the cathode plate placed on 
top of the wetted filter paper, completing the transfer cell. A constant voltage of 15 volts for 1 
hour was then applied to the apparatus and protein transfer confirmed by observing the 
presence of prestained markers on the membrane. 
 
A near infrared fluorescence system was used for protein detection. Protein containing 
membranes were washed in blocking solution (5 % (w/v) marvel powdered milk, PBS, 0.1% 
(v/v) Tween 20) for one hour at room temperature. The membrane was transferred to a 50 ml 
centrifuge tube and challenged with primary antibody diluted in blocking buffer (20 ml) for 1 
hour at room temperature with gentle rotation. Following copious washes (4 x 5 minutes 
washed) in PBS containing 0.1% (v/v) Tween 20 the membrane was then challenged with the 
secondary antibody, diluted in blocking buffer, for 1 hour at room temperature with gentle 
rotation. After four washes in PBS containing 0.1% (v/v) Tween 20 and two in PBS alone, 
detection of the near infrared fluorescence signal was monitored using an Odyssey® CLx 
infrared imaging system (LI-COR). Band signal intensity measurements were carried out using 
the Analysis Tool in Image Studio™ Lite (Li-COR Biosciences).  
 
The primary antibodies used during this project were a rabbit anti-γH2AX (supplied by Dr 
R. McCulloch, University of Glasgow) at a 1:1,000 dilution and a rabbit anti-enolase (Prof J. 
Lukes, University of South Bohemia) at a 1:150,000 dilution. The secondary antibodies used 
were a goat anti-rabbit IRDye™ 800CW antibody (LI-COR) and an goat anti-mouse IRDye™ 






3. Evaluating the extent of the T. brucei ICL REPAIRtoire 
3.1 Identifying trypanosomal ICL repair proteins  
In many model organisms, ICL repair is a complex process. It involves the concerted action 
of factors from various DNA repair pathways (e.g. HR, NER, and FA etc.) that function to 
resolve this lesion in a cell cycle dependent manner. Work from the McHugh, Moses, 
Hashimoto, and Symington laboratories (K F Grossmann et al., 2001; Lam, Krogh and 
Symington, 2008; Iyama et al., 2015; Hashimoto, Anai and Hanada, 2016) has shown that 
enzymes such as SNM1, MRE11, CSB, EXO1, REV2 and REV3 all play a role in repairing 
ICLs. This chapter will involve the construction and characterisation of T. brucei null mutant 
lines lacking TbMRE11, TbCSB, TbEXO1, TbREV2 and TbREV3 with the goal of identifying 
which of these constitute components of the parasites ICL REPAIRtoire.  
 
3.2 Creation and validation of single null lines 
3.2.1 Generation of gene disruption vectors  
To assess whether a T. brucei DNA repair enzyme plays a role in the repair of ICLs, a 
classical genetic-based approach was taken. This involved the construction of parasite lines 
that lack a specific activity by deleting or interrupting the encoding gene from the trypanosome 
genome. This can then be followed up using phenotypic screens to characterise such 
recombinant cells. To initiate this, a series of DNA constructs were designed to facilitate 
replacement (for Tbcsb (Tb927.7.4080)) or disruption (for Tbmre11 (Tb927.2.4390), Tbexo1 
(Tb927.8.3220), Tbrev2 (Tb927.7.1090), Tbrev3 (Tb927.8.3290)) of each allelic copy of the 
gene target with an appropriate drug resistance marker. A schematic diagram outlining how 
such plasmids were made is shown in Figure 2.2. Briefly, DNA fragments containing the 5’ or 
3’ flanking or coding sequences from the gene of interest were amplified from wild type T. 
brucei genomic DNA. These were then digested with restriction enzymes (5’ sequences were 
processed with SacI (or SacII, where appropriate) and XbaI while 3’ sequences were treated 
with ApaI and KpnI) and cloned either side of a DNA cassette containing a gene that encodes 
for the hygromycin B phosphotransferase (hyg), neomycin phosphotransferase (neo), 
blasticidin-S deaminase (bla) or puromycin N-acetyltransferase (pac) and supplementary 
sequences (T. brucei βα tubulin and αβ tubulin intergenic regions) needed for the correct 
processing of the transcript. The cloned fragments in the resultant gene interruption plasmids 




3.2.2 Development of null mutant lines  
To generate parasite null mutant lines, the gene deletion/disruption plasmids (see Table 2.4) 
were digested to completion with SacI/KpnI, for vectors containing the neo, hyg, or pac 
resistance cassettes, or SacII/KpnI, for vectors containing the bla resistance cassette. The 
resultant fragments were purified, heat-treated at 70°C for 30 minutes to minimise 
contamination and then introduced into wild type T. brucei by nucleofection. To remove both 
allelic copies of the target gene, two rounds of nucleofection were performed to firstly create 
heterozygous and then null mutant lines. The latter cells were subsequently validated by DNA 
amplification approaches using genomic DNA or cDNA as template. Below, an example of the 
above strategy is given detailing how trypanosomes lacking Tbcsb were made. 
 
The plasmids pKO-Tbcsb-neo and pKO-Tbcsb-hyg, which facilitate deletion of Tbcsb and 
are based around the neo and hyg resistance cassettes, were digested with SacI/KpnI and the 
resultant DNA fragments purified. The SacI/KpnI-treated pKO-Tbcsb-hyg DNAs were 
introduced into wild type T. brucei with hygromycin resistant putative Tbcsb heterozygote 
parasite clones obtained 5 to 7 days post-transformation. These cells were then transformed 
with SacI/KpnI-treated pKO-Tbcsb-neo DNAs with hygromycin and G418 resistant putative 
TbcsbΔ null mutant trypanosomes selected 5 to 7 days post transformation. 
 
To confirm that integration of the introduced DNA fragment had occurred at the correct 
genetic loci, DNA amplifcation reactions using gDNA extracted from T. brucei wild type and 
putative TbcsbΔ as template were performed. Such PCRs used primer combinations that 
generate biomarker fragments specific for the intact Tbcsb gene or the hyg and neo disrupted 
alleles (Tbcsb –hyg and Tbcsb –neo, respectively). When using a primer combination designed 
to detect intact Tbcsb (Tbcsb-KO1/Tbcsb-q2), DNA amplification generated a band of the 
expected size (~1.4 kb) from gDNA extracted from wild type parasites with no band(s) 
observed in DNA isolated from T. brucei TbcsbΔ cells (Figure 3.1b). In contrast, primer 
combinations that detect the Tbcsb-hyg (Tbcsb-KO1/hyg-2) or Tbcsb-neo (Tbcsb-KO1/neo-1) 
alleles generated amplicons of the predicted size (~1.7 and ~1.5 kb, respectively) but only from 
the gDNA purified from T. brucei TbcsbΔ null mutant line: No band(s) was observed when 





Figure 3.1: Generation of T. brucei line lacking TbCSB.  
A. Schematic representation of the Tbcsb allele and the effects of gene disruption using genes 
encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbcsb-KO1), P2 (Tbcsb-
q2), P3 (neo-2) and P4 (hyg-2) correspond to the regions where the primers anneal to in the 
appropriate allele.  
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1) and T. brucei TbcsbΔ (lane 2) using primer combinations that specifically amplify 
biomarkers corresponding to the Tbcsb (Tbcsb-KO1/Tbcsb-q2), Tbcsb-hyg (Tbcsb-KO1/hyg-
2) or Tbcsb-neo (Tbcsb-KO1/neo-2) alleles.  
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1) or T. brucei TbcsbΔ (lane 2) using primer combinations that 
specifically amplify intact Tbcsb (Tbcsb-q1/Tbcsb-q2). In both cases, the integrity of the 
cDNA (and hence RNA) was evaluated by amplification of a control fragment, Tbtert.  
 
 
To show that the T. brucei TbcsbΔ null mutant line was not expressing the interrupted gene, 
PCRs were performed using a primer combination (Tbcsb-q1/Tbcsb-q2) designed to generate 
a Tbcsb specific amplicon against cDNA generated from total RNA (Figure 3.1c). When using 
wild type cDNA as template, a single band of the expected size (~140 bp) was observed with 
no band(s) detected in material derived from T. brucei TbcsbΔ. To confirm that RNA had been 
extracted from both cell lines and that cDNA had indeed been made, control reactions 
amplifying Tbtert were conducted in parallel. For all tested samples a band of the expected size 




Parasites lines null for other T. brucei genes (Tbmre11, Tbexo1, Tbrev2 or Tbrev3) were 
generated as described above. Validation of the resultant recombinant trypanosomes was 
performed using similar PCR strategies with this showing that integration of the input DNA 
fragments had successfully occurred into the appropriate loci in the parasite’s genome and 
confirmed that the Tbmre11, Tbexo1, Tbrev2 or Tbrev3 transcripts were not expressed by the 
corresponding null mutant. All the confirmatory data relating to the validation of T. brucei 
Tbmre11Δ, Tbexo1Δ, Tbrev2Δ and Tbrev3Δ is presented in Appendices 2a-2d.  
 
3.3 Phenotypic analysis of null lines 
3.3.1 Growth analysis 
To assess whether lack of a given DNA repair activity affected parasite growth, the growth 
properties of the null mutants generated in Section 3.2 (TbcsbΔ Tbmre11Δ, Tbexo1Δ, Tbrev2Δ 
and Tbrev3Δ) was determined and compared against wild type T. brucei grown in parallel 
(Figure 3.2). For all lines tested, three independent cultures containing 1 x 104 parasites ml-1 
were established. Every day over a period of 8 days, the number of cells in each culture was 
determined using a haemocytometer with the cells in these cultures maintained in the 
exponential phase of growth:  Cultures with a density approaching ~1x106 cells ml-1 were used 
to establish a new culture containing 1x104 cells ml-1. From the resultant cumulative cell 
density curves, the Tbexo1Δ, TbcsbΔ, Tbrev2Δ and Tbrev3Δ lines all exhibited a profile 
equivalent to wild type. From this data the growth rate, expressed as the mean generation or 
doubling time, of wild type cells was calculated to be 6.2 hours as compared to 6.5, 6.4, 6.1 
and 6.3 hours displayed by the Tbexo1Δ, TbcsbΔ, Tbrev2Δ, and Tbrev3Δ lines, respectively. 
In contrast, cells lacking TbMRE11 exhibited a slightly longer mean generation time relative 
to wild type: Tbmre11Δ and wild type parasites had a mean generation time of 7.5 and 6.2 
hours, respectively. This is in keeping with previous findings from the McCulloch and Cross 
Laboratories (Robinson, McCulloch, Conway, Browitt and David Barry, 2002; Tan, Leal and 








Figure 3.2: Cumulative growth of T. brucei null mutants.  
The cumulative cell density of T. brucei Tbexo1Δ, Tbmre11Δ, TbcsbΔ, Tbrev2Δ and Tbrev3Δ (dashed line) cultures was followed for 8 days and 
compared against wild type T. brucei (solid line) cultures grown in parallel. Each data point represents the mean cell density ± standard deviation 
from three independent cultures.   
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3.3.2 Cell cycle analysis  
To further evaluate the above growth characteristics, the cell cycle progression of Tbmre11Δ 
and TbcsbΔ was evaluated relative to wild type and Tbsnm1Δ lines. Asynchronous cultures of 
bloodstream form parasites in the exponential phase of growth (cultures contained ~5 to 10 x 
105 trypanosomes ml-1) were fixed, permeabilised and their nuclear (N) and mitochondrial 
(known as the kinetoplast (K)) genomes stained with DAPI. By determining the ratio of these 
two DNA-containing structures in a single trypanosome, the stage that each parasite is in within 
the cell cycle can be determined. T. brucei in the G1/S phase of the cell cycle have a 1K1N 
arrangement, those that possess a 2K1N ratio are said to be in the G2/M phase while 
trypanosomes displaying a 2K2N profile are in the post M phase (Figure 3.3a) (Woodward and 
Gull, 1990; T.N. Siegel, D.R. Hekstra, 2008; Glover and Horn, 2012). For wild type T. brucei, 
Tbsnm1Δ and TbcsbΔ, most cells (~75%) in the asynchronous population were in G1/S phase, 
with ~20% in the G2/M phase and ~5% in the post M phase of the cell cycle (Figure 3.3b). In 
contrast, fewer Tbmre11Δ cells (~55%) were in the G1/S phase, with a concomitant increase 
(~40%) of cells in the G2/M phase and 5% in the post M phase of the cell cycle. This indicates 
that the increased mean generation time exhibited by Tbmre11Δ cells may be due the stalling 
of the replication forks. This causes a delay at this point in the cell cycle, an event probably 
driven by a reduced ability of this null mutant line to repair DNA damage via HR pathways 
(Grossmann, Ward and Moses, 2000; Robinson, McCulloch, Conway, Browitt and Barry, 
2002; Tan, Leal and Cross, 2002). This cell cycle checkpoint checks the integrity of DNA 
before the final commitment of cell division, therefore, preventing cells containing damaged 
DNA progressing into mitosis. In contrast to our data, other researchers have not observed the 
above trait in relation to TbMRE11-deficient cells (Robinson, McCulloch, Conway, Browitt 









Figure 3.3: Cell cycle analysis of T. brucei null mutants.  
A. The ratio of DAPI-stain kinetoplast (K) and one nuclear (N) genomes in one trypanosomes 
represents a frequently used marker for the T. brucei cell cycle. Images show cells with a 1K1N, 
2K1N and 2K2N arrangement which is indicative of the G1/S, G2/M and post M stages, 
respectively.  
B. The relative number of nuclear and mitochondrial genomes structures from asynchronous 
cultures of wild type, Tbmre11Δ Tbsnm1Δ and TbcsbΔ parasites was evaluated. The number 
of cells analysed per cell line is given above each bar.  
 
 
3.3.3 Susceptibility of T. brucei null mutants towards DNA damaging agents 
To evaluate whether lack of a given DNA repair activity affects parasite susceptibility to 
various types of DNA damaging agent, a series of growth inhibition assays were performed. 
The treatments used were hydroxyurea (which promotes base oxidation), phleomycin (causes 
DNA DSBs), methyl methanesulfonate (MMS; alkylation leading to DNA DSBs) and 
ultraviolet radiation (UV; pyrimidine dimer formation). In many organisms, specific pathways 
operate to repair the type of DNA damage these treatments induce e.g. the NER pathway 
functions in the repair of UV induced lesions while HR plays a central role in resolving DNA 
DSBs. In these inhibition assays, parasites (T. brucei wild type, Tbmre11Δ, TbcsbΔ, Tbexo1Δ, 
Tbrev2Δ and Tbrev3Δ; Tbsnm1Δ as analysed in parallel) were grown for 3 days in the presence 
70 
 
of different concentrations of compound (hydroxyurea, phleomycin, MMS) or exposed to a 
single bolus prior to culturing for 3 days (UV) with the number of cells in each sample then 
determined using the vital dye resazurin. The resultant data was then plotted to generate dose 
response curves from which the treatment EC50 value was calculated (see Materials and 
Methods). Figure 3.4 illustrates the type of dose response curves generated using T. brucei wild 
type and Tbmre11Δ against the four previously noted treatments with all the calculated EC50 
values shown in Table 3.1. A bar chart emphasising the fold differences displayed by each 
treatment against each cell lines is also shown (Figure 3.5). 
 
 
Figure 3.4: Susceptibility of T. brucei Tbmre11 null mutant towards various DNA 
damaging treatments.  
Dose response curves of T. brucei wild type (solid line) and Tbmre11Δ (dotted line) to 
hydroxyurea, UV, phleomycin and MMS. All data points are mean values ± standard deviations 

























Table 3.1:  Susceptibility of T. brucei null lines to DNA damaging treatments.  
Data represents EC50 values of T. brucei wild type, Tbsnm1Δ, Tbexo1Δ, Tbmre11Δ, TbcsbΔ, Tbrev2Δ and Tbrev3Δ against hydroxyurea, 
phleomycin, MMS and UV. All values are means ± standard deviations from experiments performed in quadruplicate. The ratio of EC50 values 
between wild type and null mutant lines is given as fold difference. *Indicates significant differences in susceptibility (P < 0.0001 between wild 
type and null lines, as assessed by Student’s t test (GraphPad Software). 
 
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbsnm1Δ     wild type Tbexo1Δ   
Hydroxyurea (µM) 47.56 ± 1.90 38.62 ± 2.71 1.3  Hydroxyurea (µM) 47.56 ± 1.90 52.59 ± 1.54 0.9 
Phleomycin (µM) 0.12 ± 0.00 0.12 ± 0.00 1.0  Phleomycin (µM) 0.12 ± 0.00 0.06 ± 0.00* 2.0 
MMS (µM) 33.02 ± 0.28 35.82 ± 0.29 0.9  MMS (µM) 27.89 ± 0.63 32.46 ± 0.71 0.9 




        
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbmre11Δ     wild type TbcsbΔ   
Hydroxyurea (µM) 53.37 ± 3.68 43.10 ± 0.84 1.3  Hydroxyurea (µM) 71.88 ± 0.89 69.00 ± 2.67 1.0 
Phleomycin (µM) 0.12 ± 0.01 0.01 ± 0.00* 12.0  Phleomycin (µM) 0.04 ± 0.00 0.04 ± 0.00 1.0 
MMS (µM) 33.02 ± 0.28 12.63 ± 0.47* 2.5  MMS (µM) 27.78 ± 5.17 26.73 ± 8.54 1.0 




        
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbrev2Δ     wild type Tbrev3Δ   
Hydroxyurea (µM) 67.39 ± 0.65 58.18 ± 0.39 1.2  Hydroxyurea (µM) 67.39 ± 0.65 50.68 ± 0.83 1.3 
Phleomycin (µM) 0.06 ± 0.00 0.04 ± 0.00 1.5  Phleomycin (µM) 0.06 ± 0.00 0.05 ± 0.00 1.2 
MMS (µM) 41.41 ± 3.56 37.82 ± 1.16 1.1  MMS (µM) 41.41 ± 3.56 38.65 ± 1.49 1.1 
UV (kJ/cm) 3.61 ± 0.29 3.74 ± 0.35 1.0  UV (kJ/cm) 3.46 ± 0.45 5.52 ± 1.08 0.6 
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Figure 3.5: Comparison of T. brucei null mutant EC50 values.  
The susceptibility of T. brucei wild type and the various null mutant lines against hydroxyurea 
(HU), phleomycin (Phleo), methyl methanesulfonate (MMS) and ultraviolet radiation (UV), as 
judged by their EC50 values, was compared and expressed as a fold difference.  
 
Based on dose response curves and extrapolated EC50 values, trypanosomes lacking 
TbSNM1, TbREV2 and TbREV3 are as equally sensitive to the tested DNA damaging 
treatments as wild type indicating that they do not play a front line role in resolving the resultant 
lesions. For TbSNM1, this confirms previously published data (Sullivan et al., 2015) while the 
TbREV2 and TbREV3 data indicates that the different DNA polymerases involved in TLS may 
be able complement for each other: T. brucei expresses at least 5 such enzymes (Zurita-Leal, 
2016).  
 
In the case of the TbcsbΔ line, a wild type response was noted towards hydroxyurea, 
phleomycin and methyl methanesulfonate. In contrast, cells lacking this helicase were 5-fold 
more sensitive to UV relative to controls. This data confirmed previous findings that TbCSB 
is only involved in the parasites NER pathway (Machado et al., 2014). 
 
Interestingly, TbEXO1-deficient cells are only slightly more susceptible (2-fold) to 
phleomycin than wild type while exhibiting wild type sensitivities towards the other 3 
treatments. It had initially been envisaged that this particular mutant should also be more 
sensitive to other dsDNA generating agents such as MMS but our observations contradict our 
initial hypothesis. This may be due to how the dsDNA break arises, for example due to base 
alkylation (MMS) or DNA intercalation (phleomycin), or which trypanosomal repair pathway 
predominants to fix such lesions. The data presented here indicates that the initial repair of 
phleomycin induced DNA damage results in base mismatches that are subsequently resolved 
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using the MMR pathway, of which TbEXO1 is part. This indicates that MMS does not cause 
such secondary alterations. 
 
For the final null line, Tbmre11Δ cells displayed increased sensitivity to 3 out of the 4 
treatments relative to wild type. As expected and in keeping with the published literature, 
TbMRE11 deficient cells were more susceptible to agents that promote dsDNA breaks 
(phleomycin and MMS) with the HR pathway well known to play a role in repairing this type 
of damage (Robinson, McCulloch, Conway, Browitt and David Barry, 2002; Tan, Leal and 
Cross, 2002). Intriguingly, these mutants were also 5-fold more sensitive to UV, not previously 
documented in relation to trypanosomes. One reason to account for this latter observation may 
stem from the formation of double-strand DNA breaks caused by the arrest of replication forks 
at UV-induced damaged sites (Limoli et al., 2002). 
 
3.3.4 Susceptibility of T. brucei null mutants towards mechlorethamine 
The above growth inhibition assays were extended to investigate the phenotype displayed by 
T. brucei null mutants towards mechlorethamine, an archetypal ICL inducing agent. As noted 
previously, the resultant cell number data was plotted as dose response curves from which EC50 
values were extrapolated (Figure 3.6: Table 3.2). Again, the fold differences displayed by each 
mutant cell line against the ICL inducing compound is emphasised in Figure 3.7.   
 
Previous work has shown that TbSNM1 plays an important role in resolving the damage caused 
by mechlorethamine with our data confirming this earlier finding (Sullivan et al., 2015): Cells 
lacking TbSNM1 are >8-fold more susceptible to this compound as compared to controls. A 
similar alteration in sensitivity was also observed in cells deficient in TbMRE11, TbCSB or 
TbEXO1. Intriguingly, the difference in EC50 values displayed by these 3 mutants relative to 
wild type was not as great as that noted for Tbsnm1Δ cells; Tbmre11Δ, TbcsbΔ and Tbexo1Δ 
cells were 3-, 4- and 2-fold more susceptible to mechlorethamine than wild type. This could 
suggest the relative importance of each enzyme in the so-called T. brucei ICL REPAIRtoire. 
In contrast, cells lacking TbREV2 or TbREV3 displayed wild type sensitivities towards the 




Figure 3.6: Susceptibility of T. brucei null mutants towards mechlorethamine and DFMO.  
Dose response curves of T. brucei wild type (solid line) and the various null mutants (dotted line) towards mechlorethamine and DFMO. All data 
points are mean values ± standard deviations from experiments performed in quadruplicate. 
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Table 3.2: Null mutants towards mechlorethamine and DFMO.   
EC50 values of T. brucei wild type, Tbsnm1Δ, Tbexo1Δ, Tbmre11Δ, TbcsbΔ, Tbrev2Δ and Tbrev3Δ against mechlorethamine and DFMO. All 
values are means ± standard deviations from experiments performed in quadruplicate. The ratio of EC50 values between wild type and null mutant 
lines is given as fold difference. *Indicates significant differences in susceptibility (P < 0.0001) between wild type and null lines, as assessed by 
Student’s t test (GraphPad Software).
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbsnm1Δ     wild type Tbexo1Δ   
mechlorethamine 50.47 ± 4.39 6.43 ± 0.49* 8.3  mechlorethamine 50.47 ± 4.39 24.94 ± 2.87* 2.0 







       
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbmre11Δ     wild type TbcsbΔ   
mechlorethamine 51.82 ± 0.32 18.76 ± 1.43* 2.7  mechlorethamine 70.08 ± 2.55 18.68 ± 1.64* 4.2 




        
Treatment T. brucei EC50 Fold 
difference 
 Treatment T. brucei EC50 Fold 
difference wild type Tbrev2Δ     wild type Tbrev3Δ   
mechlorethamine 70.94 ± 1.25 60.17 ± 0.90 1.2  mechlorethamine 61.94 ± 1.90 75.20 ± 2.22 0.8 




Figure 3.7: Comparison of T. brucei null mutant EC50 values.  
The susceptibility of T. brucei wild type and the various null mutant lines against 
mechlorethamine and DFMO, as judged by their EC50 values, was compared and expressed as 
a fold difference.  
 
To confirm that the above phenotyping was due to the engineered gene deletion/disruption 
events and not due to off target effects, the susceptibility of all mutants towards the non-DNA 
damaging trypanocidal agent DFMO was analysed. In all cases the null lines were as equally 
sensitive to this compound as each other and the wild type, providing evidence that the above 
susceptibility profiles are specific for each DNA damaging treatment. The above data 
implicates TbSNM1, TbCSB, TbMRE11 and TbEXO1 in the bloodstream form T. brucei ICL 
repair system and thus constituting a part of this parasites ICL REPAIRtoire. 
 
3.3.5 Production of DNA double strand breaks by mechlorethamine  
Previous work on the formation of ICLs has shown that crosslinked DNA can be further 
processed to form double strand breaks (Li and Moses, 2003). In many cases, nuclear damage 
(some of which may include DSBs), results in the phosphorylation of histone H2A to form 
γH2A, with this post-translational modification representing a useful biomarker for detecting 
DNA damage (Fernandez-Capetillo, Allis and Nussenzweig, 2004). This response is well 
conserved in eukaryotes and has been shown to take place in T. brucei (Glover and Horn, 2012). 
 
To demonstrate whether mechlorethamine promotes nuclear damage which is associated 
with this phosphorylation event, wild type parasites were treated with mechlorethamine (30, 
10 and 3 µM) with samples taken from these cultures at various time points over an 8-hour 
period. Protein extracts from these cells were generated and probed for γH2A formation by 
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western blot analysis using antiserum against this modified histone and enolase as a loading 
control (Figure 3.8). The band intensities of γH2A and enolase for each treatment on each cell 
line were determined using Image Studio™ Lite (Li-COR Biosciences) with the signals 
normalised against untreated controls (Figure 3.9).  
 
For all mechlorethamine concentrations tested, a gradual increase in the γH2A signal is 
observed peaking around 4 hours after initiating treatment. The marker then began to decline 
over the next 4 hours indicating resolution of the DNA damage. When these studies were 
extended to the null lines, various outcomes were observed. TbSNM1- and TbEXO1-deficient 
cells behaved in a similar way to wild type cells. It is tempting to speculate that this nuclear 
damage is due to ICL-induced DSBs and that these enzymes play no role in processing the such 
lesions. In TbcsbΔ cells, the formation of γH2A was delayed, peaking around 6 hours after 
initiating treatment and staying at the elevated level for the remainder of the experiment. This 
indicates that these null cells are unable to effectively recognise and resolve the ICL-induced 
DSBs: In other organisms, stalling of the transcriptional machinery at such sites leads to post-
translational modification of the RNA polymerase which then acts to recruit CSB to the DSB 
(Batenburg et al., 2015). Intriguingly, when following γH2A in cells lacking TbMRE11, no 
alteration in signal intensity was observed suggesting this enzyme plays an important role in 
detecting nuclear damage, which leads to phosphorylation of histone H2A (Lavin, 2008; Zha, 
Boboila and Alt, 2009; Panier and Durocher, 2013). 
 
To further evaluate mechlorethamine and DSB formation in mutant lines, cells treated for 8 
hours in the presence of the ICL inducing agent (30 µM) were analysed using 
immunofluorescence microscopy to detect γH2A (Figure 3.10). For wild type, Tbsnm1Δ, 
TbcsbΔ and Tbexo1Δ, a signal throughout the whole nucleus was observed showing that 
nuclear damage formation occurs throughout the whole genome; no discrete foci were 
observed, even when analysing earlier time points (data not shown). In contrast, and confirming 






Figure 3.8: γH2A formation in mechlorethamine treated wild type and null lines.  
T. brucei wild type, Tbsnm1Δ, Tbmre11Δ, TbcsbΔ and Tbexo1Δ were treated with 30, 10 or 3µM concentrations of mechlorethamine. Cell lysates 
were generated at time intervals (0, 1, 2, 4, 6, and 8 hours) and analysed by western blot using anti-T. brucei enolase (loading control) and anti-T. 




Figure 3.9: Comparison of γH2A signals in mechlorethamine treated T. brucei null mutants.  
The γH2A and enolase signal intensities obtained from western blot analysis were determined using Image Studio™ Lite (Li-COR Biosciences) 





Figure 3.10: Comparison of γH2A formation in mechlorethamine treated T. brucei null mutants.  
T. brucei wild type, Tbsnm1Δ, Tbmre11Δ, TbcsbΔ and Tbexo1Δ were treated with 30µM of mechlorethamine for 8 hours and analysed by 
immunofluorescence assay using anti-T. brucei γH2A antisera. Florescence, DAPI and phase images were captured using a Leica SP5 confocal 




3.4 Chapter Summary  
In this chapter we have: 
1. Successfully deleted Tbcsb and disrupted Tbexo1, Tbmre11, Tbrev2 and Tbrev3 from 
the T. brucei genome to create null mutant lines 
2. Demonstrated that, in agreement with the published literature, cells lacking TbMRE11 
display a growth defect due to a delay in the progression through the G2/M phase of 
the cell cycle 
3. Shown that cells lacking TbMRE11 are more susceptible to chemical (in agreement 
with the published literature) and UV-induced dsDNA breaks relative to controls 
4. Confirmed that TbCSB deficient cells are more susceptible to UV DNA damage 
5. Established that TbMRE11, TbCSB and TbEXO1 represent key components of the T. 
brucei ICL REPAIRtoire  
6. Shown that TbREV2 and TbREV3 do not function in ICL repair in the parasite 
7. Revealed that mechlorethamine induced ICLs in trypanosomes promote nuclear 
damage, most likely in the form of dsDNA breaks  








4. Studying the interplay of ICL repair proteins 
The interplay between components of the S. cerevisiae / human ICL repair system has been 
evaluated with studies showing these organisms express multiple, complementary and 
overlapping mechanisms to mediate repair of this type of DNA damage (Hashimoto, Anai and 
Hanada, 2016). However, the precise molecular basis of these pathways in a given organism 
remains unclear. Broadly, these ICL repair mechanisms operate in a cell cycle dependent 
manner with HR based pathways predominating during the S-phase, while through the 
remainder of the cell cycle factors from NER, TLS, and MMR prevail (Zhang and Walter, 
2014). In yeast, the assignment of a DNA repair activity to a given system was established 
using a genetics-based approach through the generation of fungal lines lacking two or more 
activities. The susceptibility of such cells to ICL inducing agents was determined to reveal 
whether the components under investigation function in an epistatic or non-epistatic manner. 
Here, we have extended this approach to evaluate the interplay of the trypanosomal ICL repair 
factors identified previously (TbSNM1;(Sullivan et al., 2015)) and in the earlier chapter 
(TbMRE11, TbCSB and TbEXO1). 
 
4.1 Evaluating the central role of TbSNM1 in ICL repair 
4.1.1 Creation and validation of T. brucei null mutant lines 
As an initial step to analysing the relationship between components of the trypanosomal ICL 
repair system, the genes encoding for TbEXO1, TbMRE11 or TbCSB were deleted or disrupted 
in a Tbsnm1-deficient T. brucei line, thereby creating a series of double null mutant lines (Table 
2.6). Although not primarily involved in resolving ICLs, TbREV2 and TbREV3 were also 
taken forward in this analysis to determine whether their activities in ICL repair become 
apparent in the absence of TbSNM1: Some yeast ICL factors are only apparent when the 
activity of another DNA repair protein is missing (Ward et al., 2012). The hyg- and neo-based 
gene integration vectors used in the previous chapter were digested to completion with 
SacI/KpnI, the fragments purified and then heat-treated (70°C for 30 minutes) to minimise 
contamination. The digested DNAs were sequentially introduced into T. brucei Tbsnm1Δ cells 
by nucleofection (in this mutant line, Tbsnm1 has been disrupted using gene integration vectors 
based around pac and bla; (Sullivan et al., 2015)) to generate heterozygous and subsequent  
null mutant lines. The recombinant cell lines were then validated by DNA amplification-based 
approaches using gDNA or cDNA templates. Below, an example of the above strategy is given 
detailing how Tbsnm1-deficient trypanosomes also lacking Tbcsb were made. 
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Purified SacI/KpnI-digested pKO-Tbcsb-hyg DNA fragments were introduced into T. 
brucei Tbsnm1Δ cells with hygromycin/blasticidin/puromycin resistant parasite clones 
(putatively designated as Tbsnm1Δ Tbcsb+/-) obtained 5 to 7 days post-transformation. These 
cells were subsequently transformed with purified SacI/KpnI-digested pKO-Tbcsb-neo DNA 
fragments with selection carried out using blasticidin/puromycin/hygromycin/G418. Clones 
resistant to the four selective agents (putatively designated as Tbsnm1Δ TbcsbΔ null mutant 
trypanosomes) were obtained 5 to 7 days post-transformation.  
 
Confirmation that the input DNA fragments had integrated at the correct genetic loci in the 
trypanosome genome was carried out by PCR (Figure 4.1). Here, gDNA extracted from four 
T. brucei lines (wild type, Tbsnm1Δ, TbcsbΔ and Tbsnm1Δ TbcsbΔ) was probed for the 
presence or absence of intact Tbsnm1 and Tbcsb, and their disrupted alleles (Tbsnm1–bla; 
Tbsnm1–pac; Tbcsb-hyg; Tbcsb-neo). When using a primer combination to detect intact 
Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), an amplicon of ~1.3 kb was detected only in gDNA 
extracted from T. brucei wild type and TbcsbΔ (no bands observed using Tbsnm1Δ and 
Tbsnm1Δ TbcsbΔ gDNA) (Figure 4.1c). In contrast, when probing for the Tbsnm1-bla 
(Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1) alleles, DNA fragments of the 
predicted size (~1.1 and ~1.7 kb, respectively) were generated only by gDNA purified from T. 
brucei Tbsnm1Δ and Tbsnm1Δ TbcsbΔ lines. Analysis of the Tbcsb loci using primers to detect 
intact Tbcsb (Tbcsb-KO1/Tbcsb-q2) amplified a band of the expected size (~1.4 kb) only from 
gDNA extracted from T. brucei wild type and Tbsnm1Δ (no band noted when using gDNA 
derived from TbcsbΔ and Tbsnm1Δ TbcsbΔ cells). When probed with Tbcsb-KO1/hyg-2 or 
Tbcsb-KO1/neo-2, primer combinations used to detect for the Tbcsb-hyg and Tbcsb-neo alleles 
respectively, bands of the expected size (~1.7 and ~1.5 kb) were detected only in gDNA derived 
from TbcsbΔ and Tbsnm1Δ TbcsbΔ. 
 
Additional validation of the double null mutant line was performed aimed at assessing 
whether Tbsnm1 and Tbcsb were expressed by T. brucei Tbsnm1Δ TbcsbΔ cells. DNA 
amplification reactions were performed on cDNA templates generated from total RNA using 
primer combinations that detect Tbsnm1 (Tbsnm1-q1/Tbsnm1-q2) or Tbcsb (Tbcsb-q1/Tbcsb-
q2). For RNA extracted from T. brucei wild type and TbcsbΔ a single, correctly sized (~110 
bp) amplicon corresponding to Tbsnm1 was observed with no band(s) detected in material 
derived from Tbsnm1Δ and Tbsnm1Δ TbcsbΔ cells (Figure 4.1d). Similarly, a single, correctly 
sized (~140 bp) amplicon corresponding to Tbcsb was only observed in reactions using cDNA 
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derived from T. brucei wild type and Tbsnm1Δ cDNA (and hence RNA) integrity used in these 
reactions was evaluated by probing the template for Tbtert (Tbtert-F/Tbtert-R). In all cases, an 
amplicon of ~100 bp was noted showing that the template nucleic acid was appropriate for 
these studies. 
 
Together, the above DNA amplification reactions validate the T. brucei Tbsnm1Δ TbcsbΔ 
double null mutant line, confirming that Tbcsb had indeed been successfully disrupted in 
Tbsnm1Δ parasites leading to the associated loss in gene expression. 
 
 
Figure 4.1: Validating the T. brucei Tbsnm1Δ TbcsbΔ null mutant line. 
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this locus 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele. 
B. Schematic representation of the Tbcsb allele and effects of disrupting this allele with genes 
encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbcsb-KO1), P2 (Tbcsb-
q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at the specific 
allele. 
C. Amplicons corresponding to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), Tbsnm1-bla 
(Tbsnm1-KO1/bla-1), Tbsnm1-pac (Tbsnm1-KO1/pac-1), Tbcsb (Tbcsb-KO1/Tbcsb-q2), 
Tbcsb-hyg (Tbcsb-KO1/hyg-2) or Tbcsb-neo (Tbcsb-KO1/neo-2) were generated from 
template gDNA extracted from T. brucei wild type (lane 1), T. brucei Tbsnm1Δ (lane 2), T. 
brucei TbcsbΔ (lane 3) and T. brucei Tbsnm1Δ TbcsbΔ (lane 4). 
D. DNA fragments amplified from cDNA derived from RNA extracted from T. brucei wild 
type (lane 1), Tbsnm1Δ (lane 2),  TbcsbΔ (lane 3) and Tbsnm1Δ TbcsbΔ (lane 4) using primer 
combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-seq1), Tbcsb 




Double null mutant parasites lines (Tbsnm1Δ Tbmre11Δ, Tbsnm1Δ TbcsbΔ, Tbsnm1Δ 
Tbrev2Δ and Tbsnm1Δ Tbrev3Δ) were generated and validated as described above. All the 
confirmatory data relating to validation is shown in Appendix 3a-3d.  
 
4.1.2 Phenotypic analysis of T. brucei double null lines 
4.1.2.1 Growth analysis of T. brucei double null lines 
To evaluate whether lack of TbSNM1 and TbCSB, TbMRE11, TbEXO1, TbREV2 or 
TbREV3 affects parasite growth, the growth properties of the double null mutants was 
determined and compared against wild type T. brucei (Figure 4.2). From the resulting 
cumulative cell density curves, Tbsnm1Δ Tbexo1Δ, Tbsnm1Δ TbcsbΔ, Tbsnm1Δ Tbrev2Δ and 
Tbsnm1Δ Tbrev3Δ all grew at roughly the same rate as wild type, with mean generation times 
of 7.0, 6.7, 7.0 and 6.6 hours respectively, in comparison to 6.6 hours for wild type cells. In 
contrast, Tbsnm1Δ Tbmre11Δ cells exhibited a slightly longer mean generation time relative 
to wild type (7.8 hours vs 6.6 hours) which is comparable to the growth properties previously 
noted for Tbmre11Δ cells (See Chapter 3; Robinson et al., 2002; Tan, Leal and Cross, 2002). 
 
4.1.2.2 Susceptibility of T. brucei double null lines towards DNA damaging agents   
Growth inhibition assays were carried out on the double null mutant lines to determine 
whether these cells exhibit altered susceptibility to different DNA damaging agents relative to 
wild type and single null mutant controls. Assays were performed as described previously (see 
Materials and Methods and Chapter 3) with the data used to create dose response curves from 
which EC50 values were derived. Figure 4.3 illustrates dose response curves generated from T. 
brucei wild type, Tbsnm1Δ, Tbmre11Δ, and Tbsnm1Δ Tbmre11Δ cells against the treatments 
used with concomitant EC50 values given in Table 4.1. A bar chart emphasising the fold 





Figure 4.2: Cumulative growth of T. brucei double mutant lines. 
The cumulative cell density of T. brucei Tbsnm1Δ Tbexo1Δ, Tbsnm1Δ Tbmre11Δ, Tbsnm1Δ TbcsbΔ, Tbsnm1Δ Tbrev2Δ, and Tbsnm1Δ Tbrev3Δ 
(▲) cultures was followed for 8 days and compared against T. brucei wild type (●) cells, grown in parallel. Each data point represents the mean 
cell density ± standard deviation from three independent cultures. 
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Figure 4.3: Susceptibility of T. brucei Tbsnm1Δ Tbmre11Δ null line towards various DNA 
damaging treatments. 
Dose response curves of T. brucei wild type (●), Tbsnm1Δ (■), Tbmre11Δ (♦), and Tbsnm1Δ 
Tbmre11Δ (ο) cell lines to hydroxyurea, UV, phleomycin and MMS. All data points are mean 
values ± standard deviations from experiments performed in quadruplicate. 
 
 
For most of the DNA damaging treatments tested, the susceptibility displayed by the double 
null mutant lines was equivalent to the more sensitive phenotype shown by the single null for 
each gene pairing. For example, all Tbcsb-deficient cell types are approximately 5-fold more 
susceptible to UV than wild type or Tbsnm1Δ lines such that the Tbsnm1Δ TbcsbΔ line have 
an EC50 similar to TbcsbΔ parasites. As such, lack of TbSNM1 and TbCSB activities in the 
same cell does not lead to an increase in susceptibility to UV. The only situation where a 
combinatorial effect on susceptibility was observed in cells lacking TbSNM1 and TbMRE11. 
Intriguingly, such double null mutant parasites were more than 20-fold more sensitive to UV-
induced lesions relative to T. brucei wild type and Tbsnm1Δ and 4-fold more sensitive relative 
to Tbmre11Δ. This difference may be an experimental artefact possibly due to how the UV 
dosage was applied or could reflect that TbSNM1 does plays a secondary role in resolving UV-




Table 4.1: Susceptibility of T. brucei double 
null lines to DNA damaging treatments. 
Data represents EC50 values of various T. 
brucei lines against hydroxyurea, phleomycin, 
MMS and UV. All values are means ± 
standard deviations from experiments 
performed in quadruplicate. The ratio of EC50 
values between wild type and single/double 
null mutant lines is shown as fold difference, 
in parentheses. *Indicates significant 
differences in susceptibility (P < 0.0001 
between wild type and null lines, as assessed 
by Student’s t test (GraphPad Software). 
 
Treatment T. brucei EC50 
Wild type Tbsnm1Δ Tbmre11Δ Tbsnm1ΔTbmre11Δ 
Hydroxyurea (μM) 53.37 ± 3.68 40.62 ± 2.26 (1.3) 43.10 ± 0.84 (1.2) 33.77 ± 0.38 (1.6) 
Phleomycin (μM) 0.12 ± 0.01 0.12 ± 0.00 (1.0) 0.01 ± 0.00 (12.0)* 0.01 ± 0.00 (12.0)* 
MMS (μM) 33.02 ± 0.28 35.82 ± 0.29 (0.9) 12.63 ± 0.47 (2.5)* 15.32 ± 1.32 (2.2)* 
UV (kJ/cm) 2.58 ± 0.39 2.66 ± 0.18 (1.0) 0.53 ± 0.11 (4.9)* 0.11 ± 0.09 (23.3)* 
     
Treatment T. brucei EC50 
Wild type Tbsnm1Δ Tbexo1Δ Tbsnm1Δ Tbexo1Δ 
Hydroxyurea (μM) 47.56 ± 1.90 38.62 ± 2.71 (1.2) 52.59 ± 1.54 (0.9) 43.59 ± 1.84 (1.1) 
Phleomycin (μM) 0.12 ± 0.00 0.12 ± 0.00 (1.0) 0.063 ± 0.00 (1.9)* 0.05 ± 0.00 (2.2)* 
MMS (μM) 27.89 ± 0.63 42.28 ± 2.89 (0.7) 32.46 ± 0.71 (0.9) 40.44 ± 1.32 (0.7) 
UV (kJ/cm) 3.54 ± 0.20 3.90 ± 0.32 (0.9) 2.07 ± 0.14 (1.7) 3.15 ± 0.98 (1.1) 
     
Treatment T. brucei EC50 
Wild type Tbsnm1Δ TbcsbΔ Tbsnm1Δ TbcsbΔ 
Hydroxyurea (μM) 71.88 ± 0.89 67.91 ± 1.80 (1.1) 69.00 ± 2.67 (1.0) 69.77 ± 2.38 (1.0) 
Phleomycin (μM) 0.04 ± 0.00 0.03 ± 0.00 (1.3) 0.04 ± 0.00 (1.1) 0.04 ± 0.00 (1.1) 
MMS (μM) 27.78 ± 5.17 30.94 ± 13.45 (0.9) 26.73 ± 8.54 (1.0) 31.22 ± 10.4 (0.9) 
UV (kJ/cm) 2.12 ± 0.18 2.47 ± 1.49 (0.9) 0.42 ± 0.14 (5.1)* 0.47 ± 0.05 (4.5)* 
     
Treatment 
  
T. brucei EC50 
Wild type Tbsnm1Δ Tbrev2Δ Tbsnm1Δ Tbrev2Δ 
Hydroxyurea (μM) 67.39 ± 0.65 50.21 ± 1.72 (1.3) 58.18 ± 0.39 (1.2) 52.20 ± 1.94 (1.3) 
Phleomycin (μM) 0.062 ± 0.00 0.046 ± 0.00 (1.4) 0.042 ± 0.00 (1.5) 0.046 ± 0.00 (1.4) 
MMS (μM) 41.41 ± 3.56 45.76 ± 0.65 (0.9) 37.82 ± 1.16 (1.1) 45.97 ± 0.38 (0.9) 
UV (kJ/cm) 3.61 ± 0.29 3.17 ± 0.34 (1.1) 3.74 ± 0.94 (1.0) 3.87 ± 0.35 (0.9) 
     
Treatment T. brucei EC50 
 Wild type Tbsnm1Δ Tbrev3Δ Tbsnm1Δ Tbrev3Δ 
Hydroxyurea (μM) 67.39 ± 0.65 50.21 ± 1.72 (1.3) 50.68 ± 0.83 (1.3) 52.20 ± 1.76 (1.3) 
Phleomycin (μM) 0.062 ± 0.00 0.046 ± 0.00 (1.4) 0.046 ± 0.00 (1.4) 0.038 ± 0.00 (1.6) 
MMS (μM) 41.41 ± 3.56 45.76 ± 0.65 (0.9) 38.65 ± 1.49 (1.0) 33.88 ± 0.70 (1.2) 
UV (kJ/cm) 3.46 ± 0.45 3.92 ± 1.56 (0.9) 5.51 ± 1.08 (0.6) 5.55 ± 0.73 (0.6) 
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Figure 4.4: Comparison of T. brucei null mutant EC50 values. 
The susceptibility of T. brucei various single and double null mutant lines against hydroxyurea 
(HU), phleomycin (Phleo), methyl methanesulfonate (MMS) and ultraviolet radiation (UV), as 
judged by their EC50 values, was compared and expressed as a fold difference relative to wild 
type. 
 
4.1.2.3 Susceptibility of T. brucei double null lines towards mechlorethamine 
As with the single null mutant lines, a series of phenotypic screens were performed using 
mechlorethamine as the selective agent. The resultant cell density data was analysed, plotted 
as dose response curves from which EC50 values was determined (Figure 4.5; Table 4.2). 
Again, the fold differences for each single and double null mutant line against the ICL inducing 
agent was displayed as a bar chart (Figure 4.6).   
 
The growth profiles and EC50 values show a number of interesting features relating to how 
components of the T. brucei ICL repair interact. Firstly, cells lacking TbSNM1 and TbMRE11 
display a hypersensitivity phenotype towards mechlorethamine as compared to wild type cells 
and Tbsnm1 or Tbmre11 single null mutant lines: Tbsnm1Δ Tbmre11Δ parasites are 
approximately 40-, 6- and 15-fold more susceptible to this agent relative to T. brucei wild type, 
Tbsnm1Δ and Tbmre11Δ, respectively. This increase in sensitivity shown by the double null 
trypanosomes is indicative that the DNA repair enzymes TbSNM1 and TbMRE11 function in 
a non-epistatic fashion and do not operate in the same ICL repair system. Secondly, cells 
lacking TbSNM1 and TbCSB exhibit a mechlorethamine sensitivity similar to Tbsnm1Δ 
parasites with both lines being more susceptible to this compound than wild type and TbcsbΔ 
cells. As the double null cells do not show an additional increase in sensitivity to the ICL-
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inducing agent, it is plausible that TbSNM1 and TbCSB are epistatic and as such do operate in 
the same ICL repair system. This epistatic interaction appears to extend across to TbEXO1 
with the Tbsnm1Δ Tbexo1Δ double null cells showing a similar trait as the Tbsnm1Δ TbcsbΔ 
line. Finally, TbREV2 and TbREV3 do not play a discernible role in trypanosomal ICL repair, 
even in the absence of TbSNM1, confirming the observations reported in Chapter 3.  
 
Control growth inhibition assays using DFMO revealed that the above susceptibility profiles 
displayed by each double mutant line were not due to off target effects as all lines showed 





Figure 4.5: Susceptibility of T. brucei null mutants towards mechlorethamine and DFMO. 
Dose response curves of T. brucei wild type (●), Tbsnm1Δ (■), single null mutant (♦) and double null mutant line (ο) towards mechlorethamine 





Table 4.2: Susceptibility of double null 
mutants towards mechlorethamine and 
DFMO.  
EC50 values of T. brucei wild type and null 
lines against mechlorethamine and DFMO (in 
µM). All values are means ± standard 
deviations from experiments performed in 
quadruplicate. The ratio of EC50 values 
between wild type and null mutant lines is 
given as fold difference in parentheses. 
*Indicates significant differences in 
susceptibility (P < 0.0001) between wild type 
and null lines, as assessed by Student’s t test 
(GraphPad Software).
Treatment T. brucei EC50 
Wild type Tbsnm1Δ Tbmre11Δ Tbsnm1ΔTbmre11Δ 
mechlorethamine 51.82 ± 0.32 7.09 ± 0.28 (7.3)* 18.76 ± 1.43 (2.8)* 1.26 ± 0.44 (41.1)* 
DFMO 34.57 ± 0.87 34.14 ± 0.37 (1.0) 42.95 ± 1.50 (0.8) 37.18 ± 3.38 (0.9) 
 
 
    
Treatment T. brucei EC50 
Wild type Tbsnm1Δ TbcsbΔ Tbsnm1Δ TbcsbΔ 
mechlorethamine 37.10 ± 8.58 1.43 ± 0.25 (26.5)* 3.10 ± 0.33 (12.0)* 1.61 ± 0.06 (23.1)* 
DFMO 57.14 ± 0.48 42.65 ± 2.72 (1.3) 57.40 ± 5.44 (1.0) 40.60 ± 1.96 (1.4) 
 
 
    
Treatment T. brucei EC50 
Wild type Tbsnm1Δ Tbexo1Δ Tbsnm1Δ Tbexo1Δ 
mechlorethamine 50.47 ± 4.39 6.43 ± 0.49 (7.5)* 24.94 ± 2.87 (2.0)* 5.68 ± 0.56 (8.9)* 
DFMO 48.77 ± 2.19 38.61 ± 2.18 (1.3) 46.41 ± 0.32 (1.1) 44.30 ± 2.04 (1.1) 
 
 
    
Treatment 
  
T. brucei EC50 
Wild type Tbsnm1Δ Tbrev2Δ Tbsnm1Δ Tbrev2Δ 
mechlorethamine 70.94 ± 1.25 5.76 ± 0.41 (12.3)* 60.17 ± 0.90 (1.2) 7.45 ± 0.21 (9.5)* 
DFMO 36.75 ± 0.57 34.09 ± 2.60 (1.1) 31.40 ± 0.54 (1.2) 36.46 ± 0.59 (1.0) 
 
 
    
Treatment T. brucei EC50 
 Wild type Tbsnm1Δ Tbrev3Δ Tbsnm1Δ Tbrev3Δ 
mechlorethamine 61.94 ± 1.90 7.87 ± 0.39 (7.9)* 75.20 ± 2.22 (0.8) 6.99 ± 0.70 (8.9)* 




Figure 4.6: Comparison of T. brucei double null mutant EC50 values. 
The susceptibility of T. brucei various single and double null mutant lines against 
mechlorethamine, as judged by their EC50 values, was compared and expressed as a fold 
difference relative to wild type. 
  
4.2 Confirming the interplay of HR, NER, and MMR pathways in ICL repair 
Based on our initial findings, we hypothesised that T. brucei expresses two distinct ICL 
repair systems, one involving the activities of TbSNM1/TbCSB/TbEXO1 with the other 
centred on TbMRE11. To explore this further a series of additional double null lines were 
generated to investigate the interplay between TbMRE11, TbCSB and TbEXO1. 
  
Using the previously described gene interruption plasmids in conjunction with 
nucleofection, T. brucei lines lacking TbCSB and TbMRE11 (TbcsbΔ Tbmre11Δ), TbEXO1 
and TbMRE11 (Tbexo1Δ Tbmre11Δ) or TbCSB and TbEXO1 (TbcsbΔ Tbexo1Δ) activities 
were made and subsequently validated (see Appendices 3e-3g). The susceptibility of these lines 
to mechlorethamine was then tested with dose response curves drawn and EC50 values 
determined and compared (Figure 4.7 & Table 4.3). Fold differences are shown in bar chart 




Figure 4.7: Susceptibility of T. brucei double null mutants towards mechlorethamine and 
DFMO.  
A. Dose response curves of T. brucei wild type (●), TbcsbΔ (■), Tbexo1Δ (■) and TbcsbΔ 
Tbexo1Δ (○) towards mechlorethamine (A) and DFMO. 
B. Dose response curves of T. brucei wild type (●), TbcsbΔ (■), Tbmre11Δ (▲) and TbcsbΔ 
Tbmre11Δ (○) towards mechlorethamine (A) and DFMO. 
C. Dose response curves of T. brucei wild type (●), Tbexo1Δ (■), Tbmre11Δ (○) and Tbexo1Δ 
Tbmre11Δ (□) towards mechlorethamine (A) and DFMO. 







T. brucei EC50  (μM) 
Wild type TbcsbΔ Tbexo1Δ TbcsbΔ Tbexo1Δ 
mechlorethamine 204.25 ± 38.44 62.19 ± 3.30 
(3.3)* 
159.35 ± 3.81 (1.6)* 44.48 ± 5.86 (4.5)* 
DFMO 41.85 ± 0.68 48.14 ± 1.00 (1.1) 46.41 ± 0.32 (1.1) 45.70 ± 4.12 (1.1) 
 Wild type TbcsbΔ Tbmre11Δ TbcsbΔ Tbmre11Δ 
mechlorethamine 140.05 ± 5.10 37.08 ± 3.03 
(3.8)* 
41.40 ± 3.62 (3.4)* 10.30 ± 1.90 (13.6)* 
DFMO 41.85 ± 0.68 48.14 ± 1.00 (1.1) 42.95 ± 1.50 (1.0) 45.88 ± 2.16 (1.1) 
 Wild type Tbexo1Δ Tbmre11Δ Tbexo1ΔTbmre11Δ 
mechlorethamine 223.43 ± 2.83 81.27 ± 1.83 
(2.8)* 
60.57 ± 3.60  (3.7)* 50.31 ± 5.91 (4.4)* 
DFMO 48.77 ± 2.16 46.41 ± 0.32 (0.9) 40.31 ± 1.74 (0.8) 34.92 ± 1.90 (0.7) 
Table 4.3: Susceptibility of null mutants towards mechlorethamine and DFMO.   
EC50 values of T. brucei wild type and null lines against mechlorethamine and DFMO. All 
values are means ± standard deviations from experiments performed in quadruplicate. The ratio 
of EC50 values between wild type and null mutant lines is given as fold difference in 
parentheses. *Indicates significant differences in susceptibility (P < 0.0001) between wild type 
and null lines, as assessed by Student’s t test (GraphPad Software).   
 
 
Figure 4.8: Comparison of T. brucei double null mutant EC50 values. 
The susceptibility of T. brucei various single and double null mutant lines against 
mechlorethamine, as judged by their EC50 values, was compared and expressed as a fold 
difference relative to wild type. 
 
As before, observations relating to the mechlorethamine growth inhibition data confirms 
our initial hypothesis. Cells lacking TbCSB and TbEXO1 reveal that these two DNA repair 
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enzymes, one involved in TC-NER and the other in MMR, function epistatically in ICL repair: 
The TbcsbΔ Tbexo1Δ parasites exhibit a mechlorethamine sensitivity similar to TbcsbΔ 
trypanosomes with both the single and double mutants being more susceptible to the ICL 
inducing compound than wild type. In contrast and analogous to observations made using the 
Tbsnm1Δ Tbmre11Δ line, T. brucei TbcsbΔ Tbmre11Δ exhibit hypersensitivity towards 
mechlorethamine relative to wild type cells and either of the single null mutant lines. This 
increase in sensitivity is indicative that TbCSB and TbMRE11 function in a non-epistatic 
fashion and do not operate in the same ICL repair system. Finally, cells lacking TbEXO1 and 
TbMRE11 exhibit an epistatic relationship with the fold difference in mechlorethamine 
susceptibility between the Tbexo1Δ Tbmre11Δ and Tbmre11Δ lines being approximately the 
same (4-fold). This indicates that TbEXO1 can also operate in the MRE11-dependent pathway. 
 
All of the double null mutant data involving TbSNM1, TbCSB, TbEXO1 and TbMRE11 
clearly shows that T. brucei expresses at least two distinct ICL repair systems with one 
involving the concerted action of TbSNM1, TbCSB and TbEXO1 with the other using 
TbMRE11 and TbEXO1. It is tempting to speculate that given TbCSB plays a role in TC-NER, 
that the former SNM1-dependent pathway functions to resolve ICLs encountered during DNA 






4.3 Chapter Summary  
This chapter has focused on understanding the relationship between various DNA repair 
proteins that function in different DNA repair pathways to help resolve ICLs. Here, we have 
shown that: 
 
1. T. brucei possesses at least two distinct ICL repair systems 
a. An SNM1-dependent ICL repair system where TbSNM1 co-operates with TC-
NER (TbCSB) and MMR (TbEXO1) enzymes to repair the encountered 
damaged, possibly triggered as a result of RNA polymerase stalling 
b. An SNM1-independent ICL repair systems which utilises components the HR 
(TbMRE11) and MMR (TbEXO1) pathways to repair the encountered 
damaged, possibly triggered as a result of DNA polymerase stalling 






5. The trypanosomal Fanconi Anaemia System 
The Fanconi Anaemia (FA) repair pathway is the major ICL repair system in mammalian 
cells. This mechanism, first discovered through genetic profiling of patients with the disorder 
Fanconi Anaemia, involves at least 30 proteins which can be divided into four groupings 
comprising of 1. The FA core complex, 2. Recruitment factors, 3. Effector proteins and 4. FA-
associated proteins (Figure 5.1). It is now recognised that other eukaryotes including fish, 
plants, insects and fungi all have their own version of the FA pathway, with such organisms 
often expressing a subset of homologues related to the human FA proteins (Moldovan and 
D’Andrea, 2009; Jones and Huang, 2012; McHugh, Ward and Chovanec, 2012; Zhang and 
Walter, 2014).  
 
This chapter focuses on the identification of FA factors present in T. brucei and further 
unravelling of their function in relation to ICL repair. To determine whether the parasite 
possesses components of this system, human, zebrafish (D. rerio), fruit fly (D. melanogaster), 
plant (A thaliana) and yeast (S. cerevisiae) FA protein sequences (complete or a specific 
domain) were used to search for trypanosome homologues held on the TriTryp and NCBI 
databases using a reciprocal Blast analysis. This revealed that T. brucei has the potential to 
express a minimal FA repair pathway, analogous to the situation noted for yeast (Ward et al., 
2012). Out of the 31 sequences examined, T. brucei has discernible homologues for 9 activities 
(Figure 5.1). Most of these are direct homologues of FA effector proteins that play or are 
postulated to function in the parasite’s HR pathway (FANCD1 (known as BRCA2; (Hartley 
and McCulloch, 2008)), FANCJ (referred to as CHL1), FANCO (or RAD51C; (Dobson et al., 
2011)), and FANCR (commonly known as RAD51; (Proudfoot and McCulloch, 2005))), NER 
pathway (FANCQ (or XPF; (Machado et al., 2014))) or as an essential spindle 
checkpoint protein (FANCV (known as MAD2)). Of the remaining trypanosomal sequences, 
only one showed homology to a component of the FA core complex (FANCM (also known as 
MPH1)) and two related to FA-associated proteins (FAN1 and USP1). Interestingly, T. brucei 






Figure 5.1: Identification of putative components of the trypanosomal FA pathway.  
Comparison of the FA pathway components expressed by Danio rerio (D. rerio; fish), 
Drosophila melanogaster (Drosophila; insect), Arabidopsis thaliana (A. thaliana; plant), 
Saccharomyces cerevisiae (S. cerevisiae; yeast) and T. brucei in relation to the system 
possessed by humans (H. sapiens). Trypanosomal FA factors were identified using a reciprocal 
Blast analysis against human FA factors. A coloured circle indicates the possibility for the 
presence of a given factor whereas no circle indicates that that component is most probably 
absent. In mammalian cells, the FA ICL repair pathway can be subdivided the FA core complex 
(red), recruitment factors (blue), FA effectors (further split as to whether it involves 
homologous recombination (HR) (purple) or other pathways (green)) and FA-associated 
proteins (orange). Figure layout derived from (Zhang et al., 2009; Dong et al., 2015).  
 
 
5.1 Analysis of the T. brucei FANCM homologue 
Analysis of the T. brucei genome database indicated that this parasite has the potential to 
express only one component of the FA core complex, namely TbFANCM (Tb927.7.2970; 
referred from now on as TbHEL1 due to presence of a helicase domain in the protein sequence). 
The deduced trypanosomal amino acid sequence showed identity to the amino termini of 
human FANCM (23 %) and DICER (21 %) with this homology centring on the DEAD 
(PF00270) and Helicase C (PF00271) domains, regions found in members of the helicase 
superfamily 2 (SF2) RigI group (Figure 5.2). Intriguingly, the equivalent HEL1 sequence was 
found in other Trypanosoma species that are predominantly found in the bloodstream of their 
mammalian host (e.g. T. congolense, T. evansi, T. vivax), some other trypanosomatids (e.g. 
Crithidia fasciculate, Leptomonas pyrrhocoris) but absent from intracellular Trypanosoma and 
Leishmania species (e.g. T. cruzi, L. major, L. donovani). Phylogenetic analysis of the 
trypanosomatid hel1 genes with their plant, fungus and vertebrate fancm counterparts using the 
Phylogeny.fr algorithm revealed that the parasite sequences are evolutionarily distinct from 
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homologues expressed in the other organisms, forming their own distinct clade (Figure 5.3). In 
relation to higher eukaryotic organisms, this difference was unsurprising given that the encoded 
proteins generally possess additional domains in their backbone (Figure 5.2). For the human 
FANCM, these extra regions facilitate 1. binding of the helicase to double stranded DNA via 
a FANCM-MHF (PF16783) domain, 2. function to activate downstream cell cycle kinases via 
a mediator of replication checkpoint 1 (MRC1; PF09444) domain and 3. cleave the target 
substrate through a ERCC4 nuclease (PF02732) domain. Given that equivalent regions are 
apparently absent from TbHEL1 then the trypanosomal enzyme, if it does function as a DNA 
helicase, does so by a mechanism distinct from its mammalian counterpart. The yeast FANCM 
homologue which has been shown to function in ICL repair (Ward et al., 2012) also lacks many 
of these additional domains but in our phylogenetic analysis the fungal sequences tend to be 
more closely rooted to the helicases expressed by vertebrates. 
 
 
Figure 5.2: Domain and sequence analysis of TbHEL1. 
Schematic diagram showing the organization of conserved domains found in H. sapiens 
FANCM (HsFANCM; BC140776), S. cerevisiae MPH1 (ScMPH1; KI893982) and TbHEL1 
(Tb927.7.2970). The regions highlighted include the DEAD (green; PF00270), Helicase C 
(red; PF00271), FANCM-MHF (purple; PF16783), MRC1 (light blue; PF09444) and ERCC4 
(yellow; PF02732) domains. The DEAD (top alignment) and Helicase C (bottom alignment) 
domains of TbHEL1 was compared with the equivalent regions from T. evansi 
(TevSTIB805.7.3080), S. cerevisiae MPH1, Arabidopsis thaliana FANCM (NM_001198212), 
Drosophilia melanogaster FANCM (EF088195), H. sapiens FANCM and Xenopus laevis 
(XM_012969053). Conserved residues (in black or grey) are highlighted with arrows marking 




Figure 5.3: Phylogenetic tree analysis of FANCM sequences. 
Phylogenetic analysis of the trypanosomatid hel1 genes (green) forms a different clade to plant 
(yellow), fungal (pink), and vertebrate genes (purple) homologues. The sequences analysed 
using the Phylogeny.fr tool were T. brucei hel1 (Tbhel1, Tb927.7.2970), T.b.gambiense hel1 
(Tbg972.7.3290), T. congolense hel1 (TcIL3000_0_22580), T. evansi hel1 
(TevSTIB805.7.3080), T. vivax hel1 (TvY486_0702830), T. grayi hel1 (DQ04_01821030), C. 
fasiculata hel1 (CFAC1_240016600), L. pyrrhocoris hel1 (LpyrH10_01_0930), B. saltans hel 
(CYKH01000268), H. sapiens fancm (BC140776), P. troglodytes fancm (XM_003314302), M. 
mulatta fancm (XM_015143628), Drosophilia melanogaster fancm (EF088195), S. cerevisiae 
mph1 (KI893982), Xenopus fancm (XM_012969053), Arabidopsis thaliana fancm 
(NM_001198212), S. pombe fml1 (NM_01018780), A. fumigatus mph1 (XM_744962), B. rape 
mph1 (XM_013864549), N. crassa mph1 (XM_958929), O.s. Japonica fml1 
(XM_015760033), and N. tomentosiformis fancm (XM_018776163). 
 
5.1.1 Construction and validation of null mutant lines 
Using the previously described gene deletion approach from Section 3, DNA constructs 
based around the hygromycin and neomycin resistance cassettes (pKO-Tbhel1-hyg and pKO-
Tbhel1-neo DNA) were generated, the DNAs processed by restriction enzyme digestion and 
fragments purified. These were sequentially transformed into T. brucei wild type and Tbsnm1-
deficient cells, creating the Tbhel1Δ and Tbsnm1Δ Tbhel1Δ lines. The gene interruption events 
and resultant loss of gene expression was validated using PCR-based approaches described 
earlier, with this data presented in Appendix 4a.   
   
5.1.2 Phenotypic analysis of T. brucei lines lacking hel1 
Following confirmation of the T. brucei single and double null Tbhel1 null mutant lines, 
their growth properties were evaluated in comparison to wild type cells. This demonstrates that 
the recombinant cell lines grew at an equivalent rate as the controls (data not shown). The 
susceptibility of Tbhel1-deficient cells to various DNA damaging agents was then tested to 
evaluate whether the encoded enzyme does function in DNA repair. For each treatment, dose 
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response curves were generated (Figure 5.4), EC50 values calculated (Table 5.1) and the fold 
difference of EC50 values between wild type and null lines determined (in parentheses of Table 
5.1).  Together, this data strongly indicates that TbHEL1 has no role in any DNA repair 
pathway tested here, including any mechanism used to resolve ICLs. 
 
 
Figure 5.4: Susceptibility of T. brucei Tbhel1-deficient null lines towards various DNA 
damaging treatments. 
Dose response curves of T. brucei wild type (●), Tbsnm1Δ (■), Tbhel1Δ (♦), and Tbsnm1Δ 
Tbhel1Δ (ο) cell lines to hydroxyurea, UV, phleomycin, MMS, mechlorethamine and DFMO. 






Table 5.1: Susceptibility of T. brucei Tbhel1 null lines to DNA damaging treatments. 
Data represents EC50 values of T. brucei wild type, Tbsnm1Δ, Tbhel1Δ and Tbsnm1Δ Tbhel1Δ 
against hydroxyurea, phleomycin, MMS, UV, mechlorethamine and DFMO. All values are 
means ± standard deviations from experiments performed in quadruplicate. The ratio of EC50 
values between wild type and null mutant lines is given as a fold difference, in parentheses. 
*Indicates significant differences in susceptibility (P < 0.0001 between wild type and null lines, 
as assessed by Student’s t test (GraphPad Software). 
 
 
5.1.3 TbHEL1 and its role in RNA interference 
Given that TbHEL1 appears to play no role in DNA repair and also has significant identity 
to the helicase domain of HsDICER, we next evaluated whether it could function in the 
trypanosomal RNA interference pathway. As with the FANCM alignment, comparison of the 
trypanosomatid HEL1s with DICERs and DRHs (DICER related helicases) from various other 
organisms showed that sequence homology was most pronounced in the DEAD (PF00270) and 
Helicase C (PF00271) domains (Figure 5.5). Again, phylogenetic analysis revealed that the 
protozoan parasites gene sequences were evolutionarily distinct from their counterparts 
possessed by other organisms, reflecting the early branching nature of trypanosomatid on the 
tree of life and potentially indicating that these pathogens have an unconventional DICER 







Treatment T. brucei EC50 (μM) 
Wild type Tbsnm1Δ Tbhel1Δ Tbsnm1ΔTbhel1Δ 
hydroxyurea 57.76 ± 2.20 48.97 ± 2.03 (1.2) 42.46 ± 0.34 (1.4) 41.12 ± 0.98 (1.4) 
phleomycin 0.12 ± 0.00 0.08 ± 0.01 (1.5) 0.10 ± 0.00 (1.2) 0.09 ± 0.01 (1.3) 
MMS 32.70 ± 0.12 36.35 ± 0.62 (0.9) 38.88 ± 0.53 (0.8) 29.90 ± 1.22 (1.1) 
UV (kJ/cm) 0.52 ± 0.15 0.84 ± 0.11 (0.6) 0.76 ± 0.17 (0.7) 0.57 ± 0.03 (0.9) 
mechlorethamine 56.85 ± 2.26 5.55 ± 0.07 (10.2)* 55.37 ± 2.08 (1.0) 3.99 ± 0.15 (14.3)* 




Figure 5.5: Domain and sequence analysis of TbHEL1. 
Comparisons between the domain structure of T. brucei HEL1 (TbHEL1; Tb927.7.2970), T.b.gambiense HEL1 (TbgHEL1; Tbg972.7.3290), C. 
fasiculata HEL1 (CfHEL1; CFAC1_240016600), H. sapiens DICER (HsDICER; NM_0012916281), D. rerio DICER (DrDICER; 
NM_001161453), C. elegans DCR1 (CeDCR1; NM_068617), A. thaliana DICER (AtDICER; JN661702), H. sapiens DDX58 (HsDDX58; 
NM_014314), and C. elegans DRH1 (CeDRH1; NM_068617) with further comparisons made on conserved residues (emphasised using arrows). 
Domains shown include DEAD domain (green; PF00270), Helicase C domain (red; PF00271), RIG-1 domain (light purple; PF11648), Dicer 
dimerization domain (dark green; PF03368), PAZ domain (dark purple; PF02170), ribonuclease domain (blue; PF00636), CARD_2 (grey; 






Figure 5.6: Phylogenetic tree analysis of TbHEL1 and DICER sequences. 
The phylogenetic tree outlines the trypanosomatid HEL genes (green) in a different clade to 
that of the plant (yellow) and vertebrate genes (purple) with plant FANCM genes outlined as 
evolutionarily distinct from that of vertebrate. Gene names and sequence identities are given 
on the end of each clade: Lpyr (L. pyrrhocoris; LpyrH10_01_0930), Cfas (C. fasciculate; 
CFAC1_240016600), Tgra (T. grayi; DQ04_01821030), Tviv (T. vivax; TvY486_0702830), 
Tcong (T. congolense; TcIL3000_0_22580), Tbrucei (T. brucei; Tb927.7.2970), Teva (T. 
evansi; TevSTIB805.7.3080), Tbgam (T. brucei gambiense; Tbg972.7.3290), Bsal (B. saltans; 
CYKH01000268), Cedrh1 (C. elegans drh1; NM_068617), BmalDRH1 (B. malayi DRH1; 
LN855620), BmalDRH3 (B. malayi DRH3; LN856998), DrerDDX58 (D. rerio DDX58; 
NM_001306095), XlaeDDX58 (X. laevis DDX58; XM_018257225), GjaDDX58 (G. 
japonicus DDX58; XM_015414538), Ptro (P. troglodytes DDX58; XM_001156662), 
HsapDDX58 (H. sapiens; NM_014314), Mmul dicer (M. mulatta dicer; NM_001257872), 
Ptrodicer (P. troglodytes dicer; XM_001154369), Hsapdicer (H. sapiens dicer; 
NM_0012916281), CcanDICER (C. canadensis DICER1; GFFV01000155), Pvamdicer (P. 
vampyrus dicer; XM_011379597), Gjapdicer (G. japonicus dicer; XM_015416341), 
XlaeDICER (X. laevis DICER; XM_018230462), Drerdicer (D. rerio dicer; NM_001161453), 
Bmal (B. malayi DCR1; LN857010), Cedcr1 (C. elegans dcr-1; NM_066360), AfumDICER 
(A. fumigatus; XM_748378), CimmCAF (C. immitis CAF; DS017001), Spomdicer (S. pombe 
dicer; NM_001023205),  SjapCAF (S. japonicus CAF; XM_002174789), BnapDICER (B. 
napus DICER; XM_013841052), AthaDicer (A. thaliana Dicer; JN661702), OsjDICER (O.s. 
Japonica DICER; CM000140) and AoffDICER (A. officinalis DICER; XM_020390741).  
 
To see whether Tbhel1 functions in the T. brucei RNAi pathway, gene integration vectors 
based around puromycin and blasticidin resistance cassettes (pKO-Tbhel1-bla and pKO-
Tbhel1-pac) were constructed, processed by restriction enzyme digestion and the resultant 
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fragments purified. These were then sequentially transformed into T. brucei lines that could be 
induced to undergo RNAi against Tbtao or TbsodB. These two lines were used because 1. the 
targeted activities, namely trypanosomal alternative oxidase or superoxide dismutase isoform 
b, respectively, are essential for the growth of bloodstream form trypanosomes (Helfert et al., 
2001; Wilkinson et al., 2006) and 2. the dsRNA that promotes down regulation of the Tbtao or 
TbsodB transcript are formed by a stem loop or linear RNA molecule, respectively. The 
resultant null parasites, designated as RNAi Tbtao Tbhel1Δ and RNAi TbsodB Tbhel1Δ, were 
then subject to PCR validation that confirmed that Tbhel1 had been successfully interrupted in 
both lines with an accompanying loss of Tbhel1 expression (Figure 5.7).  
 
 
Figure 5.7:  Confirming the deletion of Tbhel1. 
A. Schematic for the representation of the Tbhel1 allele and effects of disrupting this allele 
with genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbhel1-KO1), 
P2 (Tbhel1-q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at 
the specific allele. 
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei RNAi-Tbtao (lane 2), T. brucei RNAi-Tbsodb (lane 3), RNAi-Tbtao 
Tbhel1Δ (lane 4), and RNAi-Tbsodb Tbhel1Δ (lane 5). Extractions from all lines were tested 
using primer combinations that specifically amplify biomarkers corresponding to the Tbhel1 
(Tbhel1-KO1/Tbhel1-q2), Tbhel1-pac (Tbhel1-KO1/pac-1) or Tbhel1-bla (Tbhel1-KO1/bla-
1) alleles. 
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbhel1Δ (lane 2), RNAi-Tbtao (lane 3), RNAi-TbsobB (lane 4), 
RNAi Tbtao Tbhel1Δ (lane 5), and RNAi TbsodB Tbhel1Δ (lane 6) using primer combinations 
that specifically amplify intact Tbhel1 (Tbhel1-q1/Tbhel1-q2) and Tbtert (Tbtert-F/Tbtert-R). 
 
Following validation, the growth properties of the various Tbhel1 null mutants that can 
undergo RNAi was determined in the presence/absence of the inducer (tetracycline) which 
promotes down regulation of the targeted transcript. Upon induction of RNAi in RNAi-Tbtao 
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and RNAi-TbsobB cells (i.e. that contain a functional Tbhel1), parasite growth was 
significantly reduced in the former and halted in the latter in agreement with previous reports 
(Helfert et al., 2001; Wilkinson et al., 2006). In contrast, Tbhel1-deficient cells undergoing 
RNAi targeting these two transcripts continued to grow at an equivalent rate to non-induced 
controls (Part A and B of Figure 5.8). This suggests that TbHEL1 plays a crucial role in the T. 
brucei RNAi machinery.  
 
 
Figure 5.8: Analysing the role of TbHEL1 in RNA interference. 
A. Cumulative growth of non-induced RNAi-Tbtao (○), induced RNAi Tbtao (♦), non-induced 
RNAi Tbtao Tbhel1Δ (●) and induced RNAi Tbtao Tbhel1Δ (▲). 
B. Cumulative growth density curves of non-induced RNAi TbsodB (○), induced RNAi 
TbsodB (■), non-induced RNAi TbsodB Tbhel1Δ (●) and induced RNAi TbsodB Tbhel1Δ 
(▲). 
C & D. The mRNA levels of Tbtao (C) or TbsodB (D) in various induced (+tet) and non-
induced parasite lines was evaluated by RT-qPCR and compared against the expression level 
of a standardized control (Tbtert). The average fold difference, as judged by 2–(ΔΔCT) from 
reactions performed in triplicate standard deviation, plotted as a measure of the relative 
expression level. 
 
To confirm that down-regulation had been blocked, RT-qPCR to detect the targeted mRNA 
(Tbtao, TbsodB) was performed. In tetracycline treated Tbhel1-proficient RNAi-Tbtao and 
RNAi-TbsobB cells, Tbtao or TbsodB expression was shown to be ~50-fold and ~3-fold lower 
than in the non-induced trypanosomes, respectively (Part C and D of Figure 5.8). When Tbhel1-
deficient parasites undergoing RNAi were analysed, transcript levels were equivalent to that 
observed in wild type and non-induced controls. This confirms that TbHEL1 does play a key 
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role in the T. brucei RNAi machinery and can interact with both linear and stem loop derived 
dsRNA templates. The precise interactions of this trypanosomal helicase with other RNAi 
components was not determined here although it is tempting to speculate that  TbHEL1 does 
interact with TbDCL1 or TbDCL2, atypical DICER enzymes that usually only possess a 
nuclease domain (Patrick et al., 2009).  
 
 
5.2 Analysis of the T. brucei FANCJ homologue 
FANCJ, also known as CHL1 or BRIP1, is one of the many FA effector proteins which are 
upregulated upon ubiquitination of the FANCD2/I complex to help unwind damaged DNA 
(Wu and Brosh, 2009; Daee and Myung, 2012; Brosh and Cantor, 2014; Wilson et al., 2017). 
Searches of the T. brucei database identified a putative TbCHL1 homologue (Tb927.10.3550) 
that shares ~20% identity to counterpart sequences expressed by other organisms with this 
homology centering on the DEAD (PF00270), DEAD_2 (PF06733) and Helicase C2 
(PF00271) domains, regions found in some members of the helicases of the SF2 RAD3 group  
 
 
Figure 5.9: Phylogenetic analysis of FANCJ sequences. 
A rooted phylogenetic tree of trypanosomatid CHL1 (purple), fungal CHL1 (pink) and 
vertebrate and plant FANCJ sequences, including humans and Aradopisis (yellow). Gene 
names and sequence identities are given on the end of each clade. T. brucei chl1 
(Tb927.10.3550), T.b.gambiense chl1 (Tbg972.10.4420), T. cruzi chl1 (TcCLB.510311.130), 
L. Mexicana chl1 (LmjF.03.0590), L. panamensis chl1 (LBRM2903_150018000), C. 
fasciculate chl1 (CFAC1_060012500), L. pyrrhocoris chl1 (LpyrH10_34_0770), H. sapiens 
fancj (NM_032043), R. norvegicus fancj (XM_340869), P. troglodytes fancj (XM_511607), 
X. laevis brip (XM_018244911), Drosophilia fancj (XM_009291678), Aradopsis rad3-like 
(AT1G79950), B. napus fancj-like (LK032238), O.s.Japonica fancj (XM_015757026), S. 
cerevisiae chl1 (Z71255), S. pombe chl1 (NM_001020408), A. fumigatus chl1 




Figure 5.10: Domain and sequence comparisons of TbCHL1. 
Schematic diagram showing the organization of conserved domains found T. brucei CHL1 (TbCHL1; Tb927.10.3550), H. sapiens FANCJ 
(HsFANCJ; NM_032043) and S. cerevisiae CHL1 (ScCHL1; Z71255). The regions highlighted include the DEAD (green; PF00270), DEAD_2 
(blue; PF06733) and Helicase C2 domain (red; PF00271) domains. Alignments of the DEAD, DEAD_2 and Helicase C2 domains of the above 
sequence with T. cruzi CHL1 (TcCHL1; TcCLB.510311.130), Arabidopsis thaliana FANCJ (AtFANCJ; AT1G79950), Xenopus laevis BRIP 
(XlBRIP; XM_018244911), and Danio rerio FANCJ (DrFANCJ; XM_009291678). Conserved residues (in black or grey) are highlighted with 
arrows marking the conserved amino acids that form the HMM logo.
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(Figure 5.10). Phylogenetic analysis of trypanosomal, fungal, vertebrate and plant fancj-like 
sequences revealed that the trypanosomatid chl1’s are evolutionarily related to their fungal 
counterparts that together form a clade distinct from vertebrate and plant homologues (Figure 
5.9). 
 
5.2.1 Construction and validation of null mutant lines 
Plasmids based around the hygromycin and puromycin resistance cassettes (pKO-Tbchl1-
hyg and pKO-Tbchl1-pac DNA) were made and processed by restriction enzyme digestion. 
The resultant fragments were purified and sequentially transformed into T. brucei wild type 
cells, creating the Tbchl1Δ line. These recombinant parasites were then taken and Tbsnm1 
deleted using gene integration fragments containing neomycin and blasticidin resistance 
cassettes. Confirmation of the cell lines at a gDNA and mRNA level is given in Appendix 4b. 
 
5.2.2 Phenotypic analysis of T. brucei lines lacking chl1 
Following confirmation that T. brucei single and double null mutant lines lack Tbchl1, their 
growth properties were evaluated relative to wild type cells. This demonstrated that the 
recombinant cell lines grew at an equivalent rate as the controls (data not shown). The 
susceptibility of Tbchl11-deficient cells to various DNA damaging agents was then tested to 
evaluate whether the encoded enzyme does function in DNA repair. For each treatment dose 
response curves were generated (Figure 5.11), EC50 values calculated (Table 5.2) and the fold 
difference of EC50 values between wild type and null lines determined (Table 5.2).  
 
Interestingly, no significant change in susceptibility to hydroxyurea, phleomycin, MMS, 
and UV was observed for Tbchl1Δ and Tbsnm1Δ Tbchl1Δ cells as compared against wild type 
T. brucei and Tbsnm1Δ (Figure 5.11). This indicates that TbCHL1 does not play a major role 
in the repair of base errors, double strand breaks and the formation of pyrimidine dimers. In 
contrast, Tbchl1Δ cells treated with mechlorethamine were 2-fold more susceptible to the ICL 
inducing compound indicating that this putative helicase plays a (minor) role in repair of such 
lesions. When these studies were extended to the Tbsnm1Δ Tbchl1Δ line, the level of sensitive 
to mechlorethamine of the double null was similar to that of Tbchl1Δ cells and not to the 
Tbsnm1-deficient line analysed in parallel. This phenotype is rather perplexing as it does not 
fit in with the “classical” epistatic/non-epistatic interactions observed with other components 
of the trypanosomal ICL REPAIRtoire. However, it may suggest that TbCHL1 and a 
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component in the TbSNM1-dependent pathway haves some sort of co-regulatory role, possibly 
suppressing the activity of other DNA repair factors. In the absence of both TbCHL1 and 
TbSNM1 these silenced/reduced activities are de-repressed and are able participate in ICL 
repair. The result observed using this Tbsnm1Δ Tbchl1Δ double null mutant line was observed 




Figure 5.11: Susceptibility of Tbchl1 null lines towards DNA damaging treatments.  
Dose response curves of T. brucei wild type (●), Tbsnm1Δ (■), Tbchl1Δ (♦), and Tbsnm1Δ 
Tbchl1Δ (ο) cell lines to hydroxyurea, UV, phleomycin, MMS, mechlorethamine and DFMO. 




















Table 5.2: Susceptibility of T. brucei Tbchl1 null lines to DNA damaging treatments. 
Data represents EC50 values of T. brucei wild type, Tbsnm1Δ, Tbchl1Δ and Tbsnm1Δ Tbchl1Δ 
against hydroxyurea, phleomycin, MMS, UV, mechlorethamine and DFMO. All values are 
means ± standard deviations from experiments performed in quadruplicate. The ratio of EC50 
values between wild type and null mutant lines is given as fold difference, in parentheses. 
*Indicates significant differences in susceptibility (P < 0.0001 between wild type and null lines, 




5.3 Analysis of the T. brucei FAN1 homologue 
Following ubiquitination of the FANCD2/FANCI complex, FAN1 (Fanconi-Associated 
Nuclease 1) is recruited to an ICL site where it functions as a nuclease to cleave the DNA 
backbone helping to excise the DNA lesion (Takahashi et al., 2015; Jin and Cho, 2017). 
Searches of T. brucei databases identified a single sequence (TbFAN1; Tb927.10.7540) that 
shares 17 – 20 % identity with FAN1’s from a range of different organisms. These enzymes 
are unique in that they represent the only proteins that contain a VRR-NUC (PF08774) domain 
found towards the carboxyl terminal (Figure 5.12). This region is centred upon a conserved 
“PDXn(D/E)XK” motif that coordinates binding of divalent metal ions (either manganese or 
magnesium) and is essential for their dual nuclease activities (Fontebasso et al., 2013). 
Additionally, these enzymes often contain additional domains (e.g. TPR_12 (PF13424), 
HIRAN (PF08797), SAP (PF02037)) that mediate protein:protein interactions with TbFAN1 
following this pattern, containing the so-called TPR_2 (Tetratricopeptide repeat 2; PF07719) 
motifs. As with TbHEL1, phylogenetic analysis of FAN1 sequences indicates that the 
trypanosomatid homologues forms an outlining group and again is evolutionary distinct from 
vertebrate, plant, nematode and fungal clades (Figure 5.13). This difference could reflect that 
for at least T. brucei, the factors that recruit FAN1 to the ICL lesion, namely the 
Treatment 
T. brucei EC50 
Wild type Tbsnm1Δ Tbchl1Δ 
Tbsnm1Δ 
Tbchl1Δ 
Hydroxyurea 67.39 ± 
0.65 
50.21 ± 1.72 (1.3) 53.90 ± 0.85 (1.2) 66.67 ± 2.27 (1.0) 
Phleomycin 0.04 ± 0.00 0.04 ± 0.00 (1.0) 0.03 ± 0.00 (1.3) 0.06 ± 0.00 (0.7) 
MMS 32.70 ± 0.12 36.35 ± 0.62 (0.9) 41.20 ± 0.77 (1.2) 33.56 ± 1.37 (1.0) 
UV (kJ/cm) 3.46 ± 0.46 4.58 ± 1.04 (0.8) 4.48 ± 2.18 (0.8) 2.98 ± 0.25 (1.2) 
Mechlorethamine 70.94 ± 
1.25 
5.76 ± 0.41 (12.2)* 46.3 ± 0.75 (1.5) 37.92 ± 1.02 (1.8) 
DFMO 41.32 ± 
0.81 
34.24 ± 0.97 (1.2) 41.30 ± 0.46 44.01 ± 0.76 (0.9) 
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FANCD2/FANCI complex, are absent and as such if it does play a role in ICL repair, how it is 




Figure 5.12 Sequence domain analysis of FAN1 sequences. 
Schematic diagram showing the domain structure of FAN1 sequences from Trypanosoma 
brucei (TbFAN1; accession number EAN78160), Homo sapiens (HsFAN1; NP_055782), 
Arabidopsis thaliana (AtFAN1; Q5XVJ4) and Schizosaccharomyces pombie (SpFAN1; 
Q9Y804). The regions corresponding to VRR_NUC (PF08774), SAP (PF02037), HIRAN 
(PF08797), TPR_2 (PF07719), TPR_12 (PF13424) and NatB_MDM20 (PF09797) domains 
are highlighted as red, purple, orange, dark blue, light blue and brown boxes, respectively. An 
alignment of the VRR_NUC domain of TbFAN1 with other FAN1 proteins is shown. Residues 
that are common with the TbFAN1 sequence are represented by dots with differences shown. 





Figure 5.13: Rooted phylogenetic tree analysis of FAN1 sequences.  
A rooted phylogenetic tree outlines how trypanosomatid FAN1 (purple) sequences are evolutionarily dissimilar to plant/fungal FAN1 sequences 
(green), nematode FAN1 sequences (red) and vertebrate FAN1 sequences (yellow). Gene names and sequence identities are given on the end of 
each clade: T. brucei fan1 (Tb927.10.7540), T. cruzi fan1 (TcCLB.510105.90), L. major fan1 (LmjF.36.2620), C. fasciculate fan1 
(CFAC1_250039400), L. braziliensis fan1 (LbrM.35.2830), L. pyrrhocoris fan1 (LpyrH10_06_0080), T. brucei gambiense fan1 
(Tbg972.10.9240), H. sapiens fan1 (NM_014967), P. troglodytes fan1 (XM_510266), A. fumigatus fan1 (XM_743888), S. pombe fan1 
(NM_001021302), B. napus fan1 (XM_013800152), O.s. Japonica fan1 (XM_015788183), A. thaliana fan1 (NM_103732), X. laevis fan1 
(XM_018253000), D. rerio fan1 (NM_001045081), C. elegans fan1 (NM_068596), T. canis fan1 (JPKZ01003248), B. malayi fan1 (LN856244), 
P. vampyrus fan1 (XM_011379121), R.  norvegicus fan1 (NM_001191633) and A. officinalis fan1 (XM_020397757).  
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5.3.1 TbFAN1 and ICL Repair  
5.3.1.1 Creating and confirming single null mutants 
As described elsewhere, Tbfan1 single null cells were created by the sequential transformation 
of processed pKO-Tbfan1-hyg and pKO-Tbfan1-neo DNA fragments into T. brucei wild type 
cells. Recombinant parasites were validated using PCR on gDNA or mRNA templates 
(Appendix 4c). 
 
5.3.1.2 Phenotypic analysis of T. brucei lines lacking fan1 
Following confirmation, the growth properties of the T. brucei Tbfan1Δ was assessed and 
compared against wild type cells cultivated in parallel. This demonstrate that the null line grew 
at an equivalent rate as the controls (data not shown). The susceptibility of Tbfan1-deficient 
cells to various DNA damaging agents was then tested to evaluate whether the encoded enzyme 
does function in DNA repair. For each treatment dose response curves were generated (Figure 
5.14), EC50 values calculated (Table 5.3) and the fold difference of EC50 values between wild 




Figure 5.14: Susceptibility of T. brucei Tbfan1 null mutant towards various DNA 
damaging treatments. 
Dose response curves of T. brucei wild type (solid line) and Tbfan1Δ (dotted line) to 
hydroxyurea, UV, phleomycin, MMS, mechlorethamine and DFMO. All data points are mean 






T. brucei EC50 
Wild type Tbfan1Δ 
Hydroxyurea 75.15 ± 1.49 74.57 ± 1.97 (1.0) 
Phleomycin 0.14 ± 0.01 0.11 ± 0.01 (1.3) 
MMS 39.24 ± 1.64 34.68 ± 1.74 (1.1) 
UV (kJ/cm) 0.79 ± 0.11 0.78 ± 0.08 (1.0) 
Mechlorethamine 76.28 ± 1.29 37.92 ± 6.03 (2.0)* 
DFMO 28.36 ± 0.54 35.64 ± 2.29 (0.8) 
Table 5.3: Susceptibility of T. brucei Tbfan1 null line to DNA damaging treatments.  
Data represents EC50 values of T. brucei wild type and Tbfan1Δ against hydroxyurea, 
phleomycin, MMS, UV, mechlorethamine and DFMO. All values are means ± standard 
deviations from experiments performed in quadruplicate. The ratio of EC50 values between 
wild type and null mutant lines is given as fold difference, in parentheses. *Indicates significant 
differences in susceptibility (P < 0.0001 between wild type and null lines, as assessed by 
Student’s t test (GraphPad Software). 
 
Analysis of the dose response curve data demonstrates that the Tbfan1Δ parasites exhibit a 
wild type-like response to hydroxyurea, phleomycin, MMS and UV indicating this putative 
nuclease plays no role in the repair of damage induced by these treatments. When the 
susceptibility of the null line to mechlorethamine was explored, recombinant cells were slightly 
(~2-fold) more sensitive to the ICL inducing agent than wild type indicating that this enzyme 
plays a role in the trypanosomal ICL REPAIRtoire. 
  
5.3.2 Investigating the role of TbFAN1 in the trypanosomal ICL repair system 
Our previous data indicates that T. brucei possess at least two ICL repair systems with one 
being dependent on TbSNM1 and the other on TbMRE11. To assess which, if any, of these 
TbFAN1 operates within, double null mutant lines lacking TbFAN1 and TbSNM1 (Tbsnm1Δ 
Tbfan1Δ) or TbFAN1 and TbMRE11 (Tbfan1Δ Tbmre11Δ) were constructed and then 
validated as described (see Appendix 4d). Culturing of Tbsnm1Δ Tbfan1Δ parasites revealed 
that they grew at the same rate at wild type and the single null mutant cells (Tbfan1Δ and 
Tbsnm1Δ) while Tbfan1Δ Tbmre11Δ trypanosomes exhibited the growth defect displayed by 
the Tbmre11Δ line (data not shown). Further phenotyping of these lines using mechlorethamine 
as selective agent generated dose response curves (Figure 5.15) and EC50 values (Table 5.4) 
indicting that TbSNM1 and TbFAN1 function non-epistatically while TbMRE11 and TbFAN1 
exhibit an epistatic interaction. Cells lacking TbSNM1 and TbFAN1 are hypersensitive to 
mechlorethamine relative to the single null lines which in turn are more susceptible to the ICL 
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inducing agent than wild type. In contrast, TbMRE11 and TbFAN1-deficient parasites display 
the same sensitivity to mechlorethamine as Tbmre11Δ. 
 
 
Figure 5.15: Susceptibility screening of T. brucei Tbfan1 double null lines against 
mechlorethamine and DFMO. 
A. Dose response curves of T. brucei wild type (●), Tbsnm1Δ (▲), Tbfan1Δ (♦), and Tbsnm1Δ 
Tbfan1Δ (ο) lines to mechlorethamine and DFMO. 
B. Dose response curves of T. brucei wild type wild type (●), Tbmre11Δ (▲), Tbfan1Δ (♦), 
and Tbmre11Δ Tbfan1Δ (ο) to mechlorethamine and DFMO. 














T. brucei EC50 (µM) 
Wild type Tbsnm1Δ Tbfan1Δ Tbsnm1Δ Tbfan1Δ 
mechlorethamine 76.28 ± 1.29 10.50 ± 0.92 (7.2)* 37.92 ± 6.03 (2.0)* 3.67 ± 0.34 (20.5)* 
DFMO 28.36 ± 0.54 31.41 ± 0.61 (1.2) 35.64 ± 2.29 (0.8) 31.20 ± 4.79 (0.9) 
     
Treatment 
T. brucei EC50 (µM) 
Wild type Tbmre11Δ Tbfan1Δ Tbmre11Δ Tbfan1Δ 
mechlorethamine 76.28 ± 1.29 10.38 ± 1.05 (7.6)* 37.92 ± 6.03 (2.0)* 9.63 ± 1.67 (7.6)* 
DFMO 41.32 ± 0.81 47.35 ± 5.16 (0.9) 39.78 ± 1.61 (1.1) 43.54 ± 3.75 (1.0) 
Table 5.4: Susceptibility of T. brucei null lines to mechlorethamine and DFMO. 
Data represents EC50 values of T. brucei wild type, Tbsnm1Δ, Tbfan1Δ, Tbmre11Δ, Tbsnm1Δ 
Tbfan1Δ and Tbfan1Δ, Tbmre11Δ cells treated with mechlorethamine and DFMO. All values 
are means ± standard deviations from experiments performed in quadruplicate. The ratio of 
EC50 values between wild type and null mutant lines is given as fold difference. *Indicates 
significant differences in susceptibility (P < 0.0001 between wild type and null lines, as 
assessed by Student’s t test (GraphPad Software). 
 
 
5.4 Role of TbFANCD1 and TbFANCR in trypanosomal ICL repair 
To evaluate other T. brucei FA repair proteins, parasite lines lacking TbFANCD1 (also 
known as TbBRCA2; (Hartley and McCulloch, 2008) and TbFANCR (also known as 
TbRAD51; (Dobson et al., 2011) were obtained from Dr Richard McCulloch, University of 
Glasgow. The susceptibility of these lines towards mechlorethamine was assessed using a 
modified version of the growth assay reported elsewhere in this thesis: Here the initial cell 
density used was 10-fold higher (105 parasites ml-1) than employed elsewhere due to the slow 
growth rate of these parasites (Hartley and McCulloch, 2008; Dobson et al., 2011). The 
resultant dose response curves (Figure 5.16) and EC50 values (Table 5.4) indicate that both 
enzymes function in the T. brucei ICL REPAIRtoire. Given that TbBRCA2 and TbRAD51 are 
known components of the HR pathway, we hypothesise that these function in the TbMRE11-
dependent ICL repair system although this may be difficult to confirm given the slow growth 
rates of all the single null lines. 
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Figure 5.16: Susceptibility screening of Tbbrca2Δ cells and Tbrad51Δ cells against 
mechlorethamine. 
A. Dose response curves of T. brucei wild type (●) and Tbbrca2Δ (♦) cells to mechlorethamine. 
B. Dose response curves of T. brucei wild type (●) and Tbrad51Δ (♦) cells to mechlorethamine. 





T. brucei EC50 
wild type Tbrad51Δ Tbbrca2Δ 
Mechlorethamine 138.00 ± 3.0 24.17 ± 1.3 (5.8) 48.47 ± 3.4 (2.9) 
Table 5.5: Susceptibility of T. brucei null lines to mechlorethamine. 
Data represents EC50 values of T. brucei wild type, Tbrad51Δ and Tbbrca2Δ cells treated with 
mechlorethamine. All values are means ± standard deviations from experiments performed in 
quadruplicate. The ratio of EC50 values between wild type and null mutant lines is given as fold 
difference. *Indicates significant differences in susceptibility (P < 0.0001 between wild type 
and null lines, as assessed by Student’s t test (GraphPad Software). 
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5.5 Chapter Summary 
This chapter has focused on characterising T. brucei components the Fanconi Anaemia repair 
system. This work has shown:   
1. T. brucei has potential to express a minimal FA pathway, containing 9 putative FA 
homologues 
2. TbHEL1 (initially believed to be a FANCM homologue) plays no role in DNA or ICL 
repair. 
3. TbHEL1 plays a crucial role in the T. brucei RNA interference machinery, potentially 
functioning as the RNA helicase that is absent from the T. brucei DICER sequence but 
present in the counterparts expressed by higher eukaryotes 
4. TbCHL1 (a FANCJ homologue) appears to play an ancillary role in the T. brucei ICL 
REPAIRtoire and may have a regulatory function 
5. TbFAN1 plays an ancillary role in the T. brucei ICL REPAIRtoire and functions in the 
MRE11-dependent ICL repair system  
6. TbBRCA2 (FANCD1) and TbRAD51 (FANCO) play roles in the T. brucei ICL 






6. Structure and function analysis of TbSNM1 
6.1 Understanding the role of conserved residues within TbSNM1 
Previous work characterising TbSNM1 identified several conserved residues that were 
hypothesised to play roles in 1. zinc co-factor binding, 2. localisation or 3. nucleic acid 
specificity (Figure 6.1) (Sullivan et al., 2015). The amino acids involved in metal ion binding 
(either histidine or aspartic acid) are mostly found in motifs that comprise the MβL domain 
while the presence of a monopartite ‘RRRH’ sequence present in the β-CASP domain has 
potential to target the enzyme to the nucleus. Additionally, a conserved valine residue found 
towards the carboxyl end of β-CASP could determine the substrate specificity of TbSNM1: 
SNM1/PSO2 proteins containing this particular residue tend to bind DNA while the presence 
of histidine results in enzymes interacting with RNA (Callebaut et al., 2002). 
 
 
Figure 6.1: Conserved residues of TbSNM1.  
TbSNM1 contains two key regions; the metallo-ß-lactamase (MßL; red) and β-CASP (purple) 
domains. Conserved residues within these domains are emphasised in blue (hypothesised to 
play a role in zinc cofactor binding), green (theorised to play a role in TbSNM1 nuclear 
localisation) and orange (TbSNM1 specificity to binding DNA).  
 
Functional analysis of TbSNM1 in BSF T. brucei has shown that cells lacking this activity 
are highly susceptible to ICL inducing agents, a phenotype that can be readily reversed by 
ectopic expression of an amino terminally GFP tagged version of the enzyme (Sullivan et al., 
2015). Using pRPa-GFP-Tbsnm1, the complementation DNA vector used in the above study 
as template, the SPRINP site-directed mutagenesis technique (Edelheit, Hanukoglu and 
Hanukoglu, 2009) was used to mutate the residues highlighted in Figure 6.1 to alanine. 
Following the introduction of the mutated GFP constructs into T. brucei Tbsnm1 heterozygotes 
(heterozygote line referred to as Tbsnm1+/-), the remaining Tbsnm1 allele was interrupted 
thereby creating the desired null mutant line. Comparison of the susceptibility profiles 
displayed by these lines against wild type, Tbsnm1Δ and Tbsnm1Δ parasites engineered to 
express GFP tagged Tbsnm1 enabled us to test whether a given residue does play a role in 
122 
 
TbSNM1 1. catalytic activity, 2. localisation and/or 2. substrate specificity. This functional 
analysis was augmented by in silico studies where the TbSNM1 protein sequence was modelled 
onto the recently described HsSNM1A (PDB:4B87) and HsSNM1B (PDB: 5AHO) structures 
(Figure 6.2) (Allerston et al., 2015) using Phyre 2 and PyMOL programs. Analysis at the gross 
level indicated that TbSNM1 contained 12 β-pleated sheets that fold to form the MβL domain 
with the β-CASP domain inserted between β-sheets 10 and 11, typical of members of the 
SNM1/PSO2 family. Further predictions indicate that the T. brucei enzyme binds one zinc ion 
similar to HsSNM1A and distinct from HsSNM1B which binds two, with analysis of 
interactions at specific sites showing the molecular effects of each individual mutation. 
 
 
Figure 6.2: Predicted model of TbSNM1.  
Molecular model of TbSNM1, as compared against HsSNM1A and HsSNM1B. Created using 
Phyre 2 and Pymol. The α-helices in TbSNM1 are shown in blue (also blue in HsSNM1A and 




6.2 Analysis of putative TbSNM1 zinc binding residues  
Comparison of the TbSNM1 sequence with other SNM1/PSO2 proteins identified several 
residues, including D40, H78, H80, D82, H83, H159, H178, D221 and H496 (numbering for 
TbSNM1), as potentially playing a role in zinc binding. Using the plasmid pRPa-gfp-Tbsnm1 
as template, the codons that translate for each of these amino acids were mutated to alanine 
using the SPRINP approach (Figure 6.3). 
 
  
Figure 6.3: Residues in TbSNM1 postulated to bind the metal ion.  
Nine conserved residues across both TbSNM1 domains (D40, H78, H80, D82, H83, H159, 
H178, D221 and H496) are hypothesised to play a role in coordination of the zinc ion. These 
were independently mutated to alanine residues.  
 
Following confirmation of their sequence, the mutated plasmids were digested with AscI 
with the purified fragments introduced into a T. brucei 2T1 Tbsnm1+/- line (this line is 
blasticidin and puromycin resistant). Cultures were placed under selective pressure and 
hygromycin/blasticidin resistance cultures selected 5 to 7 days post-transformation: integration 
of RPa-GFP-Tbsnm1 is selected for using hygromycin while blasticidin is used to maintain 
selection for the Tbsnm1 disruption. Cells were then tested for puromycin sensitivity (2T1, the 
parental line, is puromycin resistant, a phenotype that should be lost upon integration of the 
ectopic construct) with susceptible clones then transformed with DNA fragments containing a 
puromycin resistant cassette that facilitates interruption of the remaining Tbsnm1 allele. As 
before, cultures were placed under selective pressure and hygromycin/blasticidin/puromycin 
resistance cultures selected 5 to 7 days post-transformation.  
 
To confirm that Tbsnm1 had been successfully interrupted, that mutated gfp-Tbsnm1 DNA 
fragment had integrated into the T. brucei genome and that the recombinant lines expressed the 
fusion gene, DNA amplification-based validation strategies were performed. To assess for 
appropriate integration events, PCR on gDNA extracted from wild type and manipulated cell 
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lines was carried out using primer combinations to amplify biomarkers corresponding to 1. 
intact Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 2. the Tbsnm1-bla and Tbsnm1-pac disrupted 
alleles (Tbsnm1-KO1/bla-1 and Tbsnm1-KO1/pac-1, respectively) and 3. the gfp-Tbsnm1 
allele (GFP/Tbsnm1-seq1) (Figure 6.4). Amplification of intact Tbsnm1 generated a band of 
1.1 kb (the size predicted from in silico mapping) in templates purified from wild type and 
Tbsnm1+/- cells with no band(s) seen in genetic material purified from the other lines tested. In 
contrast, primer combinations that detect the Tbsnm1-bla and Tbsnm1-pac alleles generated 
amplicons of the predicted size (~1.3 and ~1.7 kb, respectively) but only from the gDNA 
purified from T. brucei Tbsnm1Δ, T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1 and all the Tbsnm1Δ 
lines engineered to express mutated versions of the GFP-TbSNM1 fusion protein. In contrast, 
no bands were observed in wild type T. brucei while only the Tbsnm1-bla allele was detected 
in the Tbsnm1+/- line. Finally, a DNA band of 0.4 kb (the size predicted from in silico mapping) 
that spans the gfp-Tbsnm1 fusion was detected only from parasites containing wild type or 
mutated Tbsnm1 in the ectopic expression vector. These strategies indicate that the appropriate 
cell lines have been made: 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-D40A  line now referred to as TbSNM1-D40A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-H78A  line now referred to as TbSNM1-H78A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-H80A line now referred to as TbSNM1-H80A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-H82A line now referred to as TbSNM1-H82A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-D83A line now referred to as TbSNM1-D83A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-H159A line now referred to as TbSNM1-H159A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-H178A  line now referred to as TbSNM1-H178A 
T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-D221A line now referred to as TbSNM1-D221A 











Figure 6.4: Validating engineered T. brucei lines. 
A. Diagram representing the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. In parallel, changes 
to the landing pad locus after integration of gfp-Tbsnm1 was also analysed. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1), P4 (pac-1) and P5 (GFP) correspond to regions where the 
primers anneal at the specific allele. 
B. DNA fragments obtained from amplification reactions on genomic DNA extracted from T. 
brucei wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ GFP-Tbsnm1 (lane 
4), TbSNM1-D40A (lane 5), TbSNM1-H78A (lane 6), TbSNM1-H80A (lane 7), TbSNM1-
D82A (lane 8), TbSNM1-H83A (lane 9), TbSNM1-H159A (lane 10), TbSNM1-H178A (lane 
11), TbSNM1-D221A (lane 12), and finally TbSNM1-H496A (lane 13) cells. Primer 
combinations amplified intact Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), Tbsnm1-bla (Tbsnm1-
KO1/bla-1), Tbsnm1-pac (Tbsnm1-KO1/pac-1), or gfp-Tbsnm1 (GFP/Tbsnm1-seq1) alleles. 
 
 
To assess whether the above recombinant lines express the GFP-TbSNM1 fusion, DNA 
amplification reactions were carried out on cDNA (generated from total RNA extracted from 
tetracycline induced parasites) using primers GFP/Tbsnm1-seq1 (Figure 6.5): ectopic 
expression of the wild type or mutated GFP-TbSNM1 protein in the 2T1 genetic background 
is under control of a tetracycline induced T7 promoter system (Alsford et al., 2005). When 
using material generated from wild type T. brucei, Tbsnm1+/- and Tbsnm1Δ cells, no band was 
observed indicating these lines do not express a version of gfp-Tbsnm1. In contrast, a band of 
the expected size (0.4 kb) was noted in all lines engineered to express variants of the fusion 
protein. The integrity of all cDNA (and hence RNA) samples was confirmed as control 
reactions amplifying Tbtert (primer combinations Tbtert-F/Tbtert-R) carried out in parallel 





Figure 6.5: Confirming expression of gfp-Tbsnm1. 
A. Schematic of integrated gfp-Tbsnm1 analysing using primer combination P2 (Tbsnm1-seq1) 
and P5 (GFP) which amplified a band of 0.4kb across the GFP and TbSNM1 fusion.  
B. DNA fragments obtained from amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ GFP-Tbsnm1 
(lane 4), TbSNM1-D40A (lane 5), TbSNM1-H78A (lane 6), TbSNM1-H80A (lane 7), 
TbSNM1-D82A (lane 8), TbSNM1-H83A (lane 9), TbSNM1-H159A (lane 10), TbSNM1-
H178A (lane 11), TbSNM1-D221A (lane 12), and finally TbSNM1-H496A (lane 13) cells 
using primer combinations that specifically amplify gfp-Tbsnm1 (GFP/Tbsnm1-seq1) and 
Tbtert (Tbtert-F/Tbtert-R).  
 
To evaluate whether a given TbSNM1 mutation effects localisation of the enzyme, the DNA 
of fixed parasites from tetracycline induced and non-induced cultures was stained with DAPI 
then imaged by epifluorescent microscopy (Figure 6.6). For most (8) TbSNM1 mutants, 
tetracycline induced expression of the GFP tagged protein within the trypanosome resulted in 
a pattern that coincided with the larger and more intense of the DAPI signals. As DAPI stains 
the trypanosomal nuclear and single mitochondrial genomes, with the latter presenting as a 
small, faint band relative to the former, the observed pattern reveals that most fusion proteins 
can be translocated to the T. brucei nucleus. It is therefore implicit that mutation of most 
putative zinc binding amino acids does not affect protein localisation and presumably folding. 
The only exception to this pattern related to the TbSNM1-D221A line where a non-specific 
GFP signal was noted throughout the cell. This suggests that this particular amino acid may 







Figure 6.6: Localisation of mutant GFP-TbSNM1 in bloodstream form T. brucei. 
T. brucei Tbsnm1Δ cells expressing GFP-TbSNM1 (wild type or mutant) were fixed, stained 
with DAPI and imaged by epifluorescent microscopy under a x40 objective. Examples of the 
phase, DAPI and GFP signal images are shown for selected cell lines: Tbsnm1Δ GFP-Tbsnm1 
(A), TbSNM1-D40A (B), TbSNM1-H80A (C), TbSNM1-D221A (D) and TbSNM1-H496A 
(E). The cells analysed were derived from tetracycline treated (induced) cultures and compared 
to parasites grown in the absence of this antibiotic (uninduced). 
 
To assess if ectopic expression of a given TbSNM1 mutation could complement for the 
susceptibility phenotype displayed by Tbsnm1Δ, the growth of recombinant parasite lines in 
the presence/absence of tetracycline and mechlorethamine was determined. The data was 
plotted as dose response curves (Figure 6.7) from which EC50 values were determined (Table 








Figure 6.7: Susceptibility of T. brucei lines towards mechlorethamine. 
Dose response curves of tetracycline induced (▲) and uninduced (▼) T. brucei Tbsnm1Δ gfp-
Tbsnm1 (A), TbSNM1-D40A (B), TbSNM1-H80A (C) and TbSNM1-H496A (D). All data 








Tbsnm1Δ gfp-Tbsnm1 4.52 ± 0.41 14.69 ± 1.78 3.3* Y 
TbSNM1-D40A 5.27 ± 0.43 6.45 ± 0.59 1.2 N 
TbSNM1-H78A 5.40 ± 0.35 16.67 ± 0.92 3.1* Y 
TbSNM1-H80A 5.52 ± 3.68 5.27 ± 0.79 1.0 N 
TbSNM1-D82A 4.50 ± 1.84 4.26 ± 0.80 0.9 N 
TbSNM1-H83A 2.00 ± 0.89 10.39 ± 0.37 5.2* Y 
TbSNM1-H159A 4.70 ± 0.25 5.00 ± 0.10 1.1 N 
TbSNM1-H178A 1.73 ± 0.58 12.91 ± 0.55 7.5* Y 
TbSNM1-D221A 3.06 ± 0.44 4.48 ± 1.67 1.5 N 
TbSNM1-H496A 5.19 ± 0.20 22.81 ± 1.80 4.4* Y 
Table 6.1: Susceptibility of T. brucei null lines to mechlorethamine. 
Data represents EC50 values of induced and uninduced null lines towards mechlorethamine. All 
values are means ± standard deviations from experiments performed in quadruplicate. The ratio 
of EC50 values between induced and uninduced null lines is given as a fold difference. 
*Indicates significant differences in susceptibility (P < 0.0001 between wild type and null lines, 




The above data demonstrates that expression of H78, H83 H178 and H496 mutant forms of 
TbSNM1 can readily compensate for the mechlorethamine sensitivity phenotype displayed by 
the TbSNM1 null line with these enzymes behaving similarly to wild type TbSNM1 analysed 
in parallel. It is therefore implicit that these residues do not play a fundamental role in the 
activity of this enzyme. In comparison, alteration of D40, H80, D82 and H159 results in 
impaired TbSNM1 activity such that expression of these mutants in the Tbsnm1Δ line fails to 
complement for the susceptibility phenotype. Molecular modelling of TbSNM1 wild type and 
mutants (Figure 6.8) structures indicates that these four residues all cluster near to the site 
where the zinc ion is predicted to sit. It is tempting to speculate that conversion of D40, H80, 
D82 and H159 to alanine affects coordination of the metal ion possibly affecting electron 
distribution in this region which can manifest itself as a reduction in the DNA cleaving activity. 
Whether the above amino acids interact directly with the zinc ion itself, function in an ancillary 
role to help with in this interaction or facilitate binding and/or cleavage of DNA backbone 
could not be determined due to the lack of an experimentally derived structure. 
 
Figure 6.8: Structure of wild type and mutated forms of TbSNM1. 
Illustration showing the effect of TbSNM1 D40A, H80A, D82A and H159A mutations (post 
mutation) in relation to wild type TbSNM1 (pre-mutation). Images were generated using the 
PyMOL in silico mutagenesis tool.  The blue sphere corresponds to where the zinc ion is 
predicted to sit and the red arrows represent the mutation under analysis.  
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6.3 Evaluating the specificity of TbSNM1 to DNA  
TbSNM1 possesses a conserved PTV motif in the carboxyl region of its β-CASP domain with 
the valine at this site (V518) possibly involved in DNA binding (Callebaut et al., 2002). To 
test this hypothesis, the codon for this amino acid was mutated to the base triplet for alanine 
(Figure 6.9) using pRPA-gfp-Tbsnm1 as template. The confirmed ‘mutant’ plasmid was used 
to generate the T. brucei 2T1 Tbsnm1Δ gfp-Tbsnm1-V518A (referred to as TbSNM1-V518A) 
line and subsequently validated as described in section 6.2 (validation shown in Appendix 5).  
 
Figure 6.9:  Location of V518 residue.  
TbSNM1 V518 (located in the β-CASP domain of the protein) was mutated into an alanine due 
to non-bulky, chemically inert nature of this residue using site directed mutagenesis on the 
pRPA-gfp-Tbsnm1 plasmid.  
 
Characterisation of the above cell line revealed that the mutated TbSNM1 was targeted to the 
nucleus (Appendix 5) while mechlorethamine susceptibility screens revealed that the modified 
enzyme could reverse the sensitivity phenotype that stems from lack of TbSNM1 expression 
from the endogenous loci (Figure 6.10; Table 6.2).  
 
 
Figure 6.10: Susceptibility of T. brucei lines towards mechlorethamine. 
Dose response curves of induced (▲) and non-induced (▼) T. brucei Tbsnm1Δ gfp-Tbsnm1 
(A) and TbSNM1-V518A (B). All data points are mean values ± standard deviations from 
experiments performed in quadruplicate. 
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Table 6.2: Susceptibility of T. brucei lines to mechlorethamine. 
Data represents EC50 values of induced and uninduced null lines towards mechlorethamine. All 
values are means ± standard deviations from experiments performed in quadruplicate. The ratio 
of EC50 values between induced and uninduced null lines is given as a fold difference. 
*Indicates significant differences in susceptibility (P < 0.0001 between wild type and null lines, 
as assessed by Student’s t test (GraphPad Software). 
 
Together, this implies that the valine at position 518 in TbSNM1 plays no role in determining 
substrate specificity. However, molecular modelling (Figure 6.11) at this site shows that 
because of the relatedness of the valine and alanine structures, the latter amino acid may, at 
least partially, be still able to promote DNA binding. As such additional experiments to analyse 
this particular residue could involve mutation of the valine to more diverse amino acids with 
one potential alteration involving conversion to histidine, the residue that may confer RNA 
interacting activity (Callebaut et al., 2002). 
 
 
Figure 6.11: Effect of the V518A mutation on TbSNM1. 













Tbsnm1Δ gfp-Tbsnm1 4.52 ± 0.41 14.69 ± 1.78 3.3* Y 
TbSNM1-V518A 3.70 ± 0.34 15.37 ± 0.68 4.2* Y 
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6.4 Dissecting the TbSNM1 nuclear localisation signal  
In silico analysis of TbSNM1 (NucPred software) predicted that the RRRH motif starting at 
position 428 could function as a nuclear localisation signal (NLS) (Sullivan et al., 2015). The 
combination of amino acids at this site (Figure 6.12) forms a classical, monopartite NLS with 
the basic amino acids in this region guiding the protein to the neutrally-charged nucleus (Lange 
et al., 2007). This type of signal has been observed to function in trypanosomatids (Marchetti 
et al., 2000).   
 
Figure 6.12: Predicted NLS of TbSNM1. 
Four key residues (R428, R429, R430, and H431A; located in the β-CASP domain of the 
protein) were identified in silico to function in TbSNM1 localisation to the nucleus. Each 
residue was mutated to alanine to study this hypothesised function.  
 
Using the approaches described above, variants of pRPA-GFP-Tbsnm1 containing appropriate 
mutations were generated, used to construct the corresponding recombinant T. brucei lines 
(Tbsnm1Δ gfp-Tbsnm1-R428A (referred to as TbSNM1-R428A), Tbsnm1Δ gfp-Tbsnm1-
R429A (referred to as TbSNM1-R429A), Tbsnm1Δ gfp-Tbsnm1-R430A (referred to as 
TbSNM1-R430A) and Tbsnm1Δ gfp-Tbsnm1-H431A (referred to as TbSNM1-H431A)) with 
these parasites then validated using the aforementioned PCR-based strategy (validation shown 
in Appendix 5).  
 
To assess the effect of each mutation on TbSNM1 localisation, the DNA of trypanosomes 
grown in the absence or presence of tetracycline was stained, the cells visualized by 
epifluorescent microscopy and the GFP pattern analysed (Figure 6.13). In situations where the 
outer two amino acids of the RRRH tetrapeptide had been mutated (ARRH or RRRA) a 
fluorescence signal within the nucleus was observed but only in tetracycline induced cultures.  
In contrast, alteration of each of the middle amino acids (RARH or RRAH) resulted in a non-
nuclear arrangement thus indicating that the arginine residues at position 429 or 430 are both 
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key for targeting TbSNM1 to this organelle. However, it must also be noted that the pattern 
observed when expressing the R429 or 430 mutants in T. brucei could also reflect that these 
proteins are incorrectly folded and therefore non-functional. 
 
 
Figure 6.13: Localisation of T. brucei mutant GFP-TbSNM1.  
Parasites expressing GFP-TbSNM1 (mutant or wild type) were stained with DAPI and 
examined by epifluorescent microscopy under a x40 objective lens with phase, DAPI and GFP 
signal images shown: Tbsnm1Δ GFP-Tbsnm1 (A), TbSNM1-R428A (B), TbSNM1-R429A 
(C), TbSNM1-R430A (D) and TbSNM1-H431A (E). 
 
To determine whether there was an association between the above localisation patterns and 
mechlorethamine susceptibility, Tbsnm1Δ parasites that also express the mutant TbSNM1s 
cultured in medium containing or lacking tetracycline were treated with the ICL inducing agent 
and growth inhibition determined. The resulting cell number data was analysed and plotted as 




Figure 6.14: Susceptibility of T. brucei conditional null lines against mechlorethamine.  
Dose response curves of induced (▲) and non-induced (▼) T. brucei Tbsnm1Δ gfp-Tbsnm1 
(A), TbSNM1-R428A (B), TbSNM1-R429A (C). TbSNM1-R430A (D) and TbSNM1-H431A 





Table 6.3: Susceptibility of T. brucei null lines to mechlorethamine. 
Data represents EC50 values of induced and uninduced null lines towards mechlorethamine. All 
values are means ± standard deviations from experiments performed in quadruplicate. The ratio 
of EC50 values between induced and uninduced null lines is given as a fold difference. 
*Indicates significant differences in susceptibility (P < 0.0001 between wild type and null lines, 
as assessed by Student’s t test (GraphPad Software). 
 
The above complementation data mirrors the localisation observations. Expression of TbSNM1 
mutated in either of the outer two amino acids (R428 and H431) readily complements for the 
mechlorethamine sensitivity displayed by cells that lack TbSNM1 expressed from an 
endogenous loci. In contrast, alteration of R429 and 430 residues in TbSNM1 to alanine 
generates variant proteins that are unable function in the same way.    
Cell line 




Tbsnm1Δ gfp-Tbsnm1 4.52 ± 0.41 14.69 ± 1.78 3.3* Y 
TbSNM1-R428A 8.44 ± 0.47 54.70 ± 1.32 6.5* Y 
TbSNM1-R429A 3.97 ± 0.14 4.14 ± 0.12 1.0 N 
TbSNM1-R430A 7.99 ± 0.26 7.81 ± 0.20 1.0 N 
TbSNM1-H432A 4.91 ± 0.32 46.63 ± 0.56 9.5* Y 
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6.5 Chapter Summary 
This chapter has focused on understanding the structure and function of TbSNM1. The 
amalgamation of alanine scanning, conditional null mutant lines, cellular localisation assays 
and susceptibility screening demonstrated that: 
1. D40, H80, D82, and H159 play a key role in TbSNM1 activity, with comparative 
studies and in silico modelling suggesting they may be involved in zinc co-factor 
binding 
2. R429 and R430, but not R428 and H431, play a crucial role in the localisation of the 
protein to the nucleus 
3. Conversion of the valine at position 518 to alanine has no effect on TbSNM1 





7. DNA damage and trypanocidal compounds 
A major challenge in the field of infectious disease biology is the development of new 
therapies to target a given pathogen. In the case of HAT, the last treatment to be added to the 
WHO List of Essential Medicines was NECT in 2009. The anti-microbial effects of this therapy 
uses two partner drugs that have been in clinical use to target trypanosomal infections for more 
than 30 years. In this chapter we have utilised the cell lines reported earlier in the thesis to 
assess whether: 1. TbSNM1 can be exploited as a drug target using compounds supplied by 
Prof Chris Scoffield (University of Oxford), 2. novel prodrugs activated by a trypanosome 
specific nitroreductase mediate their downstream effects by promoting DNA damage and 3. 
existing nitroheterocyclic-based therapies cause DNA damage within the parasite. 
 
7.1 Evaluating trypanocidal effects of HaSNM1A inhibitors 
ICL inducing agents are extensively used in medicine to treat a range of conditions with 
compounds including mitomycin C, cisplatin, cyclophosphamide and mechlorethamine being 
used to target certain forms of cancer (Huang and Li, 2013). It is envisaged that cells 
compromised in their ICL repair systems should be more susceptible to such therapies. This 
has led to the identification of several cephalosporin-based SNM1 inhibitors that are believed 
to interact with this nuclease via their MβL fold (Lee et al., 2016): Cephalosporins are β-lactam 
antibiotics target bacterial cell wall biosynthesis with resistance mediated by β-lactamases, 
enzymes that contain a MβL domain. 
 
To examine whether these SNM1 inhibitors display activity against BSF T. brucei, the 
growth inhibition of Ceftriaxone (a cephalosporin) and four other compounds (ML302-HCl, 
ML302-F, LBE314, Si4-33) against the BSF of the parasites was assessed (Figure 7.1; Table 
7.1). This revealed that two of the structures (Ceftriaxone and ML302-F) do not have any 
trypanocidal effects at concentrations up to 100 µM. In contrast, the remaining three 
compounds displayed moderate, unimpressive, activity against this form of the parasite (EC50 
values between 15 to 30 µM).  
 
To elucidate whether this growth inhibition targets TbSNM1, the susceptiblity of T. brucei 
lacking or over expressing this activity was determined (Sullivan et al., 2015) (Figure 7.1; 
Table 7.1). In all cases, the recombinant lines were as sensitive as wild type to each of the three 
chemicals tested. Therefore, it is implicit that the trypanocidal activity displayed by these 
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compounds does not involve TbSNM1 inhibition. Analysis of the TriTryp genome database 
indicates that in addition to TbSNM1, T. brucei expresses at least 8 other sequences that contain 
a β-lactamase like domain with potentially one (or more) of these being inhibited by the 
compounds tested here.  
 
 
Figure 7.1: Susceptibility screening of T. brucei against inhibitors of HaSNM1A.  
Dose response curves of wild type T. brucei (●), Tbsnm1Δ (■), and Tbsnm1++ (♦) lines against 
ML302-HCl, Si4-33, LBE314, ML302-F and ceftriaxone. All data points are mean values ± 
standard deviations from experiments performed in quadruplicate. 
 
 
  T. brucei EC50 (µM) 
Wild type Tbsnm1Δ Tbsnm1++ 
ML302-HCl 26.57 ± 0.99 24.28 ± 1.75 28.45 ± 0.90 
ML302-F Na >100 - - 
LBE314 13.51 ± 0.25 16.33 ± 1.57 13.02 ± 0.69 
Si4-33 15.41 ± 1.33 12.03± 0.80 11.16 ± 0.76 
Ceftriaxone >100 - - 
Table 7.1: Susceptibility of T. brucei lines to inhibitors of HaSNM1A.  
Data represents EC50 values of wild type T. brucei, Tbsnm1Δ and Tbsnm1++ lines towards 
ML302-HCl, Si4-33, LBE314, ML302-F and ceftriaxone. All values are means ± standard 
deviations from experiments performed in quadruplicate. 
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7.2 Unravelling the mode of action of nitro-based prodrugs 
Ongoing work in the Wilkinson lab involves determining how nitro-based trypanosomal 
agents mediate their trypanocidal mode of action (Hall et al., 2010; Bot et al., 2010, Hall, 
Meredith and Wilkinson, 2012; Meredith et al., 2017). One theme arising from these studies is 
that the most potent agents with the best selectivity contain chemical motifs that in other 
organisms promote DNA (specifically ICL) damage. To determine whether this was the case, 
various trypanocidal nitroaromatic compounds, including benznidazole, nifurtimox, CB1954 
and LH34, were screened against a number of single and double null mutant lines engineered 
to lack different DNA repair proteins (see section 3.2 and 4.1). The data was expressed as dose 




Figure 7.2: Susceptibility of T. brucei null lines towards anti-trypanosomal agents.  
Dose response curves of T. brucei wild type (●), Tbsnm1Δ (■), TbcsbΔ (♦) and Tbsnm1Δ 
TbcsbΔ (ο) to benznidazole, nifurtimox, CB1954 and LH34. All data points are mean values ± 




Table 7.2: Susceptibility of T. brucei double null lines to anti-trypanosomal agents. 
Data represents EC50 values of various T. brucei lines against benznidazole, nifurtimox, 
CB1954 (all in μM) and LH34 (in nM). All values are means ± standard deviations from 
experiments performed in quadruplicate. *Indicates significant differences in susceptibility (P 
< 0.0001 between wild type and null lines, as assessed by Student’s t test (GraphPad Software).  
 
The above data reveals that TbEXO1 plays no role in the trypanocidal mechanism of action 
of any of the nitroaromatic compounds tested: Cells lacking TbEXO1 display sensitivities to 
benznidazole, nifurtimox, CB1954 and LH34 similar to that observed with wild type cells while 
T. brucei lacking both TbEXO1 and TbSNM1 exhibit susceptibilities equivalent to those that 
are deficient only for TbSNM1. This implies that these agents do not promote a form of DNA 
damage that involves the MMR pathway. 
 
Cells that lack TbCSB, either in a wild type or Tbsnm1-deficient background, are as equally 
susceptible to benznidazole and nifurtimox as controls. This indicates that these compounds do 
Treatment T. brucei EC50 
wild type Tbsnm1Δ Tbmre11Δ Tbsnm1ΔTbmre11
Δ 
Benznidazole 57.28 ± 4.82 44.84 ± 5.50 
(1.3) 
22.88 ± 3.50 
(2.6)* 
24.19 ± 2.76 (2.4)* 
Nifurtimox 3.90 ± 0.02 5.31 ± 0.20 (0.8) 2.86 ± 0.05 (1.3 ) 4.67 ± 0.22 (0.9) 
CB1954 3.67 ± 0.24 1.49 ± 0.03 
(2.5)* 
0.91 ± 0.03 (4.1)* 0.42 ± 0.04 (9.3)* 
LH34 197.85 ± 8.92 9.71 ± 0.88 
(20)* 
33.40 ± 1.01 (6)* 2.55 ± 0.68 (66)* 
     
 wild type Tbsnm1Δ Tbexo1Δ Tbsnm1Δ 
Tbexo1Δ 
Benznidazole 57.28 ± 4.82 45.57 ± 4.70 
(1.3) 
69.27 ± 11.40 
(0.8) 
50.29 ± 2.76 (1.1) 
Nifurtimox 3.90 ± 0.02 5.31 ± 0.20 (0.8) 3.50 ± 0.05 (1.1) 6.07 ± 0.26 (0.7) 
CB1954 2.68 ± 0.04 0.71 ± 0.04 
(3.9)* 
2.88 ± 0.08 (0.9) 0.68 ± 0.05 (3.9)* 
LH34 188.23 ± 8.94 18.07 ± 1.28 
(10)* 
222.50 ± 13.20 
(0.8) 
22.25 ± 3.82 (8.5)* 
     
 wild type Tbsnm1Δ TbcsbΔ Tbsnm1Δ TbcsbΔ 
Benznidazole 66.24 ± 0.84 76.39 ± 1.01 
(0.9) 
62.14 ± 2.59 (1.1) 60.19 ± 1.61 (1.1) 
Nifurtimox 3.28 ± 0.10 3.15 ± 0.23 (1.0) 3.71 ± 1.84 (0.9) 3.62 ± 0.19 (0.9) 
CB1954 3.67 ± 0.24 0.72 ± 0.05 
(5.3)* 
1.56 ± 0.16 (2.5)* 0.07 ± 0.02 (53)* 
LH34 280.45 ± 
13.47 
15.36 ± 1.41 
(18.7)* 
91.93 ± 5.91 
(3.0)* 




not cause a type of DNA damage that involves resolution using the NER pathway. In contrast, 
TbcsbΔ cells are up to 3-fold more susceptible to CB1954 or LH34 relative to wild type. When 
examining the sensitivity of cells lacking both TbSNM1 and TbCSB towards these two agents, 
certain differences were noted. For the LH compound, an epistatic interaction between 
TbSNM1 and TbCSB was noted with the EC50 value for the Tbsnm1Δ line being similar to that 
observed using Tbsnm1Δ TbcsbΔ cells. This suggests that this nitrogen mustard containing 
compound mediates most of its trypanocidal activity through the formation of ICLs. In the case 
of CB1954, the double null line (Tbsnm1Δ TbcsbΔ) was hypersensitive to this aziridinyl in 
relation to the Tbsnm1Δ or TbcsbΔ nulls indicating that the two encoded enzymes function 
non-epistatically to resolve any DNA damage that may ensue. This may reflect that CB1954 
can promote various types of lesion within T. brucei that require different systems to repair. It 
is implicit that as TbSNM1 deficient cells are susceptible to CB1954 then one form of DNA 
damage caused by this agent are ICLs: this enzyme can only function to repair this type of 
lesion. Other forms of damage that this aziridinyl-based structure could generate include 
intrastrand crosslinks and monoalkylation products (Nicolini, 1988) that can be resolved using 
the NER system, a pathway that does not require SNM1 activity. 
 
Cells lacking TbMRE11 (Tbmre11Δ and Tbsnm1Δ Tbmre11Δ) are as sensitive to 
nifurtimox as wild type showing that this nitrofuran does not cause a form of DNA damage 
that can be repaired by the HR pathway. With benznidazole, parasites deficient in TbMRE11 
(Tbmre11Δ and Tbsnm1Δ Tbmre11Δ) are ~2-fold more sensitive to this compound than the 
parental line suggesting that these agents do cause a type of DNA damage that can be repaired 
via the HR pathway. This mechanism of action involving TbMRE11 was shown to extend 
across to megazol (data not shown), a nitroimidazole that has previously been shown to 
generate HR repaired lesions (Carvalho et al., 2014). When screening CB1954 and LH34 
against the above lines, cells lacking just TbMRE11 were between 4- and 6-fold more 
susceptible to these agents respectively relative to wild type indicating that the HR pathway 
does play a role in repairing the damage caused by either compound. This repair activity is 
non-epistatic with TbSNM1 as cells lacking both enzymes are hypersensitive to the treatments.  
 
7.3 Activation of benznidazole promotes DNA damage  
It is now established that activation of benznidazole involves a parasite specific type I 
nitroreductase (TbNTR) (Wilkinson et al., 2008). To determine whether the DNA damaging 
activity noted above is linked to this trigger mechanism, parasite lines over expressing TbNTR 
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while null for TbMRE11 were constructed and validated (Appendix 6b). As a control, a 
TbEXO1 deficient, TbNTR expressing control line was generated in parallel (Appendix 6a). 
The susceptibility of the resultant lines towards benznidazole was then tested: The effect of 
DFMO was also analysed as drug control. The growth inhibition data, expressed as dose 
response curves (Figure 7.3) and as EC50 values (Table 7.3), revealed that cells lacking only 
TbEXO1 were as equally susceptible to benznidazole as wild type, confirming our previous 
findings, while cells additionally engineered to over express TbNTR were as sensitive to this 
nitroimidazole as parasite expressing only elevated levels of the nitroreductase.  
 
 
Figure 7.3: Susceptibility of T. brucei lines expressing altered levels of TbEXO1, 
TbMRE11 and/or TbNTR to benznidazole.  
Dose response curves of wild type (●), Tbexo1Δ (♦), TbNTR over expression (■), and Tbexo1Δ 
TbNTR over expression (○) T. brucei to benznidazole (A) or DFMO (B).  
Dose response curves of wild type (●), Tbmre11Δ (♦), TbNTR overexpression (■), and 
Tbmre11Δ TbNTR overexpressing (○) T. brucei to benznidazole (C) or DFMO (D).  All data 
points are mean values ± standard deviations from experiments performed in quadruplicate. 
 
When benznidazole was tested against T. brucei cells expressing altered levels of TbNTR 
and/or TbMRE11, a different outcome was observed. For TbMRE11-deficient cells or parasites 
expressing elevated levels of just TbNTR, treatment with the nitroimidazole resulted in 
increased susceptibility when compared against controls, with the TbNTR overexpressing cells 
being more sensitive than the null line: Tbmre11Δ cells and T. brucei expressing an ectopic 
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copy of Tbntr were ~1.6- and ~6.5-fold more sensitive to benznidazole, respectively than wild 
type. For TbMRE11 null parasites overexpressing TbNTR, this increase in potency was 
enhanced with these cells showing a 19-fold increase in susceptibility indicating a link between 
activation of benznidazole by TbNTR and downstream DNA lesion formation.  
 
 
Treatment T. brucei EC50 (μM) 





Benznidazole 48.73 ± 2.30 39.67 ± 2.45 (1.3) 5.67 ± 0.66 (8.6)* 5.91 ± 0.79 (8.2)* 
DFMO 23.93 ± 1.02 26.42 ± 1.17(0.8) 21.35 ± 1.30 (1.1) 21.57 ± 1.26 (1.1) 
 
Treatment T. brucei EC50 (μM) 





Benznidazole 65.49 ± 2.90* 42.97 ± 3.53 (1.6)* 10.24 ± 0.73 (6.5)* 3.47 ± 0.28 (22)* 
DFMO 18.79 ± 2.08 26.19 ± 3.18 (0.7) 24.19 ± 3.72 (0.7) 19.46 ± 1.98 (1.0) 
Table 7.3: Data represents EC50 values of genetically engineered lines against 
benznidazole and DFMO.  
All values are means ± standard deviations from experiments performed in quadruplicate. The 
ratio of EC50 values between wild type and null mutant lines is given as fold difference, in 
parentheses. *Indicates significant differences in susceptibility (P < 0.0001 between wild type 
















7.4 Chapter Summary 
This chapter has focused on evaluating whether TbSNM1 can be exploited as a drug traget 
and determining if various trypanocidal agents mediate at least part of the mode of action by 
promoting DNA damage. We have demonstrated that: 
1. Some of the SNM1 inhibitors tested displayed trypanocidal activity but this did not 
involve targeting TbSNM1. 
2. Nifurtimox does not appear to promote DNA damage that is repaired by selected 
components of the NER, MMR, HR or ICL pathways/systems . 
3. The nitrogen mustard LH34 promotes formation of ICLs that are resolved using 
SNM1-dependent and SNM1-independent repair systems. 
4. The azrinidyl agent CB1954 promotes formation of ICLs that are resolved using the 
SNM1-dependent and SNM1-independent repair systems 
5. The azrinidyl agents CB1954 also promotes formation of additional DNA leisons that 
are repaired by components of the NER pathway 
6. Activation of benznidazole results in cytotoxic moities that promote a form of DNA 









The plan for the eradication of HAT by 2030 can only take place by the development of 
new, active preventative/curative therapies. Work carried out in the Wilkinson laboratory has 
studied clinically used HAT treatment regimes to identify and study the mode of action of novel 
trypanocidal agents. These studies have broadened our repository of trypanocidal agents and 
our understanding of trypanosomal cell and molecular biology (Wilkinson and Kelly, 2009; 
Meredith et al., 2017). These structure–activity relationship studies have focused on nitrogen- 
and quinone-containing chemicals which have revealed that many of these compounds promote 
mutagenic and clastogenic effects in the cell. These prodrugs, activated by a type 1 
nitroreductase (TbNTR), are processed in the parasite to form an open aziridine structure which 
has the ability to form adducts with negatively charged DNA, predominantly at guanine bases, 
with a repeat of this event resulting in the formation of interstrand crosslinks (Hall, Bot and 
Wilkinson, 2011; Bot et al., 2013; Meredith et al., 2017).  
 
This is the first study to comparatively analyse how trypanosomes repair crosslinks in DNA, 
with previous work carried out by the Machado & McCulloch laboratories speculating a role 
for the TC-NER pathway in trypanosomal intrastrand crosslink repair (Machado et al., 2014). 
Using an in vitro genetics-based approach, a series of null mutant lines were generated to 
delete/disrupt key components of ‘classical’ DNA repair pathways. Growth inhibition assays 
were carried out on these cell lines using various agents which promote DNA damage to assess 
the relative importance of each DNA repair protein in trypanosomal DNA and ICL repair 
mechanisms. This enabled us to 1. understand whether the DNA repair protein has a role in 
removing lesions introduced in the genome, 2. appreciate if the enzyme has a role(s) in 
removing ICLs and 3. unravel the epistatic/non-epistatic relationship between trypanosomal 
ICL repair factors to create the first model of trypanosomal ICL repair systems. The same cell 
lines generated for this project were used to evaluate how clinically relevant and novel 
trypanocidal agents mediate their cytotoxic activities by analysing the prodrug mode of action, 
especially in relation to ICL formation.  
 
The construction of null mutant lines was carried out using a traditional plasmid- and 
homologous recombination-based approach. This project could have exploited the newly-
developed CRISPR-Cas9 system created for T. cruzi and Leishmania organisms in T. brucei 
(Peng et al., 2014; Beneke et al., 2017) but given the ease of creating genetically engineered 
145 
 
null lines in T. brucei and readily available resources to carry this out, the development and 
exploitation of a CRISPR-Cas9 system in this parasite was not deemed necessary. However, it 
would be interesting to use this now well-established tool to confirm observations made in this 
thesis and to expand these studies into analysis of ICL repair systems in other protozoan 
parasites.  
 
Phenotypic screening was carried out on all null lines after a PCR-based approach was 
exploited to validate the genetically engineered lines: Confirmation at the protein level using 
western blotting-based techniques was not deemed necessary as absent RNA expression can 
be correlated to a lack of protein expression. This susceptibility screening was not extended 
out to heterozygote null mutants (which would give us an understanding into 
haploinsufficiency) due to time constraints with multiple, independently-generated clones 
analysed to confirm observations made. These phenotypic screens used mechlorethamine as 
the ICL inducing agent of choice to enable valid comparisons to be made against similar studies 
carried out in fungal lines (Lam, Krogh and Symington, 2008) and because mechlorethamine 
binds DNA with high affinity to produce stable ICLs (Bauer and Povirk, 1997). The use of 
other ICL inducing agents (e.g. psoralen-based compounds) would have confirmed conclusions 
made in this thesis but due to time constraints, this was not deemed a priority.  
 
8.1 Trypanosomal ICL repair systems 
The afore-mentioned approach has revealed that trypanosomes utilise the activities of 
TbSNM1, TbMRE11 (HR pathway), TbCSB (NER pathway) and TbEXO1 (MMR pathway) 
alongside factors of the FA pathway (TbRAD51, TbBRCA2, TbFAN1 and TbCHL1) for repair 
of ICLs with all data summarised in Table 8.1. Intriguingly, no evidence for a role of TbREV2 
and TbREV3 (TLS pathway) was identified.  Further studies using double null mutant lines 
lacking two DNA repair proteins revealed that trypanosomes possess at least two distinct 
pathways for the repair of ICLs; an SNM1-dependent ICL repair pathway which employs the 
functions of TbSNM1, TbCSB and TbEXO1 and an SNM1-independent ICL repair pathway, 
which utilised the functions of TbMRE11, TbFAN1, TbEXO1, and possibly the activities of 
TbRAD51 and TbBRCA2. Which system predominates in trypanosomes is yet to be answered 
but it is clear that similar pathways are being exploited by this parasite as seen in E. coli, yeast 




Alongside this work on dissecting trypanosomal ICL repair systems, studies on how 
crosslinked DNA is processed to form DSBs were undertaken and demonstrated a clear time-
dependent formation of γH2A, a marker for DSBs, in cells treated with the mechlorethamine. 
It was clear from these results that this ICL inducing agent forms damage in the trypanosome 
which can be processed to form DSBs, in keeping with previous observations on the processing 
of crosslinked DNA with the exact mechanism behind this still to be unravelled (Bessho, 2003; 
Sczepanski et al., 2009). Accumulation of DSBs in mechlorethamine treated cells peaked at 4 
hours incubation time which possibly reflects the time taken for the ICL inducing agent to 
crosslink DNA and produce the DSB. If this is the case, it would be interesting to understand 
the limiting factor for cleaving ICLs as well as how this relates to the different ICL repair 
systems. This could be evaluated using PFGE DNA fragmentation studies, the comet assay or 
the I-SceI meganuclease system (Singh et al., 1988; Lam, Krogh and Symington, 2008; 
Chiurillo et al., 2016).  
 
8.1.1 SNM1-dependent ICL repair system 
Studies on the trypanosomal SNM1-dependent ICL repair system has hypothesised that this 
mechanism functions by 1. stalling of RNA polymerase for recruitment of TbCSB, which 
unwinds damaged and neighbouring nucleotides for the recruitment of nucleases, 2. nucleolytic 
degradation of the unhooked DNA by TbSNM1 up to and past the crosslinked bases, and 3. 
TbEXO1 nuclease activity on crosslinked DNA as well as processing of base errors introduced 
into the genome during ICL repair. If this hypothesis is true, the SNM1-dependent ICL repair 
system operates like that seen in the transcription-coupled ICL repair system identified in 
mammalian cells as well as the dominant, PSO2-dependent mechanism employed by yeast (K 
F Grossmann et al., 2001; Enoiu, Jiricny and Schärer, 2012).  Given these similarities, the 
enzymes employed to carry out the initial ICL unhooking event needs to be evaluated to fully 
understand this pathway (Clauson, Schärer and Niedernhofer, 2013).  
 
8.1.1.1 Nuclease activity of TbSNM1  
Studies on the SNM1/PSO2 family of proteins has centered around the key and specific 
activity of this metallonuclease towards ICLs, as demonstrated in mammalian cells (Munari et 
al., 2013), yeast (Hazrati et al., 2008), C. elegans (Wilson et al., 2017), A. thaliana (Johnson, 
Hellens and Love, 2011) and  O. sativa (rice) (Kimura et al., 2005). This activity has been 
extended out to T. brucei with parasites lacking TbSNM1 displaying an increased sensitivity 
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towards ICL-inducing agents, as shown in both this study and published literature (Sullivan et 
al., 2015). This project has also shown that cells lacking TbSNM1 do not display any growth 
defects or arrest at any point in the cell cycle, with no growth defects also noted in yeast and 
C. elegans (Li, Hejna and Moses, 2005; Wilson et al., 2017). This is possibly linked to 
TbSNM1 functioning independently of the homologous recombination-coupled ICL repair 
system.  
 
Moreover, data represented here has not directly implicated TbSNM1 in the repair of 
pyrimidine dimers, double strand breaks or base oxidation, in keeping with previously 
published work (Sullivan et al., 2015). However, work shown in this thesis has indicated that 
TbSNM1 plays a compensatory role for the repair of UV-induced damage in the absence of 
TbMRE11, indicating that both proteins have common substrates for this form of damage. This 
observation has not been noted in any previous reports of SNM1/PSO2 activity other than 
expression of PSO2 is inducible by UV (Wolter, Siede and Brendel, 1996). Both SNM1 and 
MRE11 possess endonuclease and exonuclease activity (Paull and Gellert, 1998; Li, Hejna and 
Moses, 2005) with the exonuclease activity being strand specific, i.e. SNM1 cleaves strands 
5’-3’ and MRE11 cleaves DNA 3’-5’. This suggests that the endonuclease activity of both 
proteins is required for processing of dimerised DNA at a collapsed replication fork (Paull and 
Gellert, 1998; Limoli et al., 2002; Li, Hejna and Moses, 2005). It is possible that this 
endonuclease activity is critical for the creation of DSBs which initiates firing of a new 
replication origin as well as HR-mediated repair (Jones and Petermann, 2012).  
 
Taking into consideration the wild type-like γH2A formation displayed by cells absent for 
TbSNM1, it is unlikely that this nuclease has a role in the incision of unhooked ICLs for DSB 
formation, which has also been observed in yeast where PSO2 nuclease activity does not lead 
to DSB formation (Dudás et al., 2007). It is most likely that TbSNM1 functions in the cleavage 
of the DNA backbone, up to and beyond the ICL, revealing the damaged site for further 
processing (Tiefenbach et al., 2007) and possibly in the processing of the double strand breaks 
formed from the interstrand cross link (Li and Moses, 2003). It would be interesting to see how 




Gene Growth properties Growth inhibition assays  DSB 
formation 
 Growth  Cell cycle Phleomycin MMS UV Hydroxyurea HN2 γH2A 
TbSNM1 WT WT WT WT WT WT ↓↓↓↓ WT 
TbCSB WT WT WT WT ↓ WT ↓↓↓ ↓ 
TbMRE11 ↓ ↑1N2K  
↓1K1N 
WT 2K2N 
↓ ↓ ↓ WT ↓↓ NIL 
TbEXO1 WT ND ↓ WT WT WT ↓ WT 
TbREV2 WT ND WT WT WT WT WT ND 
TbREV3 WT ND WT WT WT WT WT ND 
TbFAN1 WT WT WT WT WT WT ↓ WT 
TbHEL1 WT ND WT WT WT WT WT ND 
TbCHL1 WT WT WT WT WT WT ↓ WT 
TbRAD51 ↓↓ WT* ↓* ↓* WT* ND* ↓↓* WT* 
TbBRCA2 ↓ ↓ 1K1N 
WT 2K2N & 
1N2K** 
↓** ↓** ND** ND** ↓↓** ND** 
Table 8.1: Summary of data presented for all trypanosomal DNA repair factors. 
Arrows indicate an increase (↑) or a decrease (↓) in phenotypic response when compared to wild type (WT) cells with multiple arrows shown for 
larger increases/decreases. ND stands for not determined for when an experiment was not performed. NIL refers to no increase or decrease seen. 
Corresponding data relating to TbBRCA2 was obtained from (Hartley and McCulloch, 2008) (denoted by *). Data obtained from (McCulloch and 
Barry, 1999; Proudfoot and McCulloch, 2005) relating to responses of TbRAD51 are denoted by **.  
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8.1.1.2 Critical role of TbCSB in damage recognition 
CSB (Tijsterman et al., 1997; Stevnsner et al., 2008) has repeatedly been shown to play a 
pivotal role in transcription-associated damage recognition, an activity which has been 
extended out to trypanosomal transcription-coupled repair (Machado et al., 2014; Wilson et 
al., 2017). TbCSB is a nuclear protein (Dean, Sunter and Wheeler, 2017) which repairs UV-
induced damage with no evidence for a direct role in repair of DSBs or base oxidation events, 
similar to observations noted by the McCulloch laboratory (Machado et al., 2014). An 
intriguing observation from these studies was a delayed accumulation of DSBs in Tbcsb-
deficient cells, as seen by a late accumulation of γH2A in mechlorethamine treated null cells. 
This could be explained by stalling of the transcriptional machinery which causes recruitment 
of CSB to the site of damage and downstream processing of such damage into double strand 
breaks for repair via the HR pathway. CSB has been associated with regulation of double strand 
breaks at sites of transcription which indicates that this helicase remains at the site of the lesion 
during the repair process, possibly for activiation of cell cycle checkpoints (Batenburg et al., 
2015). Given that CSB is one of the first factors to be called upon at a stalled RNA polymerase, 
this key role in transcription-associated recognition of multiple types of damage is plausible 
(Tijsterman et al., 1997).  
 
The role of TbCSB in repair of crosslinked DNA has been previously studied using cells 
expressing reduced levels of the helicase coupled with phenotypic screening using the 
crosslinking agents cisplatin and cyclophosphamide (Machado et al., 2014). This project has 
extended this initial work by screening of Tbcsb-deficient cells against the archetypal ICL 
inducing agent, mechlorethamine which has confirmed the role of TbCSB in ICL repair, 
specifically via the SNM1-dependent ICL repair system. The epistatic interaction between 
SNM1 and CSB has been extensively studied in mammalian cells (Iyama et al., 2015) with no 
discernible role for the yeast CSB homolog, RAD26, shown for ICL repair (Lambert et al., 
2003; Barber et al., 2005). This work on mammalian cells has revealed that HsCSB stimulates 
the activity of HsSNM1A to help promote ICL processing in a transcription-associated, 
replication-independent repair system (Iyama et al., 2015). The process of HsCSB upregulation 
occurs through halting of the RNA polymerase which leads to a hyperphosphorylation event 
of the polymerase and immediate upregulation of CSB (Luo et al., 2001; Lagerwerf et al., 
2011). HsCSB enhances the substrate specificity of HsSNM1A at the lesion site for processing 
of the unhooked ICL (carried out by the activities of XPF-ERCC1). It would be convienent to 
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assume that a similar post-translational modification of trypanosomal RNA polymerases could 
lead to TbCSB recruitment to site of DNA damage with further studies needed to evaluate this 
(Deaconescu, 2013). Biochemical in vitro assays are also needed to prove that the epistatic 
interaction of TbCSB and TbSNM1 is extended out to a physical, protein-protein interaction. 
With this information, the non-epistatic interaction between TbCSB and TbMRE11 was 
unsurprising as there is no currently evidence for a role of CSB in recombination-coupled ICL 
repair (Enoiu, Jiricny and Schärer, 2012).  
 
It is important to note that TbCSB has also been linked to promoting TLS polymerase 
activity to bypass damaged DNA (Machado et al., 2014). If this is the case, TbCSB may play 
a critical role in this repair mechanism, acting as a regulator for all steps during transcription-
associated repair. Whether CSA plays a similar role in ICL repair is yet to be studied (Iyama, 
Wilson and III, 2016). 
 
8.1.1.3 The combinatorial role of TbEXO1 in trypanosomal ICL repair 
This is the first study to look into the role of TbEXO1, an important nuclease of the MMR 
pathway, in trypanosomal DNA repair with other factors of the MMR previously studied 
elsewhere (Bell et al., 2004). This project has shown absence of TbEXO1 does not cause any 
growth defects, cell cycle defects or enhanced sensitivity to agents which promote base 
oxidation or pyrimidine dimers. Intriguingly, enhanced sensitivity of this null mutant line was 
seen towards phleomycin but not MMS, despite both agents promoting DSB formation. This 
may reflect the differences in how DSBs are generated by both agents with the length of the 
flap overhang (Pizzolato et al., 2015) affecting the efficiency of the 5’-3’ exonuclease activity 
of TbEXO1 (Keijzers, Bohr and Rasmussen, 2015). DSBs formed from stalling of the 
replication fork (as seen with MMS (Ensminger et al., 2014)) produce large overhangs, with 
these substrates displaying a reduced processing efficiency towards EXO1. This differs from 
DSBs formed from phleomycin-induced oxygen free radicals which create DSBs with 
overhangs of only a few nucleotides. In this latter case, efficiency/binding of EXO1 to the 
damaged DNA is higher (Keijzers, Bohr and Rasmussen, 2015). Given the MMR pathway 
repairs single/few damaged bases, this low processing power for EXO1 is understandable and 





EXO1 has been implicated in the fungal replication-coupled, PSO2-independent ICL repair 
system for the cleavage of unhooked DNA prior to strand annealing (Lam, Krogh and 
Symington, 2008; Ward et al., 2012; Kato, Kawasoe, Williams, Coates, Roy, Shi, Lorena S. 
Beese, et al., 2017). It has been shown that EXO1 acts as the alternative 5'-3' exonuclease in 
the absence of PSO2 (alongside factors of the MMR factors e.g. MutSa) (Ward et al., 2012). 
This differs from the situation seen in trypanosomes as TbEXO1 functions in both the SNM1-
dependent and -independent ICL repair systems, epistatically interacting with TbSNM1, 
TbCSB and TbMRE11. Trypanosomes may utilise the activity of TbEXO1 in both systems to 
1. function as the alternative nuclease in the SNM1-independent ICL repair pathway (as seen 
in yeast (Ward et al., 2012; Kato, Kawasoe, Williams, Coates, Roy, Shi, Lorena S Beese, et 
al., 2017)) and 2. repair errors introduced by the error-prone, SNM1-dependent ICL repair 
system (this mechanism is called ‘error-prone’ as the activity of TLS polymerases promotes 
base errors). To further evaluate the latter hypothesis, similar epistatic/non-epistatic studies 
should be carried out on cells lacking multiple factors of the MMR pathway, with the best 
candidate for this study being MSH2 given its well-characterised role in ICL repair (Williams 
et al., 2011; Ward et al., 2012; Kato, Kawasoe, Williams, Coates, Roy, Shi, Lorena S. Beese, 
et al., 2017).   
 
8.1.1.4 Absent role for TLS factors TbREV2 & TbREV3 
The TLS pathway plays a crucial role in ICL repair, filling gaps created by the cleavage 
activity of nucleases (Ho et al., 2011). Work in yeast has shown us that not all TLS polymerases 
play a role in ICL repair, where only five out of the fifteen polymerases are shown to function 
in this system (Kozmin and Jinks-Robertson, 2013). Absence of a growth, DNA or ICL repair 
phenotype for both TbREV2 and TbREV3, trypanosomal TLS enzymes, was peculiar but given 
that only two out of five of the TLS polymerases present in T. brucei were studied, it is still 
plausible that the TLS pathway plays a key role in trypanosomal ICL repair. Evidence for this 
can be seen when analysing the role of the TLS factor polymerase theta (Θ) of the protozoan 
parasite Leishmania infantum which has been shown to play a key role in repair of interstrand 
crosslinks (Fernández-Orgiler et al., 2016). Furthermore, trypanosomal TLS polymerases 
could be acting in a compensatory manner, functioning on behalf of another trypanosomal TLS 
polymerase when one is absent. With this in mind, a different approach may have to be 
undertaken to understand whether these TLS polymerases function in ICL repair. It is 
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hypothesised that the TLS pathway functions in both the SNM1-dependent and -independent 
pathway, given how these ICL repair systems operate in yeast and mammalian cells.  
 
8.1.2 SNM1-independent ICL repair system 
It is clear that trypanosomes possess a separate ICL repair system which utilises the 
activities of components of the homologous recombination and mismatch repair pathways, 
functioning independently of TbSNM1. It is hypothesised that this pathway involves 1. stalling 
of the replication fork resulting in the recruitment of nucleases to unhook the ICL, 2. cleavage 
of crosslinked DNA by the nuclease activity of TbMRE11, TbEXO1 and TbFAN1 (possibly 
resulting in DSB formation), and 3. error-free repair by the HR pathway utilising the activities 
of the TbRAD51, TbBRCA2 and TbCHL1 proteins. Trypanosomal FA homologues have been 
implicated in this system as many of the components identified in the parasites genome have 
additional roles in the HR pathway, a mechanism which has already been associated with the 
SNM1-independent ICL repair pathway by the activity of TbMRE11.  
 
8.1.2.1 Concerted actions of TbMRE11 & TbEXO1 
Studies carried out here on the role of TbMRE11 in trypanosomes has brought to light many 
interesting observations. The growth defect and G2/M cell cycle arrest displayed by the 
Tbmre11 null lines suggests this nuclease has a role in nuclear DNA replication. Work in 
mammalian cells has shown that ATM (ATM serine/threonine kinase) and ATR (Ataxia 
Telangiectasia) acts in the recruitment of MRE11 at the site of a collapsed replication fork 
(Trenz et al., 2006). This recruitment of MRE11 initiates the restart of the replication fork, thus 
preventing accumulation of DSBs and chromosomal abnormalities. T. brucei possesses 
homologues for both ATM (Tb927.2.2260) and ATR (Tb927.11.14680), which could make up 
the replication-coupled, DNA damage signalling network in trypanosomatids, alongside the 
recognition and repair activities of TbMRE11. This agrees with observations made from assays 
looking at γH2A formation, an indicator for DSBs, where Tbmre11 null cells show no 
phosphorylation event for this histone in mechlorethamine treated cells, indicating a key role 
for this nuclease in detection of DSBs and warrants further investigation into the regulation 
and checkpoint signalling of trypanosomal repair systems. 
 
Phenotypic screening of Tbmre11-deficient cells revealed a clear role for this nuclease in 
repair of lesions created by phleomycin, MMS, UV and mechlorethamine. Growth inhibition 
153 
 
data relating to MMS and phleomycin agrees with the McCulloch and Cross laboratories which 
have shown that cells lacking TbMRE11 are more sensitive to phleomycin and MMS, 
respectively, implicating this nuclease in the HR pathway (Robinson, McCulloch, Conway, 
Browitt and Barry, 2002; Tan, Leal and Cross, 2002).  Our results have also implicated a role 
for TbMRE11 in repair of UV-induced lesions with work in mammalian cells relating this 
observation to stalling of the replication fork at the site of dimerised DNA. This event leads to 
recruitment of the MRN complex for replication fork restart (Limoli et al., 2002), connecting 
observations made in both trypanosomal and mammalian cell lines.   
 
The role of TbMRE11 in trypanosomal ICL repair was unsurprising due to the well-
documented role of MRE11 in both mammalian and yeast cells, functioning independently of 
SNM1/PSO2 (Pichierri, Averbeck and Rosselli, 2002; Lam, Krogh and Symington, 2008). The 
epistatic interaction of TbEXO1 and TbMRE11 has been linked with processing of unhooked 
ICLs as MRE11 possesses 3’-5’ exonuclease activity and EXO1 has 5’-3’ exonuclease activity, 
ideal for cleavage at this site (Barber et al., 2005). Whether this processing leads to DSB 
formation is yet to be studied. This data could also explain why trypanosomes do not require 
the activity of TbSNM1 in the MRE11-dependent system: TbEXO1 is able to compensate for 
the activity of SNM1 (Pizzolato et al., 2015). It is tempting to speculate that this system is 
coupled with ICLs encountered during replication due to the correlation between factors of the 
homologous recombination pathway and DNA damage at a DNA replication fork (S-phase of 
the cell cycle). This also explains the non-epistatic interaction of TbMRE11 and TbCSB; 
unwinding of the double helix is not required due to the presence of the large replication bubble.  
 
8.1.2.2 Trypanosomal FA factors and the SNM1-independent ICL repair system 
This study has identified and characterised trypanosomal homologues of FA factors with 
these results demonstrating that trypanosomes employ a similar system to yeast where these 
FA proteins function alongside the classical DNA repair pathways to resolve such lesions 
(Daee and Myung, 2012; McHugh, Ward and Chovanec, 2012). The early branching nature of 
the trypanosomatid tree of life has resulted in trypanosomes exploiting components of classical 
DNA repair pathways for the removal of crosslinks as opposed to evolving a dedicated ICL 
repair pathway. Many organisms including A. thaliana (Molinier, Stamm and Hohn, 2004) and 
S. cerevisiae function in a similar mechanism with these factors predominantly acting in 
SNM1/PSO2 independent DNA repair pathways. Zebrafish are one of the few organisms, other 
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than humans, which possess all homologues of the FA core complex with these factors also 
playing a role in sex determination and genomic stability (Rodríguez-Marí and Postlethwait, 
2011).  
 
The FA pathway consists of 1. recognition of the damaged DNA and assembly of eight 
proteins that form the so-called FA core complex, 2. activation of the FANCD2/FANCI 
heterodimer that functions as a recruitment complex, and 3. association of effector proteins that 
operate to resolve the ICL. The absence of all components of the FA core complex (except 
FANCM) in and homologues of FANCD2 and FANCI suggests that trypanosomes employ a 
separate mechanism for ICL recognition and factor recruitment, possibly via stalling of the 
replication fork leading to the recruitment of ATM and/or ATR, which when phosphorylated, 
are able to upregulate DNA repair factors e.g. EXO1/MRE11 (Moldovan and D’Andrea, 2009). 
This also explains the absence of UHRF1 and UAF1, both of which are involved in 
recruitment/deubiquitination of FANCD2, respectively (Moldovan and D’Andrea, 2009; Liang 
et al., 2015).  
 
Many FA effector proteins are also putatively absent from the trypanosome genome. 
FANCP, SLX4, is a key endonuclease which plays a role in the initial incision step for 
unhooking of the ICL and resolution of the Holliday junction (Cybulski and Howlett, 2011). 
Its absence in trypanosomes is intriguing given various endonucleases are exploited for 
cleavage of ICLs in mammalian cells. Studies in this thesis have implicated endonucleases 
TbSNM1, TbMRE11 and TbFAN1 in ICL repair and given that trypanosomes are simple 
eukaryotes, these parasites may only require a minimal number of nucleases for ICL 
processing, possibly explaining the absence of FANCP. Furthermore, absence of FANCN 
(PALB2), FANCS and FANCU (XRCC2) can be explained by TbBRCA2 and TbRAD51 
paralogues carrying out their given roles in the FA pathway (Simhadri et al., 2014; Park et al., 
2016). The nuclear localisation of FA effector proteins and RAD51-heterodimer formation for 
strand exchange, which is associated with the activities of these FA factors, can be carried out 
by TbBRCA2 and TbRAD51 paralogues, explaining their absence from the trypanosomal 
genome (Dobson et al., 2011; Genois et al., 2014) 
 
Despite the absence of many FA factors, trypanosomes express some FA effector proteins, 
primarily belonging to the HR pathway. Studies in this thesis have shown a key role for 
TbRAD51 (or TbFANCR), TbBRCA2 (or TbFANCD1), TbCHL1 (or TbFANCJ) and 
155 
 
TbFAN1 in trypanosomal ICL repair with TbHEL1 being the only trypanosomal FA factor to 
display no evidence for a role in ICL repair. The only FA factors yet to be studied include 
FANCQ, FANCV and USP1. 
8.1.2.3 Functions of TbRAD51 and TbBRCA2 in trypanosomal ICL repair 
It is unsurprising that TbRAD51 and TbBRCA2 play a role in ICL repair as both proteins have 
been extensively characterised in fungal and mammalian ICL repair systems (K F Grossmann 
et al., 2001; Noll, Mason and Miller, 2006; Ward et al., 2012). TbRAD51 and TbBRCA2 
possess recombinase/helicase activity, respectively, to search for homologous sequences on 
sister chromatid DNA for error-free ICL repair. It would be interesting to understand the role 
of the four RAD51 paralogs identified within the T. brucei genome (RAD51-3 (also known as 
FANCO), RAD51-4, RAD51-5 and RAD51-6) and how they influence this activity and ICL 
repair (Dobson et al., 2011). It would also be interesting to identify whether a single residue in 
these proteins aids ICL repair, as seen with mammalian RAD51 (Wang et al., 2015), a feature 
that may be exploitable in terms of chemotherapeutic development. 
 
It would have been interesting to carry out epistatic/non-epistatic relationship studies 
between TbMRE11 and these enzymes but due to the growth defects observed by the single 
null lines and the need for the HR pathway to generate these genetically engineered lines, this 
was not possible. A new approach is needed to fully understand the interaction of these HR 
factors with one possible method exploiting tagged-TbMRE11 lines generated in the Wilkinson 
laboratory for co-immunoprecipitation studies with this approach being an excellent tool for 
understanding this ICL repair at a protein-protein level by revealing the physically interacting 
partners of TbMRE11.  
 
8.1.2.4 Nuclease activities of TbFAN1 on crosslinked DNA 
Recent work has highlighted the importance of FAN1 in this repair system with many 
research groups demonstrating its function as comparable to SNM1 with activities carried out 
by a highly conserved and FAN1-specific VRR-NUC domain (O’Donnell and Durocher, 2010; 
Jin and Cho, 2017). TbFAN1, a  nuclear DNA repair protein (Dean, Sunter and Wheeler, 2017), 
possesses a similar VRR-NUC domain and “PDXn(D/E)XK” motif which was sufficient 
evidence to state this protein as true TbFAN1 homologue (Fontebasso et al., 2013). Phenotypic 
susceptibility screening of TbFAN1-deficient cells revealed no altered sensitivity to 
hydroxyurea, UV, MMS and phleomycin with a clear increase in susceptibility to 
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mechlorethamine. It would be interesting to analyse the sensitivity of this null line to 
mitomycin C, the archetypal DNA damaging agent for characterisation of FA factors (Jin and 
Cho, 2017).  
 
This clear role for FAN1 in trypanosomes has further developed our understanding on how 
damaged DNA is processed for the BRCA2-RAD51 complex. Previous work on the role of 
FAN1 in ICL repair has shown that upon recruitment by FANCD2, this nuclease cleaves 
around the damaged DNA and acts as a replication fork recovery factor. Mammalian cells 
absent for FANCD2 cause MRE11-dependent access for FAN1 at a stalled replication fork to 
degrade damaged DNA strands (Indrajit Chaudhury, Stroik and Sobeck, 2014). Given that no 
trypanosomal homologue of FANCD2 has been identified and TbFAN1 and TbMRE11 
function epistatically, a similar FANCD2-independent incision event may occur in 
trypanosomes. Upon stalling of the replication fork, it is hypothesised that these nucleases 
(TbMRE11 and TbFAN1) carry out extensive nucleolytic degradation of the DNA strands to 
create substrates which RAD51 is able to bind, thus promoting HR repair. Alongside this, they 
function in creating a new replication origin for fork restart to help promote DNA replication. 
New replication fork origins are needed to repair DNA without affecting the speed of DNA 
replication (Stanojcic et al., 2016). As FAN1 homologues incise DNA three or four nucleotides 
near the ICL, transversing the crosslink, it is predicted that FAN1 can unhook the ICL and 
incise flapped DNA surrounding the ICL which may explain how ICL-induced DSBs are 
formed in trypanosomes (Pizzolato et al., 2015).  
 
8.1.2.5 The baffling function of TbCHL1 
TbCHL1, a nuclear ATP-dependent helicase (Dean, Sunter and Wheeler, 2017), has been 
implicated as a trypanosomal ICL repair factor and taken together with information from 
literature, TbCHL1 is hypothesised to function in the SNM1-independent (Brosh and Cantor, 
2014). As seen with TbFAN1-deficient cells, Tbchl1 null lines display no altered susceptibility 
to phleomycin, MMS, UV or hydroxyurea with additional work needed to look at susceptibility 
to mitomycin C to confirm a role in the FA pathway.  
 
Analysis into the role of TbCHL1 in trypanosomal ICL repair has revealed some interesting 
findings with dose response curves against mechlorethamine demonstrating a regulatory role 
for TbCHL1 in ICL repair. It is hypothesised that TbCHL1 is acting as a co-regulator for the 
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activities of ICL repair factors with these factors acting to compensate for the activity of 
TbSNM1. Absence of both TbSNM1 and TbCHL1 releases these activities, restoring the cells 
ability to repair ICLs. Typically, FANCJ acts as a unique helicase which unwinds 5’ssDNA 
forked duplex substrates which contains at least 15 nucleotides (Wu and Brosh, 2009). In yeast 
cells, FANCJ plays a role in the Pso2-independent ICL repair pathway, functioning alongside 
the Mph1-Mgm101-MutSα complex for the activation and recruitment of Exo1 to the damage 
site (Ward et al., 2012). This contrasts observations made in this thesis as a classical, non-
epistatic interaction would have been predicted if TbSNM1 and TbCHL1 functioned in 
independent ICL repair systems, as seen in yeast. Further studies are needed to explore the role 
of TbCHL1 in detail. 
 
8.1.3 Summary  
Our data and the work carried out on yeast and mammalian cells suggests that there is more 
than one system for the repair of ICLs, dependent on the temporal and spatial nature of ICL 
detection, with each system differing in relation to enzymes employed to the site of damage 
(Shen and Li, 2010). Whether the SNM1-independent or -dependent system is the central ICL 
repair mechanism is yet to be evaluated: ICL repair studies carried out on mammalian cells 
indicates that the FA, replication-coupled system is the dominant ICL repair mechanism. Given 
the multigenic nature of transcription in this parasite, we hypothesise the SNM1-dependent 
ICL repair pathway is the preferred repair system as regulation at a transcriptional level is of 
great importance in the parasite. It is tempting to speculate the fold differences observed 
between wild type and null lines reflects the relative importance of the ICL repair protein being 
tested however it is more likely that the variation observed here reflects the role of that enzyme 
in repair associated with transcription or replication: an asynchronous culture of trypanosomes 
contains more transcriptionally active cells than dividing cells. A summary of both 





Figure 8.1: Current model for trypanosomal ICL repair. 
 
 
8.2 TbSNM1 structure and function 
Initial in silico analyses carried out on TbSNM1 were extended to understand the proteins 
1. catalytic activity, 2. substrate specificity and 3. nuclear localisation (Sullivan et al., 2015). 
This work was carried out by ectopic, inducible expression of either wild type or mutated GFP-
tagged TbSNM1 in a genetic background absent for TbSNM1 which has proven to be an 
excellent tool to developing a clear understanding of which residues play a key role in this 
enzymes activity. Results from this analysis have demonstrated a role for residues D40, H80, 
D82 and H159 in TbSNM1 catalytic activity, residues R429 and R430 in protein localisation 
and a possible structural role for the D221 residue (Table 8.2). Structural consequences of 
mutating TbSNM1 were analysed in silico using a predicted TbSNM1 model created from both 
human SNM1 proteins as the structural templates. Ideally the residues hypothesised to be 
responsible for the coordination of the zinc metal ion in TbSNM1 would have been confirmed 
biochemically (e.g. using isothermal titration calorimetry) but given time constraints and lack 
of appropriate resources, this was not carried out. This model predicted TbSNM1 to bind one 
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zinc ion, possibly in an octahedral arrangement, similar to that observed by HaSNM1A, which 
may indicate that TbSNM1 solely functions in ICL repair, as seen with HaSNM1A (Sengerová 
et al., 2012).  
 
Putative function TbSNM1 Mutation Localisation Complementation 
Co-factor binding D40A Nuclear No 
 H78A Nuclear Yes 
 H80A Nuclear No 
 D82A Nuclear No 
 H83A Nuclear Yes 
 H159A Nuclear No 
 H178A Nuclear Yes 
 D221A Non-specific No 
 H496A Nuclear Yes 
Localisation R428A Nuclear Yes 
 R429A Non-specific No 
 R430A Non-specific No 
 H431A Nuclear Yes 
Substrate specificity V518A Nuclear Yes 
Table 8.2: Summary of TbSNM1 mutational analysis. 
8.2.1 Key residues in TbSNM1 nuclease activity  
Four key residues have been implicated in TbSNM1 nuclease activity with one of these 
residues being the arginine at position 40. The analogous residue in HsSNM1B, D14, has an 
important structural role for formation of hydrogen bonds to coordinate H36 (motif 2) and H99 
(motif 3) residues, with both of these motifs having a direct role in enzyme catalytic activity 
(Allerston et al., 2015). Molecular modelling places the D40 residue in close proximity to 
residues of motif 2 (78-HxHxDH-83), suggesting that this residue may be playing a critical 
role in the coordination of this motif to the zinc ion as opposed to a direct role in zinc binding.  
 
Furthermore, it was identified that residues H80 and D82 of the ‘HxHxDH’ motif play an 
important role in TbSNM1 catalytic activity with both residues in close proximity to the zinc 
metal ion. Given all residues of this motif in HsSNM1A play a role in coordination of the metal 
ion, it was predicted that mutation of H78 and H83 would have also displayed a similar 
phenotype as mutation of H80 and D82 residues (Hazrati et al., 2008). It is likely that the exact 
activity of these residues can only be revealed by biochemical analysis of the TbSNM1 




Studies on the H159 residue of motif 3 have shown a key role in protein enzyme function. 
In HaSNM1A, this residue also plays a critical role in enzyme function to coordinate the third 
bond with the zinc ion, with the other two bonds coordinated by motifs 1 and 2, alongside motif 
4 (Allerston et al., 2015). It is hypothesised that the residue H159 also functions in a similar 
manner as molecular modelling shows a clear interaction of this motif with all other TbSNM1 
motifs. The conserved residue of motif 4, H178, did not display any evidence for a role in 
TbSNM1 catalytic activity, despite this motif playing a clear role in HaSNM1A activity. 
Furthermore, residue H496 did not show any indication for a role in TbSNM1 nuclease activity 
with the respective conserved residue in HsSNM1A (H994) also not displaying any evidence 
for a role in nucleotide hydrolysis. However, the corresponding residue in PSO2 (H611) does 
show evidence for mediating the catalytic reaction with damaged DNA (Sengerová et al., 2012) 
which confirms that TbSNM1 functions in a similar manner to HsSNM1A and not HsSNM1B 
or PSO2. This data demonstrates that conserved residues found in motifs 1, 2 and 3 all play a 
key role in TbSNM1 nuclease activity which differs from other SNM1 homologs where all 4 
motifs have catalytic functions. It is hypothesised that this histidine-rich coordination of the 
zinc metal ion aids redistribution of electrons around the aromatic imidazole ring of the amino 
acid to carry out the nucleophilic attack on DNA.  
 
Further to this, it has been hypothesised that the D221 residue of motif 4 plays an important 
structural role in TbSNM1. Motif 4 in other SNM1 homologs contributes to the bridge between 
zinc ions and residues (Allerston et al., 2015), playing a critical process in maintaining this 
structure. This could explain why mutation of D221 into alanine resulted in a loss of TbSNM1 
structural integrity; this residue plays a key role in maintaining this structure, potentially aiding 
the connection between the zinc binding pocket and the rest of the protein. Inhibitors of this 
residue could prove to be great therapeutic targets against TbSNM1.  
 
8.2.2 Evaluating TbSNM1 substrate specificity   
TbSNM1 substrate specificity has been associated with a conserved valine residue at 
position 518 with mutation of this residue displaying no evidence for altered TbSNM1 activity. 
This result has also been observed with HsSNM1A when mutation of the equivalent residue to 
either alanine or histidine maintained the nucleases enzymatic activity (Sengerová et al., 2012). 
It is plausible that many residues confer substrate specificity in the SNM1 family of proteins. 
Residues E213 and H254 in HsSNM1A have been hypothesised to aid this DNA specificity 
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which suggests that a triple mutation of all three residues may alter the enzymes ability to bind 
DNA efficiently (de Villartay et al., 2009). Although equivalent and conserved residues to 
E213 and H254 have not been identified in TbSNM1, further work on identifying residues 
responsible for TbSNM1 DNA binding is important to gain a full understanding of the proteins 
activity.  
 
8.2.3 Dissecting the TbSNM1 nuclear localisation signal 
This study has implicated two key residues, R429 and R430, in TbSNM1 nuclear 
localisation with no analogous role for R428 and R431 residues seen. With no comparable 
work carried out in mammalian and yeast homologues of this nuclease, it is hard to determine 
whether this trait is conserved within other organisms. It is tempting to speculate that residues 
R428 and R431 in TbSNM1 are required for protein localisation given that all four amino acids 
interact directly on the model of TbSNM1 and are all exposed on the surface of the protein, an 
attribute which is vital when targeting proteins to the nucleus. To test this, mutation of multiple 
residues may be required. Regardless, this data could be exploited for the development of 
inhibitors against TbSNM1.   
 
8.2.4 Summary 
The results observed here merit further investigation into the structural properties of 
TbSNM1. These same cell lines can be used to carry out pull-down assays to identify if these 
mutations affect the physical interacting partners of TbSNM1. The plasmids used for this assay 
can also be used for protein purification and in vitro activity assays to develop our knowledge 
on this structure-function relationship. Studies could also be broadened out to understand how 
mutation of two residues affects TbSNM1 catalytic activity. It would be interesting to 
undertake a biochemical analysis of TbSNM1 to analyse the enzymes binding specificity 
towards single stranded DNA and double stranded DNA. This could reveal how TbSNM1 
hydrolyses DNA and whether it acts in a similar manner to HsSNM1A where small activity 
towards RNA is also seen. Structural, biophysical and fluorometric assays could be used to 
understand the processing power of TbSNM1 in relation to its efficiency in digesting past the 
ICL, as seen with HsSNM1A (Sengerová et al., 2012). This high processing power of 
HsSNM1A has been related to residues K904-K906 with mutations of these residues reducing 
the processing power of the enzyme but not affecting the enzymes catalytic activity (Allerston 
et al., 2015). This mutation resulted in a reduced capacity to digest substrate DNA with 
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premature termination of digestion. These lysine residues are semi-conserved in TbSNM1 with 
arginine residues present in the trypanosomal sequence, both of which are positively charged 
amino acids.  Given that mutation of these residues does not affect the enzymes nuclease 
activity, studies carried out in this study cannot be used to evaluate the role of these residues 
with biochemical studies needed to dissect the function of these conserved arginine residues.  
 
8.3 Cytotoxic effects of trypanocidal compounds 
The cytotoxic effects towards DNA of clinically used and novel trypanocidal agents were 
evaluated to reveal that nifurtimox does not cause the formation of any DNA damage on the 
parasites genome, benznidazole promotes DNA damage which is repaired by the HR pathway 
(Campos et al., 2017), LH34 promotes ICL formation and CB1954 promotes both adduct and 
ICL formation in the parasite. The damage incurred by benznidazole involves prodrug 
activation which creates electrophilic drug metabolites which can lead to oxidative stress and 
adduct formation. Nitroreduction of CB1954 can result in the production of 4-hydroxylamine 
which can be processed to act as an electrophilic intermediate, alkylating cellular nucleophiles 
such as DNA (Meredith et al., 2017). This nitroreduction event can also result in the formation 
of 2-nitroso and 2-amine metabolites, both of which are able to alklyate DNA to create 
monoadducts (Mitchell and Minchin, 2008). Arizidinyl compounds vary in their structure 
which is reflected in the type of lesions formed on DNA. This could explain why LH34 only 
displays evidence for promotion of ICLs and no other adducts. This can help broaden our 
understanding of how arizidinyl-containing compounds function intracellularly, potentially 
extending the number of compounds which can be used in anti-tumour therapy.  Many ICL-
inducing agents are exploited to target cancer, with arizidine-containing compounds no 
exception.  
 
8.4 An unexpected journey 
TbHEL1, initially presumed to be a homologue of FANCM, displayed no evidence for a 
role in DNA repair, despite in silico analyses indicating a typical FANCM-like conserved 
protein domain and sequence structure. Given this, it was clear why trypanosomes are also 
absent for some ancillary FA factors (e.g. FAAP100, FAAP24, FAAP16 and FAAP20) as these 
proteins aid in FANCM localisation to chromatin and recognition of ICLs. Further studies on 
this enzyme has indicated a key role in trypanosomal RNA interference, possibly acting as the 
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missing helicase from DICER (Patrick et al., 2009).  It is postulated that TbHEL1 directly 
interacts with TbDCL1 and TbDCL2 for the cleavage of double stranded RNA (dsRNA) 
molecules to produce siRNA molecules which are degraded by the RISC complex (Hammond, 
2005). TbHEL1 could operate to determine which RNA molecules undergo dicer-mediated 
cleavage and process hairpin precursor microRNAs. Given that most DICER proteins possess 
both incision and helicase activities, this arrangement is rather strange but has been noted in 
other species e.g. Sporotrichum thermophile where dicer related helicases operate in a separate 
system to the DICER enzyme (Kidwell, Chan and Doudna, 2014). Other protozoan parasites 
are also able to undergo RNA interference but by different mechanisms which indicates that 
this silencing event in eukaryotes occurred at a very early point in evolution. Gene silencing in 
Plasmodium and Giardia species is hypothesised to operate in a classical RNA interference 
system, as seen in mammalian cells, with other trypanosomal RNA interference mechanisms 
similar to the above, multifactorial system (Ullu, Tschudi and Chakraborty, 2004). It is 
plausible that this complex RNA interference pathway requires the aid of additional helicases 
and ancillary proteins which are yet to be identified and studied in this parasite. It would be 
interesting to analyse the interaction of dsRNA and TbHEL1, including conserved residues 
responsible for this interaction and how the length of the dsRNA molecule affects the helicase 







9. Future work 
This is the first comprehensive study to look at how trypanosomes repair ICLs with many 
unanswered questions still remaining. Which other DNA repair factors are employed to remove 
ICLs? Are there any additional ICL repair systems employed by the parasite? Does T. brucei 
possess additional ICL repair specific factors currently not identified in prokaryotes or 
eukaryotes? How do these results compare with ICL repair systems in other protozoan parasites 
e.g. T. cruzi or Leishmania?  
 
The next step for this project is confirming the dominant ICL repair system, particularly in 
relation to the different stages of the cell cycle. This could be carried out by stalling null lines 
at distinct stages of the cell cycle with further evaluation of their response to mechlorethamine 
(Nair et al., 2014). Evaluating whether these ICL repair systems are coupled to stalling of the 
transcription/replication machinery can be tested using inhibitors of RNA/DNA polymerases 
to evaluate how this affects sensitivity of null lines to ICL inducing agents. Furthermore, 
SMARD can be used to look at replication changes, both rate and direction, in 
mechlorethamine treated null cells (Calderano et al., 2015) with the hypothesis that any factors 
involved in replication-coupled ICL repair will display a prolonged rate of replication due to 
the lack of ICL repair. A similar study can be used to study transcription-coupled ICL repair 
factors with RT-qPCR carried out on a single polycistron to look at transcriptional changes 
upon treatment with mechlorethamine. 
 
Identification of other trypanosomal ICL repair factors should focus on understanding how 
the initial unhooking event occurs in the parasite. A similar genetics-based approach (either 
using plasmid-based knockouts or the CRISPR-Cas9 system) coupled with susceptibility 
screening can be used to look at the ICL repair activities of TbXPG (Tb927.9.11760), 
TbERCC1 (Tb927.7.2060), TbXPF (Tb927.5.3670), TbMUS81 (Tb927.8.6740), TbSLX1 
(Tb927.3.1220) with EME1 and SLX4 absent from the trypanosome genome (Genois et al., 
2014; Machado et al., 2014). TbXPG has been studied for a role in the TC-NER pathway and 
is hypothesised to carry out these nuclease activities in the SNM1-dependent repair pathway 
(Machado et al., 2014). The activity of TbXPF was not assessed in the aforementioned study 
but given its activity in mammalian cells, it can be hypothesised to function alongside 
TbERCC1 in the SNM1-dependent repair pathway. The endonuclease activities of both these 
nucleases in trypanosomes can be tested by incubation of purified proteins with crosslinked, 
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circular DNA with cleavage activities confirmed by linearization of DNA (Wood, 2011; Klein 
Douwel et al., 2017). TbMUS81 has been functionally characterised by the McCulloch 
laboratory in relation to its role in recombination repair (Devlin, 2015) with its role in ICL 
repair currently unstudied. Given the interacting partner of TbMUS81 is absent, EME1, it is 
highly unlikely that this complex plays a role in removal of ICL lesions. 
 
Identifying the role of the remaining FA factors identified in the trypanosome genome 
(FANCO, FANCQ, FANCV and USP1) would complete this analysis into the role of the 
trypanosomal FA pathway. FANCQ (XPF) is hypothesised to play a nuclease function for the 
unhooking of damaged DNA. FANCO, RAD51-C, has been studied for its auxiliary role in the 
HR pathway and may function alongside TbRAD51 and TbBRCA2 for strand invasion 
(Dobson et al., 2011). FANCV, MAD2, functions as a cell cycle checkpoint protein in spindle 
assembly during the metaphase-anaphase transition and has been hypothesised to play a role in 
the SNM1-independent ICL repair pathway for regulation of the cell cycle (Actis et al., 2016).  
Finally, USP1 functions in the deubiquitination of FANCD2 with several potential homologues 
of USP1 identified in the parasite genome (Kim and Kim, 2016). With the absence of FANDC2 
in the parasite, this hydrolase may function in other regulatory mechanisms e.g. the post-
translational modification of TbBRCA2 for protein activation (Schoenfeld et al., 2004). Studies 
identifying new ICL repair factors should also be carried out using a genome wide RNAi 
screen, RIT-seq (RNAi target sequencing) screen with mechlorethamine as the selective agent 
of choice (Stortz et al., 2017).  This would reveal any novel DNA repair proteins involved in 
the trypanosomal ICL repair system as well as the ICL damage signalling pathways.  
 
An extension of the above-mentioned biochemical analysis for TbSNM1 will reveal any 
potential targetable sites for the development of inhibitors of this protein. This can involve 
carrying out pull down assays on the ectopic expression of an amino terminally GFP tagged 
version of the enzyme to evaluate the physically interacting partners of TbSNM1, potentially 
identifying trypanosome-specific ICL repair factors. Further to this, purification of TbSNM1 
and crystallisation studies would help advance the structure and function analysis shown in this 
thesis. This work would confirm the exo- and endonuclease activity of TbSNM1, substrate 
specificity, and interactions with the zinc co-factor. With components of the trypanosomal ICL 
repair systems identified, it would be interesting to develop the understanding of their 
helicase/nuclease activities using in vitro enzyme activity assays carried out on purified 




1. T. brucei possesses at least two distinct ICL repair systems 
a. An SNM1-dependent ICL repair system where TbSNM1 co-operates with TC-
NER (TbCSB) and MMR (TbEXO1) enzymes to repair the encountered 
damaged, possibly triggered as a result of RNA polymerase stalling 
b. An SNM1-independent ICL repair systems which utilises components of the 
HR (TbMRE11 and potentially also TbRAD51 and TbBRCA2), MMR 
(TbEXO1) and FA (TbFAN1) pathways to repair the encountered damaged, 
possibly triggered as a result of DNA polymerase stalling 
2. TbHEL1 plays a crucial role in the T. brucei RNA interference machinery, potentially 
functioning as the RNA helicase that is absent from the T. brucei DICER sequence but 
present in the counterparts expressed by higher eukaryotes 
3. TbCHL1 (a FANCJ homologue) appears to play an ancillary role in the T. brucei ICL 
REPAIRtoire and may have a regulatory function 
4. The TbREV2 and TbREV3 TLS enzymes appear to play no role in ICL repair 
suggesting that other TLS factors may function in trypanosomal ICL repair systems 
5. D40, H80, D82, and H159 residues play a key role in TbSNM1 activity, with 
comparative studies and in silico modelling suggesting they may be involved in zinc 
co-factor binding 
6. R429 and R430, but not R428 and H431, residues play a crucial role in the localisation 
of the protein to the nucleus 
7. Activation of benznidazole results in cytotoxic moities that promote a form of DNA 
damage that can be resolved using components of the HR pathway 
8. The nitrogen mustard LH34 promotes formation of ICLs that are resolved using 
SNM1-dependent and SNM1-independent repair systems 
9. The aziridinyl agent CB1954 promotes formation of ICLs that are resolved using the 
SNM1-dependent and SNM1-independent repair systems and additional DNA leisons 







Appendix 1: Stocks 
Plasmid Source 
pKO-TcFHM-HYG (de Padua et al., 2017) 
pKO-TcFHM -NEO (de Padua et al., 2017) 
pKO-TcFHM -BLA (de Padua et al., 2017) 
pKO-TcFHM -PAC (de Padua et al., 2017) 
pKO-TbSNM1-BLA (Sullivan et al., 2015) 
pKO-TbSNM1-PAC (Sullivan et al., 2015) 
pRPa-GFP-TbSNM1  (Sullivan et al., 2015) 
Appendix 1a: Starting plasmids used in this study. 
 
 
All primers used in this study are listed and were sourced from Sigma Aldrich. All primers 
were resuspended in 1mL of sterile water, roughly equating to 50-100 pmol µl-1.  











Tbcsb-KO3 5’-aaagggcccGAGGGATCGTAAAGTGACCTT -3’ 









Tbfan1-KO1 5’-aaagagctcccgcggATGACAGGTGACGTCTGCCCT -3’ 
Tbfan1-KO2 5’-aaatctagaGCCGAAAGATCGCCTTACCAT -3’ 
Tbfan1-KO3 5’-aaagggcccTTTGGACCCTGAGGAGTTTCC -3’ 
Tbfan1-KO4 5’-aaaggtaccTTATACAGGAGGGTGCGCTCC -3’ 
Tbrev2-KO1  5’-aaagagctcccgcggATGCCACCGAGGAAGAGAAG-3’ 
Tbrev2–KO2  5’-aaatctagaGTCAAATCCAACGCACGGCAA-3’ 
Tbrev2-KO3  5’-aaagggcccTTTCAAACGAAACTACCGCCC-3’ 
Tbrev2-KO4  5’-aaaggtaccTCACGCTTGTTGCGCTTGAAG-3’ 
Tbrev3-KO1  5’-aaagagctcccgcggATGAACTTGTACGTAGTCTC-3’ 
Tbrev3-KO2  5’-aaatctagaAGTGCCTCCATAGCAACCGAC-3’ 
Tbrev3-KO3  5’-aaagggcccCATTGTTCCTACGCTCGACAG-3’ 
Tbrev3-KO4  5’-aaaggtaccTCAGCGAGTCGTTACGTAGTC-3’ 
NEO-2 5’- CTAGAAGAACTCGTCAAGAAG-3’ 
168 
 
HYG-2 5’- CTATTCCTTTGCCCTCGGACG-3’ 
BLA1 5’- CTGGCTAATGTTAAAGGTTTTCAT -3’ 
PAC1 5’- CGGGCTTGCGGGTCATGCACCA-3’ 
GFP 5’- GGCATGGACGAGCTGTACAAG -3’ 
Tbsnm1-KO1 5’-aaagagctcccgcggGCAGGTGGAGCTGCAGGTAAG -3’ 
Tbsnm1-seq1 5’-CACCAGATCACCATTGCGGAG -3’ 
Tbsnm1-q1 5’-AGATGCTAAACAAGAAGAGTC -3’ 
Tbexo1-q1 5’-TCGGTGCCGGATGTCATTCGG -3’ 
Tbexo1-q2 5’-CAACGCACGTTTCACCGGGTC -3’ 
Tbmre11-q1 5’-GGGTTTGACATCATTCAGCCG -3’ 
Tbmre11-q2 5’-CCGGACGACAGGACGAATACT -3’ 
Tbcsb-q1 5’-GGTCTAGCAGCGTTAGAAGCT -3’ 













Appendix 1b: Primer names and sequences used in this study. Lowercase, italicised 




Appendix 2: Validation of single null mutant lines 
 
Appendix 2a: Generation of T. brucei line lacking TbMRE11.  
A. Representation of the Tbmre11 gene and disrupted alleles using genes encoding for 
neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbmre11-KO1), P2 (Tbmre11-q2), P3 
(neo-2) and P4 (hyg-2) correspond to the regions where the primers anneal too in the 
appropriate allele.  
B. Amplified products after multiplex PCR on gDNA extracted from T. brucei wild type (lane 
1) and T. brucei Tbmre11Δ (lane 2) using primer combinations that specifically amplify alleles 
corresponding to the Tbmre11 (Tbmre11-KO1/Tbmre11-q2), Tbmre11-hyg (Tbmre11-
KO1/hyg-2) or Tbmre11-neo (Tbmre11-KO1/neo-2) alleles.  
C. Amplified products obtained after PCR on cDNA derived from RNA extracted from T. 
brucei wild type (lane 1) or T. brucei Tbmre11Δ (lane 2) using primer combinations that 
specifically amplify intact Tbmre11 (Tbmre11-q1/Tbmre11-q2). In both cases, the integrity of 





Appendix 2b: Generation of T. brucei line lacking TbEXO1.  
A. Diagram of the Tbexo1 gene and disrupted alleles using genes encoding for neomycin (neo) 
and hygromycin (hyg) resistance. P1 (Tbexo1-KO1), P2 (Tbexo1-q2), P3 (neo-2) and P4 (hyg-
2) correspond to the regions where the primers anneal too in the appropriate allele.  
B. DNA products created after amplification reactions carried out on gDNA extracted from T. 
brucei wild type (lane 1) and T. brucei Tbexo1Δ (lane 2) using primer combinations that 
specifically amplify alleles corresponding to the Tbexo1 (Tbexo1-KO1/Tbexo1-q2), Tbexo1-
hyg (Tbexo1-KO1/hyg-2) or Tbexo1-neo (Tbexo1-KO1/neo-2) alleles.  
C. DNA products amplified by PCR on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1) or T. brucei Tbexo1Δ (lane 2) using primer combinations that specifically 
amplify intact Tbexo1 (Tbexo1-q1/Tbexo1-q2). In both cases, the integrity of the cDNA (and 

















Appendix 2c: Generation of T. brucei line lacking TbREV2.  
A. Diagram of the Tbrev2 gene and disrupted alleles using genes encoding for neomycin (neo) 
and hygromycin (hyg) resistance. P1 (Tbrev2-KO1), P2 (Tbrev2-q2), P3 (neo-2) and P4 (hyg-
2) correspond to the regions where the primers anneal too in the appropriate allele.  
B. DNA products created after amplification reactions carried out on gDNA extracted from T. 
brucei wild type (lane 1) and T. brucei Tbrev2Δ (lane 2) using primer combinations that 
specifically amplify alleles corresponding to the Tbrev2 (Tbrev2-KO1/Tbrev2-q2), Tbrev2-
hyg (Tbrev2-KO1/hyg-2) or Tbrev2-neo (Tbrev2-KO1/neo-2) alleles.  
C. DNA products amplified by PCR on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1) or T. brucei Tbrev2Δ (lane 2) using primer combinations that specifically 
amplify intact Tbrev2 (Tbrev2-q1/Tbrev2-q2). In both cases, the integrity of the cDNA (and 





Appendix 2d: Generation of T. brucei line lacking TbREV3.  
A. Schematic representation of the Tbrev3 allele and the effects of gene disruption using genes 
encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbrev3-KO1), P2 (Tbrev3-
q2), P3 (neo-2) and P4 (hyg-2) correspond to the regions where the primers anneal too in the 
appropriate allele.  
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1) and T. brucei Tbrev3Δ (lane 2) using primer combinations that specifically amplify 
biomarkers corresponding to the Tbcsb (Tbrev3-KO1/Tbrev3-q2), Tbrev3-hyg (Tbrev3-
KO1/hyg-2) or Tbrev3-neo (Tbrev3-KO1/neo-2) alleles.  
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1) or T. brucei Tbrev3Δ (lane 2) using primer combinations that 
specifically amplify intact Tbrev3 (Tbrev3-q1/Tbrev3-q2). In both cases, the integrity of the 









Appendix 3: Validation of double null lines 
 
Appendix 3a: Disruption and confirmation of Tbsnm1Δ Tbmre11Δ.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele.  
B. Schematic for the representation of the Tbmre11 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbmre11-KO1), 
P2 (Tbmre11-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal 
at the specific allele. C. DNA fragments obtained after amplification on gDNA extracted from 
T. brucei wild type (lane 1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbmre11Δ (lane 3), and T. 
brucei Tbsnm1Δ Tbmre11Δ (lane 4). Extractions from all 4 lines were tested using primer 
combinations that specifically amplify biomarkers corresponding to the Tbsnm1 (Tbsnm1-
KO1/Tbsnm1-seq1), Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1), 
Tbmre11 (Tbmre11-KO1/Tbmre11-q2), Tbmre11-hyg (Tbmre11-KO1/hyg-2) or Tbmre11-
neo (Tbmre11-KO1/neo-2) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1Δ (lane 2),  Tbmre11Δ (lane 3) and Tbsnm1Δ Tbmre11Δ 
(lane 4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-










Appendix 3b: Disruption and confirmation of Tbsnm1Δ Tbexo1Δ null line.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele.  
B. Schematic for the representation of the Tbexo1 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbexo1-KO1), 
P2 (Tbexo1-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbexo1Δ (lane 3), and T. brucei Tbsnm1Δ 
Tbexo1Δ (lane 4). Extractions from all 4 lines were tested using primer combinations that 
specifically amplify biomarkers corresponding to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 
Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1), Tbexo1 (Tbexo1-
KO1/Tbexo1-q2), Tbexo1-hyg (Tbexo1-KO1/hyg-2) or Tbexo1-neo (Tbexo1-KO1/neo-2) 
alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1Δ (lane 2),  Tbexo1Δ (lane 3) and Tbsnm1Δ Tbexo1Δ (lane 
4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-






Appendix 3c: Disruption and confirmation of Tbsnm1Δ Tbrev2Δ.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele.  
B. Schematic for the representation of the Tbrev2 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbrev2-KO1), 
P2 (Tbrev2-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbrev2Δ (lane 3), and T. brucei Tbsnm1Δ 
Tbrev2Δ (lane 4). Extractions from all 4 lines were tested using primer combinations that 
specifically amplify biomarkers corresponding to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 
Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1), Tbrev2 (Tbrev2-
KO1/Tbrev2-q2), Tbrev2-hyg (Tbrev2-KO1/hyg-2) or Tbrev2-neo (Tbrev2-KO1/neo-2) 
alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1Δ (lane 2),  Tbrev2Δ (lane 3) and Tbsnm1Δ Tbrev2Δ (lane 
4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-







Appendix 3d: Disruption and confirmation of Tbsnm1Δ Tbrev3Δ.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele.  
B. Schematic for the representation of the Tbrev3 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbrev3-KO1), 
P2 (Tbrev3-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbrev3Δ (lane 3), and T. brucei Tbsnm1Δ 
Tbrev3Δ (lane 4). Extractions from all 4 lines were tested using primer combinations that 
specifically amplify biomarkers corresponding to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 
Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1), Tbrev3 (Tbrev3-
KO1/Tbrev3-q2), Tbrev3-hyg (Tbrev3-KO1/hyg-2) or Tbrev3-neo (Tbrev3-KO1/neo-2) 
alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1Δ (lane 2),  Tbrev3Δ (lane 3) and Tbsnm1Δ Tbrev3Δ (lane 
4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-








Appendix 3e: Disruption and confirmation of TbcsbΔ Tbexo1Δ.  
A. Schematic for the representation of the Tbcsb allele and effects of disrupting this allele with 
genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbcsb-KO1), P2 
(Tbcsb-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at the 
specific allele.  
B. Schematic for the representation of the Tbexo1 allele and effects of disrupting this allele 
with genes encoding for blastidicin (bla) and puromycin (pac) resistance. P1 (Tbexo1-KO1), 
P2 (Tbexo1-q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei TbcsbΔ (lane 2), T. brucei Tbexo1Δ (lane 3), and T. brucei TbcsbΔ Tbexo1Δ 
(lane 4). Extractions from all 4 lines were tested using primer combinations that specifically 
amplify biomarkers corresponding to Tbcsb (Tbcsb-KO1/Tbcsb-q2), Tbcsb-hyg (Tbcsb-
KO1/hyg-2) or Tbcsb-neo (Tbcsb-KO1/neo-2), Tbexo1 (Tbexo1-KO1/Tbexo1-q2), Tbexo1-
pac (Tbexo1-KO1/pac-1) or Tbexo1-bla (Tbexo1-KO1/bla-1) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), TbcsbΔ (lane 2),  Tbexo1Δ (lane 3) and TbcsbΔ Tbexo1Δ (lane 4) 
using primer combinations that specifically amplify intact Tbcsb (Tbcsb-q1/Tbcsb-q2), Tbexo1 








Appendix 3f: Disruption and confirmation of TbcsbΔ Tbmre11Δ.  
A. Schematic for the representation of the Tbcsb allele and effects of disrupting this allele with 
genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbcsb-KO1), P2 
(Tbcsb-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at the 
specific allele.  
B. Schematic for the representation of the Tbmre11 allele and effects of disrupting this allele 
with genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbmre11-KO1), 
P2 (Tbmre11-q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei TbcsbΔ (lane 2) and T. brucei TbcsbΔ Tbmre11Δ (lane 3). Extractions from 
all 3 lines were tested using primer combinations that specifically amplify biomarkers 
corresponding to Tbcsb (Tbcsb-KO1/Tbcsb-q2), Tbcsb-hyg (Tbcsb-KO1/hyg-2) or Tbcsb-neo 
(Tbcsb-KO1/neo-2), Tbmre11 (Tbmre11-KO1/Tbmre11-q2), Tbmre11-pac (Tbmre11-
KO1/pac-1) or Tbmre11-bla (Tbmre11-KO1/bla-1) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), TbcsbΔ (lane 2) and TbcsbΔ Tbmre11Δ (lane 3) using primer 
combinations that specifically amplify intact Tbcsb (Tbcsb-q1/Tbcsb-q2), Tbmre11 (Tbmre11-






Appendix 3g: Disruption and confirmation of Tbexo1Δ Tbmre11Δ.  
A. Schematic for the representation of the Tbexo1 allele and effects of disrupting this allele 
with genes encoding for blastidicin (bla) and puromycin (pac) resistance. P1 (Tbexo1-KO1), 
P2 (Tbexo1-q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at 
the specific allele.  
B. Schematic for the representation of the Tbmre11 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbmre11-KO1), 
P2 (Tbmre11-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal 
at the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei Tbexo1Δ (lane 2), T. brucei Tbmre11Δ (lane 3) and T. brucei Tbexo1Δ 
Tbmre11Δ (lane 4). Extractions from all 4 lines were tested using primer combinations that 
specifically amplify biomarkers corresponding to Tbexo1 (Tbexo1-KO1/Tbexo1-q2), Tbexo1-
pac (Tbexo1-KO1/pac-1) or Tbexo1-bla (Tbexo1-KO1/bla-1), Tbmre11 (Tbmre11-
KO1/Tbmre11-q2), Tbmre11-hyg (Tbmre11-KO1/hyg-2) or Tbmre11-neo (Tbmre11-
KO1/neo-2) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), T. brucei Tbexo1Δ (lane 2), T. brucei Tbmre11Δ (lane 3) and T. 
brucei Tbexo1Δ Tbmre11Δ (lane 4) using primer combinations that specifically amplify intact 


















Appendix 4: Validation of lines lacking a trypanosomal FA factor  
 
 
Appendix 4a: Disruption and confirmation of Tbhel1Δ and Tbsnm1Δ Tbhel1Δ null line.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci 
using genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbsnm1-KO1), 
P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal 
at the specific allele.  
B. Schematic for the representation of the Tbhel1 allele and effects of disrupting this allele 
with genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbhel1-KO1), 
P2 (Tbhel1-q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at 
the specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type 
(lane 1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbhel1Δ (lane 3), and T. brucei Tbsnm1Δ 
Tbhel1Δ (lane 4). Extractions from all 4 lines were tested using primer combinations that 
specifically amplify biomarkers corresponding to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 
Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-pac (Tbsnm1-KO1/pac-1), Tbhel1 (Tbhel1-
KO1/Tbhel1-q2), Tbhel1-hyg (Tbhel1-KO1/hyg-2) or Tbhel1-neo (Tbhel1-KO1/neo-2) 
alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from 
T. brucei wild type (lane 1), Tbsnm1Δ (lane 2),  Tbhel1Δ (lane 3) and Tbsnm1Δ Tbhel1Δ (lane 
4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-




Appendix 4b: Disruption and confirmation of Tbchl1-deficient null lines.  
A. Diagram illustrating the Tbsnm1 allele and resultant changes upon disruption of this loci using genes encoding for blasticidin (bla) and neomycin 
(neo) resistance. P1 (Tbsnm1-KO1), P2 (Tbsnm1-seq1), P3 (bla-1) and P4 (neo-2) correspond to regions where the primers anneal at the specific 
allele.  
B. Schematic for the representation of the Tbchl1 allele and effects of disrupting this allele with genes encoding for puromycin (pac) and 
hygromycin (hyg) resistance. P1 (Tbchl1-KO1), P2 (Tbchl1-q2), P3 (pac-1) and P4 (hyg-2) correspond to regions where the primers anneal at the 
specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 1), T. brucei Tbchl1Δ (lane 2) and T. brucei 
Tbsnm1Δ Tbchl1Δ (lane 3). Extractions from all 4 lines were tested using primer combinations that specifically amplify biomarkers corresponding 
to the Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), Tbsnm1-bla (Tbsnm1-KO1/bla-1) or Tbsnm1-neo (Tbsnm1-KO1/neo-2), Tbchl1 (Tbchl1-
KO1/Tbchl1-q2), Tbchl1-hyg (Tbchl1-KO1/hyg-2) or Tbchl1-pac (Tbchl1-KO1/pac-1) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei wild type (lane 1), Tbsnm1Δ (lane 2), 
Tbchl1Δ (lane 3) and Tbsnml1Δ Tbchl1Δ (lane 4) using primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-seq1), 
Tbchl1 (Tbchl1-q1/Tbchl1-q2) and Tbtert (Tbtert-F/Tbtert-R).  
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Appendix 4c: Confirmation of Tbfan1 null line.  
A. Schematic representation of the Tbfan1 allele and the effects of gene disruption using genes 
encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbfan1-KO1), P2 (Tbfan1-q2), 
P3 (neo-2) and P4 (hyg-2) correspond to the regions where the primers anneal too in the appropriate 
allele.  
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 
1) and T. brucei Tbfan1Δ (lane 2) using primer combinations that specifically amplify biomarkers 
corresponding to the Tbfan1 (Tbfan1-KO1/Tbfan1-q2), Tbfan1-hyg (Tbfan1-KO1/hyg-2) or Tbfan1-
neo (Tbfan1-KO1/neo-2) alleles.  
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1) or T. brucei Tbfan1Δ (lane 2) using primer combinations that specifically amplify 
intact Tbfan1 (Tbfan1-q1/Tbfan1-q2). In both cases, the integrity of the cDNA (and hence RNA) was 













Figure 4d: Validating Tbfan1 double null lines.  
A. Diagram illustrating the Tbfan1 allele and resultant changes upon disruption of this loci using 
genes encoding for neomycin (neo) and hygromycin (hyg) resistance. P1 (Tbfan1-KO1), P2 (Tbfan1-
q2), P3 (neo-2) and P4 (hyg-2) correspond to regions where the primers anneal at the specific allele.  
B. Schematic for the representation of the Tbmre11 allele and effects of disrupting this allele with 
genes encoding for blasticidin (bla) and puromycin (pac) resistance. P1 (Tbmre11-KO1), P2 
(Tbmre11-q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at the 
specific allele.  
C. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 
1), T. brucei Tbsnm1Δ (lane 2), T. brucei Tbfan1Δ (lane 3), and T. brucei Tbsnm1Δ Tbfan1Δ (lane 
4). Extractions from all 4 lines were tested using primer combinations that specifically amplify 
biomarkers corresponding to Tbfan1 (Tbfan1-KO1/Tbfan1-q2), Tbfan1-hyg (Tbfan1-KO1/hyg-2) or 
Tbfan1-neo (Tbfan1-KO1/neo-2) alleles.  
D. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. 
brucei wild type (lane 1), Tbsnm1Δ (lane 2), Tbfan1Δ (lane 3) and Tbsnm1Δ Tbfan1Δ (lane 4) using 
primer combinations that specifically amplify intact Tbsnm1 (Tbsnm1-q1/Tbsnm1-seq1), Tbfan1 
(Tbfan1-q1/Tbfan1-q2) and Tbtert (Tbtert-F/Tbtert-R).  
E. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 
1), Tbmre11Δ (lane 2), Tbfan1Δ (lane 3) and Tbmre11Δ Tbfan1Δ (lane 4). Extractions from all 4 
lines were tested using primer combinations that specifically amplify biomarkers corresponding to 
intact Tbmre11 (Tbmre11-KO1/Tbmre11-q2), Tbmre11-pac (Tbmre11-KO1/pac-1) or Tbmre11-bla 
(Tbmre11-KO1/bla-1) alleles.  
F. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1), Tbmre11Δ (lane 2), Tbfan1Δ (lane 3) and Tbmre11Δ Tbfan1Δ (lane 4) using 
primer combinations that specifically amplify intact Tbfan1 (Tbfan1-q1/Tbfan1-q2), Tbmre11 






Appendix 5: Structure and function studies on TbSNM1 
 
 
Appendix 4.1: Validating the Tbsnm1Δ gfp-Tbsnm1-V518A line.  
A. Diagram representing the Tbsnm1 allele and resultant changes upon disruption of this loci using 
genes encoding for blasticidin (bla) and puromycin (pac) resistance. Alongside this, changes to the 
landing pad locus after integration of gfp-Tbsnm1 was also analysed. P1 (Tbsnm1-KO1), P2 
(Tbsnm1-seq1), P3 (bla-1), P4 (pac-1) and P5 (GFP) correspond to regions where the primers anneal 
at the specific allele.  
B. DNA fragments obtained from amplification reactions on genomic DNA extracted from T. brucei 
wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ gfp-Tbsnm1 (lane 4), TbSNM1-
V518A (lane 5) cells. Primer combinations amplified intact Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), 






Appendix 4.2: Confirming expression of gfp-Tbsnm1.  
A. Schematic of integrated gfp-Tbsnm1 analysing using primer combination P2 (Tbsnm1-seq1) and 
P5 (GFP) which amplified a band of 0.4kb across the GFP and TbSNM1 fusion.  
B. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ gfp-Tbsnm1 (lane 4), TbSNM1-
V518A (lane 5) cells using primer combinations that specifically amplify gfp-Tbsnm1 (GFP/Tbsnm1-




Appendix 4.3: Localisation of mutant GFP-TbSNM1 in bloodstream form T. brucei. Parasites 
expressing GFP-TbSNM1 (mutant or wild type) were stained with DAPI and examined by 
epifluorescent microscopy under a x40 objective lens with phase, DAPI and GFP signal images 






Appendix 4.4: Validating conditional null lines.  
A. Diagram representing the Tbsnm1 allele and resultant changes upon disruption of this loci using 
genes encoding for blasticidin (bla) and puromycin (pac) resistance. Alongside this, changes to the 
landing pad locus after integration of gfp-Tbsnm1 was also analysed. P1 (Tbsnm1-KO1), P2 
(Tbsnm1-seq1), P3 (bla-1), P4 (pac-1) and P5 (GFP) correspond to regions where the primers anneal 
at the specific allele.  
B. DNA fragments obtained from amplification reactions on genomic DNA extracted from T. brucei 
wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ gfp-Tbsnm1 (lane 4), TbSNM1-
R428A (lane 5), TbSNM1-R429A (lane 6), TbSNM1-R430A (lane 7) and TbSNM1-H431A (lane 8) 
cells. Primer combinations amplified intact Tbsnm1 (Tbsnm1-KO1/Tbsnm1-seq1), Tbsnm1-bla 















Appendix 4.5: Confirming expression of gfp-Tbsnm1.  
A. Schematic of integrated gfp-Tbsnm1 analysing using primer combination P2 (Tbsnm1-seq1) and 
P5 (GFP) which amplified a band of 0.4kb across the GFP and TbSNM1 fusion.  
B. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1), Tbsnm1+/- (lane 2), Tbsnm1Δ (lane 3), Tbsnm1Δ gfp-Tbsnm1 (lane 4), TbSNM1-
R428A (lane 5), TbSNM1-R429A (lane 6), TbSNM1-R430A (lane 7) and TbSNM1-H431A (lane 8) 






Appendix 6: Validation of Tbntr expressing lines 
 
Appendix 5a: Validating the interruption of Tbexo1 in T. brucei.  
A. Representative diagram of the Tbexo1 allele and effects of disrupting this allele with genes 
encoding for blastidicin (bla) and puromycin (pac) resistance. P1 (Tbexo1-KO1), P2 (Tbexo1-q2), 
P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at the specific allele.  
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 
1), 2T1 BSF-TbNTR 9e10 (lane 2) and 2T1 BSF-TbNTR 9e10 Tbexo1Δ (lane 3). Extractions from 
all 3 lines were tested using primer combinations that specifically amplify biomarkers corresponding 
to Tbexo1 (Tbexo1-KO1/Tbexo1-q2), Tbexo1-pac (Tbexo1-KO1/pac-1) or Tbexo1-bla (Tbexo1-
KO1/bla-1) alleles.  
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1) and 2T1 BSF-TbNTR 9e10 Tbexo1Δ (lane 2) using primer combinations that 








Appendix 5b: Validating the interruption of Tbmre11 in T. brucei.  
A. Representative diagram of the Tbmre11 allele and effects of disrupting this allele with genes 
encoding for blastidicin (bla) and puromycin (pac) resistance. P1 (Tbmre11-KO1), P2 (Tbmre11-
q2), P3 (bla-1) and P4 (pac-1) correspond to regions where the primers anneal at the specific allele.  
B. DNA fragments obtained after amplification on gDNA extracted from T. brucei wild type (lane 
1), 2T1 BSF-TbNTR 9e10 (lane 2) and 2T1 BSF-TbNTR 9e10 Tbmre11Δ (lane 3). Extractions from 
all 3 lines were tested using primer combinations that specifically amplify biomarkers corresponding 
to Tbmre11 (Tbmre11-KO1/Tbmre11-q2), Tbmre11-pac (Tbmre11-KO1/pac-1) or Tbmre11-bla 
(Tbmre11-KO1/bla-1) alleles.  
C. DNA fragments obtained after amplification on cDNA derived from RNA extracted from T. brucei 
wild type (lane 1) and 2T1 BSF-TbNTR 9e10 Tbmre11Δ (lane 2) using primer combinations that 
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All living cells are subject to agents that promote DNA 
damage. A particularly lethal lesion are interstrand 
cross-links (ICL), a property exploited by several anti-
cancer chemotherapies. In yeast and humans, an 
enzyme that plays a key role in repairing such damage 
are the PSO2/SNM1 nucleases. Here, we report that 
Trypanosoma brucei, the causative agent of African 
trypanosomiasis, possesses a bona fide member of this 
family (called TbSNM1) with expression of the parasite 
enzyme able to suppress the sensitivity yeast pso2 
mutants display towards mechlorethamine, an ICL-
inducing compound. By disrupting the Tbsnm1 gene, we 
demonstrate that TbSNM1 activity is non-essential to the 
medically relevant T. brucei life cycle stage. However, 
trypanosomes lacking this enzyme are more susceptible 
to bi- and tri-functional DNA alkylating agents with this 
phenotype readily comple-mented by ectopic expression 
of Tbsnm1. Genetically modified variants of the null 
mutant line were subse-quently used to establish the 
anti-parasitic mecha-nism of action of 
nitrobenzylphosphoramide mustard and aziridinyl 
nitrobenzamide prodrugs, compounds previously 
shown to possess potent trypanocidal properties while 
exhibiting limited toxicity to mamma- 
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lian cells. This established that these agents, following 
activation by a parasite specific type I nitroreductase, 
produce metabolites that promote formation of ICLs 




The socioeconomic development of sub-Saharan Africa has 
been hindered by a group of medical and veterinary infections 
collectively known as African trypanosomiasis. The causative 
agents of many of these diseases are protozoan parasites 
belonging to the species Trypano-soma brucei, organisms 
that live and multiply extracellu-larly in the bloodstream and 
tissue fluids of their mammalian hosts. Transmission occurs 
via the blood-feeding habits of the insect vector, the tsetse fly. 
Over the last 15 years implementation of improved health 
surveil-lance programmes combined with new treatment 
regimens has led to a dramatic fall in the estimated number 
of new cases of the human form of the disease, known as 
human African trypanosomiasis (HAT) from around 450 000 
in 1997 to about 20 000 in 2012 (Barrett, 2006; WHO, 2014). 
This situation has resulted in World Health Organization 
aiming to eliminate HAT as a public health problem by 2020. 
In contrast, animal African trypanosomiasis, particu-larly in 
domesticated livestock, remains a major problem with these 
infections killing around 3 million head of cattle each year and 
causing an annual loss of income estimated to be about 
US$4.75 billion (UNFAO, 2004). 
With no immediate prospect of a vaccine or chemopro-
phylaxis and with vector control being problematic, drug 
treatment represents the only option available to combat 
HAT. However, the current chemotherapies used are few in 
number and their use is controversial, as they can be costly, 
often require medical supervision for administration, some 
have limited efficacy and may cause adverse side effects, 
with drug resistance becoming more widespread (Wilkinson 
and Kelly, 2009; Alsford et al., 2013). One way to facilitate the 
development of new drugs targeting HAT is to better 
understand the mechanism of action of existing treatments 
with the properties that underlie parasite selec-tivity 
incorporated into the development of new trypano-cidal 
agents. For example, melamine rings have been incorporated 
into several compounds to exploit the sub-strate specificity 
displayed by the P2 adenosine trans- 
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porter, a permease implicated in the uptake of pentamidine 
and melarsoprol (Stewart et al., 2004; Baliani et al., 2005; 
Chollet et al., 2009; Klee et al., 2010; Capes et al., 2012; 
Giordani et al., 2014). Similarly, a parasite nitroreductase 
(NTR), an enzyme responsible for the activation of nifurti-mox 
(Wilkinson et al., 2008; Hall et al., 2011), has been used to 
screen nitroaromatic libraries for anti-T. brucei properties (Bot 
et al., 2010; 2013; Hall et al., 2010; 2012; Hu et al., 2011; 
Papadopoulou et al., 2011; 2012; 2013). In the latter case, 
several NTR-activated chemicals contain-ing nitrogen 
mustard or aziridine functional groups that promote DNA 
damage via formation of cross-linkages have been identified 
as having significant anti-parasitic activities and low 
mammalian cell toxicity (Bot et al., 2010; Hall et al., 2010; Hu 
et al., 2011). 
Genomes are constantly challenged by endogenous and 
exogenous agents that promote DNA damage, with 
interstrand cross-links (ICLs) representing a particularly 
dangerous lesion (O’Connor and Kohn, 1990). Formed when 
the two complementary strands within the DNA double helix 
become covalently linked, ICLs block essen-tial cellular 
process that require DNA strand separation including DNA 
replication and transcription, leading to chromosomal 
breakage, rearrangements, or cell death (Dronkert and 
Kanaar, 2001; McHugh et al., 2001; Deans and West, 2011; 
Sengerova et al., 2011). Estimates indi-cate that a single ICL 
can kill a unicellular microbe with as few as 20 being fatal to 
a mammalian cell (Magana-Schwencke et al., 1982; Lawley 
and Phillips, 1996). In order to preserve the integrity and 
functionality of DNA, eukaryotic cells have evolved a series 
of complementary and overlapping pathways to repair ICLs, 
although the precise mechanisms involved in these systems 
are not fully understood (Deans and West, 2011). In 
Saccharomy-ces cerevisiae, many of the major DNA repair 
pathways [nucleotide excision repair (NER), mismatch repair, 
post-replication repair/translesion synthesis and homologous 
recombination] have been implicated in fixing ICL damage, 
although only a few proteins specifically involved in ICL lesion 
repair have been identified (Barber et al., 2005; Lehoczky et 
al., 2007; Daee et al., 2012; Ward et al., 2012). Of these, 
Pso2p (also known as Snm1) is of great interest as cells 
lacking this activity are specifically and highly susceptible to 
ICL-forming agents including pso-ralen, cisplatin and 
mechlorethamine but not to any other forms of DNA damage 
(Henriques and Moustacchi, 1980; Ruhland et al., 1981a,b). 
The precise role played by Pso2p in this repair system 
remains unknown, although biochemi-cal studies have 
shown that it displays a 5′ exonuclease activity (Li et al., 
2005). This coupled with the observation that pso2 cells 
exposed to ICL-inducing compounds tend to accumulate 
DNA double stranded breaks indicates that Pso2p does not 
function in the initial incision event, which in yeast is primarily 
controlled by NER, but may be involved 
 
in the processing of DNA ends created during the genera-tion 
of ICL-associated DNA double stranded breaks (Li and 
Moses, 2003; Barber et al., 2005; Dudas et al., 2007). 
Intriguingly, Pso2p also displays a structure-specific DNA 
hairpin opening endonuclease activity providing evidence 
that it may have other functions outside ICL repair 
(Tiefenbach and Junop, 2012). 
Here, we report that T. brucei expresses a Pso2/Snm1 
homologue that can readily complement for the suscepti-
bility phenotype exhibited by pso2 yeast cells towards an 
ICL forming agent. Deletion of the gene, designated 
Tbsnm1, from the parasite genome revealed that although 
the encoded enzyme is not essential for viability and 
growth of bloodstream form (BSF) trypanosomes, cells 
lacking this activity were more susceptible to bifunctional 
nitrogen mustard- and aziridine-based ICL-inducing 
agents. Using recombinant T. brucei expressing altered 
levels of Tbsnm1, we establish that the trypanocidal 
mechanism of several potent nitroaromatic-based agents 
that contain ICL-promoting grouping are dependent on an 
initial activation catalysed by a parasite specific type I NTR 





Identifying trypanocidal chemical tools for studying 
DNA repair 
 
Previous screening studies have identified nitroaromatic-
based azirindyl/nitrogen mustard compounds to be effec-tive 
trypanocidal agents (Bot et al., 2010; Hall et al., 2010; Hu et 
al., 2011). The antimicrobial activity of these involves a 
parasite specific activation step catalysed by a type I NTR that 
leads to metabolites postulated to promote DNA damage. To 
determine if the above compounds do function via this 
pathway, a range of anti-cancer compounds known to 
mediate their cytotoxicity by promoting DNA cross-linkages 
were screened for trypanocidal activity against BSF T. brucei. 
The structures tested included non-nitroaromatic-based 
aziridines and nitrogen mustards, nitrosoureas, platinum 
complexes, an alkyl sulfonate and non-classical DNA cross-
linking agents. 
Out of the non-nitroaromatic anti-cancer compounds 
assessed, 17 had no effect on parasite growth at concen-
trations of up to 30 μM, including busulfan, the only alkyl 
sulfonate analysed here, and all five non-classical DNA 
cross-linking agents (Table 1). These were not analysed 
further. For the remaining compounds, the concentration that 
inhibits parasite growth by 50% (IC50’s) was deter-mined 
(Table 1). For all the remaining classes of DNA cross-linking 
agents, two or more compounds displayed trypanocidal 
activities with IC50 values ranging from 13 nM for mitomycin 
C, the most potent agent identified here, to approximately 35 
μM for mechlorethamine and ThioTEPA. 
 




Table 1. Susceptibility of T. brucei lines to DNA damaging agents.  
 
   T. brucei IC50   
    
Compound  Wild type Tbsnm1−/− 
Nitrogen mustards 
>30.000 
   
Chlorambucil, nd 
cyclophosphamide,       
uramustine, trofosfamide,       
ifosfamide, bendamustine       
Mechlorethamine 34.240 ± 1.270 8.210 ± 1.180 
Melphalan 8.660 ± 0.660 3.960 ± 0.320 
Estramustine 9.370 ± 1.150 nd 
Prednimustine 13.870 ± 1.330 nd 
LH7 10.870 ± 0.240 0.580 ± 0.050 
LH17 4.160 ± 0.130 0.380 ± 0.040 
LH32 0.245 ± 0.079 0.021 ± 0.004 
LH33 0.215 ± 0.008 0.015 ± 0.000 
LH34 0.067 ± 0.006 0.006 ± 0.001 
LH37 0.097 ± 0.009 0.005 ± 0.000 





ThioTEPA 37.830 13.880 0.970 
Triethylenemelamine 1.130 ± 0.150 0.300 ± 0.020 
Mitomycin C 0.013 ± 0.001 0.010 ± 0.001 
CB1954 3.900 ± 0.420 0.690 ± 0.050 
NH1 0.120 ± 0.004 0.044 ± 0.013 
Nitrosoureas 
>30.000 
   
Carmustine, nimustine, nd 
NSC270516       
Lomustine 16.650 ± 0.440 17.310 ± 0.210 
Streptozotocin 21.800 ± 5.020 nd 
Semustine 4.760 ± 0.050 3.780 ± 0.070 
Alkyl sulfonate 
>30.000 
   
Busulfan nd 
Non-classical DNA       
cross-linking agents 
>30.000 
   
Altretamine, pipobroman, nd 
dacarbazine,       
temozolomide,       
mitobronitol       
Platinum-based 
>30.000 
   
Oxaliplatin, nedaplatin nd 
Cisplatin 2.280 ± 0.130 3.400 ± 0.280 
Carboplatin 5.030 ± 0.040 nd 





Hydroxyurea 105.970 88.200 7.300 
H2O2 43.710 ± 5.950 50.06 ± 7.520 
UV irradiation 214.000 ± 13.000 196.000 ± 30.000 
MMS 16.125 ± 1.379 14.020 ± 1.343 
DMFO 24.150 ± 3.940 24.240 ± 6.710 
Nifurtimox 2.850 ± 0.020 2.250 ± 0.090 
Benznidazole 46.140 ± 1.440 37.680 ± 1.630  
 
 
The cell lines analysed were T. brucei (wild type) and T. brucei null mutants (Tbsnm1−/−). IC50  values 
are given in μM 
 
except for UV irradiation, which is in J m−1. LH7, LH17, LH32-34, 
LH37, CB1954 and NH1 represent structures previously identified as 
trypanocidal agents (Bot et al., 2010; Hall et al., 2010; Hu et al., 




Identification of the DNA repair enzyme TbSNM1 
 
In other eukaryotes, the SNM1/PSO2 family of nucleases 
play an important role in repairing damage caused by DNA 
cross-linking agents (Cattell et al., 2010). Analysis of the T. 
b. brucei genome database (Aslett et al., 2010) 
Characterising a trypanosomal DNA repair enzyme 3  
 
identified a single hypothetical gene (designated as Tbsnm1) 
of 2163 bp located on chromosome 4 with potential to encode 
for a 79.5 kDa enzyme (TbSNM1; Gene ID: Tb927.4.1480) 
related to this family of enzymes. Full-length TbSNM1 is 42% 
identical to the T. cruzi homo-logue (GenBank accession no. 
XP_816034) and has 27–32% identity to the leishmanial 
enzymes LmSNM1 (XP_001686430) and LdSNM1 
(XP_003864463). When compared with yeast, plant and 
mammalian counterparts sequence identity ranged from 15% 
to 24%. Based on sequence, TbSNM1 can be divided into two 
regions (Fig. 1). The amino terminal section (residues 36–
182) constitutes a non-canonical metallo-ß-lactamase (MBL; 
pfam12706) domain containing four motifs (motifs 1–4), 
including a characteristic HxHxDH signature (motif 2), that in 
other SNM1/PSO2 proteins cooperate to mediate zinc 
cofactor binding. The second section represents a β-CASP 
(named after its representative members CPSF, Artemis, 
SNM1 and PSO2; pfam10996) region (residues 213–519) 
that contains within it a stretch of 31 amino acids comprising 
a DRMBL (DNA repair metallo-ß-lactamase; pfam07522) 
domain (residues 488–519). The β-CASP region contains a 
fifth zinc binding motif (motif 5) but as with other SNM1/PSO2 
sequences the precise location of this has yet to be defined: 
in silico analysis of TbSNM1 indicates that D220 or H497 
(motifs 5′ and 5″ respectively) may fulfil this role with H497 
being the most likely of the two candidate residues (Callebaut 
et al., 2002). The β-CASP domain of TbSNM1 also contains 
a diagnostic valine residue (position 519) that indicates that 
the parasite enzyme is involved in DNA processing: DNA 
processing MBLs contain a valine residue at the equiva-lent 
site, whereas RNA processing MBLs contain a histi-dine 
(Callebaut et al., 2002). 
 
To investigate whether the T. brucei enzyme is a SNM1/ 
PSO2 homologue, Tbsnm1 minus its ATG initiation codon 
was amplified and cloned into a version of the yeast 
expression vector pYCYlac111 that contains a DNA 
sequence encoding for the FLAG-tag epitope. The result-ant 
plasmid was transformed into the S. cerevisiae wild type and 
pso2 strains and expression of recombinant TbSNM1 
confirmed by western blot analysis (Fig. 2A). The 
susceptibility of the fungal lines to mechlorethamine, a DNA 
cross-linking agent, was then determined and from the 
resultant dose-response curves the IC50 value for each 
strain calculated (Fig. 2B and C). Yeast lacking pso2 were 
clearly more susceptible to the nitrogen mustard than wild 
type with the null mutant displaying an IC50 value approxi-
mately 40% that of the control strain. When Tbsnm1 was 
expressed in wild type yeast a slight (1.4-fold) resistance 
was noted. This phenotype was also observed in the pso2 
strain expressing Tbsnm1 correlating with an increase in the 
IC50 value from 1.3 μM in cells lacking Pso2p to 5.7 μM in 

































Fig. 1. Sequence analysis of TbSNM1. The sequence corresponding to the metallo-ß-lactamase (MBL; grey box) and β-CASP (hatched box) domains of 
TbSNM1 was aligned with other members of the SNM1A/PSO2 family of nucleases. The residues that are common with the TbSNM1 sequence are 
represented by dots. Sequence differences when compared with TbSNM1 are shown. In the alignments, amino acids marked with an asterisks (solid line 
in TbSNM1 schematic) correspond to motif 1–4, regions postulated to co-ordinate the metal (zinc) cofactor binding. The two possible residues that may 
represent motif 5 (5′ or 5″; dotted line in TbSNM1 schematic) are also shown. The down arrow highlights the amino acid that distinguishes DNA from RNA 
processing metallo-β-lactamases, whereas the RRRH sequence corresponds to a putative nuclear ‘pattern 4’ targeting signal. The sequences aligned are: 
T. brucei TbSNM1 (GenBank AAZ10739), Saccharomyces cerevisiae ScPSO2 (NP_013857), Arabidopsis thaliana AtSNM1 (NP_189302) and Homo 
sapiens HsSNM1A (NP_001258745). 
 
clearly show that TbSNM1 can complement for the pso2 
mutation and that the trypanosomal enzyme is a bona 
fide SNM1/PSO2 homologue. 
 
TbSNM1 is targeted to the T. brucei nucleus 
 
When analysed using the PSORTII and WoLFPSORT 
algorithms, TbSNM1 was predicted to be targeted to the 
nucleus via a ‘four pattern’ RRRH (residues 428–431) 
nuclear localisation signal. To confirm this, the full-length 
Tbsnm1 gene minus its ATG initiation codon was ampli-
fied and ligated in-frame and downstream of the gene 
encoding for the enhanced green fluorescence protein 
(GFP) in a trypanosomal vector that facilitated tetracycline 
inducible gene expression (Alsford et al., 2005). The 
resultant construct was used to transform BSF T. brucei, 
and parasite clones were selected.  
To induce expression of the tagged protein, cells were 
incubated in the presence of tetracycline for 48 hours. 
Recombinant parasites were examined by Western blot-ting 
using a monoclonal antibody against GFP (Fig. 3A), with 
extracts derived from these cells containing a band of the 
expected size (∼ 105 kDa), or were fixed and examined by 
confocal microscopy (Fig. 3B). For parasites expressing 
GFP-TbSNM1, GFP fluorescence was restricted to a large 
 
single spot, a pattern reported for trypanosomal proteins 
localised to nucleus (Fig. 3B). To confirm this, cells were 
co-stained with the DNA dye, DAPI. When the images 
were compared, the pattern of localisation indicated that 
GFP-TbSNM1 was located in the larger of two 
compartments (the nucleus) where DAPI is found with the 
smaller, faint spot corresponding to the kinetoplast, the 
genome found in the parasites’ single mitochondrion. 
 
Functional analysis of TbSNM1 in T. brucei 
 
To  assess  whether  TbSNM1  was  essential  to  BSF  
T. brucei, an RNAi-based approach was initially employed. A 
DNA fragment corresponding to an internal region of 
Tbsnm1 was cloned into p2T7Ti (Wilkinson et al., 2003) and 
the construct transformed into BSF T. brucei. In the absence 
of tetracycline, recombinant clones were found to grow at 
approximately the same rate as the parental cells. Addition of 
tetracycline to parasites harbouring the RNAi construct did 
not affect the growth rate suggesting that TbSNM1 is not 
essential to BSF T. brucei. To confirm this,  
DNA fragments corresponding to the 5′ flank of Tbsnm1 and 
the 3′ region of the Tbsnm1 gene were cloned either side of 
a cassette containing blasticidin or puromycin resistance 
markers. The integration constructs were trans- 
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Fig. 2. Complementation of the yeast pso2 mutation.  
A. Western blot analysis was carried out using a monoclonal antibody to the FLAG-tag epitope on cell extracts made from S. cerevisiae BY4742 
(wild type) and pso2 strains expressing the FLAG epitope (control) or FLAG-TbSNM1. A band of ∼ 80 kDa (indicated by **) was observed in 
lysates derived from cell expressing the recombinant trypanosomal protein. A cross-reactive epitope (*) and Ponceau S staining of the 
membrane (not shown) were used as loading controls.  
B and C. The susceptibility of wild type (a and b) and pso2 (c and d) yeast strains expressing FLAG (a and c) or FLAG-TbSNM1 (b and d) to 
different concentrations of mechlorethamine. All data are mean values ± standard deviations from experiments performed in triplicate. In C, the 
values given in parenthesis represent the fold difference in IC50 values (in μM) relative to wild-type controls. 
 
formed into BSF T. brucei with heterozygote (Tbsnm1+/−) and 
then null mutant (Tbsnm1−/−) lines selected. Southern 
hybridisation was used to confirm each integration event 
demonstrating that both copies of the Tbsnm1 gene could 
readily be deleted from the parasite genome (Fig. 4A and B), 
whereas quantitative RT-PCR data analysed using the 
comparative CT method showed that a full-length Tbsnm1 
mRNA was not expressed (data not shown) (Schmittgen and 
Livak, 2008). Reduction or lack of TbSNM1 had no effect on 
trypanosome growth (data not shown). Therefore, TbSNM1 
is non-essential to BSF T. brucei under normal culture 
conditions confirming the RNAi observations.  
To evaluate whether deletion of both copies of Tbsnm1 from 
the T. brucei genome altered sensitivity to chemicals that 
promote DNA cross-linkage, null mutant cells were grown in 
the presence of these agents, and the IC50 values for each 
compound were determined (Table 1). 
 
Cells lacking TbSNM1 were more susceptible to a range 
of nitrogen mustard and aziridinyl compounds, including 
several of the trypanocidal nitroaromatic structures previ-
ously identified (Bot et al., 2010; Hall et al., 2010; Hu et 
al., 2011). Intriguingly, Tbsnm1−/− cells exhibited a larger 
difference in their sensitivities to the nitrogen mus-tards 
screened than that observed when using the aziridi-nyl 
compounds. When these growth assays were extended to 
look at other DNA damaging agents including mitomycin 
C, semustine, cisplatin, methyl methanesul-phonate 
(MMS), H2O2, hydroxyurea and UV light, and to the 
clinically used trypanocidal drugs nifurtimox, benzni-
dazole or difluoromethylornithine (DFMO), no difference 
in IC50 was observed.  
In order to demonstrate conclusively that the altered 
susceptibility phenotypes were specifically due to lack of 
TbSNM1, a complementation strategy was used. In 
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Fig. 3. Localisation of TbSNM1 in bloodstream form T.brucei.  
A. Expression of GFP-TbSNM1 was examined by probing a blot containing cell lysates from T. brucei wild type (lane 1) and GFP-TbSNM1 
expressing cells (lane 2) using an anti-GFP antibody (upper panel). Protein from 1.5 × 107 cells was loaded in each track and a cross-reactive 
epitope (lower panel) and by Coomassie staining (not shown) were used as loading controls.  
B. Parasites expressing GFP-TbSNM1 were co-stained with DAPI (DNA) and the cells examined by confocal microscopy. The TbSNM1 signal 
is coincidental with the nucleus (n; large DAPI spot); the smaller DAPI spot corresponds to the kinetoplast (k), the trypanosome mitochondrial 
genome. 
 
these experiments, Tbsnm1−/− cells were transformed 
with a vector that facilitates constitutive expression of an 
ectopic copy of Tbsnm1 integrated into one of the para-
site’s tubulin arrays: wild-type cells also expressing this 
vector were also generated. The IC50 of these parasites 
towards selected nitrogen mustard and aziridinyl com-
pounds was determined and compared with values 
obtained using wild type and Tbsnm1 null mutant lines 
(Fig. 5A). When the susceptibility of the complemented 
line to the nitrobenzyl-containing nitrogen mustard (LH34) 
and aziridinyl (NH1) compounds was tested, the resultant 
dose response curves (and associated IC50 values) were 
distinct from the Tbsnm1−/− cells, which 
 
displayed increased sensitivity to both agents, and 
equivalent to the plots observed using Tbsnm1 express-
ing parasites (wild type and wild-type cells engineered to 
express elevated levels of TbSNM1) (Fig. 5A). When the 
screens were extended to investigate the complemented 
line’s susceptibility to non-nitroaromatic nitrogen mustard 
(mechlorethamine) and aziridinyl (triethylenemelamine) 
compounds, a resistance phenotype was noted, with the 
dose response curves (and associated IC50 values) in the 
complemented line mirroring that obtained for wild-type 
parasites expressing elevated levels of TbSNM1 (Fig. 5A): 
trypanosomes (wild type and Tbsnm1 null mutants) 


















Fig. 4. Disruption of Tbsnm1 in T. brucei.  
A. Diagram of the Tbsnm1 alleles and the effects of gene disruption. A 5′ Tbsnm1 flanking sequence and a 3′ Tbsnm1 coding region were 
amplified and cloned sequentially either side of a puromycin (pac) or blasticidin (bla) cassette (plus T. brucei tubulin intergenic elements 
required for processing of mRNA (hashed boxes). The dotted lines correspond to the probe used to check integration. The position of the 
predicted MluI sites plus the band sizes (in kbp) obtained after hybridisation are shown. 
B. Southern blot analysis of MluI digested genomic DNA from T. brucei (lane 1), Tbsnm1+/− bla and Tbsnm1+/− pac heterozygous clones (lanes 
































Fig. 5. Susceptibility of T. brucei lines expressing altered levels of TbSNM1 to DNA damaging agents.  
A. Growth inhibitory effects (expressed as IC50 values in μM or nM) of the T. brucei wild type, Tbsnm1
−/− null mutant, Tbsnm1−/− expressing an 
ectopic copy of Tbsnm1 (Tbsnm1−/−+ Tbsmn1++) and T. brucei expressing elevated levels of Tbsnm1 (wild type + Tbsmn1++) lines towards 
DNA damaging agents. Integration of the Tbsnm1 expression vector into a single tubulin array was confirmed by Southern hybridisation and 
expression evaluated through qPCR (data not shown).  
B. Growth inhibitory effects (expressed as IC50 values in μM or nM) of T. brucei wild type, Tbsnm1
−/− null mutant, T. brucei expressing an 
ectopic copy of Tbntr (wild type + Tbntr9e10++ and Tbsnm1−/− expressing elevated levels of Tbntr (Tbsnm1−/− + Tbntr9e10++) towards DNA 
damaging agents. Expression of Tbntr was evaluated through qPCR (data not shown). Data in panels A and B are mean values ± standard 
deviations from experiments performed in quadruplicate. 
 
 
to 2.1-fold more resistant to mechlorethamine and trieth-
ylenemelamine than wild type.  
The above complementation studies indicate that para-
sites (wild type or Tbsnm1−/−) ectopically expressing 
Tbsnm1 are resistant to non-nitroaromatic DNA cross-
linking agents but not to the nitroaromatic-containing com-
pounds. One reason for this could reflect that the latter 
structures function as prodrugs and must undergo an 
NTR catalysed activation step before mediating their tryp-
anocidal DNA damaging activities. 
 
Linking prodrug activation with DNA damage 
 
To identify any link between the DNA damaging and the NTR-
activating pathways, both copies of the Tbsnm1 gene were 
deleted from T. brucei cells, expressing an ectopic copy of 
Tbntr and the susceptibilities of these recombinant cells 
towards selected nitrogen mustard and aziridinyl compounds 
determined (Fig. 5B). When treated with mechlorethamine or 
triethylenemelamine, both Tbsnm1 expressing cell lines (wild 
type and trypano-somes expressing elevated levels of Tbntr) 
displayed similar dose response curves and therefore had 
similar 
 
IC50s to either agent (Fig. 5B). When these studies were 
expanded to investigate the susceptibility of parasites 
lacking TbSNM1, the Tbsnm1−/− null mutant line and 
Tbsnm1−/− cells expressing the ectopic copy of Tbntr dis-
played equivalent IC50 values, with both being more sen-
sitive to mechlorethamine and triethylenemelamine than 
wild type (Fig. 5B). Importantly, no difference in IC50 was 
observed using either of the lines lacking Tbsnm1 indicat-
ing that Tbntr plays no role in metabolising either mechlo-
rethamine or triethylenemelamine.  
When the nitrobenzyl-containing DNA cross-linking agents 
LH34 and NH1 were tested against the parasite lines 
expressing altered levels of Tbsnm1 and/or Tbntr, a different 
outcome was observed (Fig. 5B). For Tbsnm1−/− parasites or 
wild-type cells expressing an ectopic copy of Tbntr, treatment 
with either damaging agents resulted in increased 
susceptibility when compared against controls, with Tbntr 
overexpressing trypanosomes being more sen-sitive to LH34 
and NH1 than the null mutant lines: Tbsnm1−/− cells and T. 
brucei overexpressing Tbntr were 18.0- and 24.0-fold more 
susceptible to LH34, respec-tively, with a 2.7- and 31.1-fold 
increase in sensitivity noted towards NH1. For Tbsnm1−/− null 
parasites express- 
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ing an ectopic copy of Tbntr, this increase in potency was 
magnified further with these cells showing a 80.0- and 38.7-
fold increase in susceptibility towards LH34 and NH1, 




Currently, very little is known about the mechanisms T. brucei 
employs to repair ICL damage even though this parasite is 
exposed to such deleterious insults throughout its cell and life 
cycles. In other unicellular eukaryotes such as budding and 
fission yeast, the processing of ICLs occurs through the 
concerted activities of several major DNA repair pathways 
with one enzyme, Pso2p, playing a central and specific role 
in fixing such lesions. Although non-essential for yeast 
viability, the importance of Pso2p is only apparent in its 
absence on exposure to ICL-inducing, bifunctional alkylating 
agents but not to monofunctional alkylating agents, ionising 
radiation or ultraviolet light (Henriques and Moustacchi, 1980; 
Ruhland et al., 1981a,b). Here, we report the characterisation 
of TbSNM1, a trypanosomal Pso2p homologue, and 
demonstrate that this enzyme plays a key role in processing 
ICL lesions when generated by bifunctional nitrogen mustard 
and aziridinyl compounds including several nitroaromatic-
based agents previously shown to have potent anti-
trypanosomal properties with low toxicity to mammalian cells 
(Bot et al., 2010; Hall et al., 2010; Hu et al., 2011). 
In terms of its sequence, TbSNM1 displays the main 
characteristics found in other PSO2/SNM1 proteins, pos-
sessing adjacent MBL and β-CASP domains that together 
form the enzyme’s zinc-binding central catalytic core (Cattell 
et al., 2010). To confirm the in silico identification, a 
complementation approach was undertaken. This involved 
ectopically expressing the trypanosomal enzyme in a yeast 
pso2 line and then evaluating the susceptibility of the 
resultant cells to mechlorethamine, a bifunctional alkylat-ing 
agent routinely used as an ICL-inducing agent. In this genetic 
background, the parasite protein was able to revert the 
susceptibility phenotype displayed by the pso2 line resulting 
in an additional slight (approximately twofold) resistance 
towards this nitrogen mustard. This confirmed that the 
trypanosomal enzyme is a genuine Pso2p homo-logue and 
that it plays a role in the processing of ICL lesions. 
Furthermore, as TbSNM1 can complement for the pso2 
mutation then the parasite enzyme may interact with the 
same partner proteins as its yeast counterpart. For example, 
Pso2p contains an ubiquitin binding zinc finger (UBZ) C2HC 
motif upstream of its catalytic core (Yang et al., 2010). By 
analogy with hSNM1A, the only human PSO2/SNM1 
homologue able to complement the yeast pso2 mutation 
(Hazrati et al., 2008), this signature sequence is able to 
facilitate binding to monoubiquinated PCNA leading to 
recruitment of this repair enzyme to 
 
ICL-stalled replication forks (Yang et al., 2010). Interest-ingly, 
in silico searches failed to identify any known UBZ C2HC 
domain or any other type of ubiquitin interaction motifs (UIMs) 
in the parasite protein sequence. Therefore, if formation of 
PSO2/SNM1-containing DNA repair com-plexes at the site of 
ICL damage does involve PCNA ubiquitylation, then the 
molecular mechanisms underlying TbSNM1 recruitment to 
such lesions occurs through an as yet uncharacterised UIM 
or via interactions involving a conserved adapter protein. 
Recently, it has been shown that the β-CASP domain of 
Pso2p can be phosphorylated leading to the suggestion that 
this event may play a role in modulating the enzyme’s exo- or 
endo-nucleolytic activity (Munari et al., 2014). Whether 
TbSNM1 undergoes a similar post-translational modification, 
and how this effects its nuclease activity has yet to be 
established. 
The endogenous function of TbSNM1 is non-essential to 
replicating T. brucei: both copies of Tbsnm1 could be 
deleted from the genome of BSF trypomastigote parasites. 
However, the importance of this enzyme to the trypano-
some only became evident following exposure to ICL-
inducing compounds: null mutant cells were more 
susceptible to bi- and tri-functional alkylating agents as 
compared with controls, whereas these recombinant cells 
display an equivalent sensitivity to wild type when exposed 
to MMS, UV irradiation and H2O2, treatments normally 
repaired by homologous recombination, nucleotide exci-sion 
repair or base excise repair pathways. This trait was solely 
due to loss of TbSNM1 activity as expression of an ectopic 
copy of Tbsnm1 in the null mutant genetic back-ground 
restored the recombinant parasites IC50 near to wild-type 
levels. Intriguingly, the range of compounds that elicits the 
change in susceptibility in the Tbsnm1−/− trypa-nosomes 
although similar to that noted for the yeast pso2 line does 
have some notable differences (Henriques and Moustacchi, 
1980; Ruhland et al., 1981a,b). For example, yeast pso2 
mutants are reported to be more susceptible to cisplatin and 
mitomycin C, whereas T. brucei lacking TbSNM1 displays 
sensitivities similar to that exhibited by wild-type parasites. 
This may be because that although both compounds can 
function as ICL-inducing agents they can also mediate their 
cytotoxic activities via other mecha-nisms including 
promoting formation of intrastrand cross-links, activating 
signal transduction pathways, stimulating redox cycling, 
acting as enzyme inhibitors or alkylating other biological 
molecules (Sharma and Tomasz, 1994; Pagano et al., 2003; 
Siddik, 2003; Rabik and Dolan, 2007; Paz et al., 2012). One 
(or a combination) of these alterna-tive modes of action (or 
possibly another unidentified mechanism) may account for 
cisplatin’s and mitomycin C’s trypanocidal properties, 
therefore negating the require-ment for a TbSNM1-
dependent ICL repair pathway. 
 
Previous trypanocidal screening programmes have identified 
nitrobenzylphosphoramide mustards and aziridi- 
 




nyl nitrobenzamides as having potent anti-parasitic activity 
(Bot et al., 2010; Hall et al., 2010; Hu et al., 2011). These 
agents function as prodrugs and must be activated before 
they can mediate their cytotoxic effects, a reaction cata-lysed 
a NADH-dependent type I NTR. This reduction causes the 
conversion of a conserved electron withdraw-ing nitro-group 
present on the compound’s benzyl ring to an electron 
donating hydroxylamine derivative (Bot et al., 2010; Hall et 
al., 2010; Hu et al., 2011). This action effec-tively acts as an 
electronic switch that is believed to turn on the alkylating 
ability of the nitrogen mustard or aziridinyl moiety causing 
ICL-mediated DNA damage. Using Tbsnm1 null mutant 
parasites engineered to express elevated levels of TbNTR, 
we have now demonstrated a link between prodrug activation 
and ICL formation. Here we observed that wild-type parasites 
exhibited the highest IC50 values towards LH34 (a 
nitrobenzylphosphoramide mustard) and NH1 (an aziridinyl 
nitrobenzamide), whereas trypanosomes lacking TbSNM1 
and cells overexpress-ing TbNTR had intermediate 
sensitivities. Interestingly, Tbsnm1 null mutants that also 
express elevated levels of TbNTR were the most prone to 
both compounds. This implies that following uptake, LH34 
and NH1 are trans-ported into mitochondrion where they 
undergo TbNTR-mediated reduction to form the bioactive 
products. These observations suggest that in parasites 
where the NTR activity is overexpressed, this conversion 
occurs at a faster rate than in wild-type cells resulting in 
increased sensitivity to the compound. A portion of the 
resulting metabolites are then able to access the nucleus 
where they induce ICL formation. In the absence of TbSNM1, 
mutant cells are less able to repair this type of DNA damage, 
resulting in an increased susceptibility to the ICL-inducing 
agent. In parasites where both TbSNM1 and TbNTR levels 
have been altered, this susceptibility phenotype is 
exacerbated. Intriguingly, the difference in sensitivities 
between Tbsnm1−/− cells expressing elevated TbNTR levels 
from those over expressing TbNTR alone was greater for 
LH34 than for NH1. This may be attributable to properties of 
the substrate/TbNTR-generated metabolites, possibly 
reflect-ing differences in cell and/or organelle uptake [TbNTR 
is a mitochondrial protein (Wilkinson et al., 2008)] or how the 
substrates interact with, or how the metabolites are released 
from, TbNTR [in vitro nitrobenzyl phosphoramide nitrogen 
mustard-based compounds interact with TbNTR more readily 
than the aziridinyl nitrobenzamide (Hall et al., 2012)]. 
Additionally, as this study only considers ICL for-mation and 
repair in the nuclear genome, it is plausible that LH34 and 
NH1 reduction products may also affect the mitochondrial 
genome with the NH1 metabolites preferen-tially affecting 
this DNA containing region and not the nucleus. 
 
We have now demonstrated that T. brucei expresses a 
bona fide homologue of the PSO2/SNM1 nuclease 
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family. The trypanosomal enzyme displays characteris-
tics of its yeast counterpart and is able to repair the DNA 
damage caused by bi- and tri-functional alkylating agents. 
By exploiting parasites lacking this enzyme we were able 
to demonstrate that following TbNTR-mediated activation 
nitrobenzylphosphoramide mustard and aziridinyl 
nitrobenzamide agents, compounds previ-ously shown to 
have potent trypanocidal properties with little/no 
cytotoxicity in mammalian cells, generate metabolites that 
promote ICL formation. Although not essential to survival 
of the medically relevant form of T. brucei, in the future 
TbSNM1 could be targeted through the use of inhibitors to 
improve the potency of other drugs that do cause parasite 






Bloodstream form Trypanosoma brucei brucei [MITat 427 strain; 
clone 221a and a derivative (2T1) engineered to express 
elevated levels of TbNTR-myc] was maintained in HMI-9 
(Invitrogen) medium supplemented with 3 g l−1 sodium 
bicarbonate, 0.014% (v/v) β-mercaptoethanol and 10% (v/v) 
foetal calf serum (Hirumi and Hirumi, 1989; Wilkinson et al., 2008) 
at 37°C under a 5% (v/v) CO2 atmosphere. The 2T1 cells were 
grown in the presence of 1 μg ml−1 phleomycin and 2 μg ml−1 
puromycin. Transformed T. brucei cells were grown in the 
presence of 2.5 μg ml−1 hygromycin, 10 μg ml−1 blasti-cidin 
and/or 2 μg ml−1 puromycin.  
Saccharomyces cerevisiae strains BY4742 (MATα his3- 1 
leu2- 0 lys2- 0 ura3- 0) and a pso2 derivative obtained from 
the Open Biosystems (Thermo Scientific) knock-out col-
lection were maintained in yeast extract-peptone broth 
containing 2% (w/v) glucose. Transformed cells were grown 





The DNA damaging agents were obtained from Drug Synthe-
sis and Chemistry Branch, Developmental Therapeutics 
Program, Division of Cancer Treatment and Diagnosis, 
National Cancer Institute except CB1954, H2O2, MMS and 
hydroxyurea (all Sigma-Aldrich), NH1 (Helsby et al., 2004) 
and LH7, LH17, LH32-34 and LH37 (Hu et al., 2003; 2011; Li 
et al., 2003). Nifurtimox and benznidazole were obtained from 
Simon Croft (London School of Hygiene and Tropical 





The vectors used to delete Tbsnm1 from the T. brucei genome 
were generated as follows. Primers were designed to amplify 897 
or 909 bp fragments from the 5′ Tbsnm1 untranslated region and 
3′ region of the Tbsnm1 gene respectively. These 
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were cloned sequentially either side of a puromycin- (pac) or 
blasticidin- (bla) containing resistance cassette. The con-
structs were linearised (SacI/KpnI for the pac vector or SacII/ 
KpnI for the bla vector) then introduced into BSF T. brucei 
using the Human T-cell Nucleofector® kit and an Amaxa® 
Nucleofector™ (Lonza AG) set to program X-001. Integration 
of the DNA constructs into the T. brucei genome results in 
deletion of 60% of the Tbsnm1 open reading frame (amino 
acids 1 to 425) including all of the non-canonical MBL 
domain. As this region is essential for Pso2p/SNM1 function 
(Li and Moses, 2003), removal of the MBL encoding DNA 
sequence from the trypanosomal genome would generate 
parasites lacking TbSNM1 activity, effectively producing 
Tbsnm1 null mutant cells.  
The Tbsnm1 trypanosomal expression vector was gener-
ated as follows: a 2166 bp DNA sequence corresponding to 
full-length Tbsnm1 was amplified from T. brucei genomic 
DNA using the primers cctgcaggATGGCAGGTGGA GCTG-
CAGGT and gcgcgccTTATTCTGAGTC ACTACTCAG 
(lower-case italics correspond to restriction sites incorporated 
into the primers to facilitate cloning), digested with SdaI/SgsI 
and ligated into the corresponding sites of vector pTubEX-
LmSpSyn (Taylor et al., 2008), replacing Lmspsyn. The NotI/ 
XhoI digested construct was introduced into T. brucei wild 
type and Tbsnm1−/− cells using nucleofection and recombi-
nant clones selected.  
For the localisation construct, a 2166 bp DNA sequence 
corresponding to full-length Tbsnm1 was amplified from T. 
brucei genomic DNA using the primers tctagaGCAGGTG-
GAGCTGC AGGTAAG and gagatctTTATTCTGAGTCACT 
ACTCAG (lower-case italics correspond to restriction sites 
incorporated into the primers to facilitate cloning), the frag-
ment digested with XbaI/BglII and ligated into the XbaI/ 
BamHI sites of vector pRPaGFP-AT2 (Alsford et al., 2005) to 
replace the Tbat2 coding sequence. The cloning was carried 
out such that the gene coding for the GFP was inserted in-
frame at the 5′ end of the Tbsnm1-derived DNA fragment. 
The AscI-digested construct was introduced into T. brucei 
2T1 parasites.  
To construct the yeast complementation vector Tbsnm1 was 
amplified from the trypanosomal localisation plasmid using the 
primers tctagaGCAGGTGGAGCTGCAGGTAA G and 
aagcttTTATTCTGAGTCACTACTCAG (lower-case italics 
correspond to restriction sites incorporated into the primers to 
facilitate cloning). The resultant fragment was digested with 
XbaI/HindIII and ligated into the corresponding sites of a 
pYCYlac111 derivative containing a DNA sequence encoding for 
the FLAG-tag epitope (Novoselova et al., 2013). The plasmid was 
transformed into yeast strains BY4742 and pso2 . In this system 
recombinant TbSNM1 is tagged at its amino-terminus with a 





BSF trypanosomes expressing GFP-TbSNM1 were washed 
twice in phosphate-buffered saline (PBS), fixed in 2% (w/v) 
paraformaldehyde/PBS and washed again in PBS. Aliquots of the 
cell suspension (105 cells) were then air dried onto micro-scope 
slides. Parasite DNA was stained using Vectashield Mounting 
Medium containing 4′,6-diamidino-2-phenylindole 
 
(DAPI) (Vectorshield Laboratories), and slides were viewed 






All assays were performed in a 96-well plate format. T. brucei 
BSF parasites were seeded at 1 × 104 ml−1 in 200 μl growth 
medium containing different concentrations of compound. For UV 
irradiation, parasites were exposed to doses up to 900 J m−2 
using a Stratalinker® UV crosslinker (Stratagene). After 
incubation at 37°C for 3 days, 2.5 μg resazurin (20 μl of 0.125 μg 
ml−1 stock in phosphate buffered saline) was added to each well, 
and the plates were incubated for a further 6–8 hours (Jones et 
al., 2010). Cell densities were determined by monitoring the 
fluorescence of each culture using a Gemini Fluorescent Plate 
Reader (Molecular Devices (UK) Ltd, Wok-ingham, UK) at an 
excitation wavelength of 530 nm, emission wavelength of 585 nm 
and a filter cutoff at 550 nm. The drug/treatment concentration 
that inhibits cell growth by 50% (IC50) was established using the 




Yeast complementation assay 
 
All assays were performed in a 96-well plate format. The cell 
density of overnight yeast cultures were equalised according 
to absorbance at 405 nm in medium containing different con-
centrations of mechlorethamine. The growth of each strain 
was then followed by monitoring the change in absorbance at 
405 nm using an Absorbance Microplate Reader (BioTek 
Instruments Ltd). The % growth for each mechlorethamine-
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Quinone-based compounds have been exploited to treat 
infectious diseases and cancer, with such chemicals often 
functioning as inhibitors of key met-abolic pathways or as 
prodrugs. Here, we screened an aziridinyl 1,4-
benzoquinone (ABQ) library against the causative agents 
of trypanosomiasis, and cutane-ous leishmaniasis, 
identifying several potent struc-tures that exhibited EC50 
values of <100 nM. However, these compounds also 
displayed signifi-cant toxicity towards mammalian cells 
indicating that they are not suitable therapies for systemic 
infec-tions. Using anti-T. brucei ABQs as chemical 
probes, we demonstrated that these exhibit different 
trypano-cidal modes of action. Many functioned as type I 
nitroreductase (TbNTR) or cytochrome P450 reduc-tase 
(TbCPR) dependent prodrugs that, following activation, 
generate metabolites which promote DNA damage, 
specifically interstrand crosslinks (ICLs). Trypanosomes 
lacking TbSNM1, a nuclease that spe-cifically repairs 
ICLs, are hypersensitive to most ABQ prodrugs, a 
phenotype exacerbated in cells also engineered to 
express elevated levels of TbNTR or TbCPR. In contrast, 
ABQs that contain substituent groups on the biologically 
active aziridine do not 
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function as TbNTR or TbCPR-activated prodrugs and do 
not promote DNA damage. By unravelling how ABQs 
mediate their activities, features that facilitate the desired 
anti-parasitic growth inhibitory effects could be 
incorporated into new, safer compounds targeting these 





The protozoan parasites Trypanosoma brucei, T. cruzi 
and various Leishmania species are the etiological agents 
of human African trypanosomiasis (HAT), Cha-gas 
disease and Leishmaniasis, respectively. Spread by the 
hematophagous habits of insect vectors, these pathogens 
cause more than 55,000 deaths per year and are 
prevalent in many regions of the world least able to deal 
with the associated economic burden (http://www. 
dndi.org/diseases-projects/). Implementation of new sur-
veillance and treatment programmes in conjunction with 
improved housing and vector control strategies has 
resulted in a dramatic reduction in disease prevalence. 
For example, the number of new cases of HAT has fallen 
from an estimated peak of 450,000 in 1997 to below 
20,000 in 2014 while Chagas disease has been 
eliminated from Chile, Uruguay and several regions of 
Argentina and Brazil (Barrett, 2006; Schofield et al., 2006; 
WHO, 2014). The success of such strategies has led to 
the World Health Organization (WHO) aiming to eliminate 
HAT as a public health problem by 2020 (WHO, 2013). 
 
Currently, drugs represent the only viable option to 
combat trypanosomal and leishmanial infections although 
their use is problematic. They often require supervision for 
administration, can be costly, have lim-ited efficacy and 
may cause significant toxicity. Addition-ally, drug 
resistance is beginning to further limit the efficacy of the 
available chemotherapeutic arsenal, with antimonials no 
longer recommended as a first line treat-ment for 
leishmaniasis on the Indian sub-continent (Wilkinson and 
Kelly, 2009; Barrett and Croft, 2012; Alsford et al., 2013; 
Perry et al., 2015). In the case of HAT and Chagas 
disease, the front line treatments involve 
nitroheterocyclic-based prodrugs with nifurtimox 
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or benznidazole monotherapies used to target T. cruzi 
while nifurtimox, in combination with difluoromethylorni-
thine (DFMO), is used against a form of HAT prevalent 
throughout West and Central Africa (Priotto et al., 2009; 
Yun et al., 2010; Wilkinson et al., 2011). To mediate their 
trypanocidal effects, nifurtimox and benznidazole undergo 
an activation reaction catalysed by an FMN-containing, 
mitochondrial type I nitroreductase (NTR), generating 
cytotoxic reduction products (Wilkinson et al., 2008; Hall 
et al., 2011; Hall and Wilkinson, 2012). For nifurtimox, this 
results in the production of an unsatu-rated open chain 
nitrile while benznidazole is processed to glyoxal via a 
series of highly reactive intermediates. As type I NTRs are 
expressed by some unicellular eukar-yotes (including 
trypanosomes and Leishmania) but not by metazoan 
organisms, the bioreductive activity of this enzyme has 
been exploited to develop a series of novel antiparasitic 
nitroaromatic- and benzoquinone-based pro-drugs 
(Wilkinson et al., 2011; Patterson and Wyllie, 2014). 
Several of these display significant potency against T. 
brucei in vitro while exhibiting little or no toxicity towards 
cultured mammalian cells. 
 
Quinones represent a class of organic compounds that 
contain two carbonyl groups attached to a six mem-bered 
carbocyclic backbone. They are ubiquitous in nature, 
functioning in various oxidoreductase cascades, with some 
natural and synthetic variants being of phar-macological 
interest. In the latter case, many quinone-based agents often 
function as prodrugs and must undergo activation before they 
can mediate their cyto-toxic effects, reactions catalysed by 
quinone oxidoreduc-tases (McKeown et al., 2007; Siegel et 
al., 2012). Based on oxygen-sensitivity, such enzymes can be 
divided into two groups. Oxygen-sensitive quinone 
oxidoreductases, such as NADH cytochrome b5 reductase 
and cyto-chrome P450 reductase (CPR), can mediate the 1e– 
reduction of one of the quinone’s carbonyl oxygens to form 
an unstable semiquinone radical that, under hypoxic 
conditions, can be further reduced to the hydro-quinone 
derivative (Powis, 1989; O’Brien, 1991). How-ever, in the 
presence of oxygen, the semiquinone radical can undergo 
futile cycling, generating superoxide anions and regeneration 
of the parent compound. In contrast, oxygen-insensitive 
quinone oxidoreductases, such as NAD(P)H quinone 
oxidoreductase 1 (NQO1), cat-alyse the simultaneous 1e– 
reduction of both the qui-none’s carbonyl oxygens to form the 
hydroquinone directly (Ernster et al., 1962; Iyanagi and 
Yamazaki, 1970; Siegel et al., 2012). Dependent on structural 
context, this conversion can result in stable 
pharmacologically active products, as is the case for the 
benzoquinone ansamycin antibiotics, or unstable metabolites 
that undergo further rearrangement before exerting their toxic 
effects, as seen 
 
with the antitumor agents mitomycin A and b-lapachone 
(Siegel et al., 2012). 
 
Due to their favorable redox and electrochemical 
properties, compounds containing a quinone pharmaco-
phore represent attractive scaffolds for antimicrobial drug 
development (Pinto and de Castro, 2009; Beena and 
Rawat, 2013). Screening against trypanosomes has 
resulted in the identification of various natural and syn-
thetic lead structures postulated to function as prodrugs 
promoting oxidative stress within the parasite or through 
formation of toxic bioreductive products (Henderson et al., 
1988; Kubata et al., 2002; Hoet et al., 2004; Pinto and de 
Castro, 2009; Ramos et al., 2009; Garavaglia et al., 2010; 
Hall et al., 2012). Using recombinant T. brucei that lack 
TbSNM1, a DNA repair enzyme that specifically fixes 
interstrand crosslinks (ICLs) (Sullivan et al., 2015), while 
expressing elevated levels of oxygen-sensitive (TbCPR) 
or –insensitive (TbNTR) quinone oxidoreductases, we 
demonstrate that many aziridinyl 1,4-benzoquinones 
(ABQs) possess significant potency towards 
trypanosomatid parasites, with different struc-tures 
undergoing distinct activation mechanisms to gen-erate 
metabolites that subsequently promote DNA damage 





Antiparasitic activity of aziridinyl benzoquinones 
 
Compounds containing an ABQ core display potent anti-
cancer properties particularly against cells where NADPH 
quinone oxidoreductase 1 (NQO1) expression is 
upregulated (Lin et al., 1972; Lusthof et al., 1989; Dehn et 
al., 2004). Recently, the antiparasitic activities of such 
compounds towards Plasmodium falciparum and T. 
brucei has been investigated with several poten-tial lead 
structures identified (Grellier et al., 2010; Hall et al., 2012). 
Here, we have expanded on these initial trypanosomal 
screens to evaluate the growth inhibitory properties of a 
larger ABQ library against T. brucei, T. cruzi and L. major 
(Table 1). Out of the 34 compounds tested, 20, 14 and 16 
had no effect on T. brucei, T. cruzi and L. major growth, 
respectively, at concentrations of up to 10 mM. These 
were not analysed further. For the remaining compounds, 
RH1 exhibited potencies, expressed as the compound 
concentration that inhibits cell growth by 50% (EC50), of 
<100 nM towards blood-stream form T. brucei, with a 
further five (DZQ, ABQ3, ABQ6, TZQ and ABQ22) 
exhibiting moderate potency towards this parasite (EC50 
values of 100–500 nM). Against T. cruzi epimastigotes, 
DZQ, TZQ and RH1 were highly active, yielding EC50 
values <10 nM, with others displaying high (EC50 values 
between 10 and 
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Table 1. Potency of aziridinyl benzoquinones.  
 
 T. bruceia   T. cruzi   L. major  
THP-1
b 
          
Compound  EC50 (nM) SI EC50 (nM) SI EC50 (nM) SI EC50 (nM) 
Nifurtimox 2700 6 100 >37 2600 6 400 >38 6280 6 40 >16 >100000 
ABQ7, 9–12, 16–19, 28, 31, 32, 34 >10000 – >10000  >10000  – 
DZQ 272 6 1 1  5 6 1 36 60 6 1 3 181 6 5 
MeDZQ 698 6 57 1  55 6 2 16 560 6 139 2 885 6 23 
ABQ3
c 
400 6 30 – 6200 6 1160 – 199 6 4 – – 
ABQ4 1180 6 160 – 106 6 25 – 663 6 6 – – 
RH1 19 6 1 <5 3 6 1 <33 68 6 1 <1 <100 
ABQ6 283 6 41 2  205 6 53 5 664 6 2 2 1067 6 159 
ABQ8 670 6 30 4  1300 6 108 2 1870 6 184 2 29516 770 
ABQ13 >10000 – 5550 6 240 – >10000 – – 
ABQ14 >10000 – 445 6 30 – 2270 6 17 – – 
ABQ15 >10000 – 3310 6 200 – >10000 – – 
AZQ 8233 6 272 – 6000 6 283 – >10000 – – 
TZQ 179 6 1 <1 3 6 1 <33 9 6 1 <11 <100 
ABQ22 148 6 1 1  55 6 2 3 218 6 20 1 138 6 25 
ABQ23 2300 6 60 <1 2180 6 670 <1 348 6 166 1 <400 
ABQ24 1470 6 120 <1 37 6 1 <11 473 6 123 <1 <400 
ABQ25 >10000 – – – 80 6 6 – – 
ABQ26 >10000 – 8638 6 736 – 2360 6 230 – – 
ABQ27 >10000 – 620 6 180 – 210 6 10 – – 
ABQ29  – – 975 6 25 – 175 6 5 – – 
ABQ30 7400 6 190 <1 980 6 25 4 174 6 10 22 3750 6 320 
ABQ33 >10000 – >10000 – 8157 6 80 – – 
            
Data represent the EC50 values of various ABQs towards bloodstream form T. brucei, T. cruzi epimastigotes, L. major promastigotes and dif-
ferentiated THP-1 cells. All values are means 6 standard deviation of four (parasites) or three (mammalian cells) independent experiments.  
a. Activity of DZQ, MeDZQ, RH1, TZQ and ABQ’s 6–9, 14, 15, 20, 22 against T. brucei was previously reported (Hall et al., 2012). 
b. Differentiated THP-1 EC50 value towards nifurtimox taken from (Voak et al., 2013). The Selectivity Index (SI) of certain compounds (fold dif-
ference in EC50 values of the THP-1 line relative to parasite) is noted. 




100 nM; MeDZQ, ABQ22 and ABQ24) or moderate (EC50 
values between 100 and 500 nM; ABQ4, ABQ6 and 
ABQ14) growth inhibitory effects. When tested against L. 
major promastigotes, TZQ exhibited an EC50 of <10 nM, 
with three other compounds (DZQ, RH1 and ABQ25) 
exhibiting high potency and eight others yielding 
moderate potency. Of all the ABQs analysed, RH1 was 
the most potent agent tested against all three parasites, 
yielding EC50 values of 19 6 1, 3 6 1 and 68 6 1 nM 




Cytotoxicity against mammalian cells 
 
To evaluate whether those ABQs that displayed activity 
against the three trypanosomatid parasites exhibited 
toxicity to mammalian cells, their inhibitory properties 
against differentiated THP-1 cells was determined (Table 
1). For all structures tested, an in vitro toxicity was 
observed (EC50 values <10 mM), with two compounds, 
including RH1, being extremely toxic and yielding EC50 
values of <100 nM. Comparison of the mammalian tox-
icity and antiparasitic EC50 data allowed a crude mea-




SI) toward the pathogen. In many cases, the ABQs dis-
played a higher potency against THP-1 cells relative to 
the parasite, resulting in a SI value <1. Of those that did 
display preferential activity against the parasite, the 
observed selective toxicity of most was equivalent to that 
seen with nifurtimox, an agent whose use in humans is 
problematic. The toxicity of these compounds towards 
cultured mammalian cells precluded any attempt to 
establish the potency of these structures against the 
intracellular amastigote forms of T. cruzi and L. major. 
 
As THP-1 cells are an immortal human monocyte line and 
ABQs have potent activity against cancerous cells (Tan et 
al., 1984; Lee et al., 1986; Moore et al., 1997), a series of 
screens using a selected quinone series on non-
cancerous mouse peritoneal macrophages were 
performed. For DZQ, RH1, TZQ and ABQ22, substantial 
toxicity towards this line was observed with the com-
pounds generating EC50 values of 255, <100, <100 and 
120 nM, respectively. This clearly demonstrates that 
ABQs are toxic to primary cells, thus supporting our THP-
1 findings. In light of the mammalian toxicity issues, our 
focus on ABQs switched from exploring them as potential 
treatments for infectious diseases to 
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Screening for RH1 resistant determinants using a genome-scale T. brucei RNAi library.  
A. The bloodstream form T. brucei RNAi library (Alsford et al., 2012) was co-treated with RH1 (30 nM) and tetracycline (1 mg ml
21
), the latter to 
induce RNAi, with the cumulative cell growth of the culture followed. The arrows correspond to culture dilution and addition of fresh RH1 (30 
nM) and tetracycline (1 mg ml
21
). Genomic DNA (as indicated by stars) was extracted from parasites at days 9 and 12. Insert shows structure 
of RH1.  
B. Amplification of the RNAi target from the RH1 screen using genomic DNA extracted on day 9 of selection and the LIB2f 
(TAGCCCCTCGAGGGCCAGT) and LIB2r (GGAATTCGATATCAAGCTTGGC) primers (lane 1) produced a major fragment mapping to the type 
I nitroreductase (Tbntr) locus (gene id Tb927.7.7230 on the TriTrypDB; http://tritrypdb.org/tritrypdb/). M indicates a size marker in bp.  
C. Genetic map (black boxes represent protein-coding sequences) of the Tbntr locus, indicating the location of the major RNAi target fragment 
(grey box) recovered from the library following RH1-selection. 
 
using them as tools to dissect trypanosomal pro-drug 
activation pathways and the structure-activity relation-
ships among this class of compound. 
 
 
Different trypanosomal mechanisms activate aziridinyl 
benzoquinone prodrugs 
 
The application of genome-scale RNAi screens has helped 
elucidate the trypanocidal mechanism of action of a number 
of agents and identify how the affected path-ways may 
impinge on drug resistance (Alsford et al., 2012; 2013). As an 
initial step to understanding how ABQs mediate their 
antiparasitic activities, a loss-of-function screen was 
conducted on bloodstream form T. brucei, using RH1 as the 
selective agent (Fig. 1A). Treat-ment of the parasite RNAi 
library with this compound resulted in reduced T. brucei 
growth over the first week followed by the outgrowth of an 
RH1-resistant population. Genomic DNA was extracted from 
the RH1-selected cells and RNAi targets were amplified, from 
which a single 1.1 kbp fragment was identified as the major 
amplicon (Fig. 1B). Sequence analysis and comparison 
against the reference genome database revealed that this 




 untranslated region and 5
0
 coding 
sequence of the open reading frame (Gene ID: 
Tb927.7.7230 on TriTrypDB - 
http://tritrypdb.org/tritrypdb/) for the type I nitroreductase, 
TbNTR (Fig. 1C). This was not unexpected given that this 
protein had been previ-ously associated with the 
activation of trypanocidal nitroheterocyclic-based 
prodrugs, nifurtimox and benzni-dazole (Wilkinson et al., 
2008; Baker et al., 2011; Hall et al., 2011; Hall and 
Wilkinson, 2012) and postulated to function as a NADH 
dependent quinone oxidoreductase (Wilkinson et al., 
2008; Alsford et al., 2012; Hall et al., 2012). 
 
To conclusively show that TbNTR is the key activator of 
ABQs, we evaluated the susceptibility of a T. brucei Tbntr 
heterozygote line to RH1. These recombinant cells 
displayed an EC50 approximately 2.5-fold greater than 
that observed using wild type parasites (Fig. 2A) 
confirming that reduction of TbNTR expression through 
loss of one of the alleles encoding for this oxidoreduc-tase 
is sufficient to generate resistance to RH1. As reduction 
of TbNTR activity leads to RH1 resistance, gain of 
function via over expression of the oxidoreduc-tase 
should have the converse effect, generating cells that are 
more susceptible to the ABQ. To determine if 
 









































Fig. 2. Susceptibility of T. brucei expressing altered levels of 
activator to RH1 or ABQ22.  
A. Dose response curve of wild type (solid line) and Tbntr 
heterozygous (dotted line) T. brucei to RH1. The extrapolated EC50 
values (in nM) of wild type (white bar) and Tbntr heterozygous (grey 
bar) T. brucei to RH1 are shown.  
B. Dose response curve of wild type (solid line) and TbNTR 
overexpressing (dotted line) T. brucei to RH1. The EC50 values (in 
nM) of wild type (white bar) and TbNTR overexpressing (grey bar) 
T. brucei to RH1 are shown.  
C. Dose response curve of wild type (solid line) and TbCPR2 
overexpressing (dotted line) T. brucei to ABQ22. The extrapolated 
EC50 values (in nM) of wild type (white bar) and TbCPR2 
overexpressing (grey bar) T. brucei to RH1 are shown.  
All data are means for experiments performed in quadruplicate 6 
standard deviation. The asterisk indicates significant differences in 
susceptibility (P < 0.01) between wild type and genetically modified 
cells to RH1, as assessed by Student’s t test (GraphPad Software). 
 
 
this was the case, the quinone-sensitivity of a T. brucei 
line engineered to express elevated levels of the enzyme 
was evaluated. In agreement with previous findings, 
parasites over expressing TbNTR were hyper-sensitive 
(approximately fourfold) to RH1 as compared to controls 
(Fig. 2B). 
 
To determine whether TbNTR plays a role in activat-ing 
other ABQs, the susceptibility of TbNTR over expressing 
parasites towards a selected group of com-pounds, was 
tested (Table 2). Out of the additional 
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Table 2. Growth inhibitory effect of ABQs towards T. brucei expressing 
elevated levels of potential activators.  
 
 EC50 (nM)    







     
DFMO 27500 6 108 30720 6 1330 33250 6 5123  
  (1.12) (1.21)   
Nifurtimox 2980 6 30 315 6 15 (0.11*) – 
DZQ 318 6 38 90 6 3 (0.28*) – 
MeDZQ 740 6 18 115 6 3 (0.16*) – 
RH1 19 6 1 3 6 1 (0.16*) 20 6 3 (1.05) 
TZQ 225 6 26 60 6 9 (0.27*) 284 6 13 (1.26) 
ABQ22 138 6 25 148 6 9 (1.07) 20 6 3 (0.14**) 
ABQ23 2935 6 420 3315 6 540 (1.13) 3556 6 96 (1.21) 
ABQ24 1470 6 120 2090 6 160 (1.42) 1698 6 23 (1.16) 
ABQ30 7400 6 190 8670 6 1670 (1.12) – 
      
Data represent the EC50 values of parasites expressing wild type 
(control), elevated levels of TbNTR (Tbntr
11
) or TbCPR2 (Tbcpr2
11
). 
All values are means 6 standard deviation of four inde-pendent 
experiments. The fold difference in EC50 values of the over 
expressing lines relative to control is given in parentheses. Para-sites 
over expressing TbCPR3 behaved similarly to those express-ing 
elevated levels of TbCPR2.  
a. Trypanocidal activity of DZQ MeDZQ, RH1, ABQ6, TZQ and 
ABQ22 towards T. brucei cells over expressing Tbntr was previ-ously 
reported (Hall et al., 2012).  
*The difference in susceptibility of wild type and Tbntr
11
 lines to 
nifurtimox, DZQ, MeDZQ, RH1 and TZQ was statistically significant 
(P < 0.01), as assessed by Student’s t test.  
**The difference in susceptibility of wild type and Tbcpr
11
 lines to 
ABQ22 was statistically significant (P < 0.01), as assessed by Stu-
dent’s t test. 
 
compounds screened, three (DZQ, MeDZQ and TZQ) 
showed the same hypersensitivity profile as RH1, with 
TbNTR over expressing T. brucei being up to 3.5-fold 
more susceptible to the aziridinyl agents than controls. In 
contrast, ABQ22–24 and 30 did not follow this pat-tern, 
with the TbNTR over expressers exhibiting an EC50 
equivalent to that observed against control cells.  
Dependent on backbone configuration, the carbonyl 
oxygen atoms in a quinone can undergo 1 or 2e– reduc-
tion, with the former reaction carried out by a range of 
ubiquitous flavoproteins, including CPR, while the latter is 
catalysed by enzymes, such as NQO1 and type I NTRs. 
To determine whether the trypanocidal activity displayed 
by selected ABQs can undergo activation via a 1e– 
reduction mechanism, the susceptibility of T. bru-cei lines 
engineered to express ectopic copies of the TbCPR2 or 3 
(Hall et al., 2011) to RH1, TZQ and ABQ22–24 was 
evaluated (Table 2). With RH1, TZQ, ABQ23 and ABQ24, 
the TbCPR over expressing lines exhibited EC50 values 
similar to those observed using control cells, indicating 
that the 1e– reduction pathway plays no significant role in 
their activation. When the T. brucei line expressing 
elevated levels of TbCPR2 or 3 was tested against 
ABQ22, the recombinant lines were hypersensitive to this 
tetra-aziridinyl agent relative to controls (Fig. 2C). 
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Fig. 3. RH1 resistance selection in T. brucei.  
A. Selection of RH1 resistant T. brucei was performed by the stepwise increase of the ABQ (black line). The cumulative cell density of three 
independent cultures (grey lines) were monitored throughout the selection with only one of these (RH1
R
) generating an outgrowth in medium 
containing >20 nM RH1. Clones from the RH1
R
 culture were then generated following limiting dilution. 
B. Cumulative cell density of wild type T. brucei (black lines) and a clone (RH1
RC1
) derived from RH1
R
 (grey lines) grown in medium lacking 
(solid lines) or containing 40 nM RH1 (dashed lines). Data points are averages 6 standard deviation from experiments performed in 
quadruplicate. A second RH1
R
 derived clone (RH1
RC2
) analysed in parallel displayed similar growth properties (data not shown).  
C. Dose response curves of wild type T. brucei (black solid line), RH1
RC1
 (black dashed line) and RH1
RC2
 (grey solid line) to RH1. All data 
points are averages from experiments performed in quadruplicate 6 standard deviation.  
D. Susceptibility of T. brucei to RH1 as judged by the EC50 values (in nM). The asterisk indicates significant differences in susceptibility 
(P < 0.001) between wild type and genetically modified cells to RH1, as assessed by Student’s t test (GraphPad Software). 
 
Based on the above data, the trypanocidal activity of 
ABQs can be divided into compounds such as RH1 and 
TZQ that function as TbNTR-dependent (oxygen-insen-
sitive quinone oxidoreductase) prodrugs, structures 
including ABQ22 that function as TbCPR-dependent 
(oxygen-sensitive quinone oxidoreductase) prodrugs and 
agents such as ABQ23 and 24 that are not activated by 
either of these two mechanisms: ABQ23 and 24 may still 
function as prodrugs undergoing activation by an 
alternative mechanism(s) to that explored here. 
 
 
Trypanosomes selected for resistance toward RH1 have 
reduced NTR expression 
 
A further approach to determine how ABQs mediate their 
trypanocidal activity involved the selection of T. brucei 
lines resistant to RH1. Wild type bloodstream form 
parasites were grown in the presence of RH1 over a 100 
day period, starting with a compound concentra-tion that 
inhibits T. brucei growth by 10% (5 nM) and 
 
progressively increasing this to twice the EC50 (40 nM) 
(Fig. 3A). The cumulative cell density of selected cul-tures 
was followed throughout the experiment. Of the three 
replica cultures analysed, two stopped growing when the 
selective pressure was increased to 20 nM. In contrast, 
cells in the third culture remained viable in 40 nM RH1 and 
parasites in this population were cloned by limiting dilution 
(designated as RH1RC). We then  
evaluated the growth properties of two RH1RC lines 
(RH1RC1 and RH1RC2) (Fig. 3B). In the absence of RH1, 
the doubling time of the two clones was comparable to the 
parental line (doubling time of 7.5 hours). When grown in 
medium containing RH1 (40 nM), the doubling time of the 
resistant clones increased 1.5-fold (dou-bling time of 10.5 
hours); by comparison, no growth of wild type T. brucei 
was detected after 24 hrs. Next, we determined the 
susceptibility of the RH1RC lines towards RH1 with this 
showing that both lines were 3.5-fold 
 
less sensitive to the ABQ than wild type (Fig. 3C and D); 
wild type, RH1RC1 and RH1RC2 exhibited EC50 val- 
ues  of  25 6 6,  83 6 2  and  92 6 1  nM  against  RH1, 
 




Table 3. Susceptibility of RH1 resistant T. brucei to trypanocidal agents.  
 
 EC50 values (nM)    
     
Compound Wild type RH1
RC1  ratio 
     
Aziridines     
Triethylenemelamine 2400 6 86 2774 6 64 1.1 
ThioTEPA 39423 6 796 56298 6 1960 1.4 
RH1
a 
25 6 6 83 6 2* 3.3 
ABQ22 197 6 31 232 6 27 1.2 
CB1954
a 
2161 6 125 13086 6 972* 6.5 
Nitrogen mustards     
Mechlorethamine 32063 6 1021 27203 6 1288 0.8 
Melphalan 8740 6 200 10430 6 230 1.2 
LH17
a 
5438 6 444 17998 6 1106* 3.6 
Nitrosoureas     
Lomustine 16650 6 443 15463 6 665 0.9 
Semustine 15025 6 3457 17100 6 3619 1.1 
Other agents     
DFMO 16763 6 2691 22177 6 383 1.3 
Nifurtimox
a 
2700 6 100 7050 6 311* 2.6 
Megazol
a 
166 6 1 454 6 4* 2.7 
      
Data represent the growth-inhibitory effect as judged by their EC50 
values of various agents on BSF T. brucei wild type and RH1
RC1
 
cells. All values are means 6 standard deviation from independent 
experiments preformed in quadruplicate. The ratio represents the fold 
difference in EC50 value between the RH1
RC1
 and wild type lines to 
a given compound.  
a. Identifies TbNTR-activated prodrugs.  
*Indicates significant differences in susceptibility (P < 0.001) between 
wild type and RH1
RC1





respectively. This resistance phenotype was not lost fol-
lowing 100 generations in medium lacking RH1. Indeed, 
the resistant lines were still 4.5-fold less sensitive to the 
ABQ than controls; wild type, RH1RC1 and RH1RC2 
exhibited EC50 values of 19 6 1, 86 6 3 and 91 6 11 nM 
against RH1, respectively. When the above susceptibility 
studies were extended to TbNTR-activated prodrugs, 
cross-resistance towards nifurtimox, benznidazole, meg-
azol, CB1954 and LH17 was observed (Table 3). This 
phenotype was specific to this class of compound, as the 
RH1 selected cells were equally sensite to the non 
TbNTR-activated compounds, including ABQ22 and other 
ICL inducing agents, as wild type T. brucei. 
 
Studies aimed at deciphering the RH1 resistance 
mechanism demonstrated that although the Tbntr copy 
number was similar and Tbntr gene sequences were 
identical in the compound selected and wild type lines, the 
RH1RC cells had a lower ( 50%) Tbntr mRNA expression 
level (Fig. 4). Intriguingly, when extended to genes 
expressed in the same polycistron as Tbntr, all the tested 
ORFs exhibited the same trait in relation to copy number 
and transcript levels. The observed reduc-tion in gene 
expression within the Tbntr-containing poly-cistron in the 
RH1 selected cells is specific to this region as additional 
ORFs present elsewhere in the T. 
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brucei genome (for example Tb927.7.7490 and 
Tb927.7.6620, and the genes encoding for the DNA repair 
enzymes TbSNM1, TbMRE11, TbRAD51, TbXPG, 
TbEXO1, TbCSB and TbMSH3) are expressed at 
equivalent levels in RH1RC and control parasites. 
 
 
Aziridinyl benzoquinones promote cell cycle arrest and 
DNA damage in trypanosomes 
 
Aziridinyl benzoquinones mediate their toxicity against 
mammalian cells through formation of ICLs that promote 
cell cycle arrest and DNA damage (Kim et al., 2004; Dehn 
et al., 2005; Begleiter et al., 2007). To determine if this is 
the case in T. brucei, parasites at various stages in the 
cell cycle were identified in asynchronous cultures by 
staining their nuclear (N) and mitochondrial (known as the 
kinetoplast (K)) genomes with DAPI; a non-dividing 
trypanosome cell usually contains one mito-chondrion 
and hence one kinetoplast. The ratio of these two DNA-
containing structures represents an excellent marker for 
the trypanosomal cell cycle, with T. brucei in the G1/S 
phase having a 1N1K arrangement, those in G2/M phase 
possessing a 1N2K ratio while cells dis-playing a 2N2K 
profile are in the post-M stage (Wood-ward and Gull, 
1990; Siegel et al., 2008; Glover and Horn, 2012). For 
untreated T. brucei and cells exposed to phleomycin, 
most (approximately 80%) were in the G1/S stage of the 
cell cycle with a smaller percentage (12 to 20%) in G2/M 
(Fig. 5). In contrast, when trypano-somes were treated 
with RH1 or mechlorethamine (a well characterized ICL 
inducing agent), 58% and 45% of the cells displayed a 
configuration typical of the G2/M phase, respectively, with 
only 37% and 53% exhibiting a 1N1K DNA staining 
pattern, respectively. This indicates that treatment of T. 
brucei with RH1 (or mechloreth-amine) results in a G2/M 
cell cycle arrest phenotype, potentially as a result of 
damaged DNA and is consist-ent with observations made 
with mammalian cells (Kim et al., 2004; Dehn et al., 2005). 
 
In most cells, ICLs are repaired through the concerted 
action of a number of complementary and overlapping 
pathways with enzymes belonging to the SNM1/PSO2 
family playing a specific role. In T. brucei, the enzyme 
TbSNM1, a member of the SNM1/PSO2 nuclease fam-ily, 
has been shown to play a specific and key role in repairing 
such damage (Sullivan et al., 2015). To evalu-ate whether 
deletion of both copies of Tbsnm1 from the T. brucei 
genome altered the cells sensitivity to ABQs, the null 
mutant trypanosomes were grown in the pres-ence of 
selected trypanocidal quinones and the EC50 values for 
each compound determined (Table 4; Fig. 6). For all the 
ABQ prodrugs tested, cells lacking the nucle-ase were up 
to 6.6-fold more susceptible to these 
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Fig. 4. Evaluating the mechanism underlying RH1 resistance in T. brucei.  
A. Schematic of T. brucei chromosome 7 that contains Tbntr. This gene is part of a 200 kbp polycistronic region (see Expanded view) that 
encodes for 60 open reading frames (ORF) (light grey arrowed box) and is approx. 75 kbp downstream from a ‘strandswitch’ region, areas on 
the trypanosomal chromosome that are postulated to be regions where polycistronic transcription is initiated (Imboden et al., 1987; Muhich and 
Boothroyd, 1988). The position of selected ORFs from the Tbntr-containing polycistronic transcriptional unit plus the telomeric repeats (black 
arrow repeats) are shown. Other selected polycistrons on chromosome 7 are also highlighted (dark grey arrowed boxes).  
B and C. The mRNA levels (panel B) and gene copy number (panel C) of selected ORFs located on chromosome 7 from wild type (grey bar) and RH1RC1 (white bar) 
cells was evaluated by qPCR. This was compared against the expression level/gene copy number of a standardized control (Tbtert) and the average fold difference, 
as judged by 2–(DDCT) from reactions performed in triplicate 6 standard deviation, plotted as a measure of the relative expression level. The asterisk and double 
asterisk indicates significant differences in relative mRNA expression levels (P <0.01 and <0.02, respectively) between the wild type and RH1RC1, as assessed by 
Student’s t test (GraphPad Software). 
 
structures than control parasites. In contrast, assays using 
ABQ23 and ABQ24, the two ABQs that do not function as 
TbNTR- or TbCPR-activated prodrugs, and the 
trypanocidal agents nifurtimox and DFMO, revealed no 
significant difference in the EC50 exhibited by the 
engineered and control lines. 
 
To conclusively demonstrate that the above altered 
susceptibility phenotype was solely due to lack of 
TbSNM1 activity, the sensitivity of null mutant cells 
expressing an ectopic copy of Tbsnm1 towards DZQ, RH1 
and ABQ22 was evaluated (Fig. 6). In all three cases, the 
TbSNM1-complemented line generated dose response 
curves and EC50 values distinct from those observed 
when using TbSNM1 null mutant cells but sim-ilar to those 
obtained using wild type parasites. 
 
 
Linking prodrug activation with DNA damage 
 
To establish whether there is a link between activation of 
the trypanocidal ABQs and the TbSNM1-mediated DNA 
repair pathway, the susceptibility of Tbsnm1 null-mutants 
expressing ectopic copies of Tbntr or Tbcpr2 towards 
selected compounds was evaluated (Fig. 7). When these 























RH1 promotes cell cycle arrest in T. brucei.   
The effect of ICL inducing agents (mechlorethamine (HN2) or RH1) on 
the trypanosome cell cycle was analysed by determining the relative 
number of nuclear (N) and mitochondrial (K) genomes structures within a 
single parasite. T. brucei in the G1/S phase have a 1N1K arrangement 
(black bar), those in G2/M phase possess a 1N2K ratio (grey bar) while 
cells displaying a 2N2K profile are in the post-M stage (hatched bar) 
(Woodward and Gull, 1990; Siegel et al., 2008; Glover and Horn, 2012). 
The number of cells (n) analysed for each treatment (untreated, 
phleomycin treated, mechlorethamine (HN2) or RH1) is given. 
 






Table 4. Susceptibility of T. brucei Tbsnm1 null mutants to ABQ 
compounds.  
 
 EC50 (nM)     
     
Compound Control DTbsnm1 Ratio 
     
Nifurtimox 2850 6 20 2250 6 090 0.79 
DFMO 27500 6 108 27100 6 850 0.99 
DZQ 157 6 23 43 6 2*  0.27 
RH1 19 6 1 5 6 1*  0.26 
TZQ 253 6 33 46 6 1*  0.18 
ABQ22 138 6 25 21 6 5*  0.15 
ABQ23 2300 6 60 2410 6 160 1.01 
ABQ24 1470 6 120 1130 6 100 0.77 
       
Data represent the EC50 values of selected ABQ compounds towards 
wild type T. brucei (control) and T. brucei Tbsnm1 null mutants 
(DTbsnm1). All values are means 6 standard deviation of four 
independent experiments. The ration of EC50 values between the two 
parasite lines are given. *Indicates significant differences in 
susceptibility (P < 0.01) between the wild type and DTbsnm1 lines, 
as assessed by Student’s t test (GraphPad Software). 
 
 
increased susceptibility was observed relative to wild type 
controls (Fig. 7A); Tbsnm1 null-mutants and T. bru-cei 
over expressing Tbntr were threefold and fivefold more 
susceptible to RH1, respectively, and 2.7- and 3.4-fold 
more susceptible to TZQ than wild type T. brucei. For 
Tbsnm1 null parasites expressing an ectopic copy of 
Tbntr, this increase in potency was magnified further, with 
these cells showing a 15-fold increase in suscepti-bility to 
both compounds as compared against wild type. 
Extending these studies to investigate the susceptibility of 
Tbsnm1 null-mutant parasites engineered to express an 
ectopic copy of Tbcpr2 towards ABQ22 yielded simi-lar 
results (Fig. 7B). When Tbsnm1 null mutants or wild type 
cells engineered to express an ectopic copy of Tbcpr2 
were treated with ABQ22 a sevenfold increase in 
susceptibility was observed by both lines compared 
against controls. The growth inhibitory effect of this  
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compound was further enhanced in trypanosomes that 
lack TbSNM1 activity while expressing elevated levels of 
TbCPR2 (Fig. 7B), with these cells being 12.5-fold more 
sensitive to ABQ22 than wild type. The above altera-tions 
in susceptibilities were specific to the ABQs as all lines 
tested exhibited equivalent sensitivities to the non-DNA 





ICLs represent a highly toxic form of DNA damage that 
blocks processes dependent on DNA strand separation, 
such as replication and transcription. As rapidly dividing 
cells are particularly susceptible to this type of lesion, 
agents that are able to promote ICLs are of interest in the 
treatment of cancer and infectious diseases (Chen and 
Hu, 2009; Deans and West, 2011; Wilkinson et al., 2011). 
Here, we report that several ABQs, ICL inducing 
chemicals originally developed as anti-cancer agents, can 
also function as highly potent anti-trypanosomatid 
prodrugs with different structures able to undergo activa-
tion via different pathways. In these cases, activation 
promotes a type of DNA damage that is repaired by a 
pathway where SNM1, a nuclease that only functions in 
ICL repair, plays a key role. 
 
Invariably, aziridine-containing compounds function as 
prodrugs with activation requiring protonation of the azir-
idinyl nitrogen. The ease with which this reaction can 
occur is governed by the compound’s chemical compo-
sition and how this influences the pKa of the aziridine. For 
certain structures (e.g., triethylenemelamine, thio-TEPA 
and ‘simple’ ABQs including ABQ11) protonation can 
readily take place in aqueous solution due to the relatively 
high pKa of the aziridine within such back-bones (Akhtar 
et al., 1975). However, for other agents, the pKa of the 
















Fig. 6. Susceptibility of T. brucei lines expressing altered levels of TbSNM1 to selected azirindinyl benzoquinones. Growth inhibitory effects, as judged 
by EC50 values, of RH1, TZQ and ABQ22 (all in nM) in the T. brucei wild type, Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null mutants expressing an 
ectopic copy of Tbsnm1 (DTbsnm1 Tbsnm1
11
) lines (Sullivan et al., 2015). DFMO (in mM) was used as a non-DNA damaging agent control. Data are 
mean values 6 standard deviations from experiments performed in quadruplicate. The asterisk indicates significant differences in susceptibility (P 
<0.001) between wild type and DTbsnm1 or between DTbsnm1 and DTbsnm1 Tbsnm1
11
 cells to RH1, as assessed by Student’s t test (GraphPad 
Software). 
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Fig. 7. Linking aziridinyl benzoquinone prodrug activation to DNA damage. 
A. Growth inhibitory effects, as judged by EC50 values, of RH1, TZQ, ABQ22 (all in nM) and DFMO (in mM) in the T. brucei wild type, T. brucei 
expressing an ectopic copy of Tbntr (Tbntr
11
), Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null mutants expressing elevated levels of Tbntr 
(DTbsnm1 Tbntr
11
) lines. The asterisk and double asterisk indicates significant differences in susceptibility (P <0.001 and <0.03, respectively) 
between the DTbsnm1 Tbntr
11
 line relative to the Tbntr
11
 or DTbsnm1 parasites to RH1 and TZQ, as assessed by Student’s t test (GraphPad 
Software).  
B. Growth inhibitory effects, as judged by EC50 values, of RH1, TZQ and ABQ22 (all in nM) in the T. brucei wild type, T. brucei expressing an 
ectopic copy of Tbcpr2 (Tbcpr2
11
), Tbsnm1 null mutant (DTbsnm1) and Tbsnm1 null mutants expressing elevated levels of Tbcpr2 (DTbsnm1 
Tbcpr2
11
) lines: the latter lines was validated as previous described (Hall et al., 2011; Sullivan et al., 2015). DMFO (in mM) was used as a non-
DNA damaging agent control. The asterisk and double asterisk indicates significant differences in susceptibility (P 5 0.01 and P < 0.003, 
respectively) between the DTbsnm1 Tbcpr2
11
 line relative to the Tbcpr2
11
 or DTbsnm1 parasites to ABQ22, as assessed by 
Student’s t test (GraphPad Software).  
Data in panels A and B are mean values 6 standard deviations from experiments performed in quadruplicate. 
 
therefore preventing the above activation event. To cir-
cumnavigate this issue, the aziridine motif can be incor-
porated into a chemical backbone that also contains a 
bioreductive moiety, such as a quinone or nitroaromatic. 
Here, enzymatic reduction of carbonyl oxygen or nitro 
groups triggers a redistribution of electrons around the 
associated cyclical structure that can raise the pKa of the 
aziridinyl ring, and thus facilitating nitrogen protona-tion 
(Fig. 8A) (Hargreaves et al., 2000). 
 
Using a combination of a whole genome loss-of-function 
screen, selection of resistant lines and/or functional 
genomic approaches, we have shown that T. brucei 
expresses at least two ABQ bioreductive sys-tems. For 
the eight compounds evaluated as potential prodrugs, half 
(DZQ, MeDZQ, RH1 and TZQ) were shown to be NTR 
activated, one (ABQ22) was shown to be dependent on a 
CPR activity, while the remainder (ABQ23, 24 and 30) 
were not reduced by any of the systems tested. For those 
that appeared not to function as prodrugs, this may be due 
to their structures, as these compounds contain methyl 
substituted aziridines (Fig. 8B). These alkyl groups may 
block protonation and 
 
thus activation of the aziridinyl nitrogen by lowering this 
motif’s pKa and/or hinder access of oxidoreductases to 
the carbonyl groups (Lusthof et al., 1989; Phillips et al., 
1999). These possibilities may also account for why other 
compounds that contain methyl/dimethyl aziridine 
substitutions (e.g., ABQs 25–30 and 31–34) consistently 
displayed no or a lower activity against T. brucei than their 
non-substituted counterparts, mirroring observa-tions 
made in high throughput oncological screens (Kim et al., 
2016). 
 
For those compounds that do function as trypanocidal 
prodrugs, the nature of the side chains found at the 3,6 
positions on the benzoquinone ring appears to influence 
which activation mechanism predominates (Fig. 8B). For 
structures possessing small substituents at one or both 
sites, reduction occurs via a type I NTR activity with this 
mechanism unaffected by the presence of equivalent 
(e.g., hydrogen for DZQ, methyl for MeDZQ) or diver-gent 
(e.g., hydroxymethyl and methyl in RH1, aziridine and 
hydrogen in TZQ) groupings at the 3,6 positions. Such 
small side chains may aid type I NTR/compound 
interaction or help the prodrug (or its activated products) 
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Fig. 8. Proposed mechanism of action and trypanocidal structure activity relationships of ICL-forming ABQs.  
A. Quinones can be reduced to hydroquinones by two distinct pathways. In one pathway, enzymes such as cytochrome P450 reductase (CPR) 
mediate the 1e
–
 reduction of the quinone to a semiquinone radical. This then undergoes further reduction to the hydroquinone. In the presence 




 and the parental quinone. In the other system, reduction of the quinone to the 
hydroquinone occurs directly via a 2e
-
 reduction event as typified by a type I nitroreductase (NTR) activity. Formation of the hydroquinone then 
facilitates protonation of the nitrogen atoms in the aziridine rings with these electrophilic intermediates undergoing nucleophilic attack (e.g., by 
DNA), promoting opening of the aziridinyls, formation of aliphatic amine intermediates and alkylation of the target. As ABQs contain two (or 
more) aziridinyls they can covalently bind the two complementary DNA strands together resulting in an interstrand crosslink. 
 
B. ABQs (e.g., DZQ, MeDZQ, RH1 and TZQ) possessing small (e.g., hydrogen, methyl, hydroxymethyl) substituent groups (small solid 
spheres) at the 3,6 positions on a benzoquinone core are more likely to be activated in T. brucei by the type I nitroreductase (NTR) but not by 
cytochrome P450 reductase (CPR) (i). ABQs that contain methyl substituted (small solid spheres) aziridines (e.g., ABQ23, 24 and 30) are not 
activated in T. brucei by NTR or CPR (ii). ABQ22, a compound that contains aziridinyl rings at the 3,6 positions on the benzoquinone core, is 
readily activated within the trypanosome by CPR but not by NTR (iii). ABQs (e.g., ABQ9–19) having bulky substituent groups (large solid 
spheres) at the 3,6 positions on the benzoquinone ring generally display no significant trypanocidal activity (iv). 
 
 
gain access to the site(s) of action. In contrast, the pres-
ence of bulkier groups (e.g., aziridines for ABQ22) at both 
sites results in CPR activation. Why this mecha-nism 
operates to reduce this particular compound is open to 
speculation but it may reflect a steric hindrance effect 
such that the four aziridine groups found in ABQ22 
preclude TbNTR from interacting with and reducing its 
quinone carbonyl groups while facilitating associations 
with TbCPR isoforms. Alternatively, this dif-ference could 
be due to subcellular localisation such that ABQ22 may 
be readily transported into the T. brucei endoplasmic 
reticulum, the organelle where the TbCPRs are believed 
to reside, but unable to gain access to the parasite’s 
mitochondrion, the site where TbNTR is found (Wilkinson 
et al., 2008). 
 
Following protonation of the aziridinyl nitrogen, the 
resultant electrophilic intermediate undergoes nucleo-
philic attack leading to opening of the heterocyclic ring, 
formation of an aliphatic amine then alkylation of the tar-
get (Fig. 8A) (Hargreaves et al., 2000). If the targeting 
compound contains multiple aziridinyl groups, as is the 
case for the ABQs tested here, and the nucleophile is 
DNA, then two nucleobases within the nucleic acid dou-
ble helix become covalently crosslinked. In many eukar-
yotes the SNM1 (also known as PSO2) nuclease plays a 
key role in resolving such DNA damage, with cells lacking 
this activity being specifically and highly 
 
 
susceptible to ICL inducing agents (Cattell et al., 2010). 
By phenotypically screening a selected set of trypanoci-
dal ABQs against a T. brucei snm1 null mutant line, we 
demonstrated that trypanosomes lacking this DNA repair 
enzyme were more susceptible to NTR and CPR 
activated prodrugs relative to wild type. Moreover, in 
parasites where TbSNM1 was absent but the activation 
mechanism (either TbNTR or TbCPR) is elevated, this 
susceptibility phenotype was exacerbated, providing a 
direct link between the two oxidoreductase activities and 
DNA damage. Extending these assays to investigate the 
trypanocidal action of ABQs that do not undergo NTR or 
CPR activation, revealed that these do not promote a form 
of DNA damage that can be repaired through an SNM1-
dependent pathway. It is plausible that these agents may 
still function as monofunctional or bifunc-tional DNA 
alkylating agents, leading to formation of a single site 
adduct or intrastrand crosslink or could act as modifiers of 
other biological molecules via their aziridinyl or quinone 
ring structures. 
 
The continuous in vitro culturing of bloodstream form T. 
brucei in the presence of RH1 generated a parasite line 
that displayed cross-resistance to a range of NTR-
activated prodrugs. Analysis of clones revealed that these 
cells had reduced Tbntr expression. Additionally, lower 
mRNA levels were also noted for other open read-ing 
frames across the 200 kb Tbntr-containing 
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Compound Structure Compound Structure 
    
ABQ1 (DZQ) R15R25X5Y5H ABQ18 R15R25NHCO(CH2)5CH3; X5Y5H 
ABQ2 (MeDZQ) R15R25CH3; X5Y5H ABQ19 R15R25NHCOPhenyl; X5Y5H 
ABQ3 R15R25Br; X5Y5H ABQ20 (AZQ) R15R25NHC(O)OCH2CH3; X5Y5H 
ABQ4 R15R25F; X5Y5H ABQ21 (TZQ) R15azirindyl; R25X5Y5H 
ABQ5 (RH1) R15CH2OH; R25CH3; X5Y5H ABQ22 R15R25azirindyl; X5Y5H 
ABQ6 R15R25OCH3; X5Y5H ABQ23 R15R25X5H;Y5CH3 (r orientation) 
ABQ7 R15R25OCH2CH3; X5Y5H ABQ24 R15R25X5H;Y5CH3 (s orientation) 
ABQ8 R15R25O(CH2)2CH3; X5Y5H ABQ25 R15R25Br; X5H; Y5CH3 
ABQ9 R15R25NH2; X5Y5H ABQ26 R15R25Br; X5Y5CH3 
ABQ10 R15R25NHCH3; X5Y5H ABQ27 R15R25Cl; X5H;Y5CH3 
ABQ11 R15R25NHCH2CH3; X5Y5H ABQ28 R15R25Cl; X5Y5CH3 
ABQ12 R15R25NH(CH2)6CH3; X5Y5H ABQ29 R15R25F; X5H;Y5CH3 
ABQ13 R15R25NH(CH3)CH3; X5Y5H ABQ30 R15R25F; X5Y5CH3 
ABQ14 R15morpholinyl; R25F; X5Y5H ABQ31 R15R25NHCOCH3; X5H; Y5CH3 
ABQ15 R15R25NHCOCH3; X5Y5H ABQ32 R15R25NHCOCH3; X5Y5CH3 
ABQ16 R15R25NHCOCH2CH3; X5Y5H ABQ33 R15R25NHCOCH2CH3; X5H;Y5CH3 
ABQ17 R15R25NHCO(CH2)2CH3; X5Y5H ABQ34 R15R25NHCOOCH2CH3; X5Y5CH3 
     




polycistron; however, this effect did not extend to the 
surrounding transcriptional units. In contrast to trypano-
somes selected for resistance towards other NTR acti-
vated prodrugs such as nifurtimox or fexinidazole 
(Wilkinson et al., 2008; Wyllie et al., 2016), the copy 
number of all tested open reading frames in the Tbntr-
containing transcriptional unit were equivalent to wild type, 
indicating that the observed reduction in gene expression 
was not due to a large (>10 kb) DNA dele-tion event; the 
‘strandswitch’ region, areas on the trypa-nosomal 
chromosome postulated to be regions where polycistronic 
transcription is initiated (Imboden et al., 1987; Muhich and 
Boothroyd, 1988), between the Tbntr-containing and 
adjacent transcriptional units is 6 kb. Although the exact 
molecular basis that leads to RH1 resistance has yet to be 
deciphered, it is plausible that the transcription initiation 
site of one of the two Tbntr-containing polycistrons (T. 
brucei has a diploid nuclear genome) may have been 
compromised resulting in the reduction in mRNA levels. 
 
We have demonstrated that ABQs display significant growth 
inhibitory activities against T. brucei, T. cruzi and L. major, 
with two compounds (RH1 and TZQ) exhibiting high potency 
(EC50 values < 100 nM) against all three pathogens. 
However, this is accompanied by toxicity against macrophage 
(-like) mammalian cells, a trait previ-ously noted in primary 
mouse splenocytes (Miliukiene 
 
 
et al., 2014). This unwanted activity may be because such 
immune cells have the ability to constitutively express or to 
upregulate quinone oxidoreductases includ-ing NQO1 and 
NQO1-independent activities that promote oxidative stress 
and/or DNA damage (Tudor et al., 2005; Potts-Kant et al., 
2012; Miliukiene et al., 2014). Although these cytotoxicity 
issues may preclude the use of these ABQs as therapies for 
the treatment of systemic infec-tions, understanding how they 
mediate their trypanocidal activities can inform drug 
development. By exploiting the chemical features that 
facilitate NTR or CPR specific acti-vation such as those 
reported here, novel trypanocidal prodrugs could be 
generated. Following their activation, these compounds 
could be designed to release cytotoxic metabolites that affect 
a range of biological processes potentially targeting different 
biochemical pathways. Such agents would be best used in a 
polytherapy, as is the case with the anti-HAT nifurtimox-








The compounds used in this study were obtained from the 
following sources: The aziridinyl benzoquinones (DZQ, 
MeDZQ, AZQ, TZQ and ABQ3–4, 6–19, 22–34) (Table 5) 
 




were supplied by the Drug Synthesis and Chemistry Branch, 
Developmental Therapeutics Program, Division of Cancer 
Treatment and Diagnosis, National Cancer Institute, United 
States, while RH1 was donated by Prof Frank Guziec Jr 
(Southwestern University, TX). The chemical, physical and 
potential toxicological properties of each compound can be 
accessed via the PubChem database 
(http://pubchem.ncbi.nlm.nih.gov/) or OSIRIS Property 
Explorer software (http://www.organic-chemistry.org/prog/). 
Nifurtimox was obtained from Prof Simon Croft (London 
School of Hygiene and Tropical Medicine, UK), DFMO from 
Prof Mike Barrett (University of Glasgow, UK), mechloreth-
amine HCl from Stratech Scientific, while puromycin, blasti-
cidin, phleomycin, hygromycin b and tetracycline were 
purchased from Melford Laboratories. 
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carried out using 20 ng ml21 phorbol 12-myristate 13-ace-
tate (Sigma-Aldrich) (Rovera et al., 1979). 
 
 
Selective screening of the T. brucei RNAi library 
 
Selection of the T. brucei RNAi library was performed as 
described (Glover et al., 2015). Parasites (5 3 106 cells) were 
treated for 24 hours with 1 lg ml21 tetracycline to induce RNAi 
prior to addition of 30 nM RH1. Periodically, the cell density 
of the culture was determined and when appropriate, diluted 
in growth medium containing fresh RH1 (30 nM) and 
tetracycline (1 mg ml21). Once an outgrowth population had 
been selected, genomic DNA was prepared for RNAi target 





Bloodstream form T. brucei brucei (MITat 427 strain; clone 
221a) cells were cultured in HMI-9 media (Life Technolo-
gies) supplemented with 36 mM sodium bicarbonate, 0.014% 
(v/v) b-mercaptoethanol and 10% (v/v) heat-inactivated foetal 
calf serum (GE Healthcare) as described (Hirumi and Hirumi, 
1989). A cell line (2T1) engineered to constitutively express 
the tetracycline repressor protein was grown in the modified 
HMI-9 medium, supplemented with 1 
 
phleomycin (Alsford et al., 2005). T. brucei Tbntr heterozygote lines were cultured in 
the presence of 10 blasticidin while transformed 2T1 parasites over 
 
expressing Tbntr, Tbcpr2 or Tbcpr3 were maintained in the 
modified HIM-9 medium supplemented with 1 lg ml21 
phleomycin, 2.5 lg ml21 hygromycin b and, where appropri-
ate, 1 lg ml21 tetracycline to induce protein expression (Hall 
et al., 2011). T. brucei lines expressing altered levels of the 
DNA repair enzyme TbSNM1 were grown in the presence 1 
lg ml21 phleomycin, 10 lg ml21 blasticidin and/ or 2 lg ml21 
puromycin, as appropriate (Sullivan et al., 2015). 
 
The epimastigote form of T. cruzi was cultured in RPMI-1640 
medium (Lonza) supplemented with 5 g l21 trypticase,  
5: g l21 HEPES pH 8.0, 20 mg l21 haemin, 0.34 g l21 sodium 
glutamate, 0.22 g l21 sodium pyruvate, 2500 U l21 penicillin, 
0.25 g l21 streptomycin (all Sigma-Aldrich) and 10% (v/v) 
heat-inactivated foetal calf serum (GE Health-care) at 258C 
(Kendall et al., 1990).  
The promastigote form of L. major MHOM/IL/80/Friedlin was 
cultured at 258C in modified M199 medium (Invitrogen) 
supplemented with 4 mM sodium bicarbonate, 40 mM  
HEPES pH 7.4, 0.1 mM adenine, 0.005% (w/v) haemin (all 
Sigma-Aldrich), 25000 U l21 penicillin, 25 mg l21 streptomy-
cin (GE Healthcare) and 10% (v/v) heat-inactivated foetal 
bovine serum (GE Healthcare) (Kapler et al., 1990).  
The human acute monocytic leukemia (THP-1) cell line was 
grown at 378C under a 5% (v/v) CO2 atmosphere in  
RPMI-1640 medium (Lonza) supplemented with 2 mM pyru-
vate, 2 mM sodium glutamate, 2.5 U ml21 penicillin and 2.5 
lg ml21 streptomycin, 20 mM HEPES pH 7.4 and 10% (v/ v) 
heat-inactivated foetal calf serum (GE Healthcare). Dif-
ferentiation of THP-1 toward macrophage-like cells was 
 
Selection of laboratory generated RH1-resistant T.  
brucei 
 
Wild type bloodstream form T. brucei seeded at 1 3 104 cells 
ml21, were cultured in the presence of sub-lethal con-
centration of RH1 (5 nM). Over a 100 day period, the ABQ 
concentration in the culture media was increased in a step-
wise manner reaching a final concentration of 40 nM. The 
resulting line (designated as RH1R) was cloned by limiting 
dilution in the presence of RH1 and the phenotype of two 
clones (RH1RC1 and RH1RC2) analysed. 
 
 
Parasite growth inhibition assays 
 
All growth inhibition assays were carried out in a 96-well plate 
format (ThermoScientific). Bloodstream form T. brucei, L. 
major promastigotes and T. cruzi epimastigotes parasites in 
the logarithmic phase of growth were seeded at 1 3 104,  
5: 3 105 and 5 3 105 cells ml21 respectively in 200 ll growth 
medium containing different concentrations of the compound 
under study. After incubation at 378C for 3 days (T. brucei), 
258C for 6 days (L. major) or 258C for 14 days  
(T. cruzi), resazurin (Sigma Aldrich) was added to each well 
at a final concentration of 12.5 mg ml21 (or 2.5 mg per well). 
The plates were further incubated at 378C for 8 hours (T. 
brucei), 258C for 24 hours (L. major) or 258C for 24–48 hours 
(T. cruzi) before measuring the fluorescence of each  
culture using a Gemini Fluorescent Plate reader (Molecular 
Devices) set at kEX 5 530 nm and kEM 5 585 nm with a fil-ter 
cut off at 550 nm. The change in fluorescence resulting  
from the reduction of resazurin is proportional to the num-ber 
of live cells. A compound’s EC50 value was established using 
the non-linear regression tool on GraphPad Prism (GraphPad 
Software) and the statistical significance of any differences in 
parasite susceptibilities assessed using the Student’s t test 
calculator (GraphPad Software). 
 
 
Mammalian inhibition assays 
 
Differentiated THP-1 cells seeded at 2.5 3 104 cells ml21 
were incubated for 3 days at 378C in a 5% (v/v) CO2 
atmosphere in 200 ll modified RMPI-1640 growth medium 




 lg ml21 
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study. Resazurin (2.5 mg per well) was added to each cul-ture 
and the plates incubated for a further 8 hours before 
determining the fluorescence of each sample.  
Experiments involving animals were approved by the Ani-mal 
Welfare and Ethics Review Board at LSHTM and con-ducted 
under license in accordance with the Animals (Scientific 
Procedures) Act 1986 (UK Home Office Project Licence 
PPL70/6997). Peritoneal macrophages were iso-lated from 
BALB/c mice by lavage 24 hours after intraperi-toneal 
injection of 2% (w/v) soluble starch (Sigma). Macrophages 
(40,000) in RPMI-1640 medium (Lonza) sup-plemented with 
10% (v/v) heat-inactivated foetal calf serum (GE Healthcare) 
were adhered overnight at 378C in a 5% (v/v) CO2 
atmosphere onto a 16-well chamber slide. Cells were then 
treated with various concentrations of the com-pound under 
study and the cultures incubated at 378C up to 5 days under 
a 5% (v/v) CO2 atmosphere. Untreated controls were 
analysed in parallel on each slide. Macro-phages were fixed 
in 100% (v/v) methanol, stained with 10% (w/v) Giemsa, 
visualized with Leica DMRA2 light microscope using a 3100 
oil immersion objective and images captured using a Retiga 
EXi Fast 1394 digital cam-era. The number of cells per field 
of view was determined with a minimum of 10 fields examined 
for each drug treat-ment. The average number of cells per 
field of view was determined and expressed as a % relative 




Quantitative PCR (qPCR) 
 
The copy number and mRNA levels of various genes were 
analysed by qPCR. Genomic DNA or total RNA was pre-
pared from wild type or RH1-resistant T. brucei using the 
DNeasy Blood and Tissue or RNeasy Extraction kits (Qia-
gen), respectively. cDNA was synthesized from total RNA 
using the Superscript VILO cDNA synthesis kit (Invitrogen). 
All qPCRs were performed in triplicate with the PerfeCTa 
qPCR FastMix kit (Quanta Biosciences) on a CFX96 Touch 
Real-Time PCR Detection System (BioRad). Fluorescence 
data was collected using the CFX Manager Software (Bio-
Rad), the products analysed by a melt curve after the final 
cycle and normalized against telomerase reverse transcrip-
tase (Tbtert; Tb11.01.10190) using the comparative CT 




Cell cycle arrest assay 
 
Wild type T. brucei (5 3 105 ml21) were cultured for 16 hours 
in the presence of mutagen (1 mg ml21 phelomycin; 35 mM 
mechlorethamine; 100 nM RH1). Cells were washed in 
phosphate buffered saline (PBS), fixed in 2% (w/v) para-
formaldehyde in PBS and washed once more in PBS. Ali-
quots of the cell suspension ( 105 cells) were air-dried onto 
microscope slides and the samples mounted in Vectashield 
containing 4, 6-diamidino-2-phenylindole (Vector 
Laboratories). Images were captured using Leica DMRA2 
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A B S T R A C T  
 
To combat the deleterious effects that oxidation of the sulfur atom in methionine to sulfoxide may bring, aerobic cells express 
repair pathways involving methionine sulfoxide reductases (MSRs) to reverse the above reaction. Here, we show that 
Trypanosoma brucei, the causative agent of African trypanosomiasis, expresses two distinct trypanothione-dependent MSRs 
that can be distinguished from each other based on sequence, sub-cellular lo-calisation and substrate preference. One enzyme 
found in the parasite's cytosol, shows homology to the MSRA family of repair proteins and preferentially metabolises the S 
epimer of methionine sulfoxide. The second, which contains sequence motifs present in MSRBs, is restricted to the 
mitochondrion and can only catalyse reduction of the R form of peptide-bound methionine sulfoxide. The importance of these 
proteins to the parasite was de-monstrated using functional genomic-based approaches to produce cells with reduced or elevated 
expression levels of MSRA, which exhibited altered susceptibility to exogenous H2O2. These findings identify new reparative 







The Trypanosomatida represent an order of parasitic protozoa be-longing to the 
Class Kinetoplastidea [1]. They are responsible for sev-eral infections in 
humans with Trypanosoma brucei and Trypanosoma cruzi causing human 
African trypanosomiasis (HAT) and Chagas dis-ease, respectively. In addition, 
more than 20 Leishmania species can trigger a spectrum of pathologies 
collectively termed leishmaniasis. Spread by the hematophagous habits of 
insect vectors, these pathogens are endemic throughout tropical and sub-
tropical regions of the world and cause more than 55,000 deaths per year 
(http://www.dndi.org/).  
All organisms living in an aerobic environment are exposed to a range of 
reactive oxygen species (ROS) primarily generated as by-pro-ducts of 
respiration. These can readily react with various macro-molecules leading to 
formation of other toxic metabolites and/or da-mage to the target. One target 
that ROS have a considerable effect on are proteins, resulting in oxidation of 
certain residues such as cysteine, histidine, tyrosine, and methionine (Met), 
which can reducing equiva-lents into change and, in some cases, modification 
of protein function [2,3]. Oxidation of Met produces methionine sulfoxide 
(MetSO) that exists as a mixture of two epimers, methionine-(S)-sulfoxide 





deleterious effect of these diastereomers, cells express several unrelated 
enzymes, known as methionine sulfoxide reductases (MSRs), that cat-alyse 
reduction of MetSO back to Met [4,5]. These distinct activities can be 
distinguished based on sequence and substrate specificity. Metabo-lism of both 
free and protein-bound Met(S)SO is performed by me-thionine sulfoxide 
reductase A (MSRA) [6,7] while reduction of free or protein-bound Met(R)O 
is mediated by free methionine-(R)-sulfoxide reductase (fRMSR) or 
methionine sulfoxide reductase B (MSRB), re-spectively [8–10]. The activity 
of these enzymes is generally driven by a thioredoxin/thioredoxin reductase-
dependent redox cascade that facil-itate transfer of reducing equivalents from 
NADPH to the MSR, al-though other molecules such as metallothionein or 
glutaredoxin, may also act as source of reductant [8,11–14]. The importance of 
these pathways has been demonstrated as organisms lacking MSR(s) are more 
susceptible to oxidative stress, often have a shortened life span and, in the case 
of bacterial pathogens, reduced virulence [7,15–19]. 
 
In contrast to their mammalian hosts, trypanosomatids lack a raft of enzymes 
including Cu/Zn- and Mn-superoxide dismutase (SOD), cata-lase, selenium-
dependent glutathione peroxidase, glutathione reductase and thioredoxin 
reductase, activities that help maintain the redox bal-ance in many other 
eukaryotic cells. Instead, they express alternative mechanisms that fulfil the 
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proposed as potential targets for chemotherapeutic intervention. For example, 
removal of superoxide anions by trypanosomes and leishma-nial parasites is 
exclusively catalysed by Fe-SOD, enzymes normally found in bacteria, lower 
eukaryotes and the chloroplasts of plants, while maintenance of the intracellular 
thiol redox homeostasis is centred upon the trypanosomatid-specific molecule 
trypanothione [20–22]. In a pathway analogous to the glutathione 
(GSH)/glutathione reductase system, trypanothione is maintained in its 
reduced, dihy-drotrypanothione (T(SH)2) form by the activity of a NADPH-
dependent flavoprotein trypanothione reductase (TR) [23,24]. T(SH)2 then 
drives a series of two component cascades, facilitating flux of reducing 
equivalents into tryparedoxins (TXNs), GSH or ascorbate which in turn reduce 
various peroxidases, reductases, glyoxalases and transferases [25,26]. 
 
One recipient of the electron flux via the T(SH)2/TXN cascade is MSRA, with 
analysis of the T. cruzi and Leishmania major homologues revealing its role as 
an anti-oxidant enzyme within the parasite [27,28]. Here, we report the 
dissection of two MetSO metabolising pathways expressed by T. brucei 
focusing on the biochemical properties, sub-cellular localisation, and 
functional importance of its MSRA and MSRB complement. 
 
 




Bloodstream form (BSF) T. brucei SMB and 2T1 trypomastigotes that 
constitutively express the tetracycline repressor protein were grown at 37 °C 
under a 5% (v/v) CO2 atmosphere in modified Iscove's medium containing 2.5 
μg ml-1 G418 (SMB) or 1 μg ml-1 phleomycin (2T1) [29–31]. Transformed 
parasites were maintained in this growth medium supplemented with 2.5 μg 
ml-1 hygromycin. DNA and total RNA were extracted from parasites using the 
DNeasy® Tissue and RNeasy® mini kits (Qiagen), respectively. T. brucei 
genes that encode for TbmsrA and TbmsrB were identified from the TriTrypDB 
(http:// tritrypdb.org/tritrypdb/) database [32]: TriTrypDB Gene ID 
Tb927.8.550 and Tb927.11.11930.1 for TbmsrA and TbmsrB, respec-tively. 
 
 
2.2. Protein purification 
 
DNA fragments containing the full length coding sequence of TbmsrA and a 
version of TbmsrB lacking its 5’ (1–130 bp) region were amplified from T. 
brucei genomic DNA using the primer combinations TbMSRA-1/TbMSRA-2 
or TbMSRB-1/TbMSRB-2 (Table 1), 
 
Table 1  
Oligonucleotides used in this study. The sequences in lower case italics correspond to restriction 
sites incorporated into the primers to facilitate cloning.  
 
Function gene Primer sequence (5’ to 3’) 
  name  
    
Protein TbmsrA TbMSRA-1 aaaggatccTGAACCCAAATGCTGTTGCTA 
expres-  TbMSRA-2 gggaagcttCCATTCACCAGTAGAGACGGT 
sion TbmsrB TbMSRB-1 aaaagatctTGACACACTGCGCAAGTAAGA 
  TbMSRB-2 aaaaagcttTTACTTCTCGGATTGAAAACG 
RNAi TbmsrA TbMSRA-3 aaaggatccACTTTTGCTGCAGGTTGCTT 
  TbMSRA-4 aaactcgagAATACCCATTGGGGTTTTCC 
 TbmsrB TbMSRB-3 aaaagatctGCCCTCTTATTTTTCCTGCC 
  TbMSRB-4 aaactcgagCGTTCGTTAGGTGGTGGATT 
Localisation TbmsrA TbMSRA-5 aaaaagcttATGAACCCAAATGCTGTTGCT 
  TbMSRA-6 aaatctagaCCAGTAGAGACGGTGTGCACA 
 TbmsrB TbMSRB-5 aaaaagcttATGCGCAGCAGGAACCTGTCC 
  TbMSRB-6 aaatctagaCTTCTCGGATTGAAAACGAAT 
qPCR TbmsrA TbMSRA-7 TAGTAGTGCTAAGGTTGTAAC 
 TbmsrB TbMSRB-7 ACGGAAATTTTATGCAATGCG 
 Tbtert Tbtert-F AGGAACTGTCACGGAGTTTGC 
  Tbtert-R GAGCGTGTGACTTCCGAAGG 
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respectively. The products were digested with BamHI/HindIII (TbmsrA) or 
BglII/HindIII (TbmsrB) and cloned into the BamHI/HindIII sites of the 
expression vector pTrcHis-C (Invitrogen).  
Protein expression and purification were conducted as previously described 
[27]. Overnight cultures of E. coli BL21 (DE3) transformed with the expression 
plasmid were diluted 1/100 in Terrific Broth (12 g l− 1 peptone, 24 g l− 1 yeast 
extract, 4 ml l− 1 glycerol, 2.3 g l− 1 KH2PO4, 12.5 g l
− 1 K2HPO4, pH 7.0) 
supplemented with 100 μg ml− 1 ampicillin and grown to exponential phase at 
37 °C with aeration. Ex-pression of the HIS-tagged recombinant protein was 
induced with 0.5 mM IPTG, followed by incubation at 25 °C. After 4 h, cells 
were harvested and bacterial pellets stored at −20 °C. Purification of re-
combinant protein was performed using a Ni2+–HiTrap column (GE 
Healthcare). Briefly, the bacterial pellet was resuspended in binding buffer (20 
mM Tris.HCl, pH 7.5, 10 mM imidazole and 400 mM NaCl) and disrupted by 
sonication. The lysate was centrifuged (10,000 g, 30 min) to remove cell debris. 
The resultant crude extract was loaded onto a Ni2+–HiTrap column (1 ml) 
previously equilibrated with binding buffer. After washing with 15 bead 
volumes of binding buffer plus 30 mM imidazole, the recombinant protein was 
eluted with elution buffer (20 mM Tris.HCl, pH 7.5, 400 mM NaCl, 300 mM 
imidazole). Purified enzyme fractions were pooled, concentrated by 
ultrafiltration, and stored at −80 °C in 20 mM Tris.HCl pH 7.5; 100 mM NaCl 




2.3. Enzyme activity 
 
MSR activity was measured by monitoring NADPH oxidation at 340 nm by 
means of a coupled assay that guaranteed the regeneration of TXNI to its 
reduced form [27]. All enzyme assays were performed at 30 °C using a 
Multiskan Ascent one-channel vertical light-path filter photometer (Thermo 
Electron Co.). The reaction mixture (final volume of 50 μl) contained (unless 
otherwise specified) 100 mM Tris.HCl, pH 7.5, 2 mM EDTA, 300 μM 
NADPH, 2 U ml−1 TcTR, 100 μM T(SH)2 (Bachem), 10 μM TcTXNI, and the 
respective MSR included in a specific range of concentrations (0.5–3.5 μM 
TbMSRA or TbMSRB). TcTXN1 was used in these assays as it was readily 
available in our laboratory and was assumed to function in an equivalent 
manner to its T. brucei counterpart (TcTXNI and TbTXN1 share 62% identity 
[33]). Reactions were started by the addition of 5 mM MetSO substrate 
(racemic N-acetyl MetSO (N-AcMetSO) (Bachem), racemic L-MetSO (Sigma-
Al-drich), L-Met(S)SO, L-Met(R)SO or N-Acetyl Met(R)SO: The enantiomers 
were prepared as previously described [34]). Addition of EDTA into the 
reaction did not affect TbMSRB activity and as such was included in assays to 
minimise heavy metal mediated thiol oxidation. 
 
For TbMSRB steady-state kinetic analysis, the assay was performed using 20–
2500 μM N-AcMet(R)SO and 0.5–20 μM TcTXNI. Kinetic data were plotted 
as initial velocity (μM min− 1) versus substrate con-centration (μM). The 
kinetic constants were acquired by fitting the data with a nonlinear least-squares 
formula and the Michaelis–Menten equation using the program Origin 7.0. 
Kinetic constants were the means of at least three independent sets of data, and 
they were re-producible within ± 10%. 
 
 
2.4. Yeast complementation 
 
In vivo MSR activity of T. brucei enzymes was checked using the triple msr 
mutant GY202 ( msrA msrB fRmsr) [18]. The Sacchar-omyces cerevisiae 
GY202 strain was transformed with parental plasmid p425GPD, p425GPD–
TbmsrA or p425GPD–TbmsrB and selected for leucine prototrophy on Yeast 
Nitrogen Based (YNB)-agar medium supplemented with L-Met [35]. To 
perform the complement assay, each recombinant clone was cultivated on 
YNB-agar medium supplemented with L-Met, a L-MetSO racemic mix, L-






































Fig. 1. Sequence analysis of T. brucei methionine sulfoxide reductases. (A). Alignment of MSRA sequences from T. brucei (AAZ12826), T. cruzi (EAN83377), Leishmania major (CAJ07082), 
Saccharomyces cerevisiae (NP_010960), Escherichia coli (WP_044721421), Arabidopsis thaliana (NP_56893) and Homo sapiens (NP_036463). Residues that are highly or moderately con-served are 
highlighted in black or grey, respectively. The catalytic (C13; triangle) and recycling (C171; diamond) cysteines are highlighted [5]. (B). Alignment of MSRB sequences from T. brucei (XP_829255), 
T. cruzi (XP_817746), Leishmania major (XP_001684552), Saccharomyces cerevisiae (NP_009897), Escherichia coli (AE016761_217) and Arabidopsis thaliana (NP_193915). Residues that are highly 
or moderately conserved are highlighted in black or grey, respectively. The putative amino terminal mitochondrial targeting sequence in the T. brucei MSRB sequence (boxed), the catalytic (C171; 
triangle), recycling (C117; diamond) and zinc binding (C99, C102, C145 and C148; asterisk) cysteines are all highlighted [5]. For both TbMSRA and B, the arrows corresponds to the primers used for 
expression of the recombinant protein (Experimental Procedures). 
 
2.5. RNA interference 
 
Fragments corresponding to internal sequences of TbmsrA (491 bp) and 
TbmsrB (426 bp) were amplified from T. brucei genomic DNA using the 
primers TbMSRA-3/TbMSRA-4 or TbMSRB-3/TbMSRB-4 (Table 1), 
respectively. The products were digested with BamHI/XhoI (TbmsrA) or 
BglII/XhoI (TbmsrB) and cloned into the BamHI/XhoI sites of the vector 
p2T7Ti [36]. In this vector, the inserted DNA is flanked by two opposing T7 
promoters with each promoter under the control of a tetracycline operator. 
Constructs were linearised with NotI, electroporated into T. brucei SMB 
parasites and transformants selected using hygromycin [37]. Induction of RNA 
interference (RNAi) was initiated by adding 1 μg ml-1 tetracycline to the 
culture. To demonstrate down regulation of the TbmsrA or TbmsrB transcript, 
cDNA generated using the Superscript® VILO™ cDNA synthesis kit 
(ThermoFisher Scientific) from total RNA extracted from cells induced to 
undergo RNAi for 48 h was subject to qPCR using the QuantiTect SYBR® 
Green PCR kit (Qiagen) and the primer combinations TbMSRA-7/TbMSRA-2 
or TbMSRB-7/TbMSRB-2 (Table 1), respectively. All reactions were 
performed in triplicate on two independently generated cDNA samples. From 
the resultant sig-moidal curves, the cycle threshold (CT) value was determined 
and normalized against standardized control (Tbtert; primer combination 
TbTERT-R and TbTERT-F) amplified in parallel [38] using the com-parative 




2.6. Trypanosomal epitope tagging vectors 
 
amplified from genomic DNA using the primer combinations TbMSRA-
5/TbMSRA-6 or TbMSRB-5/TbMSRB-6 (Table 1), respectively. The products 
were digested with HindIII/XbaI and cloned into the corre-sponding sites of the 
vectors pRPaC-GFP or BSF-9e10 [31,40]. The cloning was carried out such that 
the sequences coding for the green fluorescence protein (GFP) or 9E10 epitope 
from the human c-myc protein were inserted in-frame at the 3’ end of the 
Tbmsr-derived DNA fragment. The AscI digested constructs were introduced 
into T. brucei 2T1 and transformants selected using hygromycin. Expression of 
the recombinant protein in the parasite was initiated by adding 1 μg ml-1 






BSF trypanosomes expressing TbMSRB-GFP were suspended at 5 × 106 cells 
ml-1 in medium containing 100 nM MitoTracker Red (Molecular Probes) and 
incubated at 37 °C for 5 min. Cells were washed twice in phosphate buffered 
saline (PBS), fixed in 2% (w/v) paraf-ormaldehyde/PBS then washed again in 
PBS. Aliquots of the cell sus-pension (105 cells) were then air dried onto 
microscope slides. Parasite DNA was stained with Vectashield containing 200 
pM. 4, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Ltd) and 
slides were viewed using a Leica SP5 confocal microscope. BSF trypanosomes 
ex-pressing TbMSRA-GFP were treated similarly except the MitoTracker Red 
step was omitted. 
 































Fig. 2. T. brucei expresses functional methionine sulfoxide reductases. (A). Coomassie-stained SDS-PAGE gel (15%) containing size standards (in kDa; lane M) and purified, recombinant TbMSRA 
(lane 1) and TbMSRB (Lane 2). (B). MSR activity of TbMSRA or TbMSRB was followed by monitoring NADPH oxidation at 340 nm using a coupled assay that maintained tryparedoxin (10 µM) to 
its reduced form (see panel E). Reactions were carried out in 100 mM Tris–HCl pH 7.5, 2 mM EDTA buffer containing NADPH (300 µM), trypanothione reductase (2 U ml-1) and T(SH)2 (100 µM), 
to generate reduced tryparedoxin, and different concentrations of TbMSRA (0.05–3.5 µM) or TbMSRB (4–270 µM). Assays were initiated by addition of N-AcMetSO (5 mM) to reactions. (C). The 
MetSO isomer specificity of TbMSRA and TbMSRB (20 µM) was performed using L-Met(S)SO or N-AcMet(R)SO (both 5 mM) as substrate (see Section 2). The data are presented as mean % activity 
values ( ± standard deviations) derived from three independent experiments relative to assays performed using racemic L-MetSO (5 mM) as substrate. (D). Proposed scheme for the metabolism of 
Met(R)SO via a tryparedoxin-mediated TbMSRB pathway. Tryparedoxin (TXNI) acts as a redox shuttle between trypanothione and TbMSRB. Trypanothione disulfide (TS2) is converted to 
dihydrotrypanothione (T[SH]2) at the expense of NADPH by the activity of trypanothione reductase (TR) with “red” and “oxi” representing the reduced and oxidized form of proteins/substrates, 
respectively. The interactions of TbMSRB with TXNI (reaction I) and Met(R)SO (reaction II) are indicated. Kinetic parameters of recombinant TbMSRs is shown in the associated Table. To study 
Reaction I, the interaction between TXNI with TbMSRB, TbMSR activity was assayed as described in panel B using different concentrations of TXN1 (0.3–20 µM) and a fixed concentration of N-
AcMet(R)SO (2.5 mM). For Reaction II, the interaction between TbMSRB with N-AcMet(R)SO, TbMSR activity was assayed as described in panel B using a fixed concentration of TXN1 (10 µM) 
and different concentrations of N-AcMet(R)SO (40–2500 µM). *Data relating to TbMSRA activity taken from Arias et al. [27]. 
 
 
2.8. Peroxide sensitivity experiments 
 
T. brucei BSF parasites were seeded at 1 × 104 ml-1 in 200 μl growth medium 
containing different concentrations of H2O2 and tetracycline (1 µg ml
-1), where 
appropriate. After incubation at 37 °C for 3 days 2.5 μg resazurin (Sigma 
Aldrich) was added to each culture and the plates incubated for a further 8 h. 
Cell densities were determined by monitoring the fluorescence of each culture 
using a Gemini Fluorescent Plate Reader (Molecular Devices (UK) Ltd, 
Wokingham, UK) at an ex-citation λ = 530 nm, emission λ = 585 nm and a 
filter cut off at 550 nm, and EC50 values established using the non-linear 





3.1. Trypanosoma brucei express functional methionine sulfoxide 
reductases 
 
Reduction of the MetSO stereoisomers to Met is mediated by distinct MSRs. 
Analysis of the T. brucei genome database [32] identified two hypothetical 
genes that encode for two such activities. One 543 bp open reading frame 
(Tb927.8.550; designated as TbmsrA) located on chro-mosome 8 has potential 
to be translated into a 20 kDa protein related to peptide MSRs, a family of 
enzymes that mediate metabolism of Met(S) SO [6,7]. The second 423 bp open 
reading frame (Tb927.11.11930.1; designated as TbmsrB) located on 
chromosome 11, has potential to encode for a 16 kDa protein that has homology 
to SelR enzymes which catalyse reduction of Met(R)SO [8]. The two T. brucei 
MSRs share no homology but do have approximately 60% identity to their 
 
 
trypanosomal and leishmanial orthologues (Fig. 1). When compared to other 
sequences, TbMSRA exhibits similar % identities (35–40%) to counterparts 
from plants, humans, fungi and bacteria while TbMSRB has higher identity to 
SelR proteins of plant (~48%) and fungal (~38%) origin relative to bacterial 
and human (both ~25%) enzymes. Based on sequence, TbMSRA is composed 
of a single peptide methionine sulf-oxide reductase (PF01625) domain that 
contains a characteristic G-CFWG motif [5]. In MSRAs from other organisms, 
cysteine (Cys13 in TbMSRA) at this site plays a key role to catalyse reduction 
of MetSO, with a second conserved cysteine (Cys171 in TbMSRA) found 
towards the carboxyl terminal helping maintain the catalytic cysteine in its re-
duced, active form (Fig. 1A). Further searches using localisation pre-diction 
algorithms (e.g. PSORT II) indicates that TbMSRA lacks any classical sub-
cellular localisation signals, suggesting that this enzyme is mostly likely found 
in the parasite's cytoplasm. Similarly, TbMSRB is composed of a single SelR 
(PF01641) domain containing several con-served cysteines [5]. MSRBs from 
other organisms also contains several conserved cysteine (or selenocysteine) 
residues. These are involved in oxidoreductase activity (Cys117 and Cys171 in 
TbMSRB), with the latter cysteine (or selenocysteine) catalysing substrate 
reduction and the former functioning to maintain the catalytic cysteine in its 
reduced, active form, or zinc co-factor binding (Cys99, Cys102, Cys145 and 
Cys148 in TbMSRB) (Fig. 1B). Here, localisation prediction algorithms (e.g. 
PSORT II, iPSORT and TargetP) suggest that the amino terminal of this 
enzyme, characterized by the presence of hydrophobic and basic amino acids 
and a lack of acidic residues, may function as a mi-tochondrial targeting signal. 
 
 
To investigate whether the trypanosomal proteins can function as MSRs, the 
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cloned into pTrcHis-C (Invitrogen) and expressed in E. coli. In this system, the 
recombinant enzymes were tagged at their amino terminus with a histidine-rich 
sequence and an epitope detectable with the anti-Xpress monoclonal antibody 
(Invitrogen). For TbMSRA, expression of the full length gene generated 
soluble recombinant protein. In contrast, the only construct that gave functional 
TbMSRB was a deletion deri-vative in which the recombinant protein lacked 
the amino terminal, mitochondrial targeting extension (Fig. 1B). After 
induction with iso-propyl β-D-thiogalactoside, these constructs generated ~24 
and ~21 kDa proteins corresponding to HIS-tagged TbMSRA and TbMSRB 
respectively, proteins that could be readily purified after one round of affinity 
chromatography on a nickel-HiTRAP column (Fig. 2A).  
Previous studies on trypanosomal MSRA revealed that their activity is driven 
by a TXN-dependent cascade, with NADPH being the source of reducing 
equivalents [27]. Using a coupled assay that guaranteed re-generation of TXN, 
the activity of TbMSRA and TbMSRB was monitored by following NADPH 
oxidation at 340 nm (Fig. 2B). Under the condi-tions employed, both enzymes 
were able to reduce N-AcMetSO con-firming that they exhibited MSR 
activities, with the rate of substrate reduction being dependent upon TbMSR 
concentration (Fig. 2B). When any of the constituents (TR, T(SH)2, TXN or 
TbMSRA/TbMSRB) of the pathway were missing, no activity was observed. 
TbMSRA was able to metabolise N-AcMetSO more readily than TbMSRB 
with TbMSRA ex-hibiting an apparent kcat > 110-fold higher than that of 
TbMSRB for this substrate: TbMSRA and TbMSRB display apparent kcat 
values of 12.3 and 0.11 min-1, respectively, towards N-AcMetSO. 
 
3.2. TbMSRs display different MetSO isomer specificity 
 
To determine TbMSRA or TbMSRB specificity, their activity was followed 
using different MetSO stereoisomers as substrate and com-pared to reactions 
using a MetSO racemic mix (Fig. 2C). In agreement with MSRs from other 
organisms [5], TbMSRA could only metabolise L-Met(S)SO while TbMSRB 
was specific for towards L-Met(R)SO.  
To investigate substrate specificity further and provide additional evidence that 
the two T. brucei enzymes do function as MSRs, the TbmsrA and TbmsrB 
DNA sequences in pTrcHis-C were transferred into the yeast expression vector 
p425-GPD. The resultant plasmids were transformed into a S. cerevisiae strain 
lacking three MSR enzymes and growth of the modified yeast on YNB agar 
plus dextrose agar supple-mented with Met or different MetSO monitored (Fig. 
3). On medium containing L-Met, the growth of all fungal line was supported. 
In con-trast, only strains expressing TbMSRA or TbMSRB could grow on 
medium where L-MetSO racemate was the sole source of L-Met. When using 
L-Met(S)SO or L-Met(R)SO supplemented YNB, only S. cerevisiae 
transformed with the TbMSRA could grow on the former medium whereas 
only yeast expressing TbMSRB displayed strong growth on the latter. 
 
Previous work revealed that TbMSRA activity could be readily sa-turated by 
TXN and L-Met(S)SO [27]. Here, we showed that free L-Met (R)SO was not 
efficiently metabolised by TbMSRB indicating that this was not the 
physiological substrate for this enzyme (Table 1). Instead TbMSRB displayed 
Michaelis-Menten type kinetics towards TXN and N-AcMet(R)SO although 
metabolism of this particular substrate via this pathway was extremely low (kcat 
of 0.085 min-1) (Fig. 2D). Comparison of Km values suggests that the rate 
limiting step within this pathway  
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may be the interaction of TbMSRB with N-AcMet(R)SO (TbMSRB has a Km 
of 1.8 ± 0.3 µM towards TXN and a Km of 429 ± 58 µM towards N-
AcMet(R)SO). These low kinetic values are typical for those reported for 
bacterial, plant and mammalian MSRBs [41–43] while the ability of the 
parasite enzyme to metabolise N-AcMet(R)SO indicates that it can ef-fectively 
reduce protein bound Met(R)SO: this form of MetSO is often used as substrate 
to test for peptide bound MSR activity [44]. 
 
3.3. TbMSRs are targeted to different cellular localisations 
 
The subcellular location of the trypanosomal MSRs was examined by 
expressing GFP-tagged versions of each enzyme in BSF parasites. The DNA 
sequences encoding for TbMSRA and TbMSRB were amplified then cloned in-
frame and upstream of the GFP gene in a trypanosomal vector that facilitated 
tetracycline inducible gene expression. The lo-calisation constructs were 
electroporated into T. brucei and re-combinant parasites selected. 
 
To induce expression of the tagged protein, cells were incubated in the presence 
of tetracycline for 48 h. The parasites were then examined by western blotting 
using an antibody against GFP (Fig. 4A), with each extract containing a single 
band of the expected size (bands of ~48 and ~45 kDa were observed in 
TbMSRA-GFP or TbMSRB-GFP containing lanes), or were fixed and 
examined by confocal microscopy (Fig. 4C and D). For T. brucei induced to 
express tagged TbMSRA, a fluorescence signal was observed throughout the 
main body of the cell but absent from the nucleus indicating that this protein is 
found in the parasite's cytoplasm (Fig. 4C). In contrast, for parasites expressing 
TbMSRB-GFP, a lattice-like structure spread throughout the cell and 
reminiscent of the pattern reported for proteins that localise to the parasite's 
large, single mitochondrion, was observed (Fig. 4D). To confirm this, cells were 
co-stained with the mitochondrial dye, MitoTracker. When the images were 
superimposed, a pattern of co-localisation (yellow staining) was noted 
indicating that TbMSRB was located in the same compartment as MitoTracker. 
When cells expressing untagged GFP were analysed, fluorescence was detected 
throughout the whole cell (Fig. 4B). The above localisation patterns were 
observed by immunofluorescence studies using parasites expressing TbMSRA 
or B variants tagged at their carboxyl terminal with the 9E10 epitope from the 




3.4. Functional analysis of TbMSRs in T. brucei 
 
To assess the importance of MSR activity to BSF T. brucei, an RNAi-based 
approach was employed. DNA fragments corresponding to the central regions 
of TbmsrA and TbmsrB were amplified and cloned into the vector p2T7Ti. The 
RNAi constructs were transformed into T. brucei and recombinant parasites 
selected.  
The effect of inducing RNAi was examined by following the cell density of 
tetracycline-treated cultures over a 4 day period and com-pared against 
untreated controls (Fig. 5A). In the absence of RNAi, all recombinant cell lines 
were found to grow at roughly the same rate as wild type control cells. For cells 
undergoing RNAi targeting the TbmsrA transcript, no significant difference in 
rate of growth was observed over the initial 24 h period (Fig. 5B). However, 
over the following 24 h, a dramatic and reproducible reduction in the cell 
density was observed in all replicates and clones tested, with this correlating to 
~75% fall in the 
 
Fig. 3. Yeast complementation assay demonstrates substrate preference of T. brucei MSRs. The 
growth of S.  cerevisiae  GY202 triple mutant ( msrA   msrB fRmsr) transformed with plasmids 
that facilitate expression of TbmsrA (msrA) or TbmsrB (msrB) on YNB agar the vectorplus 
dextrose agar supplemented with Met or different MetSOs was compared against control strains 
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Fig. 4. Localisation of TbMSRs in bloodstream form T. brucei. (A). Expression of GFP tagged TbMSRs was examined by probing a blot containing cell lysates from T. brucei wild type (lane 1) and 
TbMSRA-GFP or TbMSRB-GFP expressing cells (lanes 2 and 3 re-spectively) using an anti-GFP antibody (upper panel). Protein from 1 × 10
7
 cells was loaded in each track and equal loading verified 
by Coomassie staining (lower panel). (B). T. brucei expressing un-tagged GFP. The blue spots correspond to the nuclear  
(N) and mitochondrial (K) genomes of a trypano-some expressing GFP alone. (C). T. brucei cells ex-pressing TbMSRA-GFP (panel 2) were co-stained with DAPI (panel 1) with the merged signals 
(panel 3) and phase image (panel 4) shown. (D). T. brucei cells expressing TbMSRB-GFP (panel 2) were co-stained with DAPI (panel 1) and Mitotraker (TM; panel 3). The merged GFP/DAPI/Mitotraker 
signals (panel 4) and phase image (panel 5) are shown, with the yellow pattern in panel 4 revealing the co-loca-lisation on TbMSRB-GFP and Mitotraker. Scale bar in B, C and D = 5 µm (For 
interpretation of the refer-ences to color in this figure legend, the reader is referred to the web version of this article.). 
 
TbmsrA transcript, as judged by qPCR. Further, the presence of cell debris was 
noted in these cultures, suggestive that a proportion of the parasite population 
had undergone lysis, while any remaining viable cells exhibited reduced 
movement. From 48 h onwards, an outgrowth of viable parasites were observed 
in all replicates, a type of reversion previously observed when targeting 
transcripts important to the growth of BSF T. brucei [36,45,46]. 
 
In contrast, cells undergoing RNAi targeting the TbmsrB transcript continued 
to grow throughout the entire period albeit with a reduced rate: over the first 24 
h, the growth rate of tetracycline-treated cells was 
roughly half that of untreated cultures with this falling further to ap-
proximately 20% in the next 24 h (Fig. 5B). Over the subsequent 48–72 h, an 
outgrowth of viable parasites were observed. 
 
Alteration of MSR expression levels in other organisms has shown that they 
play an important role in protecting cells from exogenous oxidants 
[7,15,19,27,28]. Here, we investigated whether down-reg-ulation of the 
trypanosomal MSR transcripts altered parasite suscept-ibility to H2O2. 
Tetracycline induced and non-induced cells harbouring the TbmsrA or TbmsrB 
RNAi constructs were grown in the presence of oxidant and the effective 


























Fig. 5. Phenotypic analysis of RNAi cell lines. (A). The TbmsrA or TbmsrB transcript levels from non-induced cells (dark grey) and trypanosomes induced for 48 h to undergo RNAi (light grey) was 
assessed by qPCR and compared against the expression level of a standardized control (Tbtert). The relative fold difference, as judged by 2-( CT) from reactions performed in triplicate ± standard 
deviation, was plotted as a measure of the relative expression level. The difference in relative expression levels between the non-induced and induced lines was judged to be statistically significant (P < 
0.01), as assessed by the Student's t-test. The TbmsrA or TbmsrB mRNAs were both ~3.5-fold lower in the corresponding RNAi line relative to controls. (B). Growth of cells induced to undergo RNAi 
(dashed lines) targeting the TbmsrA or TbmsrB transcript was compared against non-induced cultures (solid line). The growth patterns shown relate to a single clone. Two other clones analysed in 
parallel exhibited the same profiles. (C). The BSF RNAi-TbmsrA and RNAi-TbmsrB lines were grown for 24 h in the presence of tetracycline (1 µg ml–1) (square, dotted line), seeded at 1 × 104 ml–1 
and then exposed to various concentrations of H2O2 (12.5–1000 µM): where applicable, RNAi induction was maintained in peroxide treated cultures by addition of fresh tetracycline to the growth 
medium. After 3 days at 37 °C, resazurin (2.5 µg) was added to each culture and used to determine cell density (Experimental Procedures). Untreated (circles, solid line) and wild type parasites were 
analysed in parallel. From the resultant dose response curves, the EC50 of each line towards H2O2 was calculated. All data points are means for experiments performed in quadruplicate ± standard 
deviation. The difference in susceptibility to H2O2 displayed by the tetracycline-treated and untreated RNAi-TbmsrA cells as judge by EC50 values was statistically significant (P < 0.0001), as assessed 
by Student's t-test. 
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Fig. 6. Overexpression of TbMSRs in bloodstream form T. brucei. (A). Expression of -myc (9e10) tagged TbMSRs was examined by probing a blot containing cell lysates from T. brucei wild type 
(lane 1) and TbMSRA-9e10 or TbMSRB-9e10 expressing cells (lanes 2 and 3 respectively) using c-myc (9e10) anti-serum (upper panel). Protein from 1 × 10
7
 cells was loaded in each track and equal 
loading verified by Coomassie staining (lower panel). (B). The T. brucei TbmsrA-9e10 and TbmsrB-9e10 lines were grown for 24 h in the presence of tetracycline (1 µg ml– 1) (diamond, dotted line), 




 and then exposed to various concentrations of H2O2 (50–500 µM). After 3 days at 37
ₒ
C, resazurin (2.5 µg) was added to each culture and used to determine cell density 
(Experimental Procedures). Untreated (circles, solid line) and wild type parasites were analysed in parallel. From the resultant dose response curves, the EC50 of each line towards H2O2 was calculated. 
All data points are means for experiments performed in quadruplicate ± standard deviation. The difference in susceptibility to H2O2 displayed by the tetracycline-treated and untreated TbmsrA-9e10 
cells as judge by EC50 values was statistically significant (P < 0.0001), as assessed by Student's t-test. 
 
growth by 50% (EC50) determined (Fig. 5C). For cells expressing re-duced 
levels of TbMSRB, no significant difference in parasite sensitivity was 
observed: the EC50 values ranged from 210 to 225 µM. In contrast, 
recombinant T. brucei induced to undergo RNAi targeting the TbmsrA 
transcript were approximately 2-fold more susceptible to H2O2 than controls: 
the EC50 of non-induced RNAi parasites was 204.7 ± 9.4 µM in comparison to 
tetracycline treated cells that exhibited an EC50 of 111.4 ± 13.5 µM. 
 
As parasites with reduced levels of TbmsrA are more susceptible to oxidative 
stress, we tested whether MSR overexpression leads to re-sistance. TbmsrA 
and TbmsrB, minus their STOP codon, were amplified then cloned in-frame 
and upstream of the DNA sequence encoding for the 9E10 epitope from the 
human c-myc protein in a trypanosomal vector that facilitated tetracycline 
inducible gene expression. The constructs were introduced into T. brucei and 
recombinant parasites selected. To verify expression of the tagged TbMSRs, 
cell extracts generated from parasites cultured in the presence of tetracycline 
for 48 h were examined by western blotting using an antibody against c-myc 
epitope (Fig. 6A). A single band was observed in lanes where TbMSRA-9e10 
(~21 kDa) or TbMSRB-9e10 (~20 kDa) expression had been induced. 
Tetracycline treated and untreated T. brucei were then grown in the presence 
of H2O2 and EC50s determined (Fig. 6B). For cells expressing TbMSRB-9e10, 
no significant difference in parasite sensi-tivity was observed. When these 
studies were extended to TbMSRA, parasites expressing the c-myc-tagged 
enzyme were 1.5-fold more re-sistant to H2O2 than controls: the EC50 of non-
induced parasites was 212.9 ± 7.7 µM in comparison to tetracycline induced 






Throughout its life cycle, T. brucei is continually exposed to ROS. To combat 
their detrimental effects, this parasite expresses a series of novel protection 
strategies that collectively constituent this pathogen's oxi-dative defence 
system. As these mechanisms are distinct from those of 
 
its mammalian host [21,22,47–49], with several components being essential for 
growth of the medically relevant parasite stage, they are viewed as potential 
targets for development of new HAT che-motherapies [21,36,49,50]. Here, we 
report the characterisation of two additional components of the trypanosomal 
oxidative defence system, showing that T. brucei expresses two structurally 
unrelated MSRs (TbMSRA and TbMSRB) that can be distinguished on the 
basis of their sequence, substrate specificity and sub-cellular localisation.  
Although functionally related, TbMSRA and TbMSRB share no sig-nificant 
sequence homology with this diversity conferring difference in substrate 
specificities. In the case of TbMSRA, the presence of a GCFWG motif in its 
sequence coupled with it being only able to metabolise the S epimer of MetSO 
establishes this as a member of the peptide methionine sulfoxide reductase, or 
MSRA, family of antioxidant proteins (Figs. 1A, 2 and 3). In contrast, 
TbMSRB contains a domain structure that places it in the SelR, or MRSB, 
group of methionine sulfoxide reductases, with enzymatic and phenotypic 
screening showing that this parasite oxi-doreductase can only mediate 
conversion of peptide-bound Met(R)SO to Met (Figs. 1B, 2 and 3). 
 
Based on sequence and substrate specificity, the two parasite en-zymes are 
typical members of the MSRA or MRSB clades although they are different in 
relation to the pathways that facilitate their reduction. In many instances, the 
concerted action of thioredoxin reductase, thioredoxin and MSR act as 
intermediaries to shuttle reducing equiva-lents from NADPH to MetSO [11]. 
As trypanosomes lack thioredoxin reductase this pathway cannot operate in T. 
brucei. In the case of TbMSRA, its in vitro activity is dependent upon TR and 
trypanothione. Using NADPH as electron donor, these parasite specific factors 
fulfil the role of 'thioredoxin reductase', functioning to maintain TXN in its re-
duced state [51], with reducing equivalents then transferred onto Met (S)SO to 
form Met via the trypanosomal MSR (Fig. 2D) [27]. Steady state kinetics 
indicate that the rate limiting step of this pathway appears to be the TbMSRA 
mediated reduction of free Met(S)SO to Met, a trait noted for MSRAs from 
other organisms [27,52–54]. As all components of this cascade are widely 
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(Fig. 4C) [47,55] and that TbMSRA exhibits reasonable kinetics towards both 
TXN and free Met(S)SO, it is hypothesized that the above pathway functions 
within T. brucei, acting to repair damaged Met, specifically free Met(S)SO, at 
this particular subcellular site. Intriguingly, our yeast complementation studies 
indicate that TbMSRA (and TbMSRB) can utilize non-trypanothione redox 
cascades as source of reducing equivalents suggesting that the activity of these 
enzymes within the trypanosome may be driven by an alternative system to that 
described above. This is analogous to the situation seen with other 
tryparedoxin-dependent enzymes, including the tryparedoxin peroxidases, 
which can exploit different thioredoxin/thioredoxin-like molecules as electron 
donor [48,56]. We postulate that the trypanosomal MSRs are able to interact 
with the yeast thioredoxin system and complement for the appropriate fungal 
mutation to produce the observed growth pheno-type. 
 
In contrast, the pathway that operates to maintain TbMSRB in its reduced state 
is unclear. Biochemical studies on recombinant enzyme has shown that the 
TR/T[SH]2/TXN system can support TbMSRB ac-tivity resulting in slow 
turnover of N-AcMet(R)SO (Fig. 2). The kinetic values exhibited by the 
parasite protein to both TXN and MetSO are on par with those noted for other 
MSRBs, with the rate of N-AcMet(R)SO reduction limited by the 
enzyme/substrate interaction [8,57]. Such observations, coupled with the 
MSRBs preference to bind and meta-bolise protein-bound Met(R)SO, has led 
to the idea that free MetSO may not be the major physiological substrate for 
these reductases [8] and may account for the fact that some organisms have 
evolved other free Met(R)SO metabolising activities (e.g. fRMSRs), with 
turnover of this particular substrate taking place at an appreciably faster rate 
than MSRBs [9,10]. Further, the components that support the trypanothione-
dependent, TbMSRB reduction cascade are not present at the same cellular site: 
TR and TbMSRB are restricted to the cytosol and mi-tochondrion, respectively, 
while TXNI is apparently found across both sites (Fig. 4B) [47,55]. By 
implication, either TbMSRB activity is sup-ported by an unidentified pathway 
found entirely within the parasite mitochondrion or the TR/T[SH]2/TXN redox 
cascade is split across different cellular compartments, with comparative 
analysis indicating that the thiol constituent being the transferable factor. In 
other eu-karyotic cells, GSH is maintained at high (mM) levels in the mi-
tochondrial lumen even though this organelle lacks the biosynthetic machinery 
to make this tripeptide. Instead, cytosolic pools of GSH are transferred into 
mitochondria via several transporters which may in-clude dicarboxylate and 2-
oxoglutarate carriers [58–60]. If an equiva-lent T[SH]2 translocation 
mechanism(s) does function in trypanosomes then given the unique properties 
of the parasite specific thiol, any transport system would be mechanistically 
distinct from that which operates in the transfer of GSH and as such would be 
of particular in-terest as a target(s) for chemotherapy. Once in the 
mitochondrion, T[SH]2 can then facilitate transfer of reducing equivalents via 
TXN and TbMSRB to Met(R)SO. Intriguingly, data released as part of the 
TrypTag project [61] indicates that trypanosomes express a classical 
thioredoxin (Tb927.9.3370 on TriTrypDB [32]) which can be readily reduced 
by T(SH)2 [62,63], present throughout the parasite mitochondrion. If correct, 
this may also function as an intermediary in shuttling reducing equivalents from 




Our data shows that TbMSRA and TbMSRB are located in the T. brucei 
cytoplasm and mitochondrion respectively, a distribution also observed with 
the S. cerevisiae counterparts (Fig. 4) [64]. Why trypa-nosomes and yeast target 
these two enzymes to only these sites is un-clear given that mammalian cells 
possess multiple isoforms of each enzyme type at different sub-cellular sites 
(mammalian cells express cytosolic, mitochondrial and nuclear versions of 
MSRA and MSRB while an isoform of the latter is also present in the 
endoplasmic reticulum [65–67]). Taking into consideration their substrate 
specificity, the specific localisation displayed by TbMSRA and TbMSRB raises 
a number of interesting questions such as how is free or protein bound 
Met(S)SO metabolised in parasite organelles and how is free or protein 
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bound Met(R)SO detoxified at non-mitochondrial sites. Part of this may be 
attributed to uncharacterised activities (e.g. T. brucei appears to have potential 
to encode for a cytoplasmic fRMSR (Tb927.5.1250 on Tri-TrypDB)) or could 
reflect the importance of various MetSO forms in different compartments of the 
cell (e.g. it may be favourable to export free MetSO epimers out of the 
mitochondrion into the cytoplasm to facilitate conversion back to Met, rather 
than carrying out this repair within the organelle). 
 
MSRs represent key components in an organism's oxidative defence armoury, 
functioning in processes such as bacterial and protozoal virulence [7,28,68–70] 
and ageing [16,17,71]. To evaluate the im-portance of trypanosomal enzymes 
to T. brucei, functional genomic approaches were used to generate parasite 
lines expressing altered le-vels of each reductase. Using RNAi, each enzyme 
was shown to be important but not essential for the growth of bloodstream form 
para-sites (Fig. 5). For trypanosomes engineered to express reduced levels of 
the TbmsrA transcript, the stalling of parasite growth was accompanied by an 
increased susceptibility to exogenous H2O2 with the reciprocal phenotype 
observed in cells engineered to over express this enzyme. In contrast, the 
reduction in cell growth observed when targeting the TbmsrB or the elevated 
expression of this reductase in T. brucei did not affect parasite sensitivity to 
H2O2. The observed susceptibility pheno-types suggest that the amount of 
exogenous oxidant added to cultures is sufficient to promote MetSO formation 
in targets found in the parasite's cytosol, damage that can be readily repaired 
by TbMSRA. However, these peroxide levels are not sufficient to cause 
significant Met oxida-tion in the trypanosomal mitochondrion, presumably 
because this oxi-dant is detoxified by the various tryparedoxin peroxidase 
systems ex-pressed by T. brucei [47,49]. 
 
 
In summary, we have demonstrated that T. brucei expresses cyto-solic and 
mitochondrial methionine sulfoxide reducing pathways which together 
constitute a new arm of this parasite's oxidative reparative defence system. As 
the redox cascades associated with these activities rely upon trypanosome-
specific factors and that the activity of the terminal reductase is important for 
pathogen growth, these mechanisms may have potential as chemotherapeutic 
targets. 
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